<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
<title>Karvea, INN - irbesartan</title>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8"/>
<meta name="generator" content="pdftohtml 0.36"/>
<meta name="author" content="CHMP"/>
<meta name="keywords" content="&#34;Karvea, INN - irbesartan&#34;"/>
<meta name="date" content="2022-11-15T11:06:01+00:00"/>
<meta name="subject" content="EPAR"/>
<style type="text/css">
<!--
.xflip {
    -moz-transform: scaleX(-1);
    -webkit-transform: scaleX(-1);
    -o-transform: scaleX(-1);
    transform: scaleX(-1);
    filter: fliph;
}
.yflip {
    -moz-transform: scaleY(-1);
    -webkit-transform: scaleY(-1);
    -o-transform: scaleY(-1);
    transform: scaleY(-1);
    filter: flipv;
}
.xyflip {
    -moz-transform: scaleX(-1) scaleY(-1);
    -webkit-transform: scaleX(-1) scaleY(-1);
    -o-transform: scaleX(-1) scaleY(-1);
    transform: scaleX(-1) scaleY(-1);
    filter: fliph + flipv;
}
-->
</style>
</head>
<body bgcolor="#A0A0A0" vlink="blue" link="blue">
<!-- Page 1 -->
<a name="1"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10{font-size:12px;font-family:ILDBYC+ArialMT;color:#000000;}
	.ft11{font-size:17px;font-family:UYDQKE+TimesNewRomanPSMT;color:#000000;}
	.ft12{font-size:17px;font-family:BJJBEQ+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page1-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft10">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft10">1&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:519px;left:412px;white-space:nowrap" class="ft12"><b>ANNEX I&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft11">&#160;</p>
<p style="position:absolute;top:557px;left:264px;white-space:nowrap" class="ft12"><b>SUMMARY OF&#160;PRODUCT&#160;CHARACTERISTICS&#160;</b></p>
</div>
<!-- Page 2 -->
<a name="2"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft23{font-size:17px;font-family:SBWUII+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page2-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft20">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft20">2&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft22"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft22"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft21">Karvea&#160;75&#160;mg&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft22"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft22"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft21">Each&#160;tablet&#160;contains&#160;75&#160;mg of&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft21">Excipient&#160;with known&#160;effect:&#160;15.37&#160;mg&#160;of&#160;lactose&#160;monohydrate&#160;per&#160;tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft21">For&#160;the full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft22"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft22"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft21">Tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft21">White&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and the&#160;number&#160;2771&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft21">engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft22"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft22"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft22"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft21">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft21">It&#160;is also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients with&#160;hypertension&#160;and&#160;type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft21">diabetes mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive medicinal&#160;product&#160;regimen&#160;(see&#160;sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft21">and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft22"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft21">Posology&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft21">The usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is 150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft21">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft21">75 mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft21">patients&#160;and in&#160;the&#160;elderly over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft21">In patients&#160;insufficiently controlled with 150 mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft21">300 mg, or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft21">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft21">effect&#160;with&#160;Karvea&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft21">In&#160;hypertensive&#160;type&#160;2 diabetic&#160;patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft21">and titrated up to&#160;300&#160;mg&#160;once&#160;daily&#160;as the preferred&#160;maintenance&#160;dose for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft21">The&#160;demonstration of&#160;renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2&#160;diabetic&#160;patients is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft21">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition&#160;to&#160;other&#160;antihypertensive agents,&#160;as needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft21">target&#160;blood&#160;pressure (see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft21">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft23"><i>Renal&#160;impairment</i>&#160;&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft21">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft21">No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;impaired&#160;renal&#160;function.&#160;A&#160;lower&#160;starting&#160;dose&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft21">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft22"><b>&#160;</b></p>
</div>
<!-- Page 3 -->
<a name="3"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft34{font-size:10px;font-family:UYDQKE+TimesNewRomanPSMT;color:#000000;}
	.ft35{font-size:17px;font-family:YXWEOW+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page3-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft30">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft30">3&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft33"><i>Hepatic&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft31">No dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;mild&#160;to&#160;moderate hepatic&#160;impairment.&#160;There is no&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft31">clinical&#160;experience&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft32"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft33"><i>Older people</i>&#160;&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft31">Although consideration should be&#160;given to initiating therapy&#160;with 75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft31">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;the&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft32"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft33"><i>Paediatric&#160;population</i>&#160;&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft31">The&#160;safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in&#160;children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft31">available&#160;data&#160;are&#160;described&#160;in sections&#160;4.8, 5.1, and&#160;5.2 but&#160;no recommendation on a&#160;posology&#160;can&#160;be&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft31">made.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft31">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft31">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft32"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft32"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft31">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in section 6.1.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft31">Second&#160;and third trimesters&#160;of&#160;pregnancy&#160;(see&#160;sections&#160;4.4 and 4.6).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft31">&#160;The concomitant&#160;use&#160;of&#160;Karvea with&#160;aliskiren-containing products&#160;is&#160;contraindicated in patients&#160;with&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft31">diabetes&#160;mellitus&#160;or&#160;renal impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft31">sections&#160;4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft31">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft32"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft32"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft31">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the&#160;first&#160;dose, may occur&#160;in&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft31">patients&#160;who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy, dietary&#160;salt&#160;restriction,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft31">diarrhoea or&#160;vomiting. Such conditions&#160;should be&#160;corrected before&#160;the&#160;administration of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft35"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft31">Renovascular&#160;hypertension:&#160;there&#160;is&#160;an&#160;increased&#160;risk of&#160;severe&#160;hypotension&#160;and&#160;renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft31">when patients&#160;with&#160;bilateral&#160;renal&#160;artery&#160;stenosis&#160;or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft31">are&#160;treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this is&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft31">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft31">antagonists.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft35"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft31">Renal&#160;impairment&#160;and&#160;kidney transplantation:&#160;when&#160;Karvea&#160;is used&#160;in&#160;patients with&#160;impaired&#160;renal&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft31">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and creatinine&#160;serum&#160;levels&#160;is&#160;recommended. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft31">experience&#160;regarding the&#160;administration of&#160;Karvea&#160;in&#160;patients&#160;with a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft35"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft31">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft31">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in the&#160;study&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft31">with&#160;patients&#160;with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared&#160;less favourable&#160;in&#160;women&#160;and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft31">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft35"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft31">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft31">There is evidence&#160;that&#160;the concomitant&#160;use&#160;of&#160;ACE-inhibitors, angiotensin&#160;II&#160;receptor&#160;blockers or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft31">aliskiren&#160;increases&#160;the&#160;risk&#160;of&#160;hypotension, hyperkalaemia&#160;and decreased&#160;renal&#160;function (including&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft31">acute&#160;renal&#160;failure). Dual&#160;blockade&#160;of&#160;RAAS&#160;through the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft31">II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1).&#160;&#160;If&#160;dual&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft31">blockade&#160;therapy&#160;is&#160;considered absolutely necessary,&#160;this&#160;should&#160;only occur&#160;under&#160;specialist&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft31">supervision&#160;and subject&#160;to&#160;frequent&#160;close&#160;monitoring&#160;of&#160;renal&#160;function, electrolytes&#160;and blood pressure.&#160;</p>
</div>
<!-- Page 4 -->
<a name="4"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page4-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft40">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft40">4&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft41">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used concomitantly&#160;in patients&#160;with&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft41">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft41">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft41">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment&#160;with&#160;Karvea,&#160;especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft41">impairment,&#160;overt&#160;proteinuria&#160;due&#160;to&#160;diabetic&#160;renal&#160;disease, and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft41">serum&#160;potassium&#160;in&#160;patients&#160;at&#160;risk&#160;is&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft45"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft41">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft41">treated&#160;with insulin or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft41">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft45"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft41">Lithium: the&#160;combination&#160;of&#160;lithium&#160;and Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft42"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft41">Aortic&#160;and mitral&#160;valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy:&#160;as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft41">special&#160;caution&#160;is indicated&#160;in&#160;patients&#160;suffering&#160;from&#160;aortic&#160;or mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft41">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft45"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft41">Primary aldosteronism: patients&#160;with&#160;primary&#160;aldosteronism generally&#160;will not&#160;respond&#160;to&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft41">antihypertensive&#160;medicinal&#160;products&#160;acting through inhibition&#160;of&#160;the&#160;renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft41">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft45"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft41">General:&#160;in patients&#160;whose&#160;vascular&#160;tone&#160;and renal&#160;function depend predominantly on the&#160;activity of&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft41">the renin-angiotensin-aldosterone&#160;system&#160;(e.g.&#160;patients&#160;with severe&#160;congestive&#160;heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft41">underlying renal&#160;disease, including renal&#160;artery stenosis),&#160;treatment with&#160;angiotensin</p>
<p style="position:absolute;top:538px;left:663px;white-space:nowrap" class="ft42"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft41">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II&#160;receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft41">with acute&#160;hypotension, azotaemia, oliguria,&#160;or rarely&#160;acute&#160;renal&#160;failure&#160;(see&#160;section 4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft41">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease&#160;in&#160;patients with&#160;ischaemic cardiopathy&#160;or&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft41">ischaemic&#160;cardiovascular&#160;disease could&#160;result&#160;in&#160;a myocardial&#160;infarction&#160;or&#160;stroke.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft41">As&#160;observed for&#160;angiotensin&#160;converting enzyme&#160;inhibitors,&#160;irbesartan and the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft41">antagonists&#160;are&#160;apparently less&#160;effective&#160;in&#160;lowering&#160;blood pressure&#160;in black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft41">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states in&#160;the&#160;black hypertensive&#160;population&#160;(see&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft41">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft41">Pregnancy:&#160;angiotensin&#160;II&#160;Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should not&#160;be&#160;initiated during pregnancy.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft41">Unless&#160;continued&#160;AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy should be&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft41">changed to&#160;alternative&#160;antihypertensive&#160;treatments which&#160;have an&#160;established&#160;safety profile for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft41">pregnancy.&#160;When&#160;pregnancy is&#160;diagnosed, treatment&#160;with&#160;AIIRAs&#160;should be&#160;stopped immediately,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft41">and, if&#160;appropriate, alternative&#160;therapy should&#160;be&#160;started (see&#160;sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft41">Paediatric&#160;population:&#160;irbesartan has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old&#160;but&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft41">the&#160;current&#160;data&#160;are&#160;insufficient&#160;to&#160;support&#160;an extension&#160;of&#160;the use in&#160;children&#160;until&#160;further&#160;data become&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft41">available (see&#160;sections&#160;4.8,&#160;5.1 and 5.2).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft41">Excipients:&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft41">Karvea&#160;75 mg&#160;tablet&#160;contains&#160;lactose.&#160;Patients&#160;with&#160;rare hereditary&#160;problems of&#160;galactose&#160;intolerance,&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft41">total&#160;lactase deficiency&#160;or&#160;glucose-galactose&#160;malabsorption&#160;should&#160;not take&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft41">Karvea&#160;75 mg&#160;tablet&#160;contains&#160;sodium. This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft41">tablet,&#160;that is&#160;to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft41">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft42"><b>4.5&#160;&#160;Interaction&#160;with other&#160;medicinal&#160;products&#160;and other&#160;forms&#160;of interaction&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft42"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft41">Diuretics&#160;and other&#160;antihypertensive agents:&#160;other&#160;antihypertensive agents&#160;may&#160;increase&#160;the&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft41">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has&#160;been&#160;safely&#160;administered&#160;with&#160;other&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft41">antihypertensive agents,&#160;such&#160;as&#160;beta-blockers, long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
</div>
<!-- Page 5 -->
<a name="5"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page5-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft50">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft50">5&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft51">diuretics.&#160;Prior&#160;treatment&#160;with&#160;high&#160;dose&#160;diuretics&#160;may result&#160;in&#160;volume&#160;depletion and&#160;a&#160;risk of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft51">hypotension when&#160;initiating therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft55"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft51">Aliskiren-containing products&#160;or&#160;ACE-inhibitors:&#160;clinical&#160;trial&#160;data&#160;has&#160;shown that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft51">the renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;through the&#160;combined use&#160;of&#160;ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft51">angiotensin&#160;II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is&#160;associated&#160;with&#160;a higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft51">such&#160;as&#160;hypotension, hyperkalaemia&#160;and decreased renal&#160;function&#160;(including acute&#160;renal&#160;failure)&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft51">compared to&#160;the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft51">Potassium&#160;supplements&#160;and&#160;potassium-sparing diuretics:<i>&#160;</i>based&#160;on&#160;experience with&#160;the use of&#160;other&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft51">medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin system, concomitant&#160;use&#160;of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft51">diuretics, potassium&#160;supplements,&#160;salt&#160;substitutes&#160;containing&#160;potassium or&#160;other&#160;medicinal products&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft51">that&#160;may&#160;increase serum&#160;potassium&#160;levels&#160;(e.g.&#160;heparin)&#160;may&#160;lead&#160;to&#160;increases&#160;in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft51">is, therefore, not&#160;recommended&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft55"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft51">Lithium:<i>&#160;</i>reversible increases in&#160;serum lithium&#160;concentrations&#160;and&#160;toxicity have&#160;been reported during&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft51">concomitant administration&#160;of&#160;lithium with&#160;angiotensin&#160;converting enzyme&#160;inhibitors. Similar&#160;effects&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft51">have&#160;been very&#160;rarely reported with irbesartan&#160;so far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft51">(see section&#160;4.4). If&#160;the&#160;combination proves&#160;necessary,&#160;careful&#160;monitoring of&#160;serum&#160;lithium&#160;levels&#160;is&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft51">recommended.<i>&#160;</i></p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft55"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft51">Non-steroidal&#160;anti-inflammatory drugs: when angiotensin II&#160;antagonists&#160;are administered&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft51">simultaneously with non-steroidal&#160;anti-inflammatory drugs&#160;(i.e. selective&#160;COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft51">acetylsalicylic&#160;acid&#160;(&gt;&#160;3 g/day)&#160;and non-selective NSAIDs),&#160;attenuation&#160;of&#160;the&#160;antihypertensive&#160;effect&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft51">may&#160;occur.&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft51">As&#160;with ACE&#160;inhibitors, concomitant&#160;use&#160;of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs may&#160;lead to an&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft51">increased risk&#160;of&#160;worsening&#160;of&#160;renal&#160;function,&#160;including possible&#160;acute&#160;renal&#160;failure, and&#160;an increase&#160;in&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft51">serum&#160;potassium,&#160;especially&#160;in&#160;patients with&#160;poor&#160;pre-existing renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft51">be administered&#160;with&#160;caution,&#160;especially&#160;in&#160;the&#160;elderly.&#160;Patients&#160;should&#160;be&#160;adequately hydrated and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft51">consideration&#160;should be&#160;given to&#160;monitoring renal&#160;function after&#160;initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft51">periodically&#160;thereafter.&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft55"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft51">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it was&#160;reported&#160;that&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft51">irbesartan&#160;increased&#160;the&#160;Cmax&#160;and AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1)&#160;by&#160;1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft51">1.3-fold,&#160;respectively,&#160;when&#160;administered&#160;1&#160;hour&#160;before&#160;repaglinide.&#160;In another&#160;study,&#160;no relevant&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft51">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two&#160;drugs&#160;were&#160;co-administered.&#160;Therefore,&#160;dose&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft51">adjustment of&#160;antidiabetic&#160;treatment&#160;such&#160;as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft55"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft51">Additional&#160;information on irbesartan interactions:&#160;in clinical&#160;studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft51">is&#160;not&#160;affected by hydrochlorothiazide. Irbesartan&#160;is&#160;mainly metabolised by CYP2C9 and to a&#160;lesser&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft51">extent&#160;by glucuronidation.&#160;No significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic&#160;interactions were&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft51">observed&#160;when&#160;irbesartan&#160;was coadministered&#160;with&#160;warfarin, a&#160;medicinal&#160;product&#160;metabolised by&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft51">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such as&#160;rifampicin on&#160;the&#160;pharmacokinetic of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft51">have&#160;not&#160;been evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin was&#160;not&#160;altered by&#160;coadministration of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft51">irbesartan.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft52"><b>4.6&#160;&#160;Fertility,&#160;pregnancy&#160;and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft52"><b>&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft51">Pregnancy&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft51">The use&#160;of&#160;AIIRAs is not&#160;recommended&#160;during&#160;the first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft51">use&#160;of&#160;AIIRAs&#160;is&#160;contraindicated during&#160;the&#160;second&#160;and&#160;third&#160;trimesters of&#160;pregnancy&#160;(see sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft51">and 4.4).&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft51">&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft51">Epidemiological&#160;evidence&#160;regarding&#160;the&#160;risk of&#160;teratogenicity following&#160;exposure&#160;to ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft51">during the&#160;first&#160;trimester&#160;of&#160;pregnancy&#160;has not&#160;been&#160;conclusive;&#160;however&#160;a small&#160;increase&#160;in&#160;risk&#160;</p>
</div>
<!-- Page 6 -->
<a name="6"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page6-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft60">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft60">6&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft61">cannot&#160;be&#160;excluded.&#160;Whilst&#160;there&#160;is&#160;no&#160;controlled epidemiological&#160;data&#160;on the&#160;risk&#160;with Angiotensin&#160;II&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft61">Receptor&#160;Antagonists (AIIRAs),&#160;similar&#160;risks may&#160;exist&#160;for&#160;this&#160;class&#160;of&#160;drugs. Unless&#160;continued&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft61">AIIRA&#160;therapy&#160;is considered&#160;essential,&#160;patients planning pregnancy&#160;should be&#160;changed to&#160;alternative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft61">antihypertensive&#160;treatments&#160;which have&#160;an established&#160;safety profile&#160;for&#160;use&#160;in pregnancy.&#160;When&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft61">pregnancy&#160;is&#160;diagnosed, treatment&#160;with AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft61">alternative therapy&#160;should be&#160;started.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft61">Exposure&#160;to AIIRA&#160;therapy&#160;during&#160;the second and third&#160;trimesters&#160;is&#160;known to induce&#160;human&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft61">fetotoxicity&#160;(decreased renal&#160;function, oligohydramnios,&#160;skull&#160;ossification retardation)&#160;and neonatal&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft61">toxicity (renal&#160;failure, hypotension, hyperkalaemia).&#160;(See&#160;section&#160;5.3).&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft61">Should exposure&#160;to&#160;AIIRAs have&#160;occurred&#160;from&#160;the&#160;second trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft61">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft61">Infants&#160;whose&#160;mothers&#160;have&#160;taken AIIRAs&#160;should be&#160;closely observed&#160;for&#160;hypotension&#160;(see&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft61">sections&#160;4.3 and&#160;4.4).&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft62"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft61">Breast-feeding&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft61">Because no information&#160;is&#160;available&#160;regarding the&#160;use&#160;of&#160;Karvea&#160;during breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft61">recommended&#160;and&#160;alternative&#160;treatments&#160;with&#160;better&#160;established&#160;safety&#160;profiles&#160;during&#160;breast-feeding&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft61">are&#160;preferable, especially while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft61">It&#160;is&#160;unknown whether&#160;irbesartan or&#160;its&#160;metabolites&#160;are&#160;excreted in&#160;human&#160;milk.&#160;&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft61">Available&#160;pharmacodynamic/toxicological data&#160;in&#160;rats&#160;have&#160;shown excretion of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft61">metabolites&#160;in&#160;milk&#160;(for&#160;details&#160;see&#160;5.3).&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft61">Fertility&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft61">Irbesartan had no&#160;effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their&#160;offspring&#160;up to the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft61">the first&#160;signs&#160;of&#160;parental toxicity&#160;(see&#160;section&#160;5.3).&#160;&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft62"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft62"><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft61">Based on&#160;its&#160;pharmacodynamic&#160;properties,&#160;irbesartan is&#160;unlikely&#160;to&#160;affect&#160;the&#160;ability&#160;to drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft61">machine. When driving vehicles&#160;or&#160;operating machines, it&#160;should be&#160;taken into account&#160;that&#160;dizziness&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft61">or&#160;weariness&#160;may occur&#160;during treatment.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft62"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft62"><b>&#160;</b></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft61">In placebo-controlled&#160;trials&#160;in patients&#160;with hypertension, the&#160;overall&#160;incidence&#160;of&#160;adverse&#160;events&#160;did&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft61">not&#160;differ&#160;between&#160;the&#160;irbesartan (56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation due&#160;to any&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft61">clinical&#160;or&#160;laboratory&#160;adverse&#160;event&#160;was less&#160;frequent&#160;for&#160;irbesartan-treated&#160;patients&#160;(3.3%)&#160;than for&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft61">placebo-treated&#160;patients&#160;(4.5%).&#160;The&#160;incidence of&#160;adverse events was not&#160;related&#160;to&#160;dose&#160;(in&#160;the&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft61">recommended dose&#160;range),&#160;gender, age, race, or&#160;duration of&#160;treatment.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft61">In diabetic&#160;hypertensive patients with&#160;microalbuminuria and&#160;normal&#160;renal&#160;function, orthostatic&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft61">dizziness&#160;and orthostatic&#160;hypotension were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft61">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft61">The&#160;following&#160;table&#160;presents&#160;the&#160;adverse&#160;drug reactions&#160;that&#160;were&#160;reported&#160;in placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft61">in which 1,965 hypertensive patients&#160;received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a star&#160;(*)&#160;refer&#160;to&#160;the&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft61">adverse reactions that&#160;were additionally&#160;reported in &gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft61">chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria&#160;and in&#160;excess&#160;of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft61">&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft61">The&#160;frequency of&#160;adverse&#160;reactions&#160;listed below&#160;is&#160;defined using&#160;the&#160;following convention:&#160;</p>
</div>
<!-- Page 7 -->
<a name="7"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft76{font-size:17px;font-family:YRDTOW+TimesNewRomanPSMT;color:#000000;}
-->
</style>
<div id="page7-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft70">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft70">7&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft76">very&#160;common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100 to&#160;&lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft76">(≥&#160;1/10,000 to &lt;&#160;1/1,000);&#160;very rare&#160;(&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft71">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft71">Adverse&#160;reactions&#160;additionally&#160;reported from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft71">reactions&#160;are&#160;derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft75"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft71">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft71">Immune&#160;system disorders&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;&#160;&#160;hypersensitivity&#160;reactions such&#160;as&#160;angioedema,&#160;rash,&#160;urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft71">anaphylactic shock<i>&#160;</i></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft71">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft71">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft71">Common:&#160;</p>
<p style="position:absolute;top:425px;left:214px;white-space:nowrap" class="ft71">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:444px;left:214px;white-space:nowrap" class="ft71">vertigo, headache&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft71">Ear&#160;and labyrinth disorder&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:500px;left:213px;white-space:nowrap" class="ft71">tinnitus&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft71">Cardiac disorders&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:577px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft71">Vascular&#160;disorders<i>&#160;</i></p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft71">Common:&#160;</p>
<p style="position:absolute;top:614px;left:214px;white-space:nowrap" class="ft71">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;flushing<i>&#160;</i></p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft71">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft71">Gastrointestinal&#160;disorders<i>&#160;</i></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft71">Common:&#160;</p>
<p style="position:absolute;top:747px;left:214px;white-space:nowrap" class="ft71">nausea/vomiting&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:785px;left:214px;white-space:nowrap" class="ft71">dysgeusia&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft71">Hepatobiliary disorders<i>&#160;</i></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:861px;left:213px;white-space:nowrap" class="ft71">hepatitis,&#160;abnormal&#160;liver&#160;function<i>&#160;</i></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft71">Skin and subcutaneous&#160;tissue&#160;disorders<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:918px;left:213px;white-space:nowrap" class="ft71">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft73"><i>&#160;</i></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft71">Musculoskeletal&#160;and&#160;connective tissue disorders<i>&#160;</i></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft71">Common:&#160;</p>
<p style="position:absolute;top:975px;left:214px;white-space:nowrap" class="ft71">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:994px;left:214px;white-space:nowrap" class="ft71">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:1013px;left:214px;white-space:nowrap" class="ft71">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft71">Renal&#160;and urinary disorders<i>&#160;</i></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft71">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1070px;left:213px;white-space:nowrap" class="ft71">&#160;impaired&#160;renal function&#160;including&#160;cases of&#160;renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1089px;left:214px;white-space:nowrap" class="ft71">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft71">&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft71">Reproductive&#160;system&#160;and breast&#160;disorders<i>&#160;</i></p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft71">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
</div>
<!-- Page 8 -->
<a name="8"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page8-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft80">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft80">8&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft81">General disorders&#160;and&#160;administration&#160;site&#160;conditions<i>&#160;</i></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft81">Common:&#160;</p>
<p style="position:absolute;top:121px;left:214px;white-space:nowrap" class="ft81">fatigue&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft81">Uncommon:&#160;&#160;chest&#160;pain<i>&#160;</i></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft83"><i>&#160;</i></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft81">Investigations<i>&#160;</i></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft81">Very&#160;common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft81">with placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft86">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred in 29.4%&#160;of&#160;the&#160;patients in&#160;the&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft81">irbesartan 300&#160;mg group&#160;and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft81">hypertensive&#160;patients&#160;with chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft86">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft81">and 26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo&#160;group.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft81">Common:&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft81">significant&#160;increases&#160;in&#160;plasma creatine kinase were commonly&#160;observed&#160;(1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft81">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft81">clinical&#160;musculoskeletal events.&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft81">In 1.7%&#160;of&#160;hypertensive patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft81">irbesartan, a&#160;decrease&#160;in&#160;haemoglobin*, which was&#160;not&#160;clinically significant, has&#160;been&#160;</p>
<p style="position:absolute;top:425px;left:214px;white-space:nowrap" class="ft81">observed.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft81">Paediatric&#160;population</p>
<p style="position:absolute;top:462px;left:247px;white-space:nowrap" class="ft82"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft81">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive&#160;children and adolescents&#160;aged&#160;6 to&#160;16&#160;years, the&#160;following&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft81">adverse&#160;reactions occurred&#160;in&#160;the 3-week double-blind&#160;phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft81">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft81">laboratory abnormalities&#160;observed&#160;were creatinine&#160;increases (6.5%)&#160;and&#160;elevated&#160;CK&#160;values in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft81">child recipients.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft81">Reporting&#160;of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft81">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;It&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft81">allows&#160;continued monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft81">professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft81">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft82"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft82"><b>&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft81">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up to 900&#160;mg/day for&#160;8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft81">likely manifestations&#160;of&#160;overdose&#160;are&#160;expected to&#160;be&#160;hypotension&#160;and tachycardia;&#160;bradycardia&#160;might&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft81">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose&#160;with&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft81">Karvea.&#160;The&#160;patient&#160;should&#160;be&#160;closely&#160;monitored,&#160;and&#160;the&#160;treatment&#160;should be&#160;symptomatic&#160;and&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft81">supportive.&#160;Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft81">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose.&#160;Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft82"><b>5.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft82"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft82"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft82"><b>5.1&#160;&#160;Pharmacodynamic&#160;properties&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft82"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft81">Pharmacotherapeutic group:&#160;Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft81">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft81">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft81">Mechanism&#160;of&#160;action</p>
<p style="position:absolute;top:1032px;left:246px;white-space:nowrap" class="ft82"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft82"><b>&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft81">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective angiotensin-II&#160;receptor&#160;(type AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft81">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated&#160;by&#160;the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft81">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II&#160;(AT1) receptors&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft81">results in&#160;increases in&#160;plasma&#160;renin&#160;levels and&#160;angiotensin-II&#160;levels,&#160;and&#160;a decrease in&#160;plasma&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft81">aldosterone&#160;concentration.&#160;Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly affected by irbesartan alone&#160;at&#160;</p>
</div>
<!-- Page 9 -->
<a name="9"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page9-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft90">&#160;</p>
<p style="position:absolute;top:1193px;left:443px;white-space:nowrap" class="ft90">9&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft91">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not inhibit ACE&#160;(kininase-II),&#160;an&#160;enzyme which&#160;generates&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft91">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive&#160;metabolites. Irbesartan does&#160;not&#160;require&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft91">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft91">Clinical efficacy&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft92"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft93"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft91">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change&#160;in&#160;heart&#160;rate.&#160;The decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft91">dose-related for&#160;once-a-day&#160;doses&#160;with&#160;a&#160;tendency&#160;towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft91">150-300&#160;mg once&#160;daily lower&#160;supine&#160;or&#160;seated blood&#160;pressures&#160;at&#160;trough&#160;(i.e.&#160;24 hours&#160;after dosing)&#160;by&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft91">an average&#160;of&#160;8-13/5-8&#160;mm&#160;Hg (systolic/diastolic)&#160;greater&#160;than&#160;those&#160;associated with placebo.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft91">Peak reduction of&#160;blood pressure&#160;is&#160;achieved within 3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft91">pressure&#160;lowering effect&#160;is&#160;maintained for&#160;at&#160;least&#160;24&#160;hours. At&#160;24 hours&#160;the&#160;reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft91">pressure was 60-70%&#160;of&#160;the&#160;corresponding&#160;peak&#160;diastolic and&#160;systolic responses&#160;at&#160;the&#160;recommended&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft91">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft91">daily dosing on&#160;the&#160;same&#160;total dose.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft91">The&#160;blood pressure&#160;lowering effect&#160;of&#160;Karvea&#160;is&#160;evident within&#160;1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft91">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft91">term&#160;therapy. After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft91">hypertension&#160;has&#160;not&#160;been observed.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft91">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan&#160;and&#160;thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft91">not&#160;adequately controlled&#160;by irbesartan alone,&#160;the&#160;addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft91">(12.5&#160;mg)&#160;to&#160;irbesartan&#160;once daily&#160;results in&#160;a&#160;further&#160;placebo-adjusted blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft91">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft91">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender. As is the case&#160;with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft91">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin&#160;system,&#160;black&#160;hypertensive patients have&#160;notably&#160;less&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft91">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft91">of&#160;hydrochlorothiazide (e.g.&#160;12.5 mg daily),&#160;the antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft91">that&#160;of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft91">There&#160;is&#160;no clinically important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft91">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft91">Reduction of&#160;blood pressure&#160;with 0.5&#160;mg/kg&#160;(low), 1.5&#160;mg/kg (medium)&#160;and 4.5&#160;mg/kg (high)&#160;target&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft91">titrated&#160;doses&#160;of&#160;irbesartan&#160;was&#160;evaluated&#160;in 318 hypertensive&#160;or&#160;at&#160;risk (diabetic,&#160;family history of&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft91">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period.&#160;At&#160;the end&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft91">three&#160;weeks&#160;the&#160;mean&#160;reduction&#160;from&#160;baseline&#160;in the&#160;primary efficacy variable, trough seated&#160;systolic&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft91">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft91">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between these&#160;doses. Adjusted mean&#160;change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft91">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as&#160;follows:&#160;3.8&#160;mmHg (low&#160;dose),&#160;3.2&#160;mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft91">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft91">to&#160;either&#160;active&#160;medicinal&#160;product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft91">in SeSBP&#160;and SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively&#160;in&#160;those&#160;on all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft91">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft91">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft93"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft93"><i>&#160;</i></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft91">The “Irbesartan&#160;Diabetic Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the progression&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft91">of&#160;renal&#160;disease&#160;in patients&#160;with chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft91">blind, controlled,&#160;morbidity&#160;and mortality&#160;trial&#160;comparing&#160;Karvea,&#160;amlodipine&#160;and&#160;placebo. In&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft91">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes,&#160;proteinuria&#160;≥&#160;900&#160;mg/day and serum&#160;creatinine&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft91">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft91">renal&#160;disease&#160;and&#160;all-cause mortality&#160;were examined.&#160;Patients were titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
</div>
<!-- Page 10 -->
<a name="10"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page10-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft100">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft100">10&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft101">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo&#160;as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft101">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4&#160;antihypertensive agents&#160;(e.g.,&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft101">diuretics, beta&#160;blockers,&#160;alpha&#160;blockers)&#160;to&#160;reach&#160;a&#160;predefined&#160;blood&#160;pressure goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft101">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft101">patients&#160;in the&#160;placebo group reached&#160;this&#160;target&#160;blood pressure&#160;whereas&#160;this figure was 76%&#160;and&#160;78%&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft101">in the&#160;irbesartan&#160;and&#160;amlodipine&#160;groups&#160;respectively. Irbesartan significantly&#160;reduced the&#160;relative&#160;risk&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft101">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft101">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan group reached&#160;the&#160;primary&#160;renal&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft101">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft101">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft101">(p&#160;=&#160;0.006)]. When&#160;the&#160;individual&#160;components&#160;of&#160;the&#160;primary endpoint&#160;were analysed,&#160;no&#160;effect&#160;in&#160;all-</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft101">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft101">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft101">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration&#160;of&#160;diabetes,&#160;baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft101">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft101">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively, a&#160;renal&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft101">benefit&#160;was&#160;not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft101">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft101">in the&#160;overall&#160;population,&#160;although&#160;an&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;for&#160;women and&#160;a&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft101">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft101">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft101">irbesartan-based&#160;regimen&#160;versus the amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft101">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft101">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft101">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive&#160;Patients&#160;with type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft101">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft101">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind&#160;morbidity&#160;study in&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft101">590&#160;patients&#160;with&#160;type&#160;2 diabetes, microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft101">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft101">effects (2&#160;years) of&#160;Karvea&#160;on the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary albumin&#160;excretion&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft101">rate&#160;(UAER)&#160;&gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft106">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft101">inhibitors, angiotensin&#160;II&#160;receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft101">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft101">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg&#160;group (5.2%)&#160;than in the&#160;placebo (14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft101">in the&#160;irbesartan&#160;150&#160;mg&#160;group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft101">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft101">improvement&#160;in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not observed&#160;during&#160;the&#160;first three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft101">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft101">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft101">frequent&#160;in the&#160;Karvea&#160;300&#160;mg&#160;group (34%)&#160;than in the&#160;placebo&#160;group (21%).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft101">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft103"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft103"><i>&#160;</i></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft101">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft101">combination with Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;VA NEPHRON-D&#160;(The Veterans Affairs&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft101">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft101">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft101">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type 2&#160;diabetes&#160;mellitus&#160;accompanied&#160;by evidence&#160;of&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft101">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft101">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft101">These&#160;studies have shown&#160;no&#160;significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes and&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft101">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft101">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft101">results&#160;are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and angiotensin&#160;II&#160;receptor&#160;blockers.&#160;</p>
</div>
<!-- Page 11 -->
<a name="11"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page11-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft110">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft110">11&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft111">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft111">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft111">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using&#160;Cardiovascular&#160;and Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft111">was&#160;a&#160;study designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft111">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft111">disease,&#160;cardiovascular&#160;disease, or&#160;both. The&#160;study was&#160;terminated early&#160;because of&#160;an&#160;increased&#160;risk&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft111">of&#160;adverse&#160;outcomes. Cardiovascular&#160;death&#160;and stroke&#160;were&#160;both numerically&#160;more&#160;frequent&#160;in the&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft111">aliskiren&#160;group&#160;than&#160;in&#160;the&#160;placebo&#160;group&#160;and&#160;adverse&#160;events and&#160;serious adverse&#160;events of&#160;interest&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft111">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft111">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft112"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft112"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft111">Absorption&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft111">After&#160;oral&#160;administration,&#160;irbesartan&#160;is well&#160;absorbed:&#160;studies of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft111">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft111">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft111">Distribution&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft111">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft111">The&#160;volume&#160;of&#160;distribution&#160;is&#160;53-93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft111">Biotransformation&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft111">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft111">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft111">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft111">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft111">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft111">Linearity /&#160;non-linearity&#160;</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft111">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft111">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft111">recommended&#160;dose)&#160;was observed;&#160;the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft111">are&#160;attained at&#160;1.5-2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and renal&#160;clearance&#160;are&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft111">157-176 and 3-3.5&#160;ml/min,&#160;respectively.&#160;The&#160;terminal&#160;elimination&#160;half-life&#160;of&#160;irbesartan&#160;is&#160;11-15&#160;hours.&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft111">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft111">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft111">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:881px;left:106px;white-space:nowrap" class="ft111">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft111">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft111">were also&#160;somewhat&#160;greater&#160;in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18-40&#160;years).&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft111">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft111">older&#160;people.&#160;</p>
<p style="position:absolute;top:976px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:995px;left:106px;white-space:nowrap" class="ft111">Elimination&#160;</p>
<p style="position:absolute;top:1014px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft111">Irbesartan and&#160;its&#160;metabolites&#160;are&#160;eliminated by&#160;both&#160;biliary and&#160;renal&#160;pathways.&#160;After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft111">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft111">remainder&#160;in&#160;the&#160;faeces.&#160;Less than&#160;2%&#160;of&#160;the dose is excreted&#160;in&#160;the urine as&#160;unchanged&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft111">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft111">&#160;</p>
</div>
<!-- Page 12 -->
<a name="12"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page12-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft120">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft120">12&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft121">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft121">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft121">four&#160;weeks. Of&#160;those&#160;23 children, 21 were&#160;evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft121">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft121">and clearance&#160;rates&#160;were&#160;comparable&#160;to those&#160;observed&#160;in adult&#160;patients&#160;receiving&#160;150&#160;mg&#160;irbesartan&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft121">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft121">dosing.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft121">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft121">In patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft121">of&#160;irbesartan are&#160;not&#160;significantly altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft121">Hepatic impairment&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft121">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft121">significantly&#160;altered.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft121">Studies have not&#160;been&#160;performed&#160;in&#160;patients with&#160;severe&#160;hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft122"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft122"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft121">There&#160;was&#160;no evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft121">non-clinical&#160;safety&#160;studies,&#160;high&#160;doses&#160;of&#160;irbesartan&#160;(≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft121">macaques)&#160;caused a&#160;reduction of&#160;red blood&#160;cell&#160;parameters&#160;(erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft126">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative changes in&#160;the&#160;kidney&#160;(such&#160;as&#160;interstitial&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft121">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft121">creatinine)&#160;were&#160;induced by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft121">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft126">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft126">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft121">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft121">hypertrophy&#160;of&#160;the renal&#160;juxtaglomerular&#160;cells does not&#160;appear&#160;to&#160;have&#160;any&#160;relevance.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft121">There was no&#160;evidence of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft121">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft121">oral&#160;doses&#160;of&#160;irbesartan&#160;causing&#160;some&#160;parental&#160;toxicity&#160;(from&#160;50 to&#160;650&#160;mg/kg/day), including&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft121">mortality&#160;at the&#160;highest dose.&#160;No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft121">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft121">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft121">Irbesartan is&#160;excreted&#160;in&#160;the&#160;milk of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft121">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft121">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft121">abortion&#160;or&#160;early resorption&#160;were&#160;noted at&#160;doses&#160;causing&#160;significant&#160;maternal&#160;toxicity, including&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft121">mortality. No&#160;teratogenic&#160;effects&#160;were&#160;observed&#160;in the&#160;rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft121">&#160;</p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft122"><b>6.&#160;</b></p>
<p style="position:absolute;top:1012px;left:149px;white-space:nowrap" class="ft122"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft122"><b>&#160;</b></p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft122"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft122"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft121">Microcrystalline cellulose&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft121">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft121">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft121">Magnesium&#160;stearate&#160;</p>
</div>
<!-- Page 13 -->
<a name="13"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page13-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft130">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft130">13&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft131">Colloidal&#160;hydrated&#160;silica&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft131">Pregelatinized&#160;maize starch&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft131">Poloxamer&#160;188&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft132"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft131">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft132"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft131">3&#160;years.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft132"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft131">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft132"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft131">Cartons&#160;of&#160;14&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft131">Cartons&#160;of&#160;28&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft131">Cartons&#160;of&#160;56&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft131">Cartons&#160;of&#160;98&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft131">Cartons&#160;of&#160;56&#160;x&#160;1&#160;tablet&#160;in&#160;PVC/PVDC/Aluminium&#160;perforated&#160;unit dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft131">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft132"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft131">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with&#160;local&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft131">requirements.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft132"><b>7.&#160;</b></p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft132"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft131">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft131">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft131">94250 Gentilly&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft131">France&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft132"><b>8.&#160;</b></p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft132"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft131">EU/1/97/049/001-003&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft131">EU/1/97/049/010&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft131">EU/1/97/049/013&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft132"><b>9.&#160;</b></p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft132"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft132"><b>&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft131">Date&#160;of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft131">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft132"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft131">Detailed&#160;information&#160;on&#160;this&#160;medicinal product&#160;is&#160;available&#160;on&#160;the website of&#160;the European&#160;Medicines&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft131">Agency http://www.ema.europa.eu&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft131">&#160;</p>
</div>
<!-- Page 14 -->
<a name="14"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page14-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft140">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft140">14&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft142"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft142"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft141">Karvea&#160;150&#160;mg&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft142"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft142"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft141">Each&#160;tablet&#160;contains&#160;150&#160;mg of&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft141">Excipient&#160;with known&#160;effect:&#160;30.75&#160;mg&#160;of&#160;lactose&#160;monohydrate&#160;per&#160;tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft141">For&#160;the&#160;full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft142"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft142"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft141">Tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft141">White&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and the&#160;number&#160;2772&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft141">engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft142"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft142"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft142"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft141">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft141">It&#160;is also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients with&#160;hypertension&#160;and&#160;type&#160;2&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft141">diabetes&#160;mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive medicinal&#160;product&#160;regimen&#160;(see&#160;sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft141">and 5.1).&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft142"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft141">Posology&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft141">The usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is 150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft141">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg&#160;once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft141">75 mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft141">patients&#160;and in&#160;the&#160;elderly over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft141">In patients&#160;insufficiently controlled with 150 mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft141">300 mg, or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft141">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft141">effect&#160;with&#160;Karvea&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft141">In&#160;hypertensive&#160;type&#160;2 diabetic&#160;patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft141">and titrated up to&#160;300&#160;mg&#160;once daily&#160;as&#160;the&#160;preferred&#160;maintenance dose&#160;for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft141">The&#160;demonstration of&#160;renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2&#160;diabetic&#160;patients is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft141">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition&#160;to&#160;other&#160;antihypertensive agents,&#160;as needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft141">target&#160;blood&#160;pressure (see&#160;sections&#160;4.3,&#160;4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft142"><b>&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft141">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft143"><i>Renal&#160;impairment</i>&#160;&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft141">&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft141">No dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;impaired&#160;renal&#160;function.&#160;A&#160;lower&#160;starting&#160;dose&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft141">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
</div>
<!-- Page 15 -->
<a name="15"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page15-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft150">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft150">15&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft152"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft153"><i>Hepatic&#160;impairment</i>&#160;&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft151">No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;mild&#160;to&#160;moderate&#160;hepatic&#160;impairment. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft151">clinical&#160;experience&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft152"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft153"><i>Older people</i>&#160;&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft151">Although consideration should be&#160;given to initiating therapy&#160;with 75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft151">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft152"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft153"><i>Paediatric&#160;population</i>&#160;&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft151">The&#160;safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in&#160;children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft151">available data are described&#160;in&#160;sections 4.8, 5.1, and&#160;5.2 but&#160;no recommendation on a&#160;posology&#160;can&#160;be&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft151">made.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft151">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft151">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft152"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft152"><b>&#160;</b></p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft151">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in section 6.1.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft151">Second&#160;and third trimesters&#160;of&#160;pregnancy (see&#160;sections&#160;4.4 and 4.6).&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft151">&#160;The concomitant&#160;use&#160;of&#160;Karvea&#160;with&#160;aliskiren-containing products&#160;is&#160;contraindicated in patients&#160;with&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft151">diabetes&#160;mellitus&#160;or&#160;renal impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft151">sections&#160;4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft151">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft152"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft152"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft151">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the&#160;first&#160;dose, may occur&#160;in&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft151">patients&#160;who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy, dietary&#160;salt&#160;restriction,&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft151">diarrhoea&#160;or&#160;vomiting. Such conditions&#160;should be&#160;corrected before&#160;the&#160;administration&#160;of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft155"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft151">Renovascular&#160;hypertension:&#160;there&#160;is&#160;an&#160;increased&#160;risk of&#160;severe&#160;hypotension&#160;and&#160;renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft151">when&#160;patients&#160;with&#160;bilateral&#160;renal artery&#160;stenosis&#160;or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft151">are treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this is&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft151">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft151">antagonists.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft155"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft151">Renal&#160;impairment&#160;and kidney&#160;transplantation:&#160;when&#160;Karvea&#160;is&#160;used&#160;in&#160;patients with&#160;impaired&#160;renal&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft151">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and creatinine&#160;serum&#160;levels&#160;is&#160;recommended. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft151">experience&#160;regarding the&#160;administration of&#160;Karvea&#160;in&#160;patients with&#160;a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft155"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft151">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft151">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in the&#160;study&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft151">with&#160;patients with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared less&#160;favourable&#160;in&#160;women and&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft151">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft155"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft151">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;there&#160;is evidence&#160;that&#160;the&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft151">concomitant&#160;use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;increases&#160;the&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft151">hypotension, hyperkalaemia&#160;and decreased renal&#160;function (including acute&#160;renal&#160;failure).&#160;Dual&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft151">blockade&#160;of&#160;RAAS&#160;through&#160;the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft151">aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1). &#160;If&#160;dual&#160;blockade&#160;therapy is&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft151">considered absolutely necessary,&#160;this&#160;should only occur&#160;under&#160;specialist&#160;supervision and subject&#160;to&#160;</p>
</div>
<!-- Page 16 -->
<a name="16"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page16-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft160">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft160">16&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft161">frequent&#160;close&#160;monitoring of&#160;renal&#160;function, electrolytes&#160;and blood&#160;pressure. ACE-inhibitors&#160;and&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft161">angiotensin&#160;II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used&#160;concomitantly&#160;in patients&#160;with&#160;diabetic&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft161">nephropathy.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft161">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft161">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment&#160;with&#160;Karvea, especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft161">impairment,&#160;overt&#160;proteinuria&#160;due&#160;to&#160;diabetic&#160;renal&#160;disease, and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft161">serum&#160;potassium&#160;in&#160;patients&#160;at&#160;risk&#160;is&#160;recommended&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft165"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft161">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft161">treated&#160;with insulin or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft161">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft165"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft161">Lithium: the&#160;combination of&#160;lithium&#160;and&#160;Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft162"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft161">Aortic&#160;and mitral&#160;valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy:&#160;as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft161">special&#160;caution&#160;is&#160;indicated&#160;in patients&#160;suffering from&#160;aortic&#160;or&#160;mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft161">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft165"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft161">Primary aldosteronism:&#160;patients&#160;with&#160;primary&#160;aldosteronism generally&#160;will not&#160;respond&#160;to&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft161">antihypertensive&#160;medicinal&#160;products&#160;acting through&#160;inhibition&#160;of&#160;the&#160;renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft161">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:501px;left:106px;white-space:nowrap" class="ft165"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft161">General: in&#160;patients whose&#160;vascular&#160;tone and renal&#160;function depend predominantly on the&#160;activity of&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft161">the renin-angiotensin-aldosterone&#160;system&#160;(e.g.&#160;patients&#160;with&#160;severe&#160;congestive&#160;heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft161">underlying renal&#160;disease,&#160;including renal&#160;artery stenosis),&#160;treatment&#160;with&#160;angiotensin</p>
<p style="position:absolute;top:557px;left:663px;white-space:nowrap" class="ft162"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft161">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II&#160;receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft161">with acute&#160;hypotension,&#160;azotaemia,&#160;oliguria,&#160;or&#160;rarely&#160;acute&#160;renal&#160;failure&#160;(see section&#160;4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft161">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease in&#160;patients&#160;with ischaemic&#160;cardiopathy or&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft161">ischaemic&#160;cardiovascular&#160;disease could&#160;result&#160;in&#160;a myocardial&#160;infarction&#160;or&#160;stroke.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft161">As&#160;observed for&#160;angiotensin&#160;converting enzyme&#160;inhibitors,&#160;irbesartan and the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft161">antagonists are apparently&#160;less&#160;effective&#160;in&#160;lowering&#160;blood pressure&#160;in black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft161">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states&#160;in&#160;the&#160;black hypertensive&#160;population&#160;(see&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft161">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft161">Pregnancy:&#160;angiotensin&#160;II&#160;Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should not&#160;be&#160;initiated during pregnancy.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft161">Unless&#160;continued AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy should&#160;be&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft161">changed to&#160;alternative&#160;antihypertensive&#160;treatments&#160;which have an&#160;established&#160;safety&#160;profile for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft161">pregnancy.&#160;When&#160;pregnancy is&#160;diagnosed,&#160;treatment with&#160;AIIRAs&#160;should be&#160;stopped immediately,&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft161">and, if&#160;appropriate, alternative&#160;therapy should&#160;be&#160;started&#160;(see sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft161">Paediatric&#160;population:&#160;irbesartan&#160;has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old but&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft161">the&#160;current&#160;data are&#160;insufficient&#160;to&#160;support&#160;an&#160;extension&#160;of&#160;the use in&#160;children&#160;until&#160;further&#160;data become&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft161">available&#160;(see sections&#160;4.8, 5.1&#160;and&#160;5.2).&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft161">Excipients:&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft161">Karvea&#160;150&#160;mg&#160;tablet&#160;contains&#160;lactose.&#160;Patients&#160;with&#160;rare&#160;hereditary&#160;problems&#160;of&#160;galactose intolerance,&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft161">total&#160;lactase deficiency&#160;or&#160;glucose-galactose&#160;malabsorption should&#160;not&#160;take&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft161">Karvea&#160;150&#160;mg&#160;tablet&#160;contains&#160;sodium.&#160;This&#160;medicine&#160;contains&#160;less&#160;than&#160;1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft161">tablet,&#160;that&#160;is to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft161">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft162"><b>4.5&#160;&#160;Interaction&#160;with&#160;other&#160;medicinal&#160;products and&#160;other forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft162"><b>&#160;</b></p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft161">Diuretics&#160;and other&#160;antihypertensive agents:&#160;other&#160;antihypertensive agents&#160;may&#160;increase the&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft161">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has been&#160;safely&#160;administered&#160;with&#160;other&#160;</p>
</div>
<!-- Page 17 -->
<a name="17"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page17-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft170">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft170">17&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft171">antihypertensive agents,&#160;such&#160;as&#160;beta-blockers, long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft171">diuretics.&#160;Prior&#160;treatment&#160;with&#160;high&#160;dose&#160;diuretics&#160;may&#160;result in&#160;volume&#160;depletion&#160;and&#160;a&#160;risk of&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft171">hypotension when&#160;initiating therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft175"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft171">Aliskiren-containing products&#160;and&#160;ACE-inhibitors:.clinical&#160;trial&#160;data&#160;has&#160;shown&#160;that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft171">the renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;through the&#160;combined use&#160;of ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft171">angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is associated&#160;with&#160;a higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft171">such&#160;as hypotension,&#160;hyperkalaemia&#160;and&#160;decreased&#160;renal&#160;function (including&#160;acute&#160;renal&#160;failure)&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft171">compared&#160;to the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft171">Potassium&#160;supplements and&#160;potassium-sparing diuretics:<i>&#160;</i>based&#160;on&#160;experience with&#160;the use of&#160;other&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft171">medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin&#160;system,&#160;concomitant&#160;use of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft171">diuretics, potassium&#160;supplements,&#160;salt&#160;substitutes containing&#160;potassium&#160;or&#160;other&#160;medicinal&#160;products&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft171">that&#160;may&#160;increase serum&#160;potassium&#160;levels&#160;(e.g.&#160;heparin)&#160;may&#160;lead&#160;to&#160;increases&#160;in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft171">is,&#160;therefore,&#160;not&#160;recommended&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft175"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft171">Lithium:<i>&#160;</i>reversible&#160;increases in&#160;serum&#160;lithium&#160;concentrations&#160;and&#160;toxicity&#160;have&#160;been reported during&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft171">concomitant&#160;administration&#160;of&#160;lithium&#160;with angiotensin&#160;converting enzyme&#160;inhibitors. Similar&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft171">have been&#160;very&#160;rarely reported with&#160;irbesartan so far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft171">(see section&#160;4.4). If&#160;the&#160;combination proves&#160;necessary,&#160;careful&#160;monitoring&#160;of&#160;serum&#160;lithium&#160;levels&#160;is&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft171">recommended.<i>&#160;</i></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft175"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft171">Non-steroidal&#160;anti-inflammatory&#160;drugs: when angiotensin&#160;II&#160;antagonists are administered&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft171">simultaneously with non-steroidal anti-inflammatory drugs&#160;(i.e. selective&#160;COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft171">acetylsalicylic&#160;acid&#160;(&gt;&#160;3 g/day)&#160;and non-selective NSAIDs),&#160;attenuation&#160;of&#160;the&#160;antihypertensive effect&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft171">may&#160;occur.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft171">As&#160;with&#160;ACE&#160;inhibitors,&#160;concomitant&#160;use&#160;of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs&#160;may&#160;lead to an&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft171">increased&#160;risk&#160;of&#160;worsening&#160;of&#160;renal&#160;function, including&#160;possible acute&#160;renal&#160;failure,&#160;and&#160;an&#160;increase&#160;in&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft171">serum&#160;potassium,&#160;especially&#160;in&#160;patients with&#160;poor&#160;pre-existing&#160;renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft171">be&#160;administered&#160;with&#160;caution, especially in the&#160;elderly.&#160;Patients&#160;should&#160;be&#160;adequately hydrated and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft171">consideration should&#160;be&#160;given&#160;to monitoring&#160;renal&#160;function after&#160;initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft171">periodically&#160;thereafter.&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft175"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft171">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to&#160;inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it was&#160;reported&#160;that&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft171">irbesartan&#160;increased&#160;the&#160;Cmax&#160;and AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1)&#160;by&#160;1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft171">1.3-fold,&#160;respectively, when administered&#160;1&#160;hour before&#160;repaglinide. In another&#160;study,&#160;no relevant&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft171">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two&#160;drugs&#160;were&#160;co-administered.&#160;Therefore,&#160;dose&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft171">adjustment of&#160;antidiabetic&#160;treatment&#160;such as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft175"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft171">Additional&#160;information on&#160;irbesartan interactions:&#160;in&#160;clinical studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft171">is&#160;not&#160;affected by hydrochlorothiazide.&#160;Irbesartan&#160;is&#160;mainly&#160;metabolised&#160;by&#160;CYP2C9&#160;and&#160;to&#160;a&#160;lesser&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft171">extent&#160;by&#160;glucuronidation.&#160;No significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic&#160;interactions were&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft171">observed&#160;when&#160;irbesartan&#160;was coadministered&#160;with&#160;warfarin,&#160;a&#160;medicinal&#160;product&#160;metabolised&#160;by&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft171">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such as&#160;rifampicin on&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft171">have not&#160;been&#160;evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin was&#160;not&#160;altered by&#160;coadministration of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft171">irbesartan.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft172"><b>4.6&#160;&#160;Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft172"><b>&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft171">Pregnancy&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft171">The&#160;use&#160;of&#160;AIIRAs is not&#160;recommended&#160;during&#160;the first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft171">use of&#160;AIIRAs is contraindicated during the&#160;second and&#160;third&#160;trimesters&#160;of&#160;pregnancy (see&#160;sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft171">and 4.4).&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft171">&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft171">Epidemiological&#160;evidence&#160;regarding the&#160;risk of&#160;teratogenicity following&#160;exposure&#160;to ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft171">during the&#160;first&#160;trimester&#160;of&#160;pregnancy has&#160;not&#160;been conclusive;&#160;however&#160;a&#160;small&#160;increase&#160;in risk&#160;</p>
</div>
<!-- Page 18 -->
<a name="18"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page18-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft180">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft180">18&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft181">cannot&#160;be&#160;excluded.&#160;Whilst&#160;there&#160;is&#160;no&#160;controlled&#160;epidemiological data&#160;on&#160;the&#160;risk&#160;with&#160;Angiotensin&#160;II&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft181">Receptor&#160;Antagonists&#160;(AIIRAs),&#160;similar&#160;risks&#160;may exist&#160;for&#160;this&#160;class&#160;of&#160;drugs.&#160;Unless&#160;continued&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft181">AIIRA&#160;therapy&#160;is considered&#160;essential, patients&#160;planning pregnancy&#160;should be&#160;changed to&#160;alternative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft181">antihypertensive&#160;treatments&#160;which have&#160;an established&#160;safety profile&#160;for&#160;use&#160;in&#160;pregnancy. When&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft181">pregnancy&#160;is&#160;diagnosed, treatment&#160;with AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft181">alternative&#160;therapy should&#160;be&#160;started.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft181">Exposure&#160;to AIIRA&#160;therapy&#160;during the&#160;second&#160;and&#160;third trimesters&#160;is&#160;known&#160;to&#160;induce&#160;human&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft181">fetotoxicity&#160;(decreased renal&#160;function, oligohydramnios, skull&#160;ossification&#160;retardation)&#160;and neonatal&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft181">toxicity&#160;(renal&#160;failure, hypotension, hyperkalaemia). (See&#160;section&#160;5.3).&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft181">Should exposure&#160;to&#160;AIIRAs have occurred&#160;from&#160;the&#160;second&#160;trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft181">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft181">Infants&#160;whose&#160;mothers have taken&#160;AIIRAs should be&#160;closely&#160;observed for&#160;hypotension&#160;(see&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft181">sections&#160;4.3 and&#160;4.4).&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft182"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft181">Breast-feeding&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft181">Because&#160;no&#160;information&#160;is&#160;available&#160;regarding the&#160;use&#160;of&#160;Karvea&#160;during breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft181">recommended&#160;and&#160;alternative treatments with&#160;better&#160;established&#160;safety&#160;profiles&#160;during&#160;breast-feeding&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft181">are&#160;preferable, especially while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft181">It&#160;is&#160;unknown whether&#160;irbesartan or&#160;its&#160;metabolites&#160;are&#160;excreted&#160;in human milk.&#160;&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft181">Available&#160;pharmacodynamic/toxicological&#160;data&#160;in&#160;rats&#160;have&#160;shown excretion of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft181">metabolites in&#160;milk&#160;(for&#160;details&#160;see&#160;5.3).&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft181">Fertility&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft181">Irbesartan had no effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their offspring&#160;up&#160;to&#160;the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft181">the&#160;first&#160;signs&#160;of&#160;parental&#160;toxicity&#160;(see&#160;section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft182"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to&#160;drive&#160;and&#160;use machines&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft182"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft181">Based&#160;on&#160;its pharmacodynamic properties,&#160;irbesartan is&#160;unlikely to&#160;affect&#160;the&#160;ability&#160;to drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft181">machines. When driving&#160;vehicles&#160;or&#160;operating&#160;machines, it&#160;should be&#160;taken&#160;into account&#160;that&#160;dizziness&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft181">or&#160;weariness&#160;may&#160;occur&#160;during&#160;treatment.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft182"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft182"><b>&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft181">In placebo-controlled&#160;trials&#160;in&#160;patients&#160;with hypertension, the&#160;overall&#160;incidence&#160;of&#160;adverse events did&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft181">not&#160;differ&#160;between&#160;the&#160;irbesartan (56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation due&#160;to any&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft181">clinical&#160;or&#160;laboratory adverse&#160;event&#160;was less&#160;frequent&#160;for&#160;irbesartan-treated&#160;patients&#160;(3.3%)&#160;than&#160;for&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft181">placebo-treated patients&#160;(4.5%). The&#160;incidence&#160;of&#160;adverse events was not&#160;related&#160;to&#160;dose&#160;(in&#160;the&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft181">recommended dose&#160;range),&#160;gender, age, race, or&#160;duration of&#160;treatment.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft181">In&#160;diabetic&#160;hypertensive patients with&#160;microalbuminuria and&#160;normal&#160;renal&#160;function,&#160;orthostatic&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft181">dizziness&#160;and orthostatic&#160;hypotension&#160;were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft181">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft181">The&#160;following&#160;table&#160;presents&#160;the&#160;adverse&#160;drug&#160;reactions&#160;that&#160;were&#160;reported&#160;in placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft181">in which 1,965&#160;hypertensive&#160;patients received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a&#160;star (*) refer to&#160;the&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft181">adverse&#160;reactions&#160;that&#160;were&#160;additionally reported&#160;in&#160;&gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive patients&#160;with&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft181">chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria&#160;and in&#160;excess&#160;of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft181">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft181">The frequency&#160;of&#160;adverse reactions listed&#160;below&#160;is&#160;defined&#160;using the&#160;following&#160;convention:&#160;</p>
</div>
<!-- Page 19 -->
<a name="19"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page19-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft190">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft190">19&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft196">very&#160;common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100 to&#160;&lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to &lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft196">(≥&#160;1/10,000&#160;to&#160;&lt;&#160;1/1,000);&#160;very rare&#160;(&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft191">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft191">Adverse&#160;reactions&#160;additionally&#160;reported from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft191">reactions&#160;are&#160;derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft195"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft191">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft191">Immune&#160;system disorders<i>&#160;</i></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;&#160;&#160;hypersensitivity&#160;reactions such&#160;as&#160;angioedema,&#160;rash,&#160;urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft191">anaphylactic shock<i>&#160;</i></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft191">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft191">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft191">Common:&#160;</p>
<p style="position:absolute;top:425px;left:214px;white-space:nowrap" class="ft191">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:444px;left:214px;white-space:nowrap" class="ft191">vertigo,&#160;headache&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft191">Ear&#160;and labyrinth disorder&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:500px;left:213px;white-space:nowrap" class="ft191">tinnitus&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft191">Cardiac disorders&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:577px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft191">Vascular&#160;disorders&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft191">Common:&#160;</p>
<p style="position:absolute;top:614px;left:214px;white-space:nowrap" class="ft191">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;flushing<i>&#160;</i></p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft191">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft191">Gastrointestinal&#160;disorders&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft191">Common:&#160;</p>
<p style="position:absolute;top:747px;left:214px;white-space:nowrap" class="ft191">nausea/vomiting&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:785px;left:214px;white-space:nowrap" class="ft191">dysgeusia&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft191">Hepatobiliary disorders&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:861px;left:213px;white-space:nowrap" class="ft191">hepatitis,&#160;abnormal&#160;liver&#160;function<i>&#160;</i></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft191">Skin and subcutaneous&#160;tissue&#160;disorders&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:918px;left:213px;white-space:nowrap" class="ft191">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft193"><i>&#160;</i></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft191">Musculoskeletal&#160;and&#160;connective tissue disorders&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft191">Common:&#160;</p>
<p style="position:absolute;top:975px;left:214px;white-space:nowrap" class="ft191">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:994px;left:214px;white-space:nowrap" class="ft191">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;</p>
<p style="position:absolute;top:1013px;left:214px;white-space:nowrap" class="ft191">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft191">Renal&#160;and urinary disorders&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft191">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1070px;left:213px;white-space:nowrap" class="ft191">&#160;impaired&#160;renal function&#160;including&#160;cases of&#160;renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1089px;left:214px;white-space:nowrap" class="ft191">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft191">&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft191">Reproductive&#160;system&#160;and breast&#160;disorders&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft191">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
</div>
<!-- Page 20 -->
<a name="20"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page20-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft200">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft200">20&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft201">General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft201">Common:&#160;</p>
<p style="position:absolute;top:121px;left:214px;white-space:nowrap" class="ft201">fatigue&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft201">Uncommon:&#160;&#160;chest&#160;pain<i>&#160;</i></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft203"><i>&#160;</i></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft201">Investigations&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft201">Very&#160;common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft201">with placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft206">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred in 29.4%&#160;of&#160;the&#160;patients in&#160;the&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft201">irbesartan 300&#160;mg group&#160;and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft201">hypertensive&#160;patients&#160;with chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft206">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft201">and 26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo&#160;group.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft201">Common:&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft201">significant&#160;increases&#160;in&#160;plasma creatine kinase were commonly&#160;observed&#160;(1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft201">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft201">clinical&#160;musculoskeletal&#160;events.&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft201">In 1.7%&#160;of&#160;hypertensive patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft201">irbesartan, a&#160;decrease&#160;in&#160;haemoglobin*, which was&#160;not&#160;clinically significant, has&#160;been&#160;</p>
<p style="position:absolute;top:425px;left:214px;white-space:nowrap" class="ft201">observed.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft201">Paediatric&#160;population</p>
<p style="position:absolute;top:462px;left:247px;white-space:nowrap" class="ft202"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft201">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive&#160;children and adolescents&#160;aged&#160;6 to&#160;16&#160;years, the&#160;following&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft201">adverse&#160;reactions occurred&#160;in&#160;the 3-week double-blind&#160;phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft201">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft201">laboratory&#160;abnormalities&#160;observed&#160;were creatinine&#160;increases (6.5%)&#160;and&#160;elevated&#160;CK&#160;values in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft201">child recipients.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft201">Reporting&#160;of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft201">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;It&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft201">allows&#160;continued monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft201">professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft201">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft202"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft201">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up to 900&#160;mg/day for&#160;8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft201">likely manifestations&#160;of&#160;overdose&#160;are&#160;expected to&#160;be&#160;hypotension&#160;and tachycardia;&#160;bradycardia&#160;might&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft201">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose&#160;with&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft201">Karvea.&#160;The&#160;patient&#160;should&#160;be&#160;closely&#160;monitored,&#160;and&#160;the&#160;treatment&#160;should be&#160;symptomatic&#160;and&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft201">supportive.&#160;Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft201">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose. Irbesartan&#160;is&#160;not removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft202"><b>5.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft202"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft202"><b>5.1&#160;&#160;Pharmacodynamic&#160;properties&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft202"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft201">Pharmacotherapeutic group:&#160;Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft201">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft201">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft201">Mechanism&#160;of&#160;action</p>
<p style="position:absolute;top:1032px;left:246px;white-space:nowrap" class="ft202"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft201">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective&#160;angiotensin-II&#160;receptor&#160;(type AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft201">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated&#160;by&#160;the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft201">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II&#160;(AT1) receptors&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft201">results in&#160;increases in&#160;plasma&#160;renin&#160;levels and&#160;angiotensin-II&#160;levels,&#160;and&#160;a decrease in&#160;plasma&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft201">aldosterone&#160;concentration.&#160;Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly affected by irbesartan alone&#160;at&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft201">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not&#160;inhibit&#160;ACE&#160;(kininase-II),&#160;an&#160;enzyme which&#160;generates&#160;</p>
</div>
<!-- Page 21 -->
<a name="21"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page21-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft210">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft210">21&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft211">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive&#160;metabolites. Irbesartan does&#160;not&#160;require&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft211">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft211">Clinical efficacy&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft212"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft213"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft211">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change in&#160;heart&#160;rate.&#160;The decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft211">dose-related for&#160;once-a-day&#160;doses&#160;with&#160;a&#160;tendency&#160;towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft211">150-300&#160;mg once&#160;daily lower&#160;supine&#160;or&#160;seated blood&#160;pressures&#160;at&#160;trough&#160;(i.e.&#160;24 hours&#160;after dosing)&#160;by&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft211">an average&#160;of&#160;8-13/5-8&#160;mm&#160;Hg (systolic/diastolic)&#160;greater&#160;than&#160;those&#160;associated with placebo.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft211">Peak reduction of&#160;blood pressure&#160;is&#160;achieved within 3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft211">pressure&#160;lowering effect&#160;is&#160;maintained for&#160;at&#160;least&#160;24&#160;hours. At&#160;24 hours&#160;the&#160;reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft211">pressure was 60-70%&#160;of&#160;the&#160;corresponding&#160;peak&#160;diastolic and&#160;systolic responses&#160;at&#160;the&#160;recommended&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft211">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft211">daily dosing&#160;on the&#160;same&#160;total dose.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft211">The&#160;blood pressure&#160;lowering effect&#160;of&#160;Karvea&#160;is&#160;evident within&#160;1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft211">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft211">term&#160;therapy. After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft211">hypertension&#160;has&#160;not&#160;been observed.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft211">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan&#160;and&#160;thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft211">not&#160;adequately controlled&#160;by irbesartan alone,&#160;the addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft211">(12.5&#160;mg)&#160;to&#160;irbesartan&#160;once daily&#160;results in&#160;a&#160;further&#160;placebo-adjusted blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft211">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft211">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender.&#160;As is&#160;the&#160;case with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft211">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin&#160;system,&#160;black&#160;hypertensive patients have&#160;notably&#160;less&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft211">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft211">of&#160;hydrochlorothiazide&#160;(e.g.&#160;12.5&#160;mg&#160;daily), the antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft211">that&#160;of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft211">There&#160;is&#160;no clinically important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft211">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft211">Reduction of&#160;blood pressure&#160;with&#160;0.5&#160;mg/kg (low), 1.5&#160;mg/kg&#160;(medium)&#160;and&#160;4.5&#160;mg/kg (high)&#160;target&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft211">titrated&#160;doses&#160;of&#160;irbesartan&#160;was&#160;evaluated&#160;in 318 hypertensive&#160;or&#160;at&#160;risk (diabetic,&#160;family history of&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft211">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period. At&#160;the end&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft211">three weeks the&#160;mean reduction from&#160;baseline&#160;in&#160;the&#160;primary&#160;efficacy&#160;variable,&#160;trough&#160;seated systolic&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft211">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft211">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between these&#160;doses.&#160;Adjusted mean&#160;change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft211">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as&#160;follows:&#160;3.8&#160;mmHg (low&#160;dose),&#160;3.2&#160;mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft211">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft211">to&#160;either&#160;active&#160;medicinal product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft211">in SeSBP&#160;and SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively&#160;in&#160;those&#160;on all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft211">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft211">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft213"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft211">The “Irbesartan&#160;Diabetic Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the progression&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft211">of&#160;renal&#160;disease&#160;in patients&#160;with chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft211">blind, controlled,&#160;morbidity&#160;and mortality trial&#160;comparing Karvea, amlodipine&#160;and&#160;placebo. In&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft211">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes,&#160;proteinuria&#160;≥&#160;900&#160;mg/day and serum&#160;creatinine&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft211">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft211">renal&#160;disease and all-cause&#160;mortality&#160;were&#160;examined.&#160;Patients were titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft211">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft211">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4 antihypertensive&#160;agents&#160;(e.g.,&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft211">diuretics, beta&#160;blockers,&#160;alpha&#160;blockers)&#160;to reach a&#160;predefined blood pressure&#160;goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft211">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft211">patients in&#160;the placebo&#160;group&#160;reached&#160;this&#160;target&#160;blood pressure&#160;whereas this&#160;figure&#160;was&#160;76%&#160;and&#160;78%&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft211">in&#160;the&#160;irbesartan&#160;and&#160;amlodipine&#160;groups&#160;respectively. Irbesartan significantly&#160;reduced the&#160;relative&#160;risk&#160;</p>
</div>
<!-- Page 22 -->
<a name="22"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page22-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft220">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft220">22&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft221">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft221">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan&#160;group&#160;reached&#160;the primary&#160;renal&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft221">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft221">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft221">(p&#160;=&#160;0.006)].&#160;When the&#160;individual&#160;components&#160;of&#160;the&#160;primary endpoint&#160;were&#160;analysed, no&#160;effect&#160;in all-</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft221">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft221">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft221">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration&#160;of&#160;diabetes, baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft221">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft221">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively,&#160;a renal&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft221">benefit&#160;was&#160;not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft221">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft221">in&#160;the&#160;overall&#160;population, although an increased incidence&#160;of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;for&#160;women&#160;and&#160;a&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft221">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft221">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft221">irbesartan-based&#160;regimen&#160;versus the amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft221">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft221">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft221">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive&#160;Patients&#160;with&#160;type&#160;2&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft221">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft221">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind&#160;morbidity&#160;study in&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft221">590&#160;patients&#160;with&#160;type&#160;2 diabetes, microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft221">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft221">effects (2&#160;years) of&#160;Karvea&#160;on the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary&#160;albumin&#160;excretion&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft221">rate&#160;(UAER) &gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft226">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft221">inhibitors, angiotensin&#160;II receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft221">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft221">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg&#160;group (5.2%)&#160;than in the&#160;placebo&#160;(14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft221">in the&#160;irbesartan&#160;150&#160;mg group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft221">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft221">improvement&#160;in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not&#160;observed during&#160;the&#160;first&#160;three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft221">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft221">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft221">frequent&#160;in&#160;the&#160;Karvea&#160;300&#160;mg&#160;group (34%)&#160;than in the&#160;placebo&#160;group (21%).&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft221">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft223"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft221">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft221">combination with Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;VA NEPHRON-D&#160;(The Veterans Affairs&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft221">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft221">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft221">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type 2&#160;diabetes mellitus&#160;accompanied&#160;by&#160;evidence of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft221">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft221">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft221">These studies&#160;have&#160;shown&#160;no&#160;significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes&#160;and&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft221">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft221">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft221">results&#160;are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft221">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft221">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft221">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using Cardiovascular&#160;and&#160;Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft221">was&#160;a&#160;study designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft221">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft221">disease,&#160;cardiovascular&#160;disease, or&#160;both. The&#160;study was&#160;terminated early because&#160;of&#160;an increased risk&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft221">of&#160;adverse outcomes.&#160;Cardiovascular&#160;death&#160;and&#160;stroke&#160;were both&#160;numerically&#160;more frequent&#160;in&#160;the&#160;</p>
</div>
<!-- Page 23 -->
<a name="23"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page23-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft230">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft230">23&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft231">aliskiren group&#160;than&#160;in&#160;the&#160;placebo&#160;group&#160;and&#160;adverse&#160;events and&#160;serious adverse&#160;events&#160;of&#160;interest&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft231">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft231">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft232"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft232"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft231">Absorption&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft231">After&#160;oral&#160;administration,&#160;irbesartan&#160;is well&#160;absorbed:&#160;studies of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft231">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft231">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft231">Distribution&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft231">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft231">The&#160;volume&#160;of&#160;distribution&#160;is&#160;53-93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft231">Biotransformation&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:445px;left:106px;white-space:nowrap" class="ft231">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft231">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft231">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft231">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft231">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft231">Linearity/&#160;non-linearity&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft231">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft231">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft231">recommended dose)&#160;was&#160;observed;&#160;the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft231">are&#160;attained at&#160;1.5-2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and renal&#160;clearance&#160;are&#160;157-</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft231">176 and 3-3.5&#160;ml/min,&#160;respectively.&#160;The&#160;terminal&#160;elimination&#160;half-life&#160;of&#160;irbesartan&#160;is 11-15 hours.&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft231">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft231">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft231">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft231">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft231">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft231">were also&#160;somewhat&#160;greater&#160;in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18-40&#160;years).&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft231">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft231">older&#160;people.&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft231">Elimination&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft231">Irbesartan&#160;and&#160;its metabolites&#160;are&#160;eliminated by&#160;both&#160;biliary and renal&#160;pathways.&#160;After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:921px;left:106px;white-space:nowrap" class="ft231">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:940px;left:106px;white-space:nowrap" class="ft231">remainder&#160;in&#160;the&#160;faeces.&#160;Less than&#160;2%&#160;of&#160;the dose is excreted&#160;in&#160;the urine&#160;as&#160;unchanged irbesartan.&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft231">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft231">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft231">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft231">four&#160;weeks. Of&#160;those&#160;23 children, 21 were&#160;evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft231">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft231">and&#160;clearance rates were comparable&#160;to&#160;those&#160;observed&#160;in&#160;adult&#160;patients&#160;receiving 150&#160;mg&#160;irbesartan&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft231">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft231">dosing.&#160;</p>
<p style="position:absolute;top:1149px;left:106px;white-space:nowrap" class="ft231">&#160;</p>
</div>
<!-- Page 24 -->
<a name="24"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page24-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft240">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft240">24&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft241">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft241">In patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft241">of&#160;irbesartan&#160;are&#160;not&#160;significantly altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft241">Hepatic impairment&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft241">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft241">significantly&#160;altered.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft241">Studies&#160;have&#160;not&#160;been&#160;performed&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft242"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft242"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft241">There&#160;was&#160;no evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft241">non-clinical&#160;safety&#160;studies,&#160;high doses&#160;of&#160;irbesartan (≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day in&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft241">macaques)&#160;caused a&#160;reduction of&#160;red blood&#160;cell&#160;parameters&#160;(erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft246">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative&#160;changes&#160;in the&#160;kidney&#160;(such&#160;as&#160;interstitial&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft241">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft241">creatinine)&#160;were&#160;induced by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft241">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft246">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft246">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft241">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft241">hypertrophy&#160;of&#160;the renal&#160;juxtaglomerular&#160;cells does not&#160;appear&#160;to&#160;have&#160;any&#160;relevance.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft241">There&#160;was&#160;no&#160;evidence&#160;of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft241">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft241">oral&#160;doses&#160;of&#160;irbesartan&#160;causing&#160;some&#160;parental&#160;toxicity&#160;(from&#160;50 to&#160;650&#160;mg/kg/day), including&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft241">mortality at&#160;the&#160;highest&#160;dose. No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft241">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft241">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and&#160;rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft241">Irbesartan is&#160;excreted&#160;in&#160;the&#160;milk of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft241">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft241">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft241">abortion&#160;or&#160;early&#160;resorption&#160;were&#160;noted&#160;at doses&#160;causing&#160;significant maternal&#160;toxicity,&#160;including&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft241">mortality. No&#160;teratogenic&#160;effects&#160;were&#160;observed&#160;in the&#160;rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft242"><b>6.&#160;</b></p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft242"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft242"><b>&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft242"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft242"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft241">Microcrystalline&#160;cellulose&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft241">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft241">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft241">Magnesium&#160;stearate&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft241">Colloidal&#160;hydrated&#160;silica&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft241">Pregelatinized&#160;maize starch&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft241">Poloxamer&#160;188&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft242"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft242"><b>&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft241">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft241">&#160;</p>
</div>
<!-- Page 25 -->
<a name="25"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page25-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft250">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft250">25&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft252"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft251">3&#160;years.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft252"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft251">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft252"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft251">Cartons&#160;of&#160;14&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft251">Cartons&#160;of&#160;28&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft251">Cartons&#160;of&#160;56&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft251">Cartons&#160;of&#160;98&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft251">Cartons&#160;of&#160;56&#160;x&#160;1&#160;tablet&#160;in&#160;PVC/PVDC/Aluminium&#160;perforated&#160;unit dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft251">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft252"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft251">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft251">requirements.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft252"><b>7.&#160;</b></p>
<p style="position:absolute;top:538px;left:149px;white-space:nowrap" class="ft252"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft251">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft251">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft251">94250 Gentilly&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft251">France&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft252"><b>8.&#160;</b></p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft252"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft251">EU/1/97/049/004-006&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft251">EU/1/97/049/011&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft251">EU/1/97/049/014&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft252"><b>9.&#160;</b></p>
<p style="position:absolute;top:804px;left:149px;white-space:nowrap" class="ft252"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft252"><b>&#160;</b></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft251">Date of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft251">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft252"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft251">Detailed&#160;information&#160;on&#160;this&#160;medicinal product&#160;is&#160;available&#160;on&#160;the&#160;website&#160;of&#160;the&#160;European Medicines&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft251">Agency http://www.ema.europa.eu&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft251">&#160;</p>
</div>
<!-- Page 26 -->
<a name="26"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page26-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft260">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft260">26&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft262"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft262"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft261">Karvea&#160;300&#160;mg&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft262"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft262"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft261">Each&#160;tablet&#160;contains&#160;300&#160;mg of&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft261">Excipient&#160;with known&#160;effect:&#160;61.50&#160;mg of&#160;lactose&#160;monohydrate&#160;per&#160;tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft261">For&#160;the full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft262"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft262"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft261">Tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft261">White&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and the&#160;number&#160;2773&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft261">engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft262"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft262"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft262"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft261">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft261">It&#160;is also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients with&#160;hypertension&#160;and&#160;type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft261">diabetes mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive&#160;medicinal&#160;product&#160;regimen&#160;(see sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft261">and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft262"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft261">Posology&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft261">The usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is 150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft261">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg&#160;once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft261">75&#160;mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft261">patients&#160;and in&#160;the&#160;elderly over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft261">In patients&#160;insufficiently controlled with 150&#160;mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft261">300&#160;mg,&#160;or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft261">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft261">effect&#160;with&#160;Karvea&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft261">In&#160;hypertensive&#160;type&#160;2&#160;diabetic patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft261">and titrated up to&#160;300&#160;mg&#160;once&#160;daily&#160;as the preferred&#160;maintenance&#160;dose for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft261">The&#160;demonstration of renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2 diabetic&#160;patients&#160;is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft261">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition&#160;to&#160;other&#160;antihypertensive agents,&#160;as needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft261">target&#160;blood&#160;pressure (see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft261">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft263"><i>Renal&#160;impairment</i>&#160;&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft261">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft261">No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients&#160;with&#160;impaired renal&#160;function. A&#160;lower&#160;starting dose&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft261">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft262"><b>&#160;</b></p>
</div>
<!-- Page 27 -->
<a name="27"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page27-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft270">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft270">27&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft273"><i>Hepatic&#160;impairment</i>&#160;&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft271">No dosage&#160;adjustment&#160;is&#160;necessary&#160;in&#160;patients&#160;with&#160;mild&#160;to&#160;moderate&#160;hepatic&#160;impairment.&#160;There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft271">clinical&#160;experience&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft272"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft273"><i>Older people</i>&#160;&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft271">Although consideration should be&#160;given to initiating therapy&#160;with 75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft271">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft272"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft273"><i>Paediatric&#160;population</i>&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft271">The&#160;safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in&#160;children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft271">available&#160;data&#160;are&#160;described&#160;in sections&#160;4.8, 5.1, and&#160;5.2 but&#160;no recommendation on a&#160;posology&#160;can&#160;be&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft271">made.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft271">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft271">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft272"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft272"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft271">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in section 6.1.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft271">Second&#160;and third trimesters&#160;of&#160;pregnancy&#160;(see&#160;sections&#160;4.4 and&#160;4.6).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft271">The concomitant&#160;use&#160;of&#160;Karvea with&#160;aliskiren-containing products&#160;is&#160;contraindicated&#160;in&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft271">diabetes&#160;mellitus&#160;or&#160;renal impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft271">sections&#160;4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft271">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft272"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft272"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft271">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the first&#160;dose,&#160;may&#160;occur&#160;in&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft271">patients&#160;who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy, dietary&#160;salt&#160;restriction,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft271">diarrhoea&#160;or&#160;vomiting. Such conditions&#160;should be&#160;corrected before&#160;the&#160;administration of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft275"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft271">Renovascular&#160;hypertension:&#160;there&#160;is&#160;an&#160;increased&#160;risk of&#160;severe&#160;hypotension&#160;and&#160;renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft271">when patients&#160;with&#160;bilateral&#160;renal&#160;artery&#160;stenosis&#160;or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft271">are&#160;treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this is&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft271">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft271">antagonists.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft275"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft271">Renal&#160;impairment&#160;and kidney transplantation:&#160;when&#160;Karvea&#160;is&#160;used in&#160;patients&#160;with impaired&#160;renal&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft271">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and creatinine&#160;serum&#160;levels&#160;is&#160;recommended. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft271">experience&#160;regarding the&#160;administration of&#160;Karvea&#160;in&#160;patients with&#160;a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft275"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft271">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft271">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in the&#160;study&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft271">with&#160;patients with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared&#160;less favourable&#160;in&#160;women&#160;and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft271">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft275"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft271">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;there&#160;is evidence&#160;that&#160;the&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft271">concomitant&#160;use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers or&#160;aliskiren&#160;increases&#160;the&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft271">hypotension, hyperkalaemia and&#160;decreased&#160;renal&#160;function&#160;(including&#160;acute&#160;renal&#160;failure).&#160;Dual&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft271">blockade&#160;of&#160;RAAS&#160;through&#160;the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft271">aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1). &#160;If&#160;dual&#160;blockade&#160;therapy&#160;is&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft271">considered absolutely necessary,&#160;this&#160;should only occur&#160;under&#160;specialist&#160;supervision and subject&#160;to&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft271">frequent&#160;close&#160;monitoring of&#160;renal&#160;function, electrolytes&#160;and blood&#160;pressure. ACE-inhibitors&#160;and&#160;</p>
</div>
<!-- Page 28 -->
<a name="28"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page28-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft280">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft280">28&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft281">angiotensin II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used concomitantly in&#160;patients&#160;with diabetic&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft281">nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft281">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft281">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment with&#160;Karvea,&#160;especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft281">impairment,&#160;overt&#160;proteinuria&#160;due&#160;to&#160;diabetic&#160;renal&#160;disease, and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft281">serum&#160;potassium&#160;in&#160;patients&#160;at&#160;risk&#160;is&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft285"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft281">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft281">treated&#160;with insulin or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft281">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft285"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft281">Lithium:&#160;the&#160;combination&#160;of&#160;lithium and&#160;Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft282"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft281">Aortic&#160;and&#160;mitral valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy:&#160;as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft281">special&#160;caution&#160;is indicated&#160;in&#160;patients&#160;suffering from&#160;aortic&#160;or&#160;mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft281">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft285"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft281">Primary aldosteronism:&#160;patients with&#160;primary&#160;aldosteronism&#160;generally will&#160;not&#160;respond to&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft281">antihypertensive&#160;medicinal&#160;products&#160;acting through inhibition&#160;of&#160;the&#160;renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft281">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft285"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft281">General:&#160;in&#160;patients whose&#160;vascular&#160;tone and renal&#160;function depend predominantly on&#160;the&#160;activity&#160;of&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft281">the renin-angiotensin-aldosterone&#160;system&#160;(e.g.&#160;patients&#160;with severe&#160;congestive&#160;heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft281">underlying renal&#160;disease,&#160;including&#160;renal&#160;artery&#160;stenosis), treatment with&#160;angiotensin</p>
<p style="position:absolute;top:538px;left:663px;white-space:nowrap" class="ft282"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft281">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft281">with acute&#160;hypotension, azotaemia, oliguria, or&#160;rarely&#160;acute&#160;renal&#160;failure&#160;(see&#160;section 4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft281">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease&#160;in&#160;patients with&#160;ischaemic cardiopathy&#160;or&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft281">ischaemic&#160;cardiovascular&#160;disease could&#160;result&#160;in&#160;a myocardial&#160;infarction&#160;or&#160;stroke.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft281">As&#160;observed&#160;for&#160;angiotensin&#160;converting enzyme&#160;inhibitors,&#160;irbesartan and the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft281">antagonists are apparently&#160;less&#160;effective&#160;in&#160;lowering&#160;blood pressure in&#160;black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft281">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states&#160;in&#160;the black&#160;hypertensive&#160;population (see&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft281">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft281">Pregnancy:&#160;angiotensin&#160;II Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should not&#160;be&#160;initiated during pregnancy.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft281">Unless&#160;continued AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy should be&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft281">changed&#160;to alternative&#160;antihypertensive&#160;treatments which&#160;have an&#160;established&#160;safety&#160;profile for&#160;use in&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft281">pregnancy.&#160;When&#160;pregnancy is&#160;diagnosed, treatment&#160;with&#160;AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft281">and, if&#160;appropriate, alternative&#160;therapy should&#160;be&#160;started (see&#160;sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft281">Paediatric&#160;population:&#160;irbesartan has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old but&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft281">the&#160;current data&#160;are&#160;insufficient&#160;to&#160;support&#160;an&#160;extension&#160;of&#160;the use in&#160;children&#160;until&#160;further&#160;data become&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft281">available (see&#160;sections&#160;4.8, 5.1&#160;and&#160;5.2).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft281">Excipients:&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft281">Karvea&#160;300&#160;mg&#160;tablet&#160;contains&#160;lactose.&#160;Patients&#160;with&#160;rare&#160;hereditary&#160;problems&#160;of&#160;galactose&#160;intolerance,&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft281">total lactase&#160;deficiency or&#160;glucose-galactose&#160;malabsorption should&#160;not&#160;take&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft281">Karvea&#160;300&#160;mg&#160;tablet&#160;contains&#160;sodium.&#160;This&#160;medicine&#160;contains&#160;less&#160;than&#160;1 mmol&#160;sodium&#160;(23 mg)&#160;per&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft281">tablet,&#160;that is&#160;to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft281">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft282"><b>4.5&#160;&#160;Interaction with&#160;other medicinal&#160;products&#160;and&#160;other&#160;forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft282"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft281">Diuretics&#160;and&#160;other&#160;antihypertensive&#160;agents:&#160;other&#160;antihypertensive agents&#160;may&#160;increase the&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft281">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has&#160;been&#160;safely&#160;administered&#160;with&#160;other&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft281">antihypertensive&#160;agents,&#160;such&#160;as beta-blockers, long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
</div>
<!-- Page 29 -->
<a name="29"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page29-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft290">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft290">29&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft291">diuretics.&#160;Prior&#160;treatment&#160;with&#160;high&#160;dose&#160;diuretics&#160;may result&#160;in volume&#160;depletion&#160;and a&#160;risk of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft291">hypotension&#160;when initiating therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft295"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft291">Aliskiren-containing&#160;products&#160;or&#160;ACE-inhibitors:&#160;clinical&#160;trial&#160;data&#160;has&#160;shown that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft291">the renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;through&#160;the&#160;combined&#160;use&#160;of&#160;ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft291">angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is&#160;associated with a&#160;higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft291">such as&#160;hypotension, hyperkalaemia&#160;and decreased renal&#160;function&#160;(including acute&#160;renal&#160;failure)&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft291">compared to the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft291">Potassium&#160;supplements&#160;and&#160;potassium-sparing&#160;diuretics:<i>&#160;</i>based&#160;on&#160;experience with&#160;the use of&#160;other&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft291">medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin system, concomitant&#160;use&#160;of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft291">diuretics,&#160;potassium&#160;supplements,&#160;salt&#160;substitutes containing&#160;potassium or&#160;other&#160;medicinal products&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft291">that may&#160;increase serum&#160;potassium&#160;levels&#160;(e.g.&#160;heparin)&#160;may&#160;lead&#160;to&#160;increases&#160;in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft291">is, therefore, not&#160;recommended&#160;(see section 4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft295"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft291">Lithium:<i>&#160;</i>reversible increases in&#160;serum&#160;lithium&#160;concentrations&#160;and&#160;toxicity have&#160;been reported during&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft291">concomitant&#160;administration&#160;of&#160;lithium&#160;with angiotensin&#160;converting enzyme&#160;inhibitors. Similar&#160;effects&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft291">have&#160;been very&#160;rarely reported&#160;with&#160;irbesartan so far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft291">(see section 4.4). If&#160;the&#160;combination proves&#160;necessary,&#160;careful&#160;monitoring of&#160;serum&#160;lithium levels&#160;is&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft291">recommended.<i>&#160;</i></p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft295"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft291">Non-steroidal&#160;anti-inflammatory drugs: when angiotensin&#160;II antagonists are administered&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft291">simultaneously with non-steroidal&#160;anti-inflammatory&#160;drugs&#160;(i.e.&#160;selective COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft291">acetylsalicylic&#160;acid&#160;(&gt;&#160;3&#160;g/day)&#160;and non-selective NSAIDs),&#160;attenuation&#160;of&#160;the&#160;antihypertensive effect&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft291">may&#160;occur.&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft291">As&#160;with ACE&#160;inhibitors, concomitant&#160;use&#160;of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs&#160;may&#160;lead to an&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft291">increased&#160;risk&#160;of&#160;worsening&#160;of&#160;renal&#160;function,&#160;including possible&#160;acute&#160;renal&#160;failure,&#160;and&#160;an&#160;increase&#160;in&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft291">serum&#160;potassium,&#160;especially&#160;in&#160;patients with&#160;poor&#160;pre-existing renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft291">be administered&#160;with&#160;caution,&#160;especially in the&#160;elderly.&#160;Patients&#160;should&#160;be&#160;adequately hydrated and&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft291">consideration should&#160;be&#160;given&#160;to monitoring&#160;renal&#160;function after&#160;initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft291">periodically thereafter.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft295"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft291">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it was&#160;reported that&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft291">irbesartan&#160;increased&#160;the&#160;Cmax&#160;and&#160;AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1)&#160;by&#160;1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft291">1.3-fold,&#160;respectively,&#160;when&#160;administered&#160;1&#160;hour&#160;before&#160;repaglinide. In another&#160;study,&#160;no relevant&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft291">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two drugs&#160;were&#160;co-administered.&#160;Therefore,&#160;dose&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft291">adjustment of&#160;antidiabetic treatment&#160;such as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft295"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft291">Additional&#160;information on irbesartan&#160;interactions:&#160;in clinical&#160;studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft291">is&#160;not affected by hydrochlorothiazide. Irbesartan&#160;is&#160;mainly&#160;metabolised&#160;by&#160;CYP2C9&#160;and&#160;to&#160;a&#160;lesser&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft291">extent&#160;by glucuronidation. No&#160;significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic&#160;interactions were&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft291">observed when irbesartan&#160;was coadministered&#160;with&#160;warfarin,&#160;a&#160;medicinal&#160;product&#160;metabolised by&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft291">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such&#160;as&#160;rifampicin&#160;on&#160;the pharmacokinetic of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft291">have&#160;not&#160;been evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin&#160;was not&#160;altered&#160;by&#160;coadministration&#160;of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft291">irbesartan.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft292"><b>4.6&#160;&#160;Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft292"><b>&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft291">Pregnancy&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft291">The use&#160;of&#160;AIIRAs is not&#160;recommended during the first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft291">use&#160;of&#160;AIIRAs&#160;is&#160;contraindicated during&#160;the&#160;second&#160;and&#160;third trimesters&#160;of pregnancy&#160;(see sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft291">and 4.4).&#160;</p>
<p style="position:absolute;top:1093px;left:106px;white-space:nowrap" class="ft291">&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft291">Epidemiological evidence&#160;regarding&#160;the&#160;risk of&#160;teratogenicity following&#160;exposure&#160;to&#160;ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft291">during&#160;the first&#160;trimester&#160;of&#160;pregnancy&#160;has not&#160;been&#160;conclusive;&#160;however&#160;a small&#160;increase&#160;in&#160;risk&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft291">cannot&#160;be&#160;excluded. Whilst&#160;there&#160;is&#160;no&#160;controlled epidemiological&#160;data&#160;on the&#160;risk with&#160;Angiotensin&#160;II&#160;</p>
</div>
<!-- Page 30 -->
<a name="30"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page30-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft300">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft300">30&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft301">Receptor&#160;Antagonists (AIIRAs),&#160;similar&#160;risks&#160;may&#160;exist&#160;for&#160;this&#160;class&#160;of&#160;drugs. Unless&#160;continued&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft301">AIIRA&#160;therapy&#160;is considered&#160;essential,&#160;patients planning pregnancy&#160;should be&#160;changed&#160;to alternative&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft301">antihypertensive&#160;treatments&#160;which have&#160;an established&#160;safety profile&#160;for&#160;use&#160;in pregnancy. When&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft301">pregnancy&#160;is&#160;diagnosed, treatment&#160;with AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft301">alternative therapy&#160;should be&#160;started.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft301">Exposure&#160;to AIIRA&#160;therapy&#160;during the&#160;second&#160;and&#160;third trimesters&#160;is&#160;known&#160;to&#160;induce&#160;human&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft301">fetotoxicity&#160;(decreased&#160;renal&#160;function, oligohydramnios, skull&#160;ossification&#160;retardation)&#160;and neonatal&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft301">toxicity (renal&#160;failure, hypotension, hyperkalaemia).&#160;(See&#160;section 5.3).&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft301">Should&#160;exposure&#160;to AIIRAs&#160;have&#160;occurred&#160;from&#160;the&#160;second trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft301">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft301">Infants&#160;whose&#160;mothers&#160;have&#160;taken AIIRAs&#160;should be&#160;closely observed&#160;for&#160;hypotension&#160;(see&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft301">sections&#160;4.3&#160;and 4.4).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft301">Breast-feeding&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft301">Because&#160;no&#160;information&#160;is available&#160;regarding the&#160;use&#160;of&#160;Karvea&#160;during breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft301">recommended&#160;and&#160;alternative treatments with&#160;better&#160;established&#160;safety&#160;profiles&#160;during&#160;breast-feeding&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft301">are preferable,&#160;especially&#160;while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft301">It&#160;is&#160;unknown whether&#160;irbesartan&#160;or&#160;its&#160;metabolites&#160;are&#160;excreted&#160;in&#160;human milk.&#160;&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft301">Available&#160;pharmacodynamic/toxicological&#160;data&#160;in&#160;rats&#160;have&#160;shown excretion of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft301">metabolites&#160;in milk (for&#160;details&#160;see&#160;5.3).&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft301">Fertility&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft301">Irbesartan had no effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their&#160;offspring&#160;up to the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft301">the&#160;first&#160;signs&#160;of&#160;parental&#160;toxicity&#160;(see&#160;section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft302"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use&#160;machines&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft301">Based on&#160;its&#160;pharmacodynamic&#160;properties,&#160;irbesartan is&#160;unlikely to&#160;affect&#160;the&#160;ability&#160;to&#160;drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft301">machine.&#160;When&#160;driving&#160;vehicles or&#160;operating machines,&#160;it&#160;should&#160;be&#160;taken into account&#160;that&#160;dizziness&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft301">or&#160;weariness&#160;may occur&#160;during treatment.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft302"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft302"><b>&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft301">In placebo-controlled&#160;trials&#160;in patients&#160;with hypertension, the&#160;overall&#160;incidence&#160;of&#160;adverse&#160;events&#160;did&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft301">not&#160;differ&#160;between&#160;the irbesartan (56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation due&#160;to any&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft301">clinical&#160;or&#160;laboratory&#160;adverse&#160;event&#160;was&#160;less frequent&#160;for irbesartan-treated patients&#160;(3.3%)&#160;than&#160;for&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft301">placebo-treated&#160;patients&#160;(4.5%).&#160;The&#160;incidence of&#160;adverse events was not&#160;related&#160;to&#160;dose (in&#160;the&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft301">recommended dose&#160;range),&#160;gender, age, race, or&#160;duration of&#160;treatment.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft301">In diabetic&#160;hypertensive patients with&#160;microalbuminuria&#160;and normal&#160;renal&#160;function, orthostatic&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft301">dizziness&#160;and orthostatic&#160;hypotension were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft301">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft301">The&#160;following&#160;table&#160;presents&#160;the&#160;adverse&#160;drug reactions&#160;that&#160;were&#160;reported in&#160;placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft301">in which 1,965&#160;hypertensive&#160;patients received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a&#160;star (*) refer to&#160;the&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft301">adverse&#160;reactions&#160;that&#160;were&#160;additionally reported&#160;in&#160;&gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft301">chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria&#160;and&#160;in&#160;excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft301">The&#160;frequency of&#160;adverse&#160;reactions&#160;listed below&#160;is&#160;defined using&#160;the&#160;following convention:&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft306">very&#160;common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100 to&#160;&lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft306">(≥&#160;1/10,000 to &lt;&#160;1/1,000);&#160;very rare&#160;(&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft301">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft301">&#160;</p>
</div>
<!-- Page 31 -->
<a name="31"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page31-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft310">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft310">31&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft311">Adverse&#160;reactions&#160;additionally&#160;reported from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft311">reactions&#160;are&#160;derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft315"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft311">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft311">Immune&#160;system disorders&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;&#160;&#160;hypersensitivity&#160;reactions such&#160;as&#160;angioedema,&#160;rash,&#160;urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft311">anaphylactic shock&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft311">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft311">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft311">Common:&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft311">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft311">vertigo, headache&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft311">Ear&#160;and labyrinth disorder&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:425px;left:213px;white-space:nowrap" class="ft311">tinnitus&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft311">Cardiac disorders&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft311">Vascular&#160;disorders&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft311">Common:&#160;</p>
<p style="position:absolute;top:538px;left:214px;white-space:nowrap" class="ft311">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;flushing&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft311">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft311">Gastrointestinal&#160;disorders&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft311">Common:&#160;</p>
<p style="position:absolute;top:671px;left:214px;white-space:nowrap" class="ft311">nausea/vomiting&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:709px;left:214px;white-space:nowrap" class="ft311">dysgeusia&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft311">Hepatobiliary disorders&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:785px;left:213px;white-space:nowrap" class="ft311">hepatitis,&#160;abnormal&#160;liver&#160;function&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft311">Skin and subcutaneous&#160;tissue&#160;disorders&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:842px;left:213px;white-space:nowrap" class="ft311">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft311">Musculoskeletal&#160;and&#160;connective tissue disorders&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft311">Common:&#160;</p>
<p style="position:absolute;top:899px;left:214px;white-space:nowrap" class="ft311">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:918px;left:214px;white-space:nowrap" class="ft311">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;</p>
<p style="position:absolute;top:937px;left:214px;white-space:nowrap" class="ft311">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft311">Renal&#160;and urinary disorders&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft311">Not&#160;known:&#160;</p>
<p style="position:absolute;top:994px;left:213px;white-space:nowrap" class="ft311">&#160;impaired&#160;renal function&#160;including&#160;cases of&#160;renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1013px;left:214px;white-space:nowrap" class="ft311">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft311">Reproductive&#160;system&#160;and breast&#160;disorders&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft311">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft311">&#160;</p>
</div>
<!-- Page 32 -->
<a name="32"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page32-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft320">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft320">32&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft321">General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft321">Common:&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft321">fatigue&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft321">Uncommon:&#160;&#160;chest&#160;pain&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft321">Investigations&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft321">Very common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:197px;left:214px;white-space:nowrap" class="ft321">with placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft326">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in&#160;29.4%&#160;of&#160;the patients in&#160;the&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft321">irbesartan&#160;300&#160;mg group&#160;and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft321">hypertensive&#160;patients&#160;with chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft326">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft321">and 26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo&#160;group.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft321">Common:&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft321">significant&#160;increases&#160;in&#160;plasma creatine kinase were commonly&#160;observed&#160;(1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft321">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft321">clinical&#160;musculoskeletal&#160;events.&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft321">In 1.7%&#160;of&#160;hypertensive patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft321">irbesartan, a&#160;decrease&#160;in&#160;haemoglobin*, which was&#160;not&#160;clinically significant, has&#160;been&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft321">observed.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft321">Paediatric&#160;population</p>
<p style="position:absolute;top:443px;left:247px;white-space:nowrap" class="ft322"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft321">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive&#160;children and adolescents&#160;aged&#160;6 to&#160;16&#160;years, the&#160;following&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft321">adverse&#160;reactions occurred&#160;in&#160;the 3-week double-blind&#160;phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft321">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft321">laboratory&#160;abnormalities&#160;observed&#160;were creatinine&#160;increases (6.5%)&#160;and&#160;elevated&#160;CK&#160;values in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft321">child recipients.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft321">Reporting&#160;of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft321">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;It&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft321">allows&#160;continued monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft321">professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft321">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft322"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft322"><b>&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft321">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up to 900&#160;mg/day for&#160;8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft321">likely manifestations&#160;of&#160;overdose&#160;are&#160;expected to&#160;be&#160;hypotension&#160;and tachycardia;&#160;bradycardia&#160;might&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft321">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose&#160;with&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft321">Karvea.&#160;The&#160;patient&#160;should&#160;be&#160;closely&#160;monitored,&#160;and&#160;the&#160;treatment&#160;should be&#160;symptomatic&#160;and&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft321">supportive.&#160;Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft321">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose. Irbesartan&#160;is&#160;not removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft322"><b>5.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft322"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft322"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft322"><b>5.1&#160;&#160;Pharmacodynamic&#160;properties&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft322"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft321">Pharmacotherapeutic group:&#160;Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft321">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft321">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft321">Mechanism&#160;of&#160;action</p>
<p style="position:absolute;top:1032px;left:246px;white-space:nowrap" class="ft322"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft322"><b>&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft321">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective&#160;angiotensin-II&#160;receptor&#160;(type&#160;AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft321">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated&#160;by&#160;the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft321">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II (AT1) receptors&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft321">results in&#160;increases in&#160;plasma&#160;renin&#160;levels and&#160;angiotensin-II&#160;levels,&#160;and&#160;a decrease in&#160;plasma&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft321">aldosterone&#160;concentration.&#160;Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly affected by irbesartan alone&#160;at&#160;</p>
</div>
<!-- Page 33 -->
<a name="33"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page33-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft330">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft330">33&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft331">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not inhibit&#160;ACE&#160;(kininase-II),&#160;an&#160;enzyme which&#160;generates&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft331">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive&#160;metabolites. Irbesartan does&#160;not&#160;require&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft331">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft331">Clinical efficacy&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft332"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft333"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft331">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change in&#160;heart&#160;rate.&#160;The decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft331">dose-related for&#160;once-a-day&#160;doses&#160;with&#160;a&#160;tendency&#160;towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft331">150-300&#160;mg once&#160;daily lower&#160;supine&#160;or&#160;seated blood&#160;pressures&#160;at&#160;trough&#160;(i.e.&#160;24 hours&#160;after dosing)&#160;by&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft331">an average&#160;of&#160;8-13/5-8&#160;mm&#160;Hg (systolic/diastolic)&#160;greater&#160;than&#160;those&#160;associated with placebo.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft331">Peak reduction of&#160;blood pressure&#160;is&#160;achieved within 3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft331">pressure&#160;lowering effect&#160;is&#160;maintained for&#160;at&#160;least&#160;24&#160;hours. At&#160;24 hours&#160;the&#160;reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft331">pressure was 60-70%&#160;of&#160;the&#160;corresponding&#160;peak&#160;diastolic and&#160;systolic responses&#160;at&#160;the&#160;recommended&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft331">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft331">daily dosing&#160;on the&#160;same&#160;total dose.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft331">The&#160;blood pressure&#160;lowering effect&#160;of&#160;Karvea&#160;is&#160;evident within&#160;1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft331">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft331">term&#160;therapy. After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft331">hypertension&#160;has&#160;not&#160;been observed.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft331">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan&#160;and&#160;thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft331">not&#160;adequately controlled&#160;by irbesartan alone, the&#160;addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft331">(12.5&#160;mg)&#160;to&#160;irbesartan&#160;once daily&#160;results in&#160;a&#160;further&#160;placebo-adjusted blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft331">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft331">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender.&#160;As is&#160;the&#160;case with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft331">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin&#160;system,&#160;black&#160;hypertensive patients have&#160;notably&#160;less&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft331">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft331">of&#160;hydrochlorothiazide&#160;(e.g.&#160;12.5&#160;mg&#160;daily), the antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft331">that&#160;of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft331">There&#160;is&#160;no clinically important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft331">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft331">Reduction of&#160;blood pressure&#160;with&#160;0.5&#160;mg/kg (low), 1.5&#160;mg/kg (medium)&#160;and&#160;4.5&#160;mg/kg (high)&#160;target&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft331">titrated&#160;doses&#160;of&#160;irbesartan&#160;was&#160;evaluated&#160;in 318 hypertensive&#160;or&#160;at&#160;risk (diabetic,&#160;family history of&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft331">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period. At&#160;the&#160;end&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft331">three weeks the&#160;mean&#160;reduction&#160;from&#160;baseline&#160;in the&#160;primary efficacy variable, trough seated&#160;systolic&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft331">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft331">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between&#160;these&#160;doses.&#160;Adjusted mean&#160;change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft331">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as&#160;follows:&#160;3.8&#160;mmHg (low&#160;dose),&#160;3.2&#160;mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft331">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft331">to&#160;either&#160;active&#160;medicinal&#160;product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft331">in SeSBP&#160;and SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively&#160;in&#160;those&#160;on all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft331">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft331">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft333"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft331">The “Irbesartan&#160;Diabetic Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the progression&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft331">of&#160;renal&#160;disease&#160;in patients&#160;with chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft331">blind, controlled,&#160;morbidity&#160;and mortality trial&#160;comparing Karvea, amlodipine&#160;and placebo.&#160;In&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft331">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes,&#160;proteinuria&#160;≥&#160;900&#160;mg/day and serum&#160;creatinine&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft331">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft331">renal&#160;disease&#160;and&#160;all-cause&#160;mortality&#160;were&#160;examined.&#160;Patients were titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft331">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft331">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4 antihypertensive&#160;agents&#160;(e.g.,&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft331">diuretics, beta&#160;blockers,&#160;alpha&#160;blockers)&#160;to&#160;reach&#160;a&#160;predefined&#160;blood&#160;pressure&#160;goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft331">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft331">patients&#160;in the&#160;placebo group reached&#160;this&#160;target&#160;blood pressure&#160;whereas this figure was 76%&#160;and&#160;78%&#160;</p>
</div>
<!-- Page 34 -->
<a name="34"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page34-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft340">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft340">34&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft341">in the&#160;irbesartan&#160;and&#160;amlodipine&#160;groups respectively.&#160;Irbesartan&#160;significantly&#160;reduced&#160;the relative risk&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft341">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft341">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan group reached&#160;the&#160;primary&#160;renal&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft341">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft341">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft341">(p&#160;=&#160;0.006)]. When&#160;the&#160;individual&#160;components&#160;of&#160;the&#160;primary&#160;endpoint&#160;were analysed,&#160;no&#160;effect&#160;in&#160;all-</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft341">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft341">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft341">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration&#160;of&#160;diabetes, baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft341">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft341">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively, a&#160;renal&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft341">benefit&#160;was not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft341">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft341">in the&#160;overall&#160;population,&#160;although&#160;an&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;was&#160;seen for&#160;women and&#160;a&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft341">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft341">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft341">irbesartan-based&#160;regimen&#160;versus the amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft341">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft341">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft341">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive&#160;Patients&#160;with type&#160;2&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft341">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft341">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind&#160;morbidity&#160;study in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft341">590&#160;patients&#160;with&#160;type&#160;2 diabetes, microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft341">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft341">effects (2&#160;years) of&#160;Karvea&#160;on the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary albumin&#160;excretion&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft341">rate&#160;(UAER) &gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft346">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft341">inhibitors, angiotensin&#160;II&#160;receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft341">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft341">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg&#160;group (5.2%)&#160;than in the&#160;placebo (14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft341">in&#160;the irbesartan&#160;150&#160;mg group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft341">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft341">improvement&#160;in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not observed&#160;during&#160;the&#160;first&#160;three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft341">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft341">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft341">frequent&#160;in the&#160;Karvea&#160;300&#160;mg&#160;group (34%)&#160;than&#160;in the&#160;placebo&#160;group (21%).&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft341">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft343"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft341">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft341">combination with Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;NEPHRON-D&#160;(The&#160;Veterans&#160;Affairs&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft341">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft341">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft341">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type 2&#160;diabetes mellitus&#160;accompanied&#160;by&#160;evidence of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft341">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft341">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft341">These&#160;studies have shown&#160;no&#160;significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft341">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft341">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft341">results&#160;are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and angiotensin&#160;II&#160;receptor&#160;blockers.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft341">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft341">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft341">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using&#160;Cardiovascular&#160;and Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft341">was a study&#160;designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft341">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft341">disease,&#160;cardiovascular&#160;disease, or&#160;both. The&#160;study was&#160;terminated&#160;early&#160;because of&#160;an&#160;increased&#160;risk&#160;</p>
</div>
<!-- Page 35 -->
<a name="35"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page35-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft350">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft350">35&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft351">of&#160;adverse outcomes.&#160;Cardiovascular&#160;death&#160;and&#160;stroke&#160;were both&#160;numerically&#160;more frequent&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft351">aliskiren group&#160;than&#160;in&#160;the&#160;placebo&#160;group&#160;and&#160;adverse&#160;events and&#160;serious adverse&#160;events of&#160;interest&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft351">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft351">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft352"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft352"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft351">Absorption&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft351">After&#160;oral&#160;administration, irbesartan is&#160;well&#160;absorbed:&#160;studies&#160;of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft351">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft351">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft351">Distribution&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft351">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft351">The&#160;volume&#160;of&#160;distribution&#160;is&#160;53-93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft351">Biotransformation&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft351">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft351">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft351">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft351">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft351">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft351">Linearity /&#160;non-linearity&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft351">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft351">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft351">recommended&#160;dose)&#160;was observed;&#160;the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft351">are&#160;attained at&#160;1.5-2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and renal&#160;clearance&#160;are&#160;157-</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft351">176 and 3-3.5&#160;ml/min,&#160;respectively.&#160;The&#160;terminal&#160;elimination&#160;half-life of&#160;irbesartan&#160;is 11-15 hours.&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft351">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft351">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft351">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan&#160;were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft351">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft351">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft351">were also&#160;somewhat&#160;greater&#160;in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18-40&#160;years).&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft351">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft351">older&#160;people.&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft351">Elimination&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft351">Irbesartan and&#160;its&#160;metabolites&#160;are&#160;eliminated by&#160;both&#160;biliary and renal&#160;pathways.&#160;After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft351">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft351">remainder&#160;in&#160;the&#160;faeces.&#160;Less than&#160;2%&#160;of&#160;the dose is excreted&#160;in&#160;the urine as&#160;unchanged&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft351">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft351">&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft351">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft351">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft351">four&#160;weeks. Of&#160;those&#160;23 children, 21&#160;were evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft351">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft351">and clearance&#160;rates&#160;were&#160;comparable&#160;to those&#160;observed&#160;in adult&#160;patients&#160;receiving&#160;150&#160;mg irbesartan&#160;</p>
</div>
<!-- Page 36 -->
<a name="36"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page36-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft360">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft360">36&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft361">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft361">dosing.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft361">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft361">In&#160;patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft361">of&#160;irbesartan are&#160;not&#160;significantly&#160;altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft361">Hepatic impairment:&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft361">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft361">significantly&#160;altered.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft361">Studies&#160;have&#160;not&#160;been performed in&#160;patients&#160;with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft362"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft362"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft361">There&#160;was&#160;no evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft361">non-clinical&#160;safety&#160;studies,&#160;high doses&#160;of&#160;irbesartan (≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day&#160;in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft361">macaques)&#160;caused a&#160;reduction of&#160;red blood&#160;cell&#160;parameters&#160;(erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft366">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative&#160;changes&#160;in the&#160;kidney&#160;(such&#160;as&#160;interstitial&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft361">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft361">creatinine)&#160;were&#160;induced by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft361">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft366">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft366">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft361">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft361">hypertrophy&#160;of&#160;the renal&#160;juxtaglomerular&#160;cells does not&#160;appear&#160;to&#160;have&#160;any&#160;relevance.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft361">There&#160;was&#160;no&#160;evidence&#160;of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft361">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft361">oral&#160;doses&#160;of&#160;irbesartan&#160;causing&#160;some&#160;parental&#160;toxicity&#160;(from&#160;50 to&#160;650&#160;mg/kg/day), including&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft361">mortality at&#160;the&#160;highest&#160;dose. No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft361">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft361">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and&#160;rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft361">Irbesartan is&#160;excreted&#160;in&#160;the&#160;milk of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft361">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft361">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft361">abortion&#160;or&#160;early&#160;resorption&#160;were&#160;noted&#160;at doses&#160;causing&#160;significant maternal&#160;toxicity,&#160;including&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft361">mortality. No&#160;teratogenic&#160;effects&#160;were&#160;observed&#160;in the&#160;rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft362"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft362"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft362"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft362"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft362"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft361">Microcrystalline&#160;cellulose&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft361">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft361">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft361">Magnesium&#160;stearate&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft361">Colloidal&#160;hydrated&#160;silica&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft361">Pregelatinized&#160;maize starch&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft361">Poloxamer&#160;188&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft361">&#160;</p>
</div>
<!-- Page 37 -->
<a name="37"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page37-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft370">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft370">37&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft372"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft371">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft372"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft371">3&#160;years.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft372"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft371">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft372"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft371">Cartons&#160;of&#160;14&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft371">Cartons&#160;of&#160;28&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft371">Cartons&#160;of&#160;56&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft371">Cartons&#160;of&#160;98&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft371">Cartons&#160;of&#160;56&#160;x&#160;1&#160;tablet&#160;in&#160;PVC/PVDC/Aluminium&#160;perforated&#160;unit dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft371">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft372"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft371">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft371">requirements.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft372"><b>7.&#160;</b></p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft372"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft371">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft371">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft371">94250 Gentilly&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft371">France&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft372"><b>8.&#160;</b></p>
<p style="position:absolute;top:747px;left:149px;white-space:nowrap" class="ft372"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft371">EU/1/97/049/007-009&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft371">EU/1/97/049/012&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft371">EU/1/97/049/015&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft372"><b>9.&#160;</b></p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft372"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft372"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft371">Date of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft371">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft372"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft371">Detailed&#160;information&#160;on&#160;this&#160;medicinal product&#160;is&#160;available&#160;on&#160;the&#160;website&#160;of&#160;the&#160;European Medicines&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft371">Agency http://www.ema.europa.eu&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft371">&#160;</p>
</div>
<!-- Page 38 -->
<a name="38"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page38-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft380">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft380">38&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft382"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft382"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft381">Karvea&#160;75&#160;mg&#160;film-coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft382"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft382"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft381">Each&#160;film-coated&#160;tablet&#160;contains&#160;75&#160;mg&#160;of&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft381">Excipient&#160;with known&#160;effect:&#160;25.50&#160;mg&#160;of&#160;lactose&#160;monohydrate&#160;per&#160;film-coated tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft381">For&#160;the&#160;full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft382"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft382"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft381">Film-coated&#160;tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft381">White&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and the&#160;number&#160;2871&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft381">engraved&#160;on the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft382"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft382"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft382"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft381">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft381">It&#160;is also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients with&#160;hypertension&#160;and&#160;type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft381">diabetes mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive medicinal&#160;product&#160;regimen&#160;(see sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft381">and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft382"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft382"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft381">Posology&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft381">The usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is 150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft381">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg&#160;once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft381">75 mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft381">patients&#160;and in&#160;the&#160;elderly over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft381">In&#160;patients&#160;insufficiently controlled with 150 mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft381">300 mg, or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft381">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft381">effect&#160;with&#160;Karvea&#160;(see&#160;section 4.5).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft381">In&#160;hypertensive&#160;type&#160;2 diabetic&#160;patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft381">and titrated up to&#160;300&#160;mg&#160;once daily&#160;as&#160;the&#160;preferred&#160;maintenance dose&#160;for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft381">The&#160;demonstration of&#160;renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2&#160;diabetic&#160;patients is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft381">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition&#160;to&#160;other&#160;antihypertensive agents,&#160;as needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft381">target&#160;blood&#160;pressure (see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft381">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft383"><i>Renal&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft381">No dosage&#160;adjustment&#160;is&#160;necessary&#160;in patients&#160;with&#160;impaired renal&#160;function. A&#160;lower&#160;starting dose&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft381">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft381">&#160;</p>
</div>
<!-- Page 39 -->
<a name="39"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page39-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft390">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft390">39&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft393"><i>Hepatic&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft391">No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;mild to&#160;moderate&#160;hepatic&#160;impairment. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft391">clinical&#160;experience&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft393"><i>Older people</i>&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft391">Although consideration should be&#160;given to initiating therapy with 75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft391">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft393"><i>Paediatric&#160;population</i>&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft391">The&#160;safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in&#160;children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft391">available data are described&#160;in&#160;section&#160;4.8,&#160;5.1 and&#160;5.2&#160;but&#160;no recommendation on a&#160;posology can&#160;be&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft391">made.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft391">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft391">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft392"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft392"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft391">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in section 6.1.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft391">Second&#160;and third trimesters&#160;of&#160;pregnancy&#160;(see&#160;sections&#160;4.4 and 4.6).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft391">&#160;The concomitant&#160;use&#160;of&#160;Karvea with&#160;aliskiren-containing products&#160;is&#160;contraindicated in patients&#160;with&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft391">diabetes&#160;mellitus&#160;or&#160;renal impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft391">sections 4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft392"><b>&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft392"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft392"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft391">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the&#160;first&#160;dose, may occur&#160;in&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft391">patients&#160;who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy, dietary&#160;salt&#160;restriction,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft391">diarrhoea&#160;or&#160;vomiting. Such conditions&#160;should be&#160;corrected&#160;before&#160;the&#160;administration of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft391">Renovascular&#160;hypertension:&#160;there&#160;is&#160;an&#160;increased&#160;risk of&#160;severe&#160;hypotension&#160;and&#160;renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft391">when patients&#160;with&#160;bilateral&#160;renal&#160;artery&#160;stenosis or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft391">are treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this is&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft391">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft391">antagonists.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft391">Renal&#160;impairment&#160;and kidney&#160;transplantation:&#160;when&#160;Karvea&#160;is used&#160;in&#160;patients with&#160;impaired&#160;renal&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft391">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and creatinine&#160;serum&#160;levels&#160;is&#160;recommended. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft391">experience&#160;regarding the&#160;administration of&#160;Karvea&#160;in&#160;patients with&#160;a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft391">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft391">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in&#160;the&#160;study&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft391">with&#160;patients with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared less&#160;favourable&#160;in&#160;women and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft391">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft391">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft391">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;there&#160;is evidence&#160;that&#160;the&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft391">concomitant&#160;use&#160;of ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;increases&#160;the&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft391">hypotension, hyperkalaemia&#160;and decreased renal&#160;function (including acute&#160;renal&#160;failure).&#160;Dual&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft391">blockade&#160;of&#160;RAAS&#160;through&#160;the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft391">aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1). &#160;If&#160;dual&#160;blockade&#160;therapy is&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft391">considered absolutely necessary,&#160;this&#160;should only occur&#160;under&#160;specialist&#160;supervision and subject&#160;to&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft391">frequent&#160;close&#160;monitoring of&#160;renal&#160;function, electrolytes&#160;and blood&#160;pressure. ACE-inhibitors&#160;and&#160;</p>
</div>
<!-- Page 40 -->
<a name="40"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page40-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft400">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft400">40&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft401">angiotensin II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used&#160;concomitantly&#160;in patients&#160;with&#160;diabetic&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft401">nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft401">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft401">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment&#160;with Karvea,&#160;especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft401">impairment,&#160;overt&#160;proteinuria&#160;due&#160;to&#160;diabetic&#160;renal&#160;disease, and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft401">serum&#160;potassium&#160;in&#160;patients&#160;at&#160;risk&#160;is&#160;recommended&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft401">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft401">treated&#160;with insulin or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft401">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft401">Lithium:&#160;the&#160;combination&#160;of&#160;lithium and&#160;Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft401">Aortic&#160;and mitral&#160;valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy:&#160;as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft401">special&#160;caution is&#160;indicated&#160;in patients&#160;suffering from&#160;aortic&#160;or&#160;mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft401">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft401">Primary aldosteronism: patients&#160;with&#160;primary&#160;aldosteronism generally&#160;will not&#160;respond&#160;to&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft401">antihypertensive&#160;medicinal&#160;products&#160;acting&#160;through inhibition&#160;of&#160;the&#160;renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft401">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft401">General:&#160;in&#160;patients whose&#160;vascular&#160;tone and renal&#160;function depend predominantly on the&#160;activity of&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft401">the renin-angiotensin-aldosterone&#160;system&#160;(e.g.&#160;patients with severe&#160;congestive&#160;heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft401">underlying renal&#160;disease,&#160;including renal&#160;artery stenosis),&#160;treatment with&#160;angiotensin</p>
<p style="position:absolute;top:538px;left:663px;white-space:nowrap" class="ft402"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft401">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II&#160;receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft401">with acute&#160;hypotension,&#160;azotaemia,&#160;oliguria,&#160;or&#160;rarely&#160;acute&#160;renal&#160;failure&#160;(see section 4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft401">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease&#160;in patients&#160;with ischaemic&#160;cardiopathy or&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft401">ischaemic&#160;cardiovascular&#160;disease could&#160;result&#160;in&#160;a myocardial infarction or&#160;stroke.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft401">As&#160;observed for&#160;angiotensin&#160;converting enzyme&#160;inhibitors, irbesartan&#160;and&#160;the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft401">antagonists are apparently&#160;less&#160;effective&#160;in&#160;lowering&#160;blood pressure&#160;in black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft401">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states&#160;in&#160;the&#160;black hypertensive&#160;population&#160;(see&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft401">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft401">Pregnancy:&#160;angiotensin&#160;II Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should&#160;not&#160;be&#160;initiated during pregnancy.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft401">Unless&#160;continued AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy&#160;should be&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft401">changed to&#160;alternative&#160;antihypertensive&#160;treatments&#160;which&#160;have an&#160;established&#160;safety&#160;profile&#160;for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft401">pregnancy. When&#160;pregnancy is&#160;diagnosed, treatment&#160;with&#160;AIIRAs&#160;should be&#160;stopped immediately,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft401">and, if&#160;appropriate, alternative&#160;therapy should be&#160;started&#160;(see&#160;sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft401">Paediatric&#160;population: irbesartan has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old&#160;but&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft401">the current&#160;data are&#160;insufficient&#160;to&#160;support&#160;an&#160;extension&#160;of&#160;the use in&#160;children&#160;until&#160;further&#160;data become&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft401">available (see&#160;sections&#160;4.8, 5.1&#160;and&#160;5.2).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft401">Excipients:&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft401">Karvea&#160;75 mg&#160;film-coated&#160;tablet&#160;contains&#160;lactose.&#160;Patients&#160;with rare&#160;hereditary&#160;problems&#160;of&#160;galactose&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft401">intolerance,&#160;total&#160;lactase&#160;deficiency&#160;or&#160;glucose-galactose&#160;malabsorption&#160;should not&#160;take this&#160;medicine.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft401">Karvea&#160;75 mg&#160;film-coated&#160;tablet&#160;contains&#160;sodium.&#160;This&#160;medicine&#160;contains&#160;less&#160;than 1 mmol&#160;sodium&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft401">(23 mg)&#160;per&#160;tablet,&#160;that&#160;is to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft401">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft402"><b>4.5&#160;&#160;Interaction&#160;with&#160;other&#160;medicinal&#160;products and&#160;other forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft402"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft401">Diuretics&#160;and other&#160;antihypertensive agents:&#160;other&#160;antihypertensive&#160;agents&#160;may&#160;increase the&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft401">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has been&#160;safely&#160;administered&#160;with other&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft401">antihypertensive agents,&#160;such&#160;as&#160;beta-blockers, long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
</div>
<!-- Page 41 -->
<a name="41"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page41-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft410">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft410">41&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft411">diuretics.&#160;Prior&#160;treatment&#160;with&#160;high&#160;dose&#160;diuretics&#160;may&#160;result&#160;in volume&#160;depletion&#160;and a&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft411">hypotension&#160;when initiating&#160;therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft411">Aliskiren-containing products&#160;or&#160;ACE-inhibitors:&#160;clinical trial&#160;data has shown&#160;that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft411">the renin-angiotensin-aldosterone system&#160;(RAAS)&#160;through&#160;the&#160;combined&#160;use&#160;of&#160;ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft411">angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is&#160;associated&#160;with&#160;a higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft411">such as&#160;hypotension, hyperkalaemia&#160;and&#160;decreased renal&#160;function&#160;(including acute&#160;renal&#160;failure)&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft411">compared to&#160;the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft411">Potassium&#160;supplements and&#160;potassium-sparing diuretics:<i>&#160;</i>based&#160;on&#160;experience with&#160;the use of&#160;other&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft411">medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin system, concomitant&#160;use&#160;of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft411">diuretics,&#160;potassium&#160;supplements,&#160;salt&#160;substitutes containing&#160;potassium or&#160;other&#160;medicinal products&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft411">that&#160;may&#160;increase serum&#160;potassium&#160;levels&#160;(e.g.&#160;heparin)&#160;may&#160;lead&#160;to&#160;increases&#160;in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft411">is,&#160;therefore,&#160;not&#160;recommended&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft411">Lithium:<i>&#160;</i>reversible increases in&#160;serum&#160;lithium&#160;concentrations&#160;and&#160;toxicity have&#160;been reported during&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft411">concomitant administration&#160;of&#160;lithium with&#160;angiotensin&#160;converting&#160;enzyme&#160;inhibitors.&#160;Similar&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft411">have&#160;been very&#160;rarely reported with&#160;irbesartan&#160;so far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft411">(see&#160;section&#160;4.4). If&#160;the&#160;combination proves&#160;necessary,&#160;careful&#160;monitoring of&#160;serum&#160;lithium&#160;levels&#160;is&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft411">recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft413"><i>&#160;</i></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft411">Non-steroidal&#160;anti-inflammatory drugs:&#160;when angiotensin&#160;II&#160;antagonists are administered&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft411">simultaneously with non-steroidal&#160;anti-inflammatory drugs (i.e.&#160;selective COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft411">acetylsalicylic&#160;acid&#160;(&gt;&#160;3 g/day)&#160;and non-selective&#160;NSAIDs), attenuation&#160;of&#160;the&#160;antihypertensive effect&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft411">may&#160;occur.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft411">As&#160;with&#160;ACE&#160;inhibitors,&#160;concomitant&#160;use&#160;of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs may&#160;lead&#160;to&#160;an&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft411">increased&#160;risk of&#160;worsening of&#160;renal&#160;function,&#160;including possible&#160;acute&#160;renal&#160;failure, and&#160;an increase&#160;in&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft411">serum&#160;potassium,&#160;especially&#160;in&#160;patients&#160;with poor&#160;pre-existing renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft411">be&#160;administered with&#160;caution, especially in the&#160;elderly.&#160;Patients&#160;should&#160;be&#160;adequately hydrated and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft411">consideration&#160;should be&#160;given to&#160;monitoring renal&#160;function&#160;after&#160;initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft411">periodically thereafter.<i><b>&#160;</b></i></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft411">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it was&#160;reported that&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft411">irbesartan&#160;increased&#160;the Cmax&#160;and AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1)&#160;by&#160;1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft411">1.3-fold,&#160;respectively, when administered 1 hour&#160;before&#160;repaglinide. In another&#160;study,&#160;no relevant&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft411">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two drugs&#160;were&#160;co-administered.&#160;Therefore,&#160;dose&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft411">adjustment of&#160;antidiabetic&#160;treatment&#160;such as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section 4.4).&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft411">Additional&#160;information on irbesartan&#160;interactions:&#160;in clinical&#160;studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft411">is&#160;not&#160;affected by hydrochlorothiazide.&#160;Irbesartan&#160;is&#160;mainly&#160;metabolised&#160;by&#160;CYP2C9&#160;and&#160;to&#160;a&#160;lesser&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft411">extent&#160;by glucuronidation. No&#160;significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic interactions&#160;were&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft411">observed&#160;when&#160;irbesartan&#160;was coadministered&#160;with&#160;warfarin,&#160;a&#160;medicinal product&#160;metabolised by&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft411">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such as&#160;rifampicin on&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft411">have&#160;not&#160;been evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin&#160;was&#160;not&#160;altered&#160;by&#160;coadministration&#160;of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft411">irbesartan.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft412"><b>4.6&#160;&#160;Fertility, pregnancy&#160;and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft412"><b>&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft411">Pregnancy&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft411">The&#160;use&#160;of&#160;AIIRAs is not&#160;recommended&#160;during&#160;the first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft411">use&#160;of&#160;AIIRAs&#160;is&#160;contraindicated during&#160;the&#160;second and&#160;third&#160;trimesters&#160;of&#160;pregnancy&#160;(see sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft411">and 4.4).&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft411">&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft411">Epidemiological&#160;evidence&#160;regarding the&#160;risk&#160;of&#160;teratogenicity following&#160;exposure&#160;to ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft411">during&#160;the&#160;first trimester&#160;of&#160;pregnancy&#160;has not been conclusive;&#160;however&#160;a&#160;small&#160;increase in&#160;risk&#160;</p>
</div>
<!-- Page 42 -->
<a name="42"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page42-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft420">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft420">42&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft421">cannot&#160;be&#160;excluded.&#160;Whilst&#160;there&#160;is&#160;no&#160;controlled&#160;epidemiological data&#160;on the&#160;risk&#160;with Angiotensin&#160;II&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft421">Receptor&#160;Antagonists&#160;(AIIRAs),&#160;similar&#160;risks&#160;may exist&#160;for&#160;this&#160;class&#160;of&#160;drugs.&#160;Unless&#160;continued&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft421">AIIRA therapy&#160;is considered&#160;essential,&#160;patients&#160;planning pregnancy&#160;should be&#160;changed to&#160;alternative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft421">antihypertensive&#160;treatments&#160;which have&#160;an&#160;established&#160;safety&#160;profile&#160;for&#160;use&#160;in pregnancy.&#160;When&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft421">pregnancy&#160;is diagnosed,&#160;treatment&#160;with&#160;AIIRAs should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft421">alternative&#160;therapy should&#160;be&#160;started.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft421">Exposure&#160;to AIIRA&#160;therapy&#160;during the&#160;second&#160;and&#160;third&#160;trimesters&#160;is&#160;known to induce&#160;human&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft421">fetotoxicity&#160;(decreased renal&#160;function, oligohydramnios, skull&#160;ossification&#160;retardation)&#160;and&#160;neonatal&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft421">toxicity&#160;(renal failure,&#160;hypotension, hyperkalaemia). (See section&#160;5.3).&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft421">Should&#160;exposure&#160;to AIIRAs&#160;have&#160;occurred&#160;from&#160;the&#160;second trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft421">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft421">Infants&#160;whose&#160;mothers have taken AIIRAs&#160;should be&#160;closely observed&#160;for&#160;hypotension (see&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft421">sections&#160;4.3 and&#160;4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft421">Breast-feeding&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft421">Because&#160;no information is&#160;available regarding the&#160;use&#160;of&#160;Karvea&#160;during breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft421">recommended&#160;and&#160;alternative treatments with&#160;better&#160;established&#160;safety&#160;profiles&#160;during&#160;breast-feeding&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft421">are preferable,&#160;especially while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft421">It&#160;is&#160;unknown whether irbesartan&#160;or its&#160;metabolites&#160;are&#160;excreted&#160;in human milk.&#160;&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft421">Available&#160;pharmacodynamic/toxicological&#160;data&#160;in rats&#160;have&#160;shown excretion&#160;of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft421">metabolites&#160;in&#160;milk&#160;(for&#160;details&#160;see&#160;5.3).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft421">Fertility&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft421">Irbesartan had no effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their&#160;offspring up&#160;to&#160;the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft421">the&#160;first&#160;signs of&#160;parental&#160;toxicity&#160;(see section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft422"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use machines&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft422"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft421">Based&#160;on&#160;its pharmacodynamic&#160;properties,&#160;irbesartan is&#160;unlikely to&#160;affect&#160;the&#160;ability&#160;to drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft421">machines. When driving&#160;vehicles&#160;or&#160;operating&#160;machines, it&#160;should be&#160;taken&#160;into account&#160;that&#160;dizziness&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft421">or&#160;weariness&#160;may occur&#160;during treatment.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft422"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft422"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft421">In&#160;placebo-controlled&#160;trials&#160;in patients&#160;with hypertension,&#160;the&#160;overall&#160;incidence&#160;of&#160;adverse&#160;events&#160;did&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft421">not&#160;differ&#160;between&#160;the&#160;irbesartan (56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation&#160;due&#160;to&#160;any&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft421">clinical&#160;or&#160;laboratory&#160;adverse event&#160;was less&#160;frequent&#160;for&#160;irbesartan-treated patients&#160;(3.3%)&#160;than&#160;for&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft421">placebo-treated&#160;patients&#160;(4.5%).&#160;The&#160;incidence of&#160;adverse events was not&#160;related&#160;to&#160;dose&#160;(in&#160;the&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft421">recommended dose&#160;range),&#160;gender, age, race,&#160;or&#160;duration&#160;of&#160;treatment.&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft421">In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;renal&#160;function, orthostatic&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft421">dizziness and orthostatic&#160;hypotension were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft421">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft421">The&#160;following table presents the&#160;adverse drug&#160;reactions&#160;that&#160;were&#160;reported&#160;in placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft421">in which 1,965 hypertensive&#160;patients received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a&#160;star (*) refer to&#160;the&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft421">adverse reactions that&#160;were additionally&#160;reported&#160;in &gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft421">chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria and&#160;in&#160;excess&#160;of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft421">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft421">The&#160;frequency of&#160;adverse reactions listed&#160;below&#160;is&#160;defined using&#160;the&#160;following convention:&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft426">very&#160;common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100 to&#160;&lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft426">(≥&#160;1/10,000 to &lt;&#160;1/1,000);&#160;very rare&#160;(&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft421">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
</div>
<!-- Page 43 -->
<a name="43"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page43-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft430">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft430">43&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft431">Adverse&#160;reactions&#160;additionally&#160;reported from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft431">reactions&#160;are&#160;derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft432"><b>&#160;</b></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft431">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft431">Immune&#160;system disorders&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft431">hypersensitivity&#160;reactions such&#160;as&#160;angioedema,&#160;rash,&#160;urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft431">anaphylactic shock&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft431">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft435"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft431">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft431">Common:&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft431">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft431">vertigo, headache&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft431">Ear&#160;and&#160;labyrinth disorder&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:444px;left:213px;white-space:nowrap" class="ft431">tinnitus&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft431">Cardiac disorders&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft431">Vascular&#160;disorders&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft431">Common:&#160;</p>
<p style="position:absolute;top:558px;left:214px;white-space:nowrap" class="ft431">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;flushing&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft431">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft431">Gastrointestinal&#160;disorders&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft431">Common:&#160;</p>
<p style="position:absolute;top:690px;left:214px;white-space:nowrap" class="ft431">nausea/vomiting&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:728px;left:214px;white-space:nowrap" class="ft431">dysgeusia&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft431">Hepatobiliary disorders&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:804px;left:213px;white-space:nowrap" class="ft431">hepatitis,&#160;abnormal&#160;liver&#160;function&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft431">Skin and subcutaneous&#160;tissue&#160;disorders&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:861px;left:213px;white-space:nowrap" class="ft431">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft431">Musculoskeletal&#160;and&#160;connective tissue disorders&#160;&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft431">Common:&#160;</p>
<p style="position:absolute;top:918px;left:214px;white-space:nowrap" class="ft431">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:937px;left:214px;white-space:nowrap" class="ft431">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;</p>
<p style="position:absolute;top:956px;left:214px;white-space:nowrap" class="ft431">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft431">Renal&#160;and urinary disorders&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft431">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1013px;left:213px;white-space:nowrap" class="ft431">&#160;impaired&#160;renal function&#160;including&#160;cases of&#160;renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1032px;left:214px;white-space:nowrap" class="ft431">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft431">Reproductive&#160;system&#160;and breast&#160;disorders&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft431">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft431">&#160;</p>
</div>
<!-- Page 44 -->
<a name="44"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page44-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft440">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft440">44&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft441">General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft441">Common:&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft441">fatigue&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft441">Uncommon:&#160;&#160;chest&#160;pain&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft441">Investigations&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft441">Very common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:197px;left:214px;white-space:nowrap" class="ft441">with placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft446">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in&#160;29.4%&#160;of&#160;the patients in&#160;the&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft441">irbesartan&#160;300&#160;mg group&#160;and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft441">hypertensive&#160;patients&#160;with chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft446">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft441">and 26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo&#160;group.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft441">Common:&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft441">significant&#160;increases&#160;in&#160;plasma creatine kinase were commonly&#160;observed&#160;(1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft441">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft441">clinical&#160;musculoskeletal&#160;events.&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft441">In 1.7%&#160;of&#160;hypertensive patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft441">irbesartan, a&#160;decrease&#160;in&#160;haemoglobin*, which was&#160;not&#160;clinically significant, has&#160;been&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft441">observed.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft443"><i>&#160;</i></p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft441">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft441">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive&#160;children&#160;and adolescents&#160;aged&#160;6 to&#160;16&#160;years, the&#160;following&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft441">adverse&#160;reactions occurred&#160;in&#160;the 3-week double-blind&#160;phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft441">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft441">laboratory&#160;abnormalities&#160;observed&#160;were creatinine&#160;increases (6.5%)&#160;and&#160;elevated&#160;CK&#160;values in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft441">child recipients.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft441">Reporting&#160;of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft441">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;It&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft441">allows&#160;continued monitoring of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft441">professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft441">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft442"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft442"><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft441">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up to 900&#160;mg/day for&#160;8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft441">likely manifestations&#160;of&#160;overdose&#160;are&#160;expected to&#160;be&#160;hypotension&#160;and tachycardia;&#160;bradycardia&#160;might&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft441">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose&#160;with&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft441">Karvea.&#160;The&#160;patient&#160;should&#160;be&#160;closely&#160;monitored,&#160;and&#160;the&#160;treatment&#160;should be&#160;symptomatic&#160;and&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft441">supportive.&#160;Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft441">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose.&#160;Irbesartan&#160;is&#160;not removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft442"><b>5.&#160;</b></p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft442"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft442"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft442"><b>5.1&#160;&#160;Pharmacodynamic&#160;properties&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft442"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft441">Pharmacotherapeutic group:&#160;Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft441">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft441">Mechanism&#160;of&#160;action&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft441">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft441">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective angiotensin-II receptor&#160;(type&#160;AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft441">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated&#160;by&#160;the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft441">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II&#160;(AT1)&#160;receptors&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft441">results in&#160;increases in&#160;plasma&#160;renin&#160;levels and&#160;angiotensin-II&#160;levels,&#160;and&#160;a decrease in&#160;plasma&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft441">aldosterone&#160;concentration.&#160;Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly affected by irbesartan alone&#160;at&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft441">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not&#160;inhibit ACE&#160;(kininase-II),&#160;an&#160;enzyme which&#160;generates&#160;</p>
</div>
<!-- Page 45 -->
<a name="45"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page45-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft450">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft450">45&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft451">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive&#160;metabolites. Irbesartan does&#160;not&#160;require&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft451">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft451">Clinical efficacy</p>
<p style="position:absolute;top:140px;left:216px;white-space:nowrap" class="ft452"><b>&#160;</b></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft452"><b>&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft453"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft451">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change&#160;in&#160;heart&#160;rate.&#160;The decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft451">dose-related for&#160;once-a-day&#160;doses&#160;with&#160;a&#160;tendency&#160;towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft451">150-300&#160;mg once&#160;daily lower&#160;supine&#160;or&#160;seated blood&#160;pressures&#160;at&#160;trough&#160;(i.e.&#160;24 hours&#160;after&#160;dosing)&#160;by&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft451">an&#160;average&#160;of&#160;8-13/5-8&#160;mm&#160;Hg (systolic/diastolic)&#160;greater&#160;than&#160;those&#160;associated with placebo.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft451">Peak reduction of&#160;blood pressure&#160;is&#160;achieved within 3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft451">pressure lowering&#160;effect&#160;is&#160;maintained&#160;for&#160;at&#160;least&#160;24&#160;hours.&#160;At&#160;24&#160;hours&#160;the&#160;reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft451">pressure was 60-70%&#160;of&#160;the&#160;corresponding&#160;peak&#160;diastolic and&#160;systolic responses&#160;at&#160;the&#160;recommended&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft451">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft451">daily dosing&#160;on&#160;the same&#160;total&#160;dose.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft451">The&#160;blood pressure&#160;lowering effect&#160;of&#160;Karvea&#160;is&#160;evident within&#160;1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft451">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft451">term&#160;therapy.&#160;After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft451">hypertension&#160;has&#160;not&#160;been observed.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft451">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan&#160;and&#160;thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft451">not&#160;adequately controlled&#160;by irbesartan alone,&#160;the&#160;addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft451">(12.5&#160;mg)&#160;to&#160;irbesartan&#160;once daily&#160;results in&#160;a&#160;further&#160;placebo-adjusted blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft451">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft451">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender.&#160;As is the&#160;case with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft451">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin&#160;system,&#160;black&#160;hypertensive patients have&#160;notably&#160;less&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft451">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft451">of&#160;hydrochlorothiazide&#160;(e.g.&#160;12.5 mg daily),&#160;the&#160;antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft451">that&#160;of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft451">There&#160;is&#160;no clinically important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft451">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft451">Reduction of&#160;blood pressure&#160;with&#160;0.5&#160;mg/kg (low),&#160;1.5&#160;mg/kg (medium)&#160;and&#160;4.5&#160;mg/kg (high)&#160;target&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft451">titrated&#160;doses&#160;of&#160;irbesartan&#160;was&#160;evaluated&#160;in 318 hypertensive&#160;or&#160;at&#160;risk (diabetic,&#160;family history of&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft451">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period. At&#160;the&#160;end&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft451">three weeks the&#160;mean&#160;reduction&#160;from&#160;baseline&#160;in the&#160;primary efficacy variable, trough seated&#160;systolic&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft451">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft451">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between&#160;these doses.&#160;Adjusted&#160;mean&#160;change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft451">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as&#160;follows:&#160;3.8&#160;mmHg (low&#160;dose),&#160;3.2&#160;mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft451">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft451">to&#160;either&#160;active&#160;medicinal&#160;product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft451">in SeSBP&#160;and SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively&#160;in&#160;those&#160;on all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft451">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft451">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft453"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft451">The&#160;“Irbesartan&#160;Diabetic Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the progression&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft451">of&#160;renal&#160;disease&#160;in patients&#160;with chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft451">blind, controlled,&#160;morbidity&#160;and mortality trial&#160;comparing&#160;Karvea, amlodipine&#160;and placebo.&#160;In&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft451">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes,&#160;proteinuria&#160;≥&#160;900&#160;mg/day and serum&#160;creatinine&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft451">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft451">renal&#160;disease and&#160;all-cause mortality&#160;were examined.&#160;Patients were titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft451">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft451">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4 antihypertensive&#160;agents&#160;(e.g.,&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft451">diuretics, beta&#160;blockers,&#160;alpha&#160;blockers)&#160;to&#160;reach&#160;a&#160;predefined&#160;blood&#160;pressure goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft451">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft451">patients in&#160;the placebo&#160;group&#160;reached&#160;this&#160;target&#160;blood pressure&#160;whereas this&#160;figure&#160;was&#160;76%&#160;and&#160;78%&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft451">in the&#160;irbesartan&#160;and&#160;amlodipine&#160;groups&#160;respectively. Irbesartan significantly&#160;reduced the&#160;relative&#160;risk&#160;</p>
</div>
<!-- Page 46 -->
<a name="46"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page46-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft460">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft460">46&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft461">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft461">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan group reached&#160;the&#160;primary&#160;renal&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft461">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft461">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft461">(p&#160;=&#160;0.006)]. When&#160;the&#160;individual&#160;components&#160;of&#160;the&#160;primary endpoint&#160;were&#160;analysed, no&#160;effect&#160;in all-</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft461">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft461">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft461">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft461">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration&#160;of&#160;diabetes, baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft461">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft461">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively, a&#160;renal&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft461">benefit&#160;was&#160;not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft461">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft461">in the&#160;overall&#160;population,&#160;although&#160;an&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;for&#160;women and&#160;a&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft461">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft461">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft461">irbesartan-based&#160;regimen&#160;versus the amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft461">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft461">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft461">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft461">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive&#160;Patients&#160;with type&#160;2&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft461">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft461">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind&#160;morbidity&#160;study in&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft461">590&#160;patients&#160;with&#160;type&#160;2 diabetes, microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft461">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft461">effects (2&#160;years) of&#160;Karvea&#160;on the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary albumin&#160;excretion&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft461">rate&#160;(UAER) &gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft466">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft461">inhibitors, angiotensin&#160;II&#160;receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft461">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft461">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg&#160;group (5.2%)&#160;than in the&#160;placebo (14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft461">in the&#160;irbesartan&#160;150&#160;mg group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft461">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft461">improvement&#160;in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not observed&#160;during&#160;the&#160;first three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft461">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft461">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft461">frequent&#160;in the&#160;Karvea&#160;300&#160;mg&#160;group (34%)&#160;than in&#160;the&#160;placebo group&#160;(21%).&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft461">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft463"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft461">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft461">combination with Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;VA NEPHRON-D&#160;(The Veterans Affairs&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft461">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft461">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft461">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type 2&#160;diabetes&#160;mellitus&#160;accompanied&#160;by evidence&#160;of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft461">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft461">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft461">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft461">These&#160;studies have shown&#160;no&#160;significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft461">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft461">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft461">results&#160;are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and angiotensin&#160;II&#160;receptor&#160;blockers.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft461">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft461">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft461">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft461">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using&#160;Cardiovascular&#160;and Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft461">was a study&#160;designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft461">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
</div>
<!-- Page 47 -->
<a name="47"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page47-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft470">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft470">47&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft471">disease,&#160;cardiovascular&#160;disease, or&#160;both. The&#160;study was&#160;terminated&#160;early&#160;because of&#160;an&#160;increased&#160;risk&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft471">of&#160;adverse&#160;outcomes. Cardiovascular&#160;death&#160;and stroke&#160;were&#160;both numerically&#160;more&#160;frequent&#160;in the&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft471">aliskiren&#160;group that&#160;in&#160;the&#160;placebo group and adverse&#160;events&#160;and&#160;serious&#160;adverse&#160;events&#160;of&#160;interest&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft471">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft471">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft472"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft472"><b>&#160;</b></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft471">Absorption&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft471">After&#160;oral&#160;administration,&#160;irbesartan&#160;is&#160;well absorbed:&#160;studies&#160;of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft471">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft471">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft471">Distribution&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft471">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft471">The&#160;volume&#160;of&#160;distribution is&#160;53&#160;-&#160;93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft471">Biotransformation&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft471">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft471">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft471">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft471">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft471">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft471">Linearity/non-linearity&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft471">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft471">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft471">recommended&#160;dose)&#160;was observed;&#160;the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft471">are&#160;attained at&#160;1.5&#160;-&#160;2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and&#160;renal&#160;clearance&#160;are&#160;157 -</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft471">&#160;176&#160;and 3&#160;-&#160;3.5&#160;ml/min,&#160;respectively.&#160;The&#160;terminal&#160;elimination&#160;half-life of&#160;irbesartan&#160;is 11&#160;-&#160;15&#160;hours.&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft471">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft471">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft471">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft471">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft471">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft471">were also&#160;somewhat&#160;greater in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18&#160;-&#160;40&#160;years).&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft471">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft471">older&#160;people.&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft471">Elimination&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:957px;left:106px;white-space:nowrap" class="ft471">Irbesartan&#160;and&#160;its metabolites are eliminated&#160;by&#160;both&#160;biliary&#160;and renal&#160;pathways. After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft471">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft471">remainder&#160;in&#160;the&#160;faeces.&#160;Less than&#160;2%&#160;of&#160;the dose is excreted&#160;in&#160;the urine as&#160;unchanged&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft471">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft471">&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft471">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft471">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft471">four&#160;weeks. Of&#160;those&#160;23 children, 21 were&#160;evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft471">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:1149px;left:106px;white-space:nowrap" class="ft471">and clearance&#160;rates&#160;were&#160;comparable&#160;to those&#160;observed&#160;in adult&#160;patients&#160;receiving&#160;150&#160;mg&#160;irbesartan&#160;</p>
</div>
<!-- Page 48 -->
<a name="48"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page48-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft480">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft480">48&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft481">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft481">dosing.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft481">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft481">In&#160;patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft481">of&#160;irbesartan are&#160;not&#160;significantly altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft481">Hepatic impairment&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft481">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft481">significantly&#160;altered.&#160;&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft481">Studies&#160;have&#160;not&#160;been performed in&#160;patients&#160;with&#160;severe&#160;hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft482"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft482"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft481">There&#160;was&#160;no evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft481">non-clinical&#160;safety&#160;studies,&#160;high&#160;doses&#160;of&#160;irbesartan&#160;(≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft481">macaques)&#160;caused a&#160;reduction of&#160;red blood&#160;cell&#160;parameters&#160;(erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft486">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative&#160;changes&#160;in&#160;the kidney&#160;(such&#160;as interstitial&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft481">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft481">creatinine)&#160;were&#160;induced by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft481">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft486">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft486">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft481">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft481">hypertrophy&#160;of&#160;the renal&#160;juxtaglomerular&#160;cells does not&#160;appear&#160;to&#160;have&#160;any&#160;relevance.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft481">There&#160;was&#160;no&#160;evidence&#160;of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft481">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft481">oral&#160;doses&#160;of&#160;irbesartan&#160;causing&#160;some&#160;parental&#160;toxicity&#160;(from&#160;50 to&#160;650&#160;mg/kg/day), including&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft481">mortality at&#160;the&#160;highest&#160;dose. No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft481">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft481">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and&#160;rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft481">Irbesartan is&#160;excreted&#160;in&#160;the&#160;milk of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft481">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft481">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft481">abortion&#160;or&#160;early resorption&#160;were&#160;noted at&#160;doses&#160;causing&#160;significant&#160;maternal&#160;toxicity, including&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft481">mortality. No&#160;teratogenic&#160;effects&#160;were&#160;observed&#160;in the&#160;rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft482"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft482"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft482"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft482"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft482"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft481">Tablet&#160;core:&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft481">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft481">Microcrystalline&#160;cellulose&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft481">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft481">Hypromellose&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft481">Silicon dioxide&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft481">Magnesium&#160;stearate.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft481">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft481">Film-coating:&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft481">Lactose&#160;monohydrate&#160;</p>
</div>
<!-- Page 49 -->
<a name="49"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page49-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft490">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft490">49&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft491">Hypromellose&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft491">Titanium dioxide&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft491">Macrogol&#160;3000&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft491">Carnauba wax.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft492"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft491">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft492"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft491">3&#160;years.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft492"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft491">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft492"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;14&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;28&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;30&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;56&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;84&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;90&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;98&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft491">Cartons&#160;of&#160;56&#160;x&#160;1&#160;film-coated tablet&#160;in PVC/PVDC/Aluminium&#160;perforated&#160;unit&#160;dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft491">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft492"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft491">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft491">requirements.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft492"><b>7.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft492"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft491">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft491">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft491">94250 Gentilly&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft491">France&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft492"><b>8.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft492"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft491">EU/1/97/049/016-020&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft491">EU/1/97/049/031&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft491">EU/1/97/049/034&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft491">EU/1/97/049/037&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft492"><b>9.&#160;</b></p>
<p style="position:absolute;top:1050px;left:149px;white-space:nowrap" class="ft492"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft492"><b>&#160;</b></p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft491">Date&#160;of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft491">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft491">&#160;</p>
</div>
<!-- Page 50 -->
<a name="50"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page50-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft500">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft500">50&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft502"><b>10.&#160;&#160;DATE&#160;OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft501">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft501">Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is available&#160;on&#160;the website of&#160;the European&#160;Medicines&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft501">Agency http://www.ema.europa.eu&#160;</p>
</div>
<!-- Page 51 -->
<a name="51"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page51-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft510">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft510">51&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft512"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft512"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft511">Karvea&#160;150&#160;mg&#160;film-coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft512"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft512"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft511">Each&#160;film-coated&#160;tablet&#160;contains&#160;150&#160;mg&#160;of irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft511">Excipient&#160;with known&#160;effect:&#160;51.00&#160;mg&#160;of&#160;lactose&#160;monohydrate&#160;per&#160;film-coated tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft511">For&#160;the full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft512"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft512"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft511">Film-coated&#160;tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft511">White to off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and&#160;the&#160;number&#160;2872&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft511">engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft512"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft512"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft512"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft511">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft511">It&#160;is also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients&#160;with&#160;hypertension and type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft511">diabetes mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive medicinal&#160;product&#160;regimen&#160;(see&#160;sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft511">and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft512"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft512"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft511">Posology&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft511">The usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is&#160;150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft511">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg&#160;once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft511">75 mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft511">patients and&#160;in&#160;the&#160;elderly over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft511">In patients&#160;insufficiently controlled with 150 mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft511">300 mg, or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft511">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft511">effect&#160;with&#160;Karvea&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft511">In&#160;hypertensive&#160;type&#160;2 diabetic&#160;patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg&#160;irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft511">and titrated up to&#160;300&#160;mg once&#160;daily as&#160;the&#160;preferred&#160;maintenance&#160;dose for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft511">The&#160;demonstration of&#160;renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2&#160;diabetic&#160;patients is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft511">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition to other&#160;antihypertensive&#160;agents, as&#160;needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft511">target&#160;blood&#160;pressure (see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft511">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft513"><i>Renal&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft511">No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;patients with&#160;impaired&#160;renal&#160;function.&#160;A&#160;lower&#160;starting dose&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft511">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft511">&#160;</p>
</div>
<!-- Page 52 -->
<a name="52"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page52-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft520">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft520">52&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft523"><i>Hepatic&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft521">No dosage&#160;adjustment&#160;is&#160;necessary&#160;in patients&#160;with&#160;mild to&#160;moderate&#160;hepatic&#160;impairment. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft521">clinical&#160;experience in&#160;patients&#160;with&#160;severe&#160;hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft523"><i>Older people</i>&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft521">Although consideration should be&#160;given to initiating therapy&#160;with 75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft521">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft523"><i>Paediatric&#160;population</i>&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft521">The safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in&#160;children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft521">available&#160;data&#160;are&#160;described&#160;in section 4.8, 5.1&#160;and 5.2&#160;but&#160;no&#160;recommendation&#160;on&#160;a&#160;posology&#160;can be&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft521">made.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft521">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft521">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft522"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft522"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft521">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft521">Second&#160;and third trimesters&#160;of&#160;pregnancy&#160;(see&#160;sections&#160;4.4 and 4.6).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft521">The concomitant&#160;use&#160;of&#160;Karvea with&#160;aliskiren-containing products&#160;is&#160;contraindicated in patients&#160;with&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft521">diabetes&#160;mellitus&#160;or&#160;renal impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft521">sections&#160;4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft522"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft522"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft521">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the&#160;first&#160;dose, may occur&#160;in&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft521">patients&#160;who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy,&#160;dietary&#160;salt&#160;restriction,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft521">diarrhoea&#160;or&#160;vomiting. Such conditions&#160;should be&#160;corrected before&#160;the&#160;administration of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft521">Renovascular&#160;hypertension:&#160;there is an&#160;increased&#160;risk&#160;of&#160;severe&#160;hypotension and renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft521">when patients&#160;with&#160;bilateral&#160;renal&#160;artery&#160;stenosis&#160;or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft521">are&#160;treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this&#160;is&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft521">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft521">antagonists.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft521">Renal&#160;impairment&#160;and kidney&#160;transplantation:&#160;when&#160;Karvea&#160;is used&#160;in&#160;patients with&#160;impaired&#160;renal&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft521">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and&#160;creatinine serum&#160;levels&#160;is recommended.&#160;There is&#160;no&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft521">experience&#160;regarding the&#160;administration of&#160;Karvea&#160;in&#160;patients with&#160;a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft521">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft521">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in the&#160;study&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft521">with&#160;patients with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared&#160;less favourable&#160;in&#160;women&#160;and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft521">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft521">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft521">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;there&#160;is&#160;evidence&#160;that&#160;the&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft521">concomitant&#160;use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;increases&#160;the&#160;risk of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft521">hypotension, hyperkalaemia&#160;and decreased renal&#160;function (including acute renal&#160;failure).&#160;Dual&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft521">blockade&#160;of&#160;RAAS&#160;through&#160;the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft521">aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1). &#160;If&#160;dual&#160;blockade&#160;therapy is&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft521">considered&#160;absolutely&#160;necessary,&#160;this&#160;should only occur&#160;under&#160;specialist&#160;supervision and subject&#160;to&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft521">frequent&#160;close&#160;monitoring of&#160;renal&#160;function, electrolytes&#160;and blood&#160;pressure. ACE-inhibitors&#160;and&#160;</p>
</div>
<!-- Page 53 -->
<a name="53"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page53-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft530">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft530">53&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft531">angiotensin II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used&#160;concomitantly&#160;in patients&#160;with&#160;diabetic&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft531">nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft531">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft531">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment&#160;with&#160;Karvea,&#160;especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft531">impairment,&#160;overt&#160;proteinuria&#160;due&#160;to&#160;diabetic&#160;renal&#160;disease, and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft531">serum&#160;potassium&#160;in&#160;patients&#160;at&#160;risk&#160;is&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft531">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft531">treated&#160;with&#160;insulin&#160;or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft531">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft531">Lithium:&#160;the&#160;combination&#160;of&#160;lithium and&#160;Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft531">Aortic&#160;and&#160;mitral&#160;valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy: as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft531">special&#160;caution is&#160;indicated&#160;in patients&#160;suffering from&#160;aortic&#160;or&#160;mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft531">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft531">Primary aldosteronism:&#160;patients&#160;with&#160;primary&#160;aldosteronism&#160;generally will&#160;not&#160;respond to&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft531">antihypertensive&#160;medicinal&#160;products&#160;acting through inhibition&#160;of&#160;the&#160;renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft531">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft531">General:&#160;in&#160;patients whose&#160;vascular&#160;tone and&#160;renal&#160;function depend predominantly on the&#160;activity of&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft531">the renin-angiotensin-aldosterone&#160;system&#160;(e.g.&#160;patients&#160;with severe&#160;congestive&#160;heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft531">underlying renal&#160;disease,&#160;including&#160;renal&#160;artery&#160;stenosis), treatment&#160;with angiotensin</p>
<p style="position:absolute;top:538px;left:663px;white-space:nowrap" class="ft532"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft531">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II&#160;receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft531">with acute&#160;hypotension,&#160;azotaemia,&#160;oliguria,&#160;or&#160;rarely&#160;acute&#160;renal&#160;failure&#160;(see&#160;section 4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft531">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease&#160;in&#160;patients&#160;with ischaemic&#160;cardiopathy or&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft531">ischaemic&#160;cardiovascular&#160;disease could&#160;result in&#160;a&#160;myocardial&#160;infarction or&#160;stroke.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft531">As&#160;observed&#160;for&#160;angiotensin&#160;converting enzyme&#160;inhibitors,&#160;irbesartan and the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft531">antagonists are apparently&#160;less effective in&#160;lowering&#160;blood pressure&#160;in black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft531">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states&#160;in&#160;the&#160;black hypertensive&#160;population (see&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft531">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft531">Pregnancy:&#160;angiotensin&#160;II&#160;Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should not&#160;be&#160;initiated&#160;during pregnancy.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft531">Unless&#160;continued AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy should be&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft531">changed to&#160;alternative&#160;antihypertensive&#160;treatments which&#160;have an&#160;established&#160;safety&#160;profile for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft531">pregnancy.&#160;When&#160;pregnancy is&#160;diagnosed,&#160;treatment&#160;with&#160;AIIRAs&#160;should be&#160;stopped immediately,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft531">and, if&#160;appropriate, alternative&#160;therapy should&#160;be&#160;started&#160;(see&#160;sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft531">Paediatric&#160;population:&#160;irbesartan has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old&#160;but&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft531">the&#160;current&#160;data are&#160;insufficient&#160;to&#160;support&#160;an&#160;extension&#160;of&#160;the use in&#160;children until&#160;further&#160;data&#160;become&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft531">available (see&#160;sections&#160;4.8, 5.1&#160;and&#160;5.2).&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft531">Excipients:&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft531">Karvea&#160;150&#160;mg&#160;film-coated&#160;tablet&#160;contains&#160;lactose.&#160;Patients&#160;with&#160;rare&#160;hereditary problems of&#160;galactose&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft531">intolerance,&#160;total&#160;lactase&#160;deficiency&#160;or&#160;glucose-galactose malabsorption&#160;should not&#160;take&#160;this&#160;medicine.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft531">Karvea&#160;150&#160;mg&#160;fil&#160;-coated&#160;tablet&#160;contains&#160;sodium.&#160;This&#160;medicine&#160;contains&#160;less&#160;than&#160;1&#160;mmol sodium&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft531">(23 mg)&#160;per&#160;tablet,&#160;that&#160;is to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft531">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft532"><b>4.5&#160;&#160;Interaction&#160;with other&#160;medicinal&#160;products&#160;and other&#160;forms&#160;of interaction&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft532"><b>&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft531">Diuretics&#160;and other&#160;antihypertensive agents: other&#160;antihypertensive&#160;agents&#160;may&#160;increase&#160;the&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft531">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has been&#160;safely&#160;administered with&#160;other&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft531">antihypertensive agents,&#160;such&#160;as&#160;beta-blockers,&#160;long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
</div>
<!-- Page 54 -->
<a name="54"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page54-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft540">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft540">54&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft541">diuretics.&#160;Prior&#160;treatment&#160;with&#160;high dose&#160;diuretics&#160;may result&#160;in&#160;volume&#160;depletion and&#160;a&#160;risk of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft541">hypotension when&#160;initiating therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft541">Aliskiren-containing products&#160;or&#160;ACE-inhibitors:&#160;clinical&#160;trial&#160;data&#160;has&#160;shown that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft541">the renin-angiotensin-aldosterone system&#160;(RAAS)&#160;through&#160;the combined&#160;use of&#160;ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft541">angiotensin&#160;II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is&#160;associated&#160;with&#160;a higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft541">such&#160;as&#160;hypotension, hyperkalaemia&#160;and decreased renal&#160;function (including acute&#160;renal&#160;failure)&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft541">compared to&#160;the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft541">Potassium&#160;supplements and&#160;potassium-sparing diuretics:<i>&#160;</i>based&#160;on&#160;experience with the&#160;use of&#160;other&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft541">medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin&#160;system,&#160;concomitant&#160;use&#160;of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft541">diuretics,&#160;potassium&#160;supplements,&#160;salt&#160;substitutes containing&#160;potassium&#160;or&#160;other&#160;medicinal products&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft541">that&#160;may&#160;increase serum&#160;potassium&#160;levels (e.g.&#160;heparin)&#160;may&#160;lead&#160;to&#160;increases&#160;in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft541">is, therefore, not&#160;recommended&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft541">Lithium:<i>&#160;</i>reversible increases in&#160;serum&#160;lithium&#160;concentrations&#160;and&#160;toxicity have&#160;been reported during&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft541">concomitant administration&#160;of&#160;lithium with&#160;angiotensin&#160;converting enzyme&#160;inhibitors. Similar&#160;effects&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft541">have been&#160;very rarely&#160;reported&#160;with irbesartan&#160;so far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft541">(see section&#160;4.4). If&#160;the&#160;combination proves&#160;necessary,&#160;careful&#160;monitoring of&#160;serum&#160;lithium&#160;levels&#160;is&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft541">recommended.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft543"><i>&#160;</i></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft541">Non-steroidal&#160;anti-inflammatory drugs:&#160;when angiotensin&#160;II&#160;antagonists&#160;are&#160;administered&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft541">simultaneously with non-steroidal&#160;anti-inflammatory drugs&#160;(i.e. selective COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft541">acetylsalicylic&#160;acid&#160;(&gt;&#160;3 g/day)&#160;and non-selective NSAIDs), attenuation&#160;of&#160;the&#160;antihypertensive&#160;effect&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft541">may&#160;occur.&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft541">As&#160;with&#160;ACE&#160;inhibitors,&#160;concomitant&#160;use of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs may&#160;lead&#160;to&#160;an&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft541">increased&#160;risk&#160;of&#160;worsening&#160;of&#160;renal&#160;function,&#160;including possible&#160;acute&#160;renal&#160;failure, and&#160;an increase in&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft541">serum&#160;potassium,&#160;especially&#160;in&#160;patients with&#160;poor&#160;pre-existing renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft541">be administered&#160;with&#160;caution,&#160;especially&#160;in&#160;the elderly.&#160;Patients should be&#160;adequately&#160;hydrated and&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft541">consideration should&#160;be&#160;given&#160;to monitoring&#160;renal&#160;function after&#160;initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft541">periodically thereafter.<i><b>&#160;</b></i></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft541">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it&#160;was&#160;reported that&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft541">irbesartan increased&#160;the Cmax&#160;and AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1) by 1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft541">1.3-fold,&#160;respectively, when administered&#160;1 hour&#160;before repaglinide.&#160;In&#160;another&#160;study,&#160;no relevant&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft541">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two&#160;drugs&#160;were co-administered.&#160;Therefore,&#160;dose&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft541">adjustment of&#160;antidiabetic&#160;treatment&#160;such as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft541">Additional&#160;information on irbesartan&#160;interactions:&#160;in clinical&#160;studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft541">is not&#160;affected&#160;by hydrochlorothiazide.&#160;Irbesartan&#160;is mainly&#160;metabolised by CYP2C9 and to a&#160;lesser&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft541">extent&#160;by&#160;glucuronidation.&#160;No significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic interactions&#160;were&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft541">observed when irbesartan&#160;was&#160;coadministered&#160;with warfarin, a&#160;medicinal&#160;product&#160;metabolised by&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft541">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such as&#160;rifampicin on&#160;the&#160;pharmacokinetic of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft541">have&#160;not&#160;been evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin&#160;was&#160;not&#160;altered&#160;by&#160;coadministration&#160;of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft541">irbesartan.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft542"><b>4.6&#160;&#160;Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft542"><b>&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft541">Pregnancy&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft541">The&#160;use&#160;of&#160;AIIRAs is not&#160;recommended&#160;during&#160;the first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft541">use of&#160;AIIRAs is contraindicated during&#160;the&#160;second and&#160;third&#160;trimesters of&#160;pregnancy&#160;(see sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft541">and 4.4).&#160;</p>
<p style="position:absolute;top:1093px;left:106px;white-space:nowrap" class="ft541">&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft541">Epidemiological&#160;evidence&#160;regarding the&#160;risk&#160;of&#160;teratogenicity&#160;following exposure&#160;to&#160;ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft541">during the&#160;first&#160;trimester&#160;of&#160;pregnancy&#160;has not&#160;been&#160;conclusive;&#160;however&#160;a&#160;small&#160;increase in&#160;risk&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft541">cannot&#160;be&#160;excluded.&#160;Whilst&#160;there&#160;is&#160;no&#160;controlled epidemiological&#160;data&#160;on the&#160;risk&#160;with Angiotensin&#160;II&#160;</p>
</div>
<!-- Page 55 -->
<a name="55"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page55-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft550">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft550">55&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft551">Receptor&#160;Antagonists&#160;(AIIRAs), similar&#160;risks may&#160;exist&#160;for&#160;this&#160;class&#160;of&#160;drugs. Unless&#160;continued&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft551">AIIRA&#160;therapy&#160;is considered&#160;essential, patients&#160;planning pregnancy&#160;should be&#160;changed to&#160;alternative&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft551">antihypertensive&#160;treatments&#160;which have&#160;an&#160;established&#160;safety profile&#160;for&#160;use&#160;in pregnancy.&#160;When&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft551">pregnancy&#160;is&#160;diagnosed, treatment&#160;with AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft551">alternative therapy&#160;should&#160;be started.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft551">Exposure&#160;to AIIRA&#160;therapy&#160;during the&#160;second&#160;and&#160;third trimesters&#160;is&#160;known to induce&#160;human&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft551">fetotoxicity&#160;(decreased&#160;renal&#160;function, oligohydramnios, skull&#160;ossification&#160;retardation)&#160;and neonatal&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft551">toxicity&#160;(renal failure,&#160;hypotension, hyperkalaemia).&#160;(See&#160;section&#160;5.3).&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft551">Should&#160;exposure&#160;to AIIRAs&#160;have&#160;occurred&#160;from&#160;the&#160;second&#160;trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft551">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft551">Infants&#160;whose&#160;mothers have taken&#160;AIIRAs should&#160;be closely observed for&#160;hypotension (see&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft551">sections&#160;4.3 and&#160;4.4).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft551">Breast-feeding&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft551">Because&#160;no&#160;information&#160;is available&#160;regarding the&#160;use&#160;of&#160;Karvea&#160;during breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft551">recommended&#160;and&#160;alternative treatments with&#160;better&#160;established&#160;safety&#160;profiles&#160;during breast-feeding&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft551">are preferable, especially while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft551">It&#160;is&#160;unknown whether&#160;irbesartan&#160;or&#160;its&#160;metabolites&#160;are&#160;excreted&#160;in human milk.&#160;&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft551">Available&#160;pharmacodynamic/toxicological&#160;data&#160;in&#160;rats&#160;have&#160;shown excretion of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft551">metabolites&#160;in&#160;milk&#160;(for&#160;details see 5.3).&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft551">Fertility&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft551">Irbesartan had no effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their&#160;offspring up&#160;to&#160;the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft551">the first&#160;signs&#160;of&#160;parental&#160;toxicity&#160;(see&#160;section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft552"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to&#160;drive&#160;and&#160;use machines&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft552"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft551">Based on&#160;its&#160;pharmacodynamic&#160;properties,&#160;irbesartan is&#160;unlikely to&#160;affect&#160;the&#160;ability&#160;to drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft551">machines. When driving&#160;vehicles&#160;or&#160;operating&#160;machines, it&#160;should be&#160;taken into&#160;account&#160;that&#160;dizziness&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft551">or&#160;weariness&#160;may&#160;occur&#160;during treatment.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft552"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft552"><b>&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft551">In placebo-controlled&#160;trials&#160;in patients&#160;with hypertension, the&#160;overall&#160;incidence&#160;of&#160;adverse&#160;events&#160;did&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft551">not&#160;differ&#160;between the&#160;irbesartan (56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation due&#160;to any&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft551">clinical&#160;or&#160;laboratory&#160;adverse event&#160;was less&#160;frequent&#160;for&#160;irbesartan-treated patients&#160;(3.3%)&#160;than&#160;for&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft551">placebo-treated&#160;patients&#160;(4.5%).&#160;The&#160;incidence of&#160;adverse events was not&#160;related to&#160;dose&#160;(in&#160;the&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft551">recommended dose&#160;range),&#160;gender, age, race, or&#160;duration of&#160;treatment.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft551">In&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;renal&#160;function, orthostatic&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft551">dizziness&#160;and orthostatic&#160;hypotension were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft551">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft551">The following&#160;table presents the&#160;adverse&#160;drug&#160;reactions that&#160;were&#160;reported in&#160;placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft551">in which 1,965&#160;hypertensive&#160;patients received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a&#160;star (*) refer to&#160;the&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft551">adverse reactions that&#160;were additionally reported&#160;in&#160;&gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft551">chronic renal&#160;insufficiency and&#160;overt&#160;proteinuria&#160;and in&#160;excess&#160;of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft551">The frequency&#160;of&#160;adverse reactions listed&#160;below is&#160;defined using&#160;the&#160;following convention:&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft556">very&#160;common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100 to&#160;&lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft556">(≥&#160;1/10,000 to &lt;&#160;1/1,000);&#160;very&#160;rare (&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft551">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft551">&#160;</p>
</div>
<!-- Page 56 -->
<a name="56"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page56-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft560">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft560">56&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft561">Adverse&#160;reactions&#160;additionally reported&#160;from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft561">reactions are derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft565"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft561">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft561">Immune&#160;system disorders&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;&#160;&#160;hypersensitivity&#160;reactions such&#160;as angioedema,&#160;rash,&#160;urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft561">anaphylactic shock&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft561">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft562"><b>&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft561">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft561">Common:&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft561">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft561">vertigo, headache&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft561">Ear&#160;and labyrinth disorder&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:425px;left:213px;white-space:nowrap" class="ft561">tinnitus&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft561">Cardiac disorders&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft561">Vascular&#160;disorders&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft561">Common:&#160;</p>
<p style="position:absolute;top:538px;left:214px;white-space:nowrap" class="ft561">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;flushing&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft561">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft561">Gastrointestinal&#160;disorders&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft561">Common:&#160;</p>
<p style="position:absolute;top:671px;left:214px;white-space:nowrap" class="ft561">nausea/vomiting&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:709px;left:214px;white-space:nowrap" class="ft561">dysgeusia&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft561">Hepatobiliary&#160;disorders&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:785px;left:213px;white-space:nowrap" class="ft561">hepatitis,&#160;abnormal&#160;liver&#160;function&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft561">Skin and subcutaneous&#160;tissue&#160;disorders&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:842px;left:213px;white-space:nowrap" class="ft561">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft561">Musculoskeletal&#160;and connective&#160;tissue&#160;disorders&#160;&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft561">Common:&#160;</p>
<p style="position:absolute;top:899px;left:214px;white-space:nowrap" class="ft561">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:918px;left:214px;white-space:nowrap" class="ft561">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;</p>
<p style="position:absolute;top:937px;left:214px;white-space:nowrap" class="ft561">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft561">Renal&#160;and urinary disorders&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft561">Not&#160;known:&#160;</p>
<p style="position:absolute;top:994px;left:213px;white-space:nowrap" class="ft561">impaired&#160;renal&#160;function&#160;including cases of&#160;renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1013px;left:214px;white-space:nowrap" class="ft561">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft561">Reproductive system&#160;and&#160;breast&#160;disorders&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft561">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft561">&#160;</p>
</div>
<!-- Page 57 -->
<a name="57"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page57-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft570">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft570">57&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft571">General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft571">Common:&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft571">fatigue&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft571">Uncommon:&#160;&#160;chest&#160;pain&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft571">Investigations&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft571">Very&#160;common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:197px;left:214px;white-space:nowrap" class="ft571">with&#160;placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft576">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in&#160;29.4%&#160;of&#160;the patients in&#160;the&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft571">irbesartan&#160;300&#160;mg group&#160;and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft571">hypertensive patients&#160;with chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft576">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft571">and 26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo&#160;group.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft571">Common:&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft571">significant increases in&#160;plasma creatine kinase were commonly&#160;observed (1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft571">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft571">clinical&#160;musculoskeletal&#160;events.&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft571">In 1.7%&#160;of&#160;hypertensive patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft571">irbesartan,&#160;a decrease in&#160;haemoglobin*, which was&#160;not&#160;clinically significant, has&#160;been&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft571">observed.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft573"><i>&#160;</i></p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft571">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft571">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive&#160;children and adolescents&#160;aged&#160;6 to&#160;16&#160;years, the&#160;following&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft571">adverse reactions&#160;occurred&#160;in the&#160;3-week double-blind phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft571">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft571">laboratory abnormalities&#160;observed&#160;were creatinine&#160;increases (6.5%)&#160;and&#160;elevated&#160;CK&#160;values&#160;in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft571">child recipients.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft571">Reporting&#160;of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft571">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important.&#160;It&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft571">allows&#160;continued&#160;monitoring&#160;of&#160;the&#160;benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft571">professionals&#160;are&#160;asked&#160;to&#160;report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft571">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft572"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft571">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up&#160;to&#160;900&#160;mg/day for&#160;8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft571">likely&#160;manifestations&#160;of&#160;overdose&#160;are&#160;expected to&#160;be&#160;hypotension&#160;and tachycardia;&#160;bradycardia&#160;might&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft571">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose with&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft571">Karvea. The&#160;patient&#160;should be&#160;closely monitored, and the&#160;treatment&#160;should&#160;be&#160;symptomatic and&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft571">supportive.&#160;Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft571">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft572"><b>5.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft572"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft572"><b>5.1&#160;&#160;Pharmacodynamic properties&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft571">Pharmacotherapeutic&#160;group:&#160;Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft571">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft571">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft571">Mechanism&#160;of&#160;action</p>
<p style="position:absolute;top:1051px;left:246px;white-space:nowrap" class="ft572"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft572"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft571">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective angiotensin-II receptor&#160;(type&#160;AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft571">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated by the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft571">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II (AT1) receptors&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft571">results&#160;in increases&#160;in&#160;plasma&#160;renin levels&#160;and angiotensin-II levels,&#160;and&#160;a decrease&#160;in&#160;plasma&#160;</p>
</div>
<!-- Page 58 -->
<a name="58"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page58-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft580">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft580">58&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft581">aldosterone&#160;concentration.&#160;Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly affected by irbesartan alone&#160;at&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft581">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not inhibit&#160;ACE&#160;(kininase-II), an&#160;enzyme&#160;which&#160;generates&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft581">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive&#160;metabolites.&#160;Irbesartan&#160;does not&#160;require&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft581">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft581">Clinical efficacy</p>
<p style="position:absolute;top:178px;left:216px;white-space:nowrap" class="ft582"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft582"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft583"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft581">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change&#160;in heart&#160;rate.&#160;The decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft581">dose-related&#160;for&#160;once-a-day&#160;doses&#160;with&#160;a&#160;tendency&#160;towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft581">150-300&#160;mg once&#160;daily lower&#160;supine&#160;or&#160;seated blood&#160;pressures&#160;at&#160;trough&#160;(i.e.&#160;24 hours&#160;after dosing)&#160;by&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft581">an average&#160;of&#160;8-13/5-8&#160;mm&#160;Hg (systolic/diastolic)&#160;greater&#160;than&#160;those&#160;associated&#160;with placebo.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft581">Peak reduction of&#160;blood pressure&#160;is&#160;achieved within 3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft581">pressure&#160;lowering effect&#160;is&#160;maintained for&#160;at&#160;least&#160;24&#160;hours. At&#160;24 hours the reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft581">pressure was 60-70%&#160;of&#160;the&#160;corresponding peak diastolic and&#160;systolic responses at&#160;the recommended&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft581">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft581">daily dosing&#160;on the&#160;same&#160;total dose.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft581">The&#160;blood pressure&#160;lowering effect&#160;of&#160;Karvea&#160;is evident&#160;within 1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft581">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft581">term&#160;therapy. After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft581">hypertension&#160;has&#160;not&#160;been&#160;observed.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft581">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan&#160;and&#160;thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft581">not&#160;adequately controlled&#160;by irbesartan alone, the&#160;addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft581">(12.5&#160;mg)&#160;to&#160;irbesartan once&#160;daily&#160;results&#160;in&#160;a&#160;further&#160;placebo-adjusted&#160;blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft581">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft581">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender.&#160;As is the case&#160;with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft581">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin system,&#160;black&#160;hypertensive patients have&#160;notably&#160;less&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft581">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft581">of&#160;hydrochlorothiazide&#160;(e.g.&#160;12.5 mg daily),&#160;the&#160;antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft581">that of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft581">There&#160;is no&#160;clinically important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft581">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft581">Reduction of&#160;blood pressure&#160;with&#160;0.5&#160;mg/kg (low), 1.5&#160;mg/kg&#160;(medium)&#160;and&#160;4.5&#160;mg/kg (high)&#160;target&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft581">titrated&#160;doses&#160;of&#160;irbesartan&#160;was&#160;evaluated in&#160;318&#160;hypertensive&#160;or at&#160;risk&#160;(diabetic,&#160;family&#160;history&#160;of&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft581">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period. At&#160;the&#160;end&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft581">three weeks&#160;the&#160;mean&#160;reduction&#160;from&#160;baseline&#160;in the&#160;primary efficacy variable, trough&#160;seated&#160;systolic&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft581">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft581">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between&#160;these&#160;doses.&#160;Adjusted&#160;mean change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft581">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as follows:&#160;3.8&#160;mmHg (low&#160;dose),&#160;3.2 mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft581">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft581">to&#160;either&#160;active&#160;medicinal&#160;product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft581">in&#160;SeSBP and&#160;SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively&#160;in&#160;those&#160;on all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft581">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft581">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft583"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft581">The “Irbesartan&#160;Diabetic&#160;Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the&#160;progression&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft581">of&#160;renal&#160;disease&#160;in patients&#160;with chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft581">blind, controlled,&#160;morbidity&#160;and mortality trial&#160;comparing Karvea, amlodipine and placebo. In&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft581">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes, proteinuria&#160;≥&#160;900&#160;mg/day and serum creatinine&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft581">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft581">renal&#160;disease&#160;and&#160;all-cause&#160;mortality&#160;were examined.&#160;Patients were titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft581">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft581">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4 antihypertensive&#160;agents&#160;(e.g.,&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft581">diuretics,&#160;beta&#160;blockers, alpha&#160;blockers)&#160;to&#160;reach a&#160;predefined blood pressure&#160;goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft581">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
</div>
<!-- Page 59 -->
<a name="59"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page59-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft590">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft590">59&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft591">patients&#160;in the&#160;placebo group reached&#160;this&#160;target&#160;blood pressure&#160;whereas this&#160;figure&#160;was&#160;76%&#160;and&#160;78%&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft591">in the&#160;irbesartan&#160;and&#160;amlodipine&#160;groups&#160;respectively. Irbesartan significantly&#160;reduced the&#160;relative&#160;risk&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft591">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft591">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan group reached&#160;the&#160;primary renal&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft591">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft591">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft591">(p&#160;=&#160;0.006)]. When&#160;the&#160;individual&#160;components&#160;of&#160;the&#160;primary endpoint&#160;were analysed,&#160;no&#160;effect&#160;in&#160;all-</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft591">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft591">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft591">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft591">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration&#160;of&#160;diabetes,&#160;baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft591">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft591">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively, a&#160;renal&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft591">benefit&#160;was not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft591">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft591">in the&#160;overall&#160;population, although an increased&#160;incidence&#160;of&#160;non-fatal&#160;MI&#160;was seen&#160;for&#160;women and&#160;a&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft591">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft591">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft591">irbesartan-based&#160;regimen&#160;versus the amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft591">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft591">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft591">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft591">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive&#160;Patients&#160;with type&#160;2&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft591">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft591">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind morbidity study&#160;in&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft591">590&#160;patients&#160;with&#160;type&#160;2 diabetes,&#160;microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft591">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft591">effects (2&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary albumin&#160;excretion&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft591">rate&#160;(UAER)&#160;&gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft596">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft591">inhibitors, angiotensin&#160;II&#160;receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft591">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft591">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg group (5.2%)&#160;than in the&#160;placebo (14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft591">in&#160;the irbesartan&#160;150&#160;mg&#160;group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft591">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft591">improvement in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not observed&#160;during&#160;the&#160;first&#160;three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft591">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft591">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft591">frequent&#160;in the&#160;Karvea&#160;300&#160;mg&#160;group (34%)&#160;than in the&#160;placebo&#160;group (21%).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft591">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft593"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft591">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft591">combination with&#160;Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;VA NEPHRON-D (The&#160;Veterans Affairs&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft591">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft591">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft591">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type 2&#160;diabetes&#160;mellitus&#160;accompanied&#160;by evidence&#160;of&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft591">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft591">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft591">These&#160;studies&#160;have&#160;shown no&#160;significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes and&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft591">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft591">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft591">results are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and angiotensin&#160;II receptor&#160;blockers.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft591">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft591">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft591">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using&#160;Cardiovascular&#160;and Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft591">was&#160;a&#160;study designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft591">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
</div>
<!-- Page 60 -->
<a name="60"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page60-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft600">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft600">60&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft601">disease,&#160;cardiovascular&#160;disease,&#160;or&#160;both.&#160;The&#160;study&#160;was&#160;terminated early&#160;because of&#160;an&#160;increased&#160;risk&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft601">of&#160;adverse outcomes.&#160;Cardiovascular&#160;death&#160;and&#160;stroke&#160;were both&#160;numerically&#160;more frequent&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft601">aliskiren group&#160;than in the&#160;placebo group&#160;and adverse&#160;events and&#160;serious adverse&#160;events of&#160;interest&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft601">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft601">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft602"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft602"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft601">Absorption&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft601">After&#160;oral&#160;administration,&#160;irbesartan&#160;is well&#160;absorbed:&#160;studies of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft601">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft601">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft601">Distribution&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft601">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft601">The&#160;volume&#160;of&#160;distribution&#160;is&#160;53 -&#160;93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft601">Biotransformation&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft601">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft601">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft601">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft601">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft601">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft601">Linearity&#160;/&#160;non-linearity&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft601">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft601">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft601">recommended&#160;dose)&#160;was observed;&#160;the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft601">are&#160;attained at&#160;1.5&#160;-&#160;2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and&#160;renal&#160;clearance&#160;are&#160;157 -</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft601">&#160;176&#160;and 3&#160;-&#160;3.5 ml/min, respectively.&#160;The terminal&#160;elimination&#160;half-life of&#160;irbesartan&#160;is 11&#160;-&#160;15&#160;hours.&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft601">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft601">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft601">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan&#160;were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft601">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft601">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female&#160;patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft601">were&#160;also&#160;somewhat&#160;greater&#160;in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18&#160;-&#160;40&#160;years).&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft601">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft601">older&#160;people.&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft601">Elimination&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft601">Irbesartan&#160;and&#160;its metabolites are eliminated&#160;by both&#160;biliary and renal&#160;pathways. After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft601">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft601">remainder&#160;in&#160;the&#160;faeces.&#160;Less than 2%&#160;of&#160;the&#160;dose&#160;is&#160;excreted&#160;in the&#160;urine&#160;as&#160;unchanged irbesartan.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft601">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft601">&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft601">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft601">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft601">four&#160;weeks. Of&#160;those&#160;23&#160;children, 21 were&#160;evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft601">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft601">and&#160;clearance rates&#160;were&#160;comparable&#160;to those&#160;observed&#160;in adult&#160;patients&#160;receiving 150&#160;mg&#160;irbesartan&#160;</p>
</div>
<!-- Page 61 -->
<a name="61"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page61-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft610">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft610">61&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft611">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft611">dosing.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft611">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft611">In patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft611">of irbesartan&#160;are&#160;not&#160;significantly altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft611">Hepatic impairment&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft611">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft611">significantly&#160;altered.&#160;&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft611">Studies have not&#160;been&#160;performed&#160;in patients&#160;with&#160;severe&#160;hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft612"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft612"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft611">There&#160;was&#160;no evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft611">non-clinical&#160;safety&#160;studies,&#160;high doses&#160;of&#160;irbesartan (≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft611">macaques)&#160;caused a&#160;reduction of&#160;red blood&#160;cell&#160;parameters&#160;(erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft616">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative&#160;changes&#160;in the&#160;kidney&#160;(such&#160;as&#160;interstitial&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft611">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft611">creatinine)&#160;were&#160;induced by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft611">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft616">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft616">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft611">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft611">hypertrophy&#160;of&#160;the renal&#160;juxtaglomerular&#160;cells does not&#160;appear&#160;to&#160;have&#160;any&#160;relevance.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft611">There&#160;was&#160;no&#160;evidence&#160;of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft611">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft611">oral&#160;doses&#160;of&#160;irbesartan&#160;causing&#160;some&#160;parental&#160;toxicity&#160;(from&#160;50 to&#160;650&#160;mg/kg/day), including&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft611">mortality at&#160;the&#160;highest&#160;dose. No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft611">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft611">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and&#160;rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft611">Irbesartan&#160;is&#160;excreted&#160;in&#160;the&#160;milk&#160;of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft611">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft611">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft611">abortion&#160;or&#160;early resorption&#160;were&#160;noted at&#160;doses&#160;causing&#160;significant&#160;maternal&#160;toxicity, including&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft611">mortality. No&#160;teratogenic&#160;effects&#160;were&#160;observed&#160;in the&#160;rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft612"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft612"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft612"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft612"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft612"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft611">Tablet&#160;core:&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft611">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft611">Microcrystalline cellulose&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft611">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft611">Hypromellose&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft611">Silicon dioxide&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft611">Magnesium&#160;stearate.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft611">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft611">Film-coating:&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft611">Lactose&#160;monohydrate&#160;</p>
</div>
<!-- Page 62 -->
<a name="62"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page62-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft620">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft620">62&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft621">Hypromellose&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft621">Titanium dioxide&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft621">Macrogol&#160;3000&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft621">Carnauba wax.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft622"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft621">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft622"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft621">3&#160;years.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft622"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft621">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft622"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;14&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;28&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;30&#160;film-coated&#160;tablets in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;56&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;84&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;90&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;98&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft621">Cartons&#160;of&#160;56&#160;x&#160;1&#160;film-coated tablet&#160;in PVC/PVDC/Aluminium&#160;perforated&#160;unit&#160;dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft621">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft622"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft621">Any&#160;unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft621">requirements.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft622"><b>7.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft622"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft621">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft621">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft621">94250 Gentilly&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft621">France&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft622"><b>8.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft622"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft621">EU/1/97/049/021-025&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft621">EU/1/97/049/032&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft621">EU/1/97/049/035&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft621">EU/1/97/049/038&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft622"><b>9.&#160;</b></p>
<p style="position:absolute;top:1050px;left:149px;white-space:nowrap" class="ft622"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft622"><b>&#160;</b></p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft621">Date&#160;of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft621">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft621">&#160;</p>
</div>
<!-- Page 63 -->
<a name="63"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page63-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft630">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft630">63&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft632"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft631">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft631">Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is&#160;available&#160;on&#160;the website of&#160;the European&#160;Medicines&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft631">Agency http://www.ema.europa.eu&#160;</p>
</div>
<!-- Page 64 -->
<a name="64"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page64-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft640">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft640">64&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft642"><b>1.&#160;</b></p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft642"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft641">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablets.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft642"><b>2.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft642"><b>QUALITATIVE&#160;AND QUANTITATIVE&#160;COMPOSITION&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft641">Each&#160;film-coated&#160;tablet&#160;contains&#160;300&#160;mg of&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft641">Excipient with&#160;known effect:&#160;102.00&#160;mg of&#160;lactose&#160;monohydrate&#160;per&#160;film-coated tablet.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft641">For&#160;the full&#160;list&#160;of&#160;excipients,&#160;see&#160;section&#160;6.1.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft642"><b>3.&#160;</b></p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft642"><b>PHARMACEUTICAL&#160;FORM&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft641">Film-coated&#160;tablet.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft641">White&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;side&#160;and the&#160;number&#160;2873&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft641">engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft642"><b>4.&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft642"><b>CLINICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft642"><b>4.1&#160;&#160;Therapeutic&#160;indications&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft641">Karvea&#160;is&#160;indicated in adults&#160;for&#160;the&#160;treatment&#160;of&#160;essential&#160;hypertension.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft641">It is&#160;also&#160;indicated&#160;for&#160;the treatment&#160;of&#160;renal&#160;disease in&#160;adult&#160;patients with&#160;hypertension and type&#160;2&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft641">diabetes mellitus&#160;as part&#160;of&#160;an&#160;antihypertensive medicinal&#160;product&#160;regimen&#160;(see&#160;sections&#160;4.3, 4.4, 4.5&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft641">and 5.1).&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft642"><b>4.2&#160;&#160;Posology&#160;and&#160;method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft642"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft641">Posology&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft641">The&#160;usual&#160;recommended&#160;initial&#160;and&#160;maintenance&#160;dose is 150&#160;mg once&#160;daily, with or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft641">Karvea&#160;at&#160;a&#160;dose&#160;of&#160;150&#160;mg&#160;once&#160;daily generally provides&#160;a&#160;better&#160;24-hour&#160;blood pressure&#160;control&#160;than&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft641">75 mg. However, initiation&#160;of&#160;therapy with 75&#160;mg&#160;could be&#160;considered, particularly in haemodialyzed&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft641">patients&#160;and in&#160;the&#160;elderly&#160;over&#160;75&#160;years.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft641">In patients&#160;insufficiently controlled with 150 mg&#160;once&#160;daily, the&#160;dose&#160;of&#160;Karvea&#160;can&#160;be increased&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft641">300 mg, or&#160;other&#160;antihypertensive&#160;agents&#160;can be&#160;added&#160;(see&#160;sections 4.3,&#160;4.4,&#160;4.5 and 5.1). In&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft641">particular, the&#160;addition of&#160;a&#160;diuretic&#160;such&#160;as&#160;hydrochlorothiazide&#160;has&#160;been shown to have&#160;an additive&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft641">effect&#160;with&#160;Karvea&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft641">In&#160;hypertensive&#160;type&#160;2 diabetic&#160;patients, therapy should be&#160;initiated&#160;at&#160;150&#160;mg&#160;irbesartan&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft641">and titrated up to&#160;300&#160;mg once&#160;daily as&#160;the&#160;preferred maintenance&#160;dose for&#160;treatment&#160;of&#160;renal&#160;disease.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft641">The&#160;demonstration of&#160;renal&#160;benefit&#160;of&#160;Karvea&#160;in hypertensive&#160;type&#160;2&#160;diabetic&#160;patients is&#160;based&#160;on&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft641">studies where&#160;irbesartan&#160;was used&#160;in&#160;addition&#160;to&#160;other&#160;antihypertensive&#160;agents,&#160;as&#160;needed,&#160;to&#160;reach&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft641">target blood&#160;pressure (see&#160;sections&#160;4.3, 4.4,&#160;4.5 and 5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft641">Special&#160;Populations&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft643"><i>Renal&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft641">No dosage&#160;adjustment&#160;is&#160;necessary&#160;in patients&#160;with&#160;impaired renal&#160;function. A&#160;lower&#160;starting dose&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft641">(75&#160;mg)&#160;should be&#160;considered for&#160;patients&#160;undergoing&#160;haemodialysis&#160;(see&#160;section&#160;4.4).&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft641">&#160;</p>
</div>
<!-- Page 65 -->
<a name="65"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page65-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft650">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft650">65&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft653"><i>Hepatic&#160;impairment</i>&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft651">No dosage&#160;adjustment&#160;is&#160;necessary&#160;in patients&#160;with&#160;mild to&#160;moderate&#160;hepatic&#160;impairment. There&#160;is&#160;no&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft651">clinical&#160;experience&#160;in&#160;patients with&#160;severe hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft653"><i>Older people</i>&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft651">Although consideration should be&#160;given to&#160;initiating&#160;therapy&#160;with&#160;75&#160;mg in patients&#160;over&#160;75 years&#160;of&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft651">age,&#160;dosage&#160;adjustment&#160;is not&#160;usually&#160;necessary&#160;for&#160;older&#160;people.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft653"><i>Paediatric&#160;population</i>&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft651">The&#160;safety&#160;and&#160;efficacy&#160;of&#160;Karvea&#160;in children aged 0&#160;to 18 has&#160;not&#160;been&#160;established. Currently&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft651">available&#160;data&#160;are&#160;described&#160;in section 4.8, 5.1&#160;and 5.2&#160;but&#160;no&#160;recommendation&#160;on&#160;a&#160;posology&#160;can be&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft651">made.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft651">Method of&#160;Administration&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft651">For&#160;oral&#160;use.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft652"><b>4.3&#160;&#160;Contraindications&#160;</b></p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft652"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft651">Hypersensitivity&#160;to the&#160;active&#160;substance&#160;or&#160;to any&#160;of&#160;the&#160;excipients&#160;listed&#160;in section 6.1.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft651">Second&#160;and third trimesters&#160;of&#160;pregnancy&#160;(see&#160;sections&#160;4.4 and 4.6).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft651">The concomitant&#160;use&#160;of&#160;Karvea with&#160;aliskiren-containing products&#160;is&#160;contraindicated in patients&#160;with&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft651">diabetes&#160;mellitus&#160;or&#160;renal&#160;impairment&#160;(glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;&lt;60&#160;ml/min/1.73m2)&#160;(see&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft651">sections&#160;4.5&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft652"><b>4.4&#160;&#160;Special&#160;warnings&#160;and&#160;precautions&#160;for&#160;use&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft652"><b>&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft651">Intravascular&#160;volume&#160;depletion:&#160;symptomatic&#160;hypotension,&#160;especially&#160;after&#160;the&#160;first&#160;dose, may occur&#160;in&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft651">patients who are&#160;volume&#160;and/or&#160;sodium&#160;depleted by&#160;vigorous&#160;diuretic&#160;therapy, dietary&#160;salt restriction,&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft651">diarrhoea&#160;or&#160;vomiting. Such conditions&#160;should be&#160;corrected before&#160;the&#160;administration of&#160;Karvea.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft651">Renovascular&#160;hypertension:&#160;there is an&#160;increased&#160;risk&#160;of&#160;severe&#160;hypotension and renal&#160;insufficiency&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft651">when&#160;patients&#160;with&#160;bilateral&#160;renal&#160;artery&#160;stenosis&#160;or&#160;stenosis&#160;of&#160;the&#160;artery to&#160;a&#160;single&#160;functioning kidney&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft651">are&#160;treated&#160;with&#160;medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin-aldosterone system.&#160;While&#160;this is&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft651">not&#160;documented with&#160;Karvea, a&#160;similar&#160;effect&#160;should&#160;be&#160;anticipated with angiotensin-II&#160;receptor&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft651">antagonists.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft651">Renal&#160;impairment&#160;and kidney&#160;transplantation:&#160;when&#160;Karvea&#160;is used&#160;in&#160;patients with&#160;impaired&#160;renal&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft651">function, a&#160;periodic&#160;monitoring&#160;of&#160;potassium&#160;and creatinine&#160;serum&#160;levels&#160;is recommended.&#160;There is&#160;no&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft651">experience regarding&#160;the administration&#160;of&#160;Karvea&#160;in&#160;patients with&#160;a&#160;recent&#160;kidney&#160;transplantation.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft651">Hypertensive&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;and&#160;renal&#160;disease:&#160;the&#160;effects&#160;of&#160;irbesartan both on&#160;renal&#160;and&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft651">cardiovascular&#160;events&#160;were&#160;not&#160;uniform&#160;across&#160;all&#160;subgroups,&#160;in&#160;an analysis&#160;carried out&#160;in the&#160;study&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft651">with&#160;patients with&#160;advanced&#160;renal&#160;disease.&#160;In&#160;particular,&#160;they&#160;appeared&#160;less favourable&#160;in&#160;women&#160;and&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft651">non-white subjects (see&#160;section&#160;5.1).&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft651">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft651">Dual&#160;blockade of&#160;the renin-angiotensin-aldosterone&#160;system&#160;(RAAS):&#160;there&#160;is&#160;evidence&#160;that the&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft651">concomitant&#160;use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;increases&#160;the&#160;risk of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft651">hypotension, hyperkalaemia&#160;and decreased renal&#160;function (including acute&#160;renal&#160;failure).&#160;Dual&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft651">blockade&#160;of&#160;RAAS&#160;through&#160;the&#160;combined use&#160;of&#160;ACE-inhibitors, angiotensin II&#160;receptor&#160;blockers&#160;or&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft651">aliskiren&#160;is&#160;therefore&#160;not&#160;recommended&#160;(see&#160;sections&#160;4.5 and 5.1). &#160;If&#160;dual&#160;blockade&#160;therapy is&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft651">considered absolutely necessary,&#160;this&#160;should only occur&#160;under&#160;specialist&#160;supervision&#160;and&#160;subject&#160;to&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft651">frequent&#160;close monitoring of&#160;renal&#160;function, electrolytes&#160;and blood&#160;pressure. ACE-inhibitors&#160;and&#160;</p>
</div>
<!-- Page 66 -->
<a name="66"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page66-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft660">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft660">66&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft661">angiotensin II&#160;receptor&#160;blockers&#160;should not&#160;be&#160;used&#160;concomitantly&#160;in patients&#160;with&#160;diabetic&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft661">nephropathy.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft661">Hyperkalaemia:&#160;as&#160;with&#160;other&#160;medicinal&#160;products&#160;that&#160;affect&#160;the renin-angiotensin-aldosterone&#160;system,&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft661">hyperkalaemia&#160;may occur&#160;during&#160;the&#160;treatment&#160;with&#160;Karvea,&#160;especially&#160;in&#160;the presence of&#160;renal&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft661">impairment,&#160;overt&#160;proteinuria due to&#160;diabetic&#160;renal&#160;disease,&#160;and/or&#160;heart&#160;failure. Close&#160;monitoring&#160;of&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft661">serum&#160;potassium&#160;in&#160;patients at&#160;risk&#160;is&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft661">Hypoglycaemia:&#160;Karvea&#160;may induce&#160;hypoglycaemia,&#160;particularly&#160;in&#160;diabetic&#160;patients.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft661">treated&#160;with insulin or&#160;antidiabetics&#160;an appropriate&#160;blood glucose&#160;monitoring should be&#160;considered;&#160;a&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft661">dose adjustment&#160;of&#160;insulin&#160;or&#160;antidiabetics&#160;may&#160;be&#160;required&#160;when indicated&#160;(see&#160;section&#160;4.5).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft661">Lithium:&#160;the&#160;combination&#160;of&#160;lithium and&#160;Karvea&#160;is&#160;not&#160;recommended&#160;(see section&#160;4.5).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft661">Aortic&#160;and&#160;mitral&#160;valve&#160;stenosis,&#160;obstructive&#160;hypertrophic&#160;cardiomyopathy:&#160;as&#160;with&#160;other&#160;vasodilators,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft661">special&#160;caution&#160;is indicated&#160;in patients&#160;suffering from&#160;aortic&#160;or&#160;mitral&#160;stenosis, or&#160;obstructive&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft661">hypertrophic&#160;cardiomyopathy.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft661">Primary aldosteronism: patients&#160;with&#160;primary&#160;aldosteronism&#160;generally will&#160;not&#160;respond to&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft661">antihypertensive&#160;medicinal products&#160;acting through inhibition&#160;of&#160;the renin-angiotensin system.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft661">Therefore, the&#160;use&#160;of&#160;Karvea&#160;is&#160;not&#160;recommended.&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft661">General:&#160;in&#160;patients whose&#160;vascular&#160;tone and&#160;renal&#160;function&#160;depend&#160;predominantly on the&#160;activity of&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft661">the renin-angiotensin-aldosterone system&#160;(e.g.&#160;patients&#160;with severe&#160;congestive heart&#160;failure&#160;or&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft661">underlying renal&#160;disease,&#160;including&#160;renal&#160;artery&#160;stenosis),&#160;treatment&#160;with&#160;angiotensin</p>
<p style="position:absolute;top:538px;left:663px;white-space:nowrap" class="ft662"><b>&#160;</b>converting&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft661">enzyme&#160;inhibitors&#160;or&#160;angiotensin-II&#160;receptor&#160;antagonists that&#160;affect&#160;this system&#160;has&#160;been&#160;associated&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft661">with acute&#160;hypotension, azotaemia, oliguria,&#160;or rarely&#160;acute&#160;renal&#160;failure&#160;(see&#160;section 4.5). As&#160;with any&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft661">antihypertensive&#160;agent,&#160;excessive blood&#160;pressure decrease&#160;in&#160;patients with&#160;ischaemic&#160;cardiopathy or&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft661">ischaemic&#160;cardiovascular&#160;disease could&#160;result&#160;in a&#160;myocardial&#160;infarction&#160;or&#160;stroke.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft661">As&#160;observed&#160;for&#160;angiotensin converting enzyme&#160;inhibitors,&#160;irbesartan and the&#160;other&#160;angiotensin&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft661">antagonists are apparently&#160;less effective&#160;in&#160;lowering&#160;blood pressure&#160;in black&#160;people&#160;than in&#160;non-blacks,&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft661">possibly because&#160;of&#160;higher&#160;prevalence&#160;of&#160;low-renin&#160;states&#160;in&#160;the&#160;black hypertensive&#160;population (see&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft661">section&#160;5.1).&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft661">Pregnancy:&#160;angiotensin&#160;II&#160;Receptor&#160;Antagonists&#160;(AIIRAs)&#160;should not&#160;be&#160;initiated during pregnancy.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft661">Unless&#160;continued AIIRA&#160;therapy&#160;is&#160;considered&#160;essential, patients&#160;planning pregnancy should be&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft661">changed&#160;to&#160;alternative&#160;antihypertensive&#160;treatments which&#160;have an&#160;established&#160;safety&#160;profile for&#160;use&#160;in&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft661">pregnancy.&#160;When&#160;pregnancy is&#160;diagnosed, treatment&#160;with&#160;AIIRAs&#160;should be&#160;stopped immediately,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft661">and, if&#160;appropriate, alternative&#160;therapy should&#160;be&#160;started (see&#160;sections&#160;4.3 and 4.6).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft661">Paediatric&#160;population:&#160;irbesartan has&#160;been studied&#160;in paediatric&#160;populations&#160;aged&#160;6&#160;to 16 years&#160;old&#160;but&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft661">the current&#160;data are&#160;insufficient&#160;to&#160;support&#160;an extension&#160;of&#160;the&#160;use&#160;in&#160;children until&#160;further&#160;data become&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft661">available (see&#160;sections&#160;4.8, 5.1&#160;and&#160;5.2).&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft661">Excipients:&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft661">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablet&#160;contains&#160;lactose.&#160;Patients with&#160;rare hereditary&#160;problems of&#160;galactose&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft661">intolerance, total&#160;lactase deficiency&#160;or&#160;glucose-galactose&#160;malabsorption&#160;should not&#160;take this&#160;medicine.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft661">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablet&#160;contains&#160;sodium.&#160;This&#160;medicine&#160;contains&#160;less&#160;than&#160;1&#160;mmol sodium&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft661">(23 mg)&#160;per&#160;tablet,&#160;that&#160;is to&#160;say&#160;essentially&#160;‘sodium-free’.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft661">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft662"><b>4.5&#160;&#160;Interaction&#160;with other&#160;medicinal&#160;products&#160;and other&#160;forms&#160;of&#160;interaction&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft662"><b>&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft661">Diuretics&#160;and&#160;other&#160;antihypertensive&#160;agents: other&#160;antihypertensive agents&#160;may&#160;increase&#160;the&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft661">hypotensive&#160;effects&#160;of&#160;irbesartan;&#160;however&#160;Karvea&#160;has been&#160;safely&#160;administered with other&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft661">antihypertensive agents,&#160;such&#160;as&#160;beta-blockers, long-acting&#160;calcium&#160;channel&#160;blockers,&#160;and&#160;thiazide&#160;</p>
</div>
<!-- Page 67 -->
<a name="67"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page67-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft670">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft670">67&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft671">diuretics.&#160;Prior&#160;treatment&#160;with high&#160;dose diuretics may&#160;result&#160;in volume&#160;depletion&#160;and a&#160;risk&#160;of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft671">hypotension when&#160;initiating therapy with&#160;Karvea&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft671">Aliskiren-containing products&#160;or&#160;ACE-inhibitors:&#160;clinical trial&#160;data&#160;has&#160;shown that&#160;dual&#160;blockade&#160;of&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft671">the renin-angiotensin-aldosterone system&#160;(RAAS)&#160;through&#160;the&#160;combined&#160;use&#160;of&#160;ACE-inhibitors,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft671">angiotensin&#160;II&#160;receptor&#160;blockers&#160;or&#160;aliskiren&#160;is associated with&#160;a higher&#160;frequency&#160;of&#160;adverse events&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft671">such as&#160;hypotension, hyperkalaemia&#160;and decreased renal&#160;function&#160;(including acute renal&#160;failure)&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft671">compared to&#160;the&#160;use&#160;of&#160;a&#160;single&#160;RAAS-acting&#160;agent&#160;(see&#160;sections&#160;4.3, 4.4&#160;and 5.1).&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft671">Potassium&#160;supplements and&#160;potassium-sparing diuretics:<i>&#160;</i>based&#160;on&#160;experience with&#160;the use of&#160;other&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft671">medicinal&#160;products&#160;that&#160;affect the&#160;renin-angiotensin system,&#160;concomitant&#160;use of&#160;potassium-sparing&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft671">diuretics,&#160;potassium&#160;supplements,&#160;salt&#160;substitutes containing&#160;potassium&#160;or&#160;other&#160;medicinal&#160;products&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft671">that&#160;may&#160;increase serum&#160;potassium&#160;levels&#160;(e.g.&#160;heparin)&#160;may lead&#160;to&#160;increases in&#160;serum&#160;potassium&#160;and&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft671">is,&#160;therefore, not&#160;recommended&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft671">Lithium:<i>&#160;</i>reversible increases in&#160;serum&#160;lithium&#160;concentrations&#160;and&#160;toxicity&#160;have&#160;been reported during&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft671">concomitant administration&#160;of&#160;lithium with&#160;angiotensin&#160;converting&#160;enzyme inhibitors.&#160;Similar&#160;effects&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft671">have been&#160;very&#160;rarely reported&#160;with&#160;irbesartan&#160;so&#160;far.&#160;Therefore,&#160;this&#160;combination is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft671">(see section&#160;4.4). If&#160;the&#160;combination&#160;proves necessary,&#160;careful monitoring&#160;of&#160;serum lithium&#160;levels&#160;is&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft671">recommended.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft673"><i>&#160;</i></p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft671">Non-steroidal&#160;anti-inflammatory drugs:&#160;when angiotensin&#160;II&#160;antagonists are administered&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft671">simultaneously with non-steroidal&#160;anti-inflammatory drugs&#160;(i.e. selective&#160;COX-2 inhibitors,&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft671">acetylsalicylic&#160;acid&#160;(&gt;&#160;3 g/day)&#160;and non-selective&#160;NSAIDs),&#160;attenuation of&#160;the antihypertensive&#160;effect&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft671">may&#160;occur.&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft671">As&#160;with&#160;ACE&#160;inhibitors, concomitant&#160;use&#160;of&#160;angiotensin&#160;II&#160;antagonists and&#160;NSAIDs may&#160;lead&#160;to&#160;an&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft671">increased&#160;risk&#160;of&#160;worsening&#160;of&#160;renal&#160;function, including&#160;possible acute&#160;renal&#160;failure,&#160;and&#160;an&#160;increase&#160;in&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft671">serum&#160;potassium,&#160;especially&#160;in&#160;patients with&#160;poor&#160;pre-existing renal&#160;function. The&#160;combination should&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft671">be&#160;administered with&#160;caution, especially in the&#160;elderly.&#160;Patients&#160;should&#160;be&#160;adequately hydrated and&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft671">consideration should&#160;be&#160;given&#160;to monitoring&#160;renal&#160;function after initiation&#160;of&#160;concomitant&#160;therapy, and&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft671">periodically thereafter.<i><b>&#160;</b></i></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft671">Repaglinide:&#160;irbesartan&#160;has&#160;the&#160;potential&#160;to inhibit&#160;OATP1B1.&#160;In&#160;a&#160;clinical&#160;study,&#160;it was&#160;reported&#160;that&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft671">irbesartan&#160;increased&#160;the&#160;Cmax&#160;and AUC&#160;of&#160;repaglinide&#160;(substrate&#160;of&#160;OATP1B1)&#160;by&#160;1.8-fold&#160;and&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft671">1.3-fold,&#160;respectively,&#160;when&#160;administered&#160;1&#160;hour&#160;before&#160;repaglinide. In another&#160;study, no&#160;relevant&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft671">pharmacokinetic interaction&#160;was&#160;reported,&#160;when&#160;the&#160;two&#160;drugs&#160;were&#160;co-administered.&#160;Therefore, dose&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft671">adjustment of&#160;antidiabetic&#160;treatment&#160;such as&#160;repaglinide&#160;may&#160;be&#160;required&#160;(see section&#160;4.4).&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft671">Additional&#160;information on irbesartan interactions:&#160;in clinical&#160;studies,&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft671">is&#160;not&#160;affected by hydrochlorothiazide.&#160;Irbesartan&#160;is&#160;mainly metabolised by CYP2C9&#160;and&#160;to&#160;a&#160;lesser&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft671">extent&#160;by glucuronidation.&#160;No significant&#160;pharmacokinetic&#160;or&#160;pharmacodynamic&#160;interactions were&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft671">observed when&#160;irbesartan&#160;was coadministered&#160;with&#160;warfarin,&#160;a&#160;medicinal&#160;product&#160;metabolised&#160;by&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft671">CYP2C9. The&#160;effects&#160;of&#160;CYP2C9 inducers&#160;such as&#160;rifampicin on&#160;the&#160;pharmacokinetic&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft671">have&#160;not&#160;been evaluated. The&#160;pharmacokinetic&#160;of&#160;digoxin was&#160;not&#160;altered by&#160;coadministration&#160;of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft671">irbesartan.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft672"><b>4.6&#160;&#160;Fertility, pregnancy and&#160;lactation&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft672"><b>&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft671">Pregnancy&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft671">The&#160;use&#160;of&#160;AIIRAs&#160;is&#160;not&#160;recommended during the&#160;first&#160;trimester&#160;of&#160;pregnancy&#160;(see&#160;section&#160;4.4).&#160;The&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft671">use of&#160;AIIRAs is contraindicated&#160;during the&#160;second&#160;and&#160;third&#160;trimesters&#160;of&#160;pregnancy&#160;(see sections&#160;4.3&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft671">and 4.4).&#160;</p>
<p style="position:absolute;top:1112px;left:106px;white-space:nowrap" class="ft671">&#160;</p>
<p style="position:absolute;top:1131px;left:106px;white-space:nowrap" class="ft671">Epidemiological&#160;evidence&#160;regarding the&#160;risk of&#160;teratogenicity&#160;following exposure&#160;to&#160;ACE&#160;inhibitors&#160;</p>
<p style="position:absolute;top:1150px;left:106px;white-space:nowrap" class="ft671">during&#160;the&#160;first&#160;trimester of&#160;pregnancy has&#160;not&#160;been conclusive;&#160;however&#160;a&#160;small&#160;increase in&#160;risk&#160;</p>
</div>
<!-- Page 68 -->
<a name="68"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page68-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft680">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft680">68&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft681">cannot&#160;be&#160;excluded.&#160;Whilst&#160;there&#160;is&#160;no&#160;controlled epidemiological&#160;data&#160;on the&#160;risk&#160;with Angiotensin II&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft681">Receptor&#160;Antagonists (AIIRAs),&#160;similar&#160;risks may&#160;exist&#160;for&#160;this&#160;class&#160;of&#160;drugs.&#160;Unless&#160;continued&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft681">AIIRA&#160;therapy&#160;is considered&#160;essential, patients&#160;planning pregnancy&#160;should be&#160;changed&#160;to alternative&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft681">antihypertensive&#160;treatments&#160;which&#160;have an&#160;established&#160;safety profile&#160;for&#160;use&#160;in&#160;pregnancy. When&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft681">pregnancy is&#160;diagnosed, treatment&#160;with AIIRAs&#160;should&#160;be&#160;stopped&#160;immediately,&#160;and, if&#160;appropriate,&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft681">alternative therapy&#160;should be&#160;started.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft681">Exposure&#160;to AIIRA&#160;therapy&#160;during the&#160;second&#160;and&#160;third trimesters&#160;is&#160;known&#160;to&#160;induce&#160;human&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft681">fetotoxicity&#160;(decreased renal&#160;function, oligohydramnios, skull&#160;ossification&#160;retardation)&#160;and neonatal&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft681">toxicity&#160;(renal failure, hypotension, hyperkalaemia). (See&#160;section&#160;5.3).&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft681">Should&#160;exposure&#160;to AIIRAs&#160;have&#160;occurred&#160;from&#160;the&#160;second trimester&#160;of&#160;pregnancy,&#160;ultrasound check&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft681">of&#160;renal&#160;function and skull&#160;is&#160;recommended.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft681">Infants&#160;whose&#160;mothers have taken&#160;AIIRAs should&#160;be closely&#160;observed for&#160;hypotension&#160;(see&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft681">sections&#160;4.3 and 4.4).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft681">Breast-feeding&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft681">Because&#160;no&#160;information&#160;is&#160;available&#160;regarding the&#160;use&#160;of&#160;Karvea&#160;during&#160;breast-feeding,&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft681">recommended&#160;and&#160;alternative treatments&#160;with better&#160;established safety profiles&#160;during breast-feeding&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft681">are preferable,&#160;especially&#160;while&#160;nursing a&#160;newborn&#160;or&#160;preterm&#160;infant.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft681">It&#160;is&#160;unknown whether&#160;irbesartan or&#160;its&#160;metabolites&#160;are&#160;excreted&#160;in human milk.&#160;&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft681">Available pharmacodynamic/toxicological&#160;data&#160;in&#160;rats&#160;have&#160;shown excretion of&#160;irbesartan&#160;or&#160;its&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft681">metabolites&#160;in&#160;milk&#160;(for&#160;details see 5.3).&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft681">Fertility&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft681">Irbesartan had no effect&#160;upon fertility&#160;of&#160;treated rats&#160;and their&#160;offspring up&#160;to the&#160;dose&#160;levels&#160;inducing&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft681">the first&#160;signs&#160;of&#160;parental toxicity&#160;(see&#160;section 5.3).&#160;&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft682"><b>4.7&#160;&#160;Effects&#160;on&#160;ability&#160;to drive&#160;and&#160;use machines&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft682"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft681">Based on&#160;its&#160;pharmacodynamic properties,&#160;irbesartan&#160;is&#160;unlikely&#160;to&#160;affect&#160;the&#160;ability&#160;to drive&#160;and&#160;use&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft681">machines. When driving&#160;vehicles&#160;or&#160;operating&#160;machines, it&#160;should be&#160;taken&#160;into account&#160;that dizziness&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft681">or&#160;weariness&#160;may occur&#160;during treatment.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft682"><b>4.8&#160;&#160;Undesirable effects&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft682"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft681">In placebo-controlled&#160;trials&#160;in patients&#160;with hypertension, the&#160;overall&#160;incidence&#160;of&#160;adverse events did&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft681">not&#160;differ&#160;between&#160;the irbesartan&#160;(56.2%)&#160;and the&#160;placebo groups&#160;(56.5%). Discontinuation due&#160;to any&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft681">clinical&#160;or&#160;laboratory&#160;adverse&#160;event&#160;was less&#160;frequent&#160;for&#160;irbesartan-treated patients&#160;(3.3%)&#160;than&#160;for&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft681">placebo-treated&#160;patients&#160;(4.5%).&#160;The&#160;incidence&#160;of&#160;adverse&#160;events&#160;was&#160;not&#160;related&#160;to dose&#160;(in the&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft681">recommended dose&#160;range),&#160;gender, age, race, or&#160;duration of&#160;treatment.&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft681">In diabetic&#160;hypertensive patients with&#160;microalbuminuria&#160;and normal&#160;renal&#160;function, orthostatic&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft681">dizziness&#160;and orthostatic&#160;hypotension&#160;were&#160;reported&#160;in&#160;0.5%&#160;of&#160;the&#160;patients&#160;(i.e.,&#160;uncommon)&#160;but&#160;in&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft681">excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft681">The&#160;following&#160;table&#160;presents&#160;the&#160;adverse&#160;drug&#160;reactions that&#160;were&#160;reported&#160;in placebo-controlled&#160;trials&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft681">in which 1,965&#160;hypertensive&#160;patients received&#160;irbesartan.&#160;Terms&#160;marked&#160;with&#160;a&#160;star&#160;(*) refer to&#160;the&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft681">adverse reactions&#160;that&#160;were&#160;additionally reported in &gt;&#160;2%&#160;of&#160;diabetic&#160;hypertensive&#160;patients&#160;with&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft681">chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria&#160;and&#160;in&#160;excess of&#160;placebo.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft681">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft681">The frequency&#160;of&#160;adverse reactions listed&#160;below&#160;is&#160;defined using&#160;the&#160;following&#160;convention:&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft681">very common&#160;(≥&#160;1/10);&#160;common (≥&#160;1/100&#160;to &lt;&#160;1/10);&#160;uncommon (≥&#160;1/1,000 to&#160;&lt;&#160;1/100);&#160;rare&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft681">(≥&#160;1/10,000 to &lt;&#160;1/1,000);&#160;very&#160;rare&#160;(&lt;&#160;1/10,000). Within each&#160;frequency grouping,&#160;undesirable&#160;effects&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft681">are presented&#160;in&#160;order&#160;of&#160;decreasing&#160;seriousness.&#160;</p>
</div>
<!-- Page 69 -->
<a name="69"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page69-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft690">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft690">69&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft691">Adverse reactions additionally&#160;reported&#160;from&#160;post–marketing&#160;experience are&#160;also&#160;listed.&#160;These adverse&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft691">reactions are derived&#160;from&#160;spontaneous&#160;reports.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft695"><i><b>&#160;</b></i></p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft691">Blood and lymphatic&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;&#160;&#160;anaemia,&#160;thrombocytopenia&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft691">Immune&#160;system disorders&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;&#160;&#160;hypersensitivity&#160;reactions such&#160;as&#160;angioedema, rash, urticaria,&#160;anaphylactic reaction,&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft691">anaphylactic shock&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft691">Metabolism&#160;and nutrition disorders&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;&#160;&#160;hyperkalaemia, hypoglycaemia&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft692"><b>&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft691">Nervous&#160;system&#160;disorders&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft691">Common:&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft691">dizziness,&#160;orthostatic dizziness*&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft691">vertigo,&#160;headache&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft691">Ear&#160;and labyrinth disorder&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:444px;left:213px;white-space:nowrap" class="ft691">tinnitus&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft691">Cardiac disorders&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;tachycardia&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft691">Vascular disorders&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft691">Common:&#160;</p>
<p style="position:absolute;top:558px;left:214px;white-space:nowrap" class="ft691">orthostatic&#160;hypotension*&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;flushing&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft691">Respiratory, thoracic&#160;and mediastinal&#160;disorders&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;cough&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft691">Gastrointestinal disorders&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft691">Common:&#160;</p>
<p style="position:absolute;top:690px;left:214px;white-space:nowrap" class="ft691">nausea/vomiting&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;diarrhoea,&#160;dyspepsia/heartburn&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:728px;left:214px;white-space:nowrap" class="ft691">dysgeusia&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft691">Hepatobiliary&#160;disorders&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;jaundice&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:804px;left:213px;white-space:nowrap" class="ft691">hepatitis,&#160;abnormal&#160;liver&#160;function&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft691">Skin and subcutaneous&#160;tissue&#160;disorders&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:861px;left:213px;white-space:nowrap" class="ft691">leukocytoclastic vasculitis&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft691">Musculoskeletal&#160;and connective&#160;tissue disorders&#160;&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft691">Common:&#160;</p>
<p style="position:absolute;top:918px;left:214px;white-space:nowrap" class="ft691">musculoskeletal&#160;pain*&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:937px;left:214px;white-space:nowrap" class="ft691">arthralgia,&#160;myalgia (in&#160;some cases associated&#160;with&#160;increased&#160;plasma creatine kinase&#160;</p>
<p style="position:absolute;top:956px;left:214px;white-space:nowrap" class="ft691">levels),&#160;muscle&#160;cramps&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft691">Renal&#160;and urinary disorders&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft691">Not&#160;known:&#160;</p>
<p style="position:absolute;top:1013px;left:213px;white-space:nowrap" class="ft691">&#160;impaired&#160;renal&#160;function including&#160;cases&#160;of renal&#160;failure&#160;in&#160;patients at&#160;risk&#160;(see&#160;</p>
<p style="position:absolute;top:1032px;left:214px;white-space:nowrap" class="ft691">section&#160;4.4)&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft691">Reproductive&#160;system&#160;and&#160;breast&#160;disorders&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft691">Uncommon:&#160;&#160;sexual&#160;dysfunction&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft691">&#160;</p>
</div>
<!-- Page 70 -->
<a name="70"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page70-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft700">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft700">70&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft701">General disorders&#160;and&#160;administration&#160;site&#160;conditions&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft701">Common:&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft701">fatigue&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft701">Uncommon:&#160;&#160;chest&#160;pain&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft701">Investigations&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft701">Very&#160;common:&#160;&#160;Hyperkalaemia*&#160;occurred&#160;more often&#160;in&#160;diabetic patients&#160;treated&#160;with&#160;irbesartan&#160;than&#160;</p>
<p style="position:absolute;top:197px;left:214px;white-space:nowrap" class="ft701">with placebo. In diabetic&#160;hypertensive&#160;patients&#160;with&#160;microalbuminuria&#160;and normal&#160;</p>
<p style="position:absolute;top:216px;left:214px;white-space:nowrap" class="ft706">renal&#160;function,&#160;hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred in 29.4%&#160;of&#160;the&#160;patients&#160;in the&#160;</p>
<p style="position:absolute;top:235px;left:214px;white-space:nowrap" class="ft701">irbesartan 300&#160;mg&#160;group and 22%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group. In diabetic&#160;</p>
<p style="position:absolute;top:254px;left:214px;white-space:nowrap" class="ft701">hypertensive&#160;patients&#160;with&#160;chronic&#160;renal&#160;insufficiency and&#160;overt&#160;proteinuria,&#160;</p>
<p style="position:absolute;top:273px;left:214px;white-space:nowrap" class="ft706">hyperkalaemia&#160;(≥&#160;5.5&#160;mEq/L)&#160;occurred&#160;in 46.3%&#160;of&#160;the&#160;patients&#160;in the&#160;irbesartan&#160;group&#160;</p>
<p style="position:absolute;top:292px;left:214px;white-space:nowrap" class="ft701">and&#160;26.3%&#160;of&#160;the&#160;patients&#160;in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft701">Common:&#160;</p>
<p style="position:absolute;top:311px;left:214px;white-space:nowrap" class="ft701">significant&#160;increases in&#160;plasma creatine kinase&#160;were&#160;commonly&#160;observed (1.7%)&#160;in&#160;</p>
<p style="position:absolute;top:330px;left:214px;white-space:nowrap" class="ft701">irbesartan&#160;treated&#160;subjects.&#160;None of&#160;these increases were associated&#160;with&#160;identifiable&#160;</p>
<p style="position:absolute;top:349px;left:214px;white-space:nowrap" class="ft701">clinical musculoskeletal&#160;events.&#160;</p>
<p style="position:absolute;top:368px;left:214px;white-space:nowrap" class="ft701">In&#160;1.7%&#160;of&#160;hypertensive&#160;patients with&#160;advanced&#160;diabetic renal&#160;disease treated&#160;with&#160;</p>
<p style="position:absolute;top:387px;left:214px;white-space:nowrap" class="ft701">irbesartan,&#160;a&#160;decrease&#160;in&#160;haemoglobin*, which&#160;was not&#160;clinically&#160;significant,&#160;has been&#160;</p>
<p style="position:absolute;top:406px;left:214px;white-space:nowrap" class="ft701">observed.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft703"><i>&#160;</i></p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft701">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft701">In a&#160;randomised&#160;trial&#160;of&#160;318&#160;hypertensive children and&#160;adolescents&#160;aged 6&#160;to&#160;16&#160;years,&#160;the&#160;following&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft701">adverse&#160;reactions occurred&#160;in&#160;the 3-week double-blind&#160;phase:&#160;headache&#160;(7.9%), hypotension (2.2%),&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft701">dizziness&#160;(1.9%), cough (0.9%).&#160;In the&#160;26-week open-label&#160;period&#160;of&#160;this&#160;trial&#160;the&#160;most&#160;frequent&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft701">laboratory abnormalities observed&#160;were&#160;creatinine&#160;increases&#160;(6.5%)&#160;and&#160;elevated&#160;CK&#160;values&#160;in&#160;2%&#160;of&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft701">child recipients.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft701">Reporting of&#160;suspected&#160;adverse reactions&#160;&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft701">Reporting&#160;suspected adverse&#160;reactions&#160;after&#160;authorisation of&#160;the&#160;medicinal&#160;product&#160;is&#160;important. It&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft701">allows continued monitoring of&#160;the benefit/risk balance&#160;of&#160;the&#160;medicinal&#160;product.&#160;Healthcare&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft701">professionals&#160;are&#160;asked to report&#160;any&#160;suspected&#160;adverse reactions via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft701">listed&#160;in Appendix V.&#160;&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft702"><b>4.9&#160;&#160;Overdose&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft702"><b>&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft701">Experience&#160;in adults&#160;exposed to doses&#160;of&#160;up to 900&#160;mg/day&#160;for 8&#160;weeks&#160;revealed no toxicity. The&#160;most&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft701">likely&#160;manifestations&#160;of&#160;overdose&#160;are expected&#160;to&#160;be&#160;hypotension&#160;and&#160;tachycardia;&#160;bradycardia might&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft701">also&#160;occur&#160;from&#160;overdose.&#160;No&#160;specific information&#160;is available&#160;on&#160;the treatment&#160;of&#160;overdose with&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft701">Karvea. The&#160;patient&#160;should be&#160;closely monitored, and the&#160;treatment&#160;should&#160;be symptomatic&#160;and&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft701">supportive. Suggested&#160;measures&#160;include induction&#160;of&#160;emesis&#160;and/or&#160;gastric lavage.&#160;Activated&#160;charcoal&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft701">may be&#160;useful&#160;in the&#160;treatment&#160;of&#160;overdose. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft702"><b>5.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft702"><b>PHARMACOLOGICAL&#160;PROPERTIES&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft702"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft702"><b>5.1&#160;&#160;Pharmacodynamic properties&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft702"><b>&#160;</b></p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft701">Pharmacotherapeutic group: Angiotensin-II&#160;antagonists, plain.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft701">ATC&#160;code:&#160;C09C&#160;A04.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft701">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft701">Mechanism&#160;of&#160;action</p>
<p style="position:absolute;top:1051px;left:246px;white-space:nowrap" class="ft702"><b>&#160;&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft702"><b>&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft701">Irbesartan&#160;is&#160;a potent,&#160;orally&#160;active,&#160;selective angiotensin-II&#160;receptor&#160;(type&#160;AT1)&#160;antagonist.&#160;It is&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft701">expected&#160;to block&#160;all&#160;actions&#160;of&#160;angiotensin-II&#160;mediated&#160;by&#160;the&#160;AT1&#160;receptor,&#160;regardless of&#160;the source&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft701">or&#160;route&#160;of&#160;synthesis&#160;of&#160;angiotensin-II.&#160;The selective&#160;antagonism&#160;of&#160;the angiotensin-II&#160;(AT1)&#160;receptors&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft701">results in&#160;increases&#160;in&#160;plasma&#160;renin levels&#160;and angiotensin-II&#160;levels,&#160;and&#160;a decrease&#160;in&#160;plasma&#160;</p>
</div>
<!-- Page 71 -->
<a name="71"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page71-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft710">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft710">71&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft711">aldosterone&#160;concentration. Serum&#160;potassium&#160;levels&#160;are&#160;not&#160;significantly&#160;affected&#160;by&#160;irbesartan&#160;alone&#160;at&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft711">the&#160;recommended&#160;doses.&#160;Irbesartan&#160;does not&#160;inhibit ACE&#160;(kininase-II),&#160;an&#160;enzyme&#160;which generates&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft711">angiotensin-II&#160;and also degrades&#160;bradykinin&#160;into&#160;inactive metabolites.&#160;Irbesartan&#160;does not&#160;require&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft711">metabolic&#160;activation&#160;for&#160;its&#160;activity.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft711">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft711">Clinical efficacy</p>
<p style="position:absolute;top:178px;left:216px;white-space:nowrap" class="ft712"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft712"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft713"><i>Hypertension&#160;</i></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft711">Irbesartan lowers&#160;blood&#160;pressure&#160;with&#160;minimal&#160;change&#160;in&#160;heart&#160;rate.&#160;The&#160;decrease in&#160;blood&#160;pressure&#160;is&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft711">dose-related for&#160;once-a-day&#160;doses with&#160;a&#160;tendency towards&#160;plateau at&#160;doses&#160;above&#160;300 mg. Doses&#160;of&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft711">150-300&#160;mg once&#160;daily&#160;lower&#160;supine&#160;or&#160;seated&#160;blood&#160;pressures at&#160;trough&#160;(i.e.&#160;24 hours&#160;after&#160;dosing)&#160;by&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft711">an&#160;average of&#160;8-13/5-8&#160;mm&#160;Hg&#160;(systolic/diastolic)&#160;greater&#160;than&#160;those associated&#160;with placebo.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft711">Peak reduction of&#160;blood pressure is achieved&#160;within&#160;3-6&#160;hours&#160;after&#160;administration&#160;and the&#160;blood&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft711">pressure lowering&#160;effect&#160;is&#160;maintained&#160;for&#160;at&#160;least&#160;24&#160;hours.&#160;At&#160;24&#160;hours&#160;the&#160;reduction of&#160;blood&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft711">pressure was 60-70%&#160;of&#160;the&#160;corresponding peak diastolic and&#160;systolic&#160;responses at&#160;the recommended&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft711">doses. Once&#160;daily dosing with 150&#160;mg produced trough and&#160;mean&#160;24-hour&#160;responses similar&#160;to&#160;twice&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft711">daily&#160;dosing on&#160;the&#160;same total&#160;dose.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft711">The&#160;blood pressure lowering&#160;effect&#160;of&#160;Karvea&#160;is&#160;evident within&#160;1-2&#160;weeks,&#160;with&#160;the&#160;maximal effect&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft711">occurring by 4-6 weeks&#160;after&#160;start&#160;of&#160;therapy. The&#160;antihypertensive&#160;effects&#160;are&#160;maintained during&#160;long&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft711">term&#160;therapy. After&#160;withdrawal&#160;of&#160;therapy, blood pressure&#160;gradually&#160;returns&#160;toward baseline. Rebound&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft711">hypertension&#160;has&#160;not&#160;been&#160;observed.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft711">The&#160;blood pressure&#160;lowering effects&#160;of&#160;irbesartan and thiazide-type diuretics&#160;are additive.&#160;In&#160;patients&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft711">not&#160;adequately controlled&#160;by irbesartan alone,&#160;the&#160;addition of&#160;a&#160;low&#160;dose&#160;of&#160;hydrochlorothiazide&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft711">(12.5&#160;mg)&#160;to&#160;irbesartan&#160;once daily&#160;results in&#160;a&#160;further&#160;placebo-adjusted blood pressure&#160;reduction at&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft711">trough&#160;of&#160;7-10/3-6&#160;mm&#160;Hg&#160;(systolic/diastolic).&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft711">The efficacy&#160;of&#160;Karvea&#160;is&#160;not&#160;influenced by&#160;age&#160;or&#160;gender.&#160;As&#160;is the case with&#160;other&#160;medicinal&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft711">products&#160;that&#160;affect&#160;the&#160;renin-angiotensin system,&#160;black&#160;hypertensive patients&#160;have notably&#160;less&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft711">response&#160;to&#160;irbesartan monotherapy.&#160;When irbesartan&#160;is&#160;administered concomitantly with a&#160;low&#160;dose&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft711">of&#160;hydrochlorothiazide&#160;(e.g.&#160;12.5&#160;mg&#160;daily), the&#160;antihypertensive&#160;response&#160;in&#160;black&#160;patients approaches&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft711">that of&#160;white&#160;patients.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft711">There&#160;is&#160;no&#160;clinically&#160;important&#160;effect&#160;on&#160;serum&#160;uric&#160;acid or&#160;urinary uric&#160;acid secretion.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft711">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft711">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft711">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft711">Reduction of&#160;blood pressure&#160;with&#160;0.5&#160;mg/kg (low),&#160;1.5&#160;mg/kg (medium)&#160;and&#160;4.5&#160;mg/kg&#160;(high)&#160;target&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft711">titrated&#160;doses of&#160;irbesartan&#160;was evaluated in&#160;318&#160;hypertensive&#160;or&#160;at&#160;risk&#160;(diabetic,&#160;family&#160;history&#160;of&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft711">hypertension)&#160;children and&#160;adolescents&#160;aged&#160;6 to&#160;16&#160;years over&#160;a three-week&#160;period. At&#160;the&#160;end of&#160;the&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft711">three&#160;weeks&#160;the mean&#160;reduction from&#160;baseline&#160;in the&#160;primary efficacy variable, trough&#160;seated&#160;systolic&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft711">blood pressure&#160;(SeSBP)&#160;was&#160;11.7&#160;mmHg&#160;(low&#160;dose), 9.3 mmHg (medium&#160;dose),&#160;13.2 mmHg (high&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft711">dose).&#160;No&#160;significant&#160;difference was apparent&#160;between&#160;these&#160;doses. Adjusted mean&#160;change&#160;of&#160;trough&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft711">seated&#160;diastolic&#160;blood&#160;pressure (SeDBP)&#160;was&#160;as&#160;follows:&#160;3.8&#160;mmHg&#160;(low&#160;dose), 3.2&#160;mmHg&#160;(medium&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft711">dose), 5.6&#160;mmHg&#160;(high dose). Over&#160;a&#160;subsequent&#160;two-week&#160;period&#160;where&#160;patients&#160;were&#160;re-randomized&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft711">to&#160;either&#160;active&#160;medicinal&#160;product&#160;or&#160;placebo, patients&#160;on placebo&#160;had&#160;increases&#160;of&#160;2.4 and 2.0&#160;mmHg&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft711">in&#160;SeSBP and&#160;SeDBP&#160;compared&#160;to&#160;+0.1 and -0.3 mmHg changes&#160;respectively in those&#160;on&#160;all&#160;doses&#160;of&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft711">irbesartan&#160;(see&#160;section&#160;4.2).&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft711">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft713"><i>Hypertension and type&#160;2&#160;diabetes&#160;with renal&#160;disease&#160;</i></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft711">The “Irbesartan&#160;Diabetic Nephropathy&#160;Trial&#160;(IDNT)” shows that&#160;irbesartan&#160;decreases&#160;the progression&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft711">of&#160;renal&#160;disease in&#160;patients&#160;with&#160;chronic&#160;renal&#160;insufficiency and overt&#160;proteinuria.&#160;IDNT&#160;was&#160;a&#160;double&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft711">blind, controlled,&#160;morbidity&#160;and mortality trial&#160;comparing&#160;Karvea, amlodipine&#160;and&#160;placebo. In&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft711">1,715 hypertensive&#160;patients&#160;with&#160;type&#160;2&#160;diabetes, proteinuria&#160;≥&#160;900&#160;mg/day and serum&#160;creatinine&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft711">ranging from&#160;1.0-3.0&#160;mg/dl,&#160;the&#160;long-term&#160;effects (mean&#160;2.6&#160;years) of&#160;Karvea&#160;on&#160;the&#160;progression of&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft711">renal&#160;disease&#160;and&#160;all-cause&#160;mortality&#160;were&#160;examined.&#160;Patients&#160;were&#160;titrated&#160;from&#160;75&#160;mg to&#160;a&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft711">maintenance&#160;dose&#160;of&#160;300&#160;mg&#160;Karvea, from&#160;2.5&#160;mg to&#160;10&#160;mg amlodipine, or&#160;placebo as&#160;tolerated.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft711">Patients in&#160;all&#160;treatment&#160;groups typically&#160;received&#160;between&#160;2 and 4 antihypertensive&#160;agents (e.g.,&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft711">diuretics,&#160;beta&#160;blockers,&#160;alpha&#160;blockers)&#160;to&#160;reach&#160;a&#160;predefined&#160;blood&#160;pressure goal&#160;of&#160;≤&#160;135/85&#160;mmHg&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft711">or&#160;a&#160;10&#160;mmHg reduction in&#160;systolic&#160;pressure&#160;if&#160;baseline&#160;was&#160;&gt;&#160;160&#160;mmHg. Sixty&#160;per&#160;cent&#160;(60%)&#160;of&#160;</p>
</div>
<!-- Page 72 -->
<a name="72"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page72-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft720">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft720">72&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft721">patients in&#160;the placebo&#160;group&#160;reached&#160;this&#160;target&#160;blood pressure whereas&#160;this figure was 76%&#160;and&#160;78%&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft721">in&#160;the irbesartan&#160;and&#160;amlodipine&#160;groups&#160;respectively. Irbesartan significantly&#160;reduced the&#160;relative&#160;risk&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft721">in the&#160;primary combined&#160;endpoint&#160;of&#160;doubling serum&#160;creatinine,&#160;end-stage&#160;renal&#160;disease (ESRD)&#160;or&#160;all-</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft721">cause&#160;mortality. Approximately 33%&#160;of&#160;patients&#160;in&#160;the&#160;irbesartan group reached&#160;the&#160;primary&#160;renal&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft721">composite&#160;endpoint&#160;compared to 39%&#160;and 41%&#160;in the&#160;placebo and amlodipine&#160;groups&#160;[20%&#160;relative&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft721">risk&#160;reduction&#160;versus&#160;placebo (p&#160;=&#160;0.024)&#160;and&#160;23%&#160;relative&#160;risk&#160;reduction&#160;compared to&#160;amlodipine&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft721">(p&#160;=&#160;0.006)].&#160;When the&#160;individual&#160;components&#160;of&#160;the&#160;primary&#160;endpoint&#160;were analysed,&#160;no&#160;effect&#160;in&#160;all-</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft721">cause&#160;mortality&#160;was observed,&#160;while a&#160;positive&#160;trend&#160;in&#160;the&#160;reduction&#160;in&#160;ESRD&#160;and&#160;a significant&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft721">reduction in doubling of&#160;serum&#160;creatinine&#160;were&#160;observed.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft721">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft721">Subgroups&#160;consisting of&#160;gender,&#160;race, age, duration of&#160;diabetes,&#160;baseline&#160;blood pressure, serum&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft721">creatinine,&#160;and&#160;albumin&#160;excretion&#160;rate were assessed&#160;for&#160;treatment&#160;effect.&#160;In&#160;the female and&#160;black&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft721">subgroups&#160;which&#160;represented 32%&#160;and 26%&#160;of&#160;the&#160;overall&#160;study population respectively, a&#160;renal&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft721">benefit&#160;was&#160;not&#160;evident,&#160;although the&#160;confidence&#160;intervals&#160;do not&#160;exclude&#160;it. As&#160;for&#160;the&#160;secondary&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft721">endpoint&#160;of&#160;fatal&#160;and non-fatal&#160;cardiovascular&#160;events,&#160;there was no&#160;difference among&#160;the&#160;three groups&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft721">in the&#160;overall&#160;population,&#160;although&#160;an&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;for&#160;women and&#160;a&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft721">decreased&#160;incidence of&#160;non-fatal&#160;MI&#160;was&#160;seen&#160;in&#160;males&#160;in&#160;the irbesartan&#160;group&#160;versus the placebo-</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft721">based&#160;regimen. An&#160;increased incidence&#160;of&#160;non-fatal&#160;MI&#160;and&#160;stroke was&#160;seen&#160;in&#160;females&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft721">irbesartan-based&#160;regimen&#160;versus the&#160;amlodipine-based&#160;regimen, while&#160;hospitalization due&#160;to heart&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft721">failure&#160;was&#160;reduced in the&#160;overall&#160;population.&#160;However,&#160;no&#160;proper&#160;explanation&#160;for&#160;these&#160;findings&#160;in&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft721">women&#160;has been&#160;identified.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft721">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft721">The&#160;study of&#160;the&#160;“Effects&#160;of&#160;Irbesartan on&#160;Microalbuminuria&#160;in Hypertensive Patients&#160;with type&#160;2&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft721">Diabetes Mellitus&#160;(IRMA&#160;2)” shows that&#160;irbesartan&#160;300&#160;mg delays&#160;progression&#160;to&#160;overt&#160;proteinuria&#160;in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft721">patients&#160;with&#160;microalbuminuria.&#160;IRMA&#160;2&#160;was a&#160;placebo-controlled double&#160;blind&#160;morbidity&#160;study in&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft721">590&#160;patients&#160;with&#160;type&#160;2&#160;diabetes, microalbuminuria&#160;(30-300&#160;mg/day)&#160;and&#160;normal&#160;renal&#160;function&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft721">(serum&#160;creatinine&#160;≤&#160;1.5&#160;mg/dl in&#160;males&#160;and&#160;&lt;&#160;1.1&#160;mg/dl&#160;in females). The&#160;study&#160;examined the&#160;long-term&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft721">effects (2&#160;years) of&#160;Karvea&#160;on the&#160;progression to clinical&#160;(overt)&#160;proteinuria&#160;(urinary albumin excretion&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft721">rate&#160;(UAER)&#160;&gt;&#160;300&#160;mg/day, and an&#160;increase&#160;in UAER&#160;of&#160;at&#160;least&#160;30%&#160;from&#160;baseline). The&#160;predefined&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft726">blood pressure&#160;goal&#160;was&#160;≤&#160;135/85&#160;mmHg.&#160;Additional&#160;antihypertensive&#160;agents&#160;(excluding&#160;ACE&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft721">inhibitors, angiotensin&#160;II&#160;receptor&#160;antagonists&#160;and&#160;dihydropyridine&#160;calcium&#160;blockers)&#160;were&#160;added&#160;as&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft721">needed&#160;to&#160;help&#160;achieve the&#160;blood&#160;pressure goal.&#160;While&#160;similar&#160;blood&#160;pressure was&#160;achieved&#160;in&#160;all&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft721">treatment&#160;groups,&#160;fewer&#160;subjects&#160;in the&#160;irbesartan 300&#160;mg&#160;group (5.2%)&#160;than in the&#160;placebo (14.9%)&#160;or&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft721">in&#160;the&#160;irbesartan&#160;150&#160;mg&#160;group (9.7%)&#160;reached the&#160;endpoint&#160;of&#160;overt&#160;proteinuria, demonstrating&#160;a&#160;70%&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft721">relative&#160;risk reduction versus&#160;placebo (p&#160;=&#160;0.0004)&#160;for&#160;the&#160;higher&#160;dose. An accompanying&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft721">improvement&#160;in&#160;the&#160;glomerular&#160;filtration&#160;rate&#160;(GFR)&#160;was&#160;not observed&#160;during&#160;the&#160;first three&#160;months&#160;of&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft721">treatment. The&#160;slowing&#160;in&#160;the&#160;progression to clinical&#160;proteinuria&#160;was&#160;evident&#160;as&#160;early as&#160;three&#160;months&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft721">and continued over&#160;the&#160;2-years&#160;period. Regression to normoalbuminuria&#160;(&lt;&#160;30&#160;mg/day)&#160;was&#160;more&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft721">frequent&#160;in the&#160;Karvea&#160;300&#160;mg group&#160;(34%)&#160;than in the&#160;placebo&#160;group (21%).&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft721">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft723"><i>Dual&#160;blockade&#160;of&#160;the&#160;renin-angiotensin-aldosterone&#160;system&#160;(RAAS)&#160;</i></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft721">Two large&#160;randomised,&#160;controlled trials&#160;(ONTARGET&#160;(ONgoing Telmisartan Alone&#160;and&#160;in&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft721">combination with Ramipril&#160;Global&#160;Endpoint&#160;Trial)&#160;and&#160;VA NEPHRON-D&#160;(The Veterans Affairs&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft721">Nephropathy in&#160;Diabetes))&#160;have&#160;examined the&#160;use&#160;of&#160;the&#160;combination&#160;of&#160;an ACE-inhibitor&#160;with an&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft721">angiotensin II&#160;receptor&#160;blocker. ONTARGET&#160;was&#160;a&#160;study conducted in&#160;patients&#160;with a&#160;history of&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft721">cardiovascular&#160;or&#160;cerebrovascular&#160;disease,&#160;or&#160;type&#160;2 diabetes&#160;mellitus&#160;accompanied&#160;by evidence&#160;of&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft721">end-organ&#160;damage.&#160;VA NEPHRON-D&#160;was&#160;a&#160;study in patients&#160;with type&#160;2&#160;diabetes&#160;mellitus&#160;and&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft721">diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft721">These&#160;studies&#160;have&#160;shown&#160;no significant&#160;beneficial&#160;effect&#160;on&#160;renal&#160;and/or&#160;cardiovascular&#160;outcomes and&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft721">mortality, while&#160;an&#160;increased risk of&#160;hyperkalaemia, acute&#160;kidney injury and/or&#160;hypotension as&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft721">compared to&#160;monotherapy&#160;was&#160;observed. Given their&#160;similar&#160;pharmacodynamic&#160;properties, these&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft721">results&#160;are&#160;also relevant&#160;for&#160;other&#160;ACE-inhibitors&#160;and angiotensin II&#160;receptor&#160;blockers.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft721">ACE-inhibitors&#160;and&#160;angiotensin II&#160;receptor&#160;blockers&#160;should&#160;therefore&#160;not&#160;be&#160;used concomitantly&#160;in&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft721">patients&#160;with diabetic&#160;nephropathy.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft721">ALTITUDE&#160;(Aliskiren Trial&#160;in Type&#160;2 Diabetes&#160;Using&#160;Cardiovascular&#160;and Renal&#160;Disease&#160;Endpoints)&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft721">was&#160;a&#160;study designed&#160;to&#160;test&#160;the&#160;benefit&#160;of&#160;adding aliskiren&#160;to a&#160;standard therapy of&#160;an ACE-inhibitor&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft721">or&#160;an&#160;angiotensin II&#160;receptor&#160;blocker&#160;in&#160;patients&#160;with&#160;type&#160;2 diabetes&#160;mellitus&#160;and chronic&#160;kidney&#160;</p>
</div>
<!-- Page 73 -->
<a name="73"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page73-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft730">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft730">73&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft731">disease,&#160;cardiovascular&#160;disease, or&#160;both. The&#160;study&#160;was&#160;terminated&#160;early&#160;because of&#160;an&#160;increased&#160;risk&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft731">of&#160;adverse outcomes.&#160;Cardiovascular&#160;death&#160;and&#160;stroke&#160;were both&#160;numerically&#160;more frequent&#160;in&#160;the&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft731">aliskiren group&#160;than&#160;in&#160;the&#160;placebo&#160;group&#160;and&#160;adverse&#160;events and&#160;serious adverse&#160;events of&#160;interest&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft731">(hyperkalaemia, hypotension and renal&#160;dysfunction)&#160;were&#160;more&#160;frequently reported&#160;in the&#160;aliskiren&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft731">group than in the&#160;placebo group.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft732"><b>5.2&#160;&#160;Pharmacokinetic properties&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft732"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft731">Absorption&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft731">After&#160;oral&#160;administration,&#160;irbesartan&#160;is well&#160;absorbed:&#160;studies of&#160;absolute&#160;bioavailability&#160;gave&#160;values&#160;of&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft731">approximately 60-80%.&#160;Concomitant&#160;food&#160;intake&#160;does&#160;not&#160;significantly influence&#160;the&#160;bioavailability of&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft731">irbesartan.&#160;&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft731">Distribution&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft731">Plasma&#160;protein binding is&#160;approximately 96%, with&#160;negligible&#160;binding to cellular&#160;blood&#160;components.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft731">The&#160;volume&#160;of&#160;distribution&#160;is&#160;53 -&#160;93&#160;litres.&#160;&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft731">Biotransformation&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft731">Following&#160;oral or&#160;intravenous&#160;administration&#160;of&#160;14C&#160;irbesartan,&#160;80-85%&#160;of&#160;the&#160;circulating plasma&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft731">radioactivity is&#160;attributable&#160;to unchanged irbesartan.&#160;Irbesartan is&#160;metabolised by&#160;the&#160;liver&#160;via&#160;</p>
<p style="position:absolute;top:521px;left:106px;white-space:nowrap" class="ft731">glucuronide&#160;conjugation&#160;and oxidation. The&#160;major&#160;circulating&#160;metabolite&#160;is&#160;irbesartan glucuronide&#160;</p>
<p style="position:absolute;top:540px;left:106px;white-space:nowrap" class="ft731">(approximately 6%).&#160;<i>In&#160;vitro</i>&#160;studies indicate that&#160;irbesartan&#160;is primarily&#160;oxidised&#160;by&#160;the&#160;</p>
<p style="position:absolute;top:559px;left:106px;white-space:nowrap" class="ft731">cytochrome&#160;P450 enzyme&#160;CYP2C9;&#160;isoenzyme&#160;CYP3A4 has&#160;negligible&#160;effect.&#160;</p>
<p style="position:absolute;top:578px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:597px;left:106px;white-space:nowrap" class="ft731">Linearity&#160;/&#160;non-linearity&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:635px;left:106px;white-space:nowrap" class="ft731">Irbesartan exhibits&#160;linear&#160;and dose&#160;proportional&#160;pharmacokinetics&#160;over&#160;the&#160;dose&#160;range&#160;of&#160;10&#160;to 600&#160;mg.&#160;</p>
<p style="position:absolute;top:654px;left:106px;white-space:nowrap" class="ft731">A&#160;less&#160;than proportional&#160;increase&#160;in oral&#160;absorption&#160;at&#160;doses&#160;beyond&#160;600&#160;mg&#160;(twice&#160;the&#160;maximal&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft731">recommended&#160;dose)&#160;was observed; the&#160;mechanism&#160;for&#160;this&#160;is&#160;unknown. Peak plasma&#160;concentrations&#160;</p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft731">are&#160;attained at&#160;1.5&#160;-&#160;2 hours&#160;after&#160;oral&#160;administration. The&#160;total&#160;body&#160;and&#160;renal&#160;clearance&#160;are&#160;157 -</p>
<p style="position:absolute;top:711px;left:106px;white-space:nowrap" class="ft731">&#160;176&#160;and 3&#160;-&#160;3.5&#160;ml/min,&#160;respectively.&#160;The&#160;terminal&#160;elimination&#160;half-life of&#160;irbesartan&#160;is&#160;11 -&#160;15&#160;hours.&#160;</p>
<p style="position:absolute;top:730px;left:106px;white-space:nowrap" class="ft731">Steady-state&#160;plasma concentrations&#160;are attained&#160;within&#160;3&#160;days after&#160;initiation&#160;of&#160;a&#160;once-daily dosing&#160;</p>
<p style="position:absolute;top:749px;left:106px;white-space:nowrap" class="ft731">regimen. Limited accumulation&#160;of&#160;irbesartan (&lt;&#160;20%)&#160;is&#160;observed&#160;in plasma&#160;upon&#160;repeated once-daily&#160;</p>
<p style="position:absolute;top:768px;left:106px;white-space:nowrap" class="ft731">dosing. In a&#160;study,&#160;somewhat&#160;higher&#160;plasma&#160;concentrations&#160;of&#160;irbesartan&#160;were&#160;observed&#160;in&#160;female&#160;</p>
<p style="position:absolute;top:787px;left:106px;white-space:nowrap" class="ft731">hypertensive&#160;patients. However,&#160;there&#160;was&#160;no difference&#160;in&#160;the&#160;half-life&#160;and accumulation&#160;of&#160;</p>
<p style="position:absolute;top:806px;left:106px;white-space:nowrap" class="ft731">irbesartan.&#160;No&#160;dosage&#160;adjustment&#160;is necessary&#160;in&#160;female patients.&#160;Irbesartan&#160;AUC&#160;and&#160;Cmax&#160;values&#160;</p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft731">were also&#160;somewhat&#160;greater&#160;in&#160;older&#160;subjects&#160;(≥&#160;65&#160;years)&#160;than those&#160;of&#160;young subjects&#160;(18&#160;-&#160;40&#160;years).&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft731">However&#160;the&#160;terminal&#160;half-life was not&#160;significantly&#160;altered.&#160;No&#160;dosage adjustment&#160;is necessary&#160;in&#160;</p>
<p style="position:absolute;top:863px;left:106px;white-space:nowrap" class="ft731">older&#160;people.&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:900px;left:106px;white-space:nowrap" class="ft731">Elimination&#160;</p>
<p style="position:absolute;top:919px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:938px;left:106px;white-space:nowrap" class="ft731">Irbesartan&#160;and&#160;its metabolites are&#160;eliminated&#160;by both&#160;biliary and renal&#160;pathways. After&#160;either&#160;oral&#160;or&#160;IV&#160;</p>
<p style="position:absolute;top:959px;left:106px;white-space:nowrap" class="ft731">administration of&#160;14C&#160;irbesartan, about&#160;20%&#160;of&#160;the&#160;radioactivity&#160;is&#160;recovered&#160;in the&#160;urine, and the&#160;</p>
<p style="position:absolute;top:978px;left:106px;white-space:nowrap" class="ft731">remainder&#160;in&#160;the&#160;faeces.&#160;Less than&#160;2%&#160;of&#160;the dose is excreted&#160;in&#160;the urine as&#160;unchanged&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:997px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:1016px;left:106px;white-space:nowrap" class="ft731">Paediatric&#160;population&#160;</p>
<p style="position:absolute;top:1035px;left:106px;white-space:nowrap" class="ft731">&#160;</p>
<p style="position:absolute;top:1054px;left:106px;white-space:nowrap" class="ft731">The&#160;pharmacokinetics&#160;of&#160;irbesartan were&#160;evaluated&#160;in&#160;23&#160;hypertensive&#160;children&#160;after&#160;the&#160;administration&#160;</p>
<p style="position:absolute;top:1073px;left:106px;white-space:nowrap" class="ft731">of&#160;single and&#160;multiple daily&#160;doses&#160;of&#160;irbesartan&#160;(2&#160;mg/kg)&#160;up&#160;to a&#160;maximum&#160;daily&#160;dose&#160;of&#160;150&#160;mg for&#160;</p>
<p style="position:absolute;top:1092px;left:106px;white-space:nowrap" class="ft731">four&#160;weeks. Of&#160;those&#160;23 children, 21 were&#160;evaluable&#160;for&#160;comparison of&#160;pharmacokinetics&#160;with adults&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft731">(twelve&#160;children over&#160;12&#160;years,&#160;nine&#160;children&#160;between&#160;6&#160;and&#160;12&#160;years).&#160;Results showed&#160;that&#160;Cmax,&#160;AUC&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft731">and&#160;clearance rates were comparable&#160;to&#160;those&#160;observed&#160;in&#160;adult&#160;patients&#160;receiving 150&#160;mg&#160;irbesartan&#160;</p>
</div>
<!-- Page 74 -->
<a name="74"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page74-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft740">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft740">74&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft741">daily. A&#160;limited accumulation of&#160;irbesartan (18%)&#160;in&#160;plasma&#160;was&#160;observed&#160;upon&#160;repeated once&#160;daily&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft741">dosing.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft741">Renal&#160;impairment&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft741">In&#160;patients&#160;with renal&#160;impairment&#160;or&#160;those&#160;undergoing&#160;haemodialysis, the&#160;pharmacokinetic&#160;parameters&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft741">of&#160;irbesartan&#160;are&#160;not&#160;significantly altered. Irbesartan&#160;is&#160;not&#160;removed by haemodialysis.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft741">Hepatic impairment&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft741">In&#160;patients with&#160;mild&#160;to&#160;moderate cirrhosis,&#160;the pharmacokinetic parameters of&#160;irbesartan&#160;are not&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft741">significantly&#160;altered.&#160;&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft741">Studies have not&#160;been&#160;performed&#160;in patients&#160;with&#160;severe&#160;hepatic&#160;impairment.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft742"><b>5.3<i>&#160;&#160;</i></b><b>Preclinical&#160;safety&#160;data&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft742"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft741">There&#160;was&#160;no&#160;evidence&#160;of&#160;abnormal&#160;systemic&#160;or&#160;target&#160;organ toxicity at&#160;clinically relevant&#160;doses.&#160;In&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft741">non-clinical&#160;safety&#160;studies,&#160;high&#160;doses&#160;of&#160;irbesartan&#160;(≥&#160;250&#160;mg/kg/day&#160;in&#160;rats&#160;and&#160;≥&#160;100&#160;mg/kg/day in&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft741">macaques)&#160;caused&#160;a&#160;reduction&#160;of&#160;red&#160;blood&#160;cell&#160;parameters (erythrocytes, haemoglobin, haematocrit).&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft746">At&#160;very high doses&#160;(≥&#160;500&#160;mg/kg/day)&#160;degenerative&#160;changes&#160;in the&#160;kidney&#160;(such as&#160;interstitial&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft741">nephritis,&#160;tubular&#160;distension, basophilic&#160;tubules, increased plasma&#160;concentrations&#160;of&#160;urea&#160;and&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft741">creatinine)&#160;were&#160;induced&#160;by&#160;irbesartan in&#160;the&#160;rat&#160;and the&#160;macaque&#160;and are&#160;considered secondary to&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft741">hypotensive&#160;effects&#160;of&#160;the&#160;medicinal&#160;product&#160;which led to decreased renal&#160;perfusion. Furthermore,&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft746">irbesartan induced&#160;hyperplasia/hypertrophy of&#160;the&#160;juxtaglomerular&#160;cells&#160;(in&#160;rats&#160;at&#160;≥&#160;90&#160;mg/kg/day, in&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft746">macaques&#160;at&#160;≥&#160;10 mg/kg/day). All&#160;of&#160;these&#160;changes&#160;were&#160;considered to be&#160;caused&#160;by the&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft741">pharmacological&#160;action of&#160;irbesartan. For&#160;therapeutic&#160;doses&#160;of&#160;irbesartan in&#160;humans, the&#160;hyperplasia/&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft741">hypertrophy of&#160;the&#160;renal&#160;juxtaglomerular&#160;cells&#160;does&#160;not&#160;appear&#160;to&#160;have any&#160;relevance.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft741">There&#160;was&#160;no&#160;evidence&#160;of&#160;mutagenicity,&#160;clastogenicity or&#160;carcinogenicity.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft741">Fertility&#160;and&#160;reproductive performance were not&#160;affected&#160;in&#160;studies of&#160;male&#160;and&#160;female rats even&#160;at&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft741">oral&#160;doses of&#160;irbesartan&#160;causing&#160;some parental&#160;toxicity (from&#160;50&#160;to&#160;650 mg/kg/day),&#160;including&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft741">mortality at&#160;the&#160;highest&#160;dose. No significant&#160;effects&#160;on&#160;the&#160;number&#160;of&#160;corpora&#160;lutea, implants,&#160;or&#160;live&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft741">foetuses&#160;were&#160;observed. Irbesartan&#160;did&#160;not&#160;affect&#160;survival, development, or&#160;reproduction of&#160;offspring.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft741">Studies&#160;in&#160;animals indicate&#160;that&#160;the radiolabelled&#160;irbesartan&#160;is detected&#160;in&#160;rat&#160;and&#160;rabbit&#160;foetuses.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft741">Irbesartan is&#160;excreted&#160;in&#160;the&#160;milk of&#160;lactating&#160;rats.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft741">Animal&#160;studies&#160;with irbesartan showed&#160;transient&#160;toxic&#160;effects&#160;(increased renal&#160;pelvic&#160;cavitation,&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft741">hydroureter&#160;or&#160;subcutaneous&#160;oedema)&#160;in rat&#160;foetuses, which were&#160;resolved after&#160;birth. In rabbits,&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft741">abortion&#160;or&#160;early resorption&#160;were&#160;noted at&#160;doses&#160;causing&#160;significant&#160;maternal&#160;toxicity, including&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft741">mortality.&#160;No&#160;teratogenic effects were observed&#160;in&#160;the rat&#160;or&#160;rabbit.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft742"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft742"><b>PHARMACEUTICAL&#160;PARTICULARS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft742"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft742"><b>6.1&#160;&#160;List&#160;of&#160;excipients&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft742"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft741">Tablet&#160;core:&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft741">Lactose&#160;monohydrate&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft741">Microcrystalline&#160;cellulose&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft741">Croscarmellose sodium&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft741">Hypromellose&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft741">Silicon dioxide&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft741">Magnesium&#160;stearate.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft741">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft741">Film-coating:&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft741">Lactose&#160;monohydrate&#160;</p>
</div>
<!-- Page 75 -->
<a name="75"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page75-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft750">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft750">75&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft751">Hypromellose&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft751">Titanium dioxide&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft751">Macrogol&#160;3000&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft751">Carnauba wax.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft752"><b>6.2&#160;&#160;Incompatibilities&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft751">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft752"><b>6.3&#160;&#160;Shelf&#160;life&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft751">3&#160;years.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft752"><b>6.4&#160;&#160;Special&#160;precautions for storage&#160;</b></p>
<p style="position:absolute;top:348px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft751">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft752"><b>6.5&#160;&#160;Nature&#160;and&#160;contents&#160;of&#160;container&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;14&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;28&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;30&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;56&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;84&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;90&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;98&#160;film-coated&#160;tablets&#160;in&#160;PVC/PVDC/Aluminium blisters.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft751">Cartons&#160;of&#160;56&#160;x&#160;1&#160;film-coated tablet&#160;in PVC/PVDC/Aluminium&#160;perforated&#160;unit&#160;dose&#160;blisters.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft751">Not&#160;all&#160;pack&#160;sizes may&#160;be marketed.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft752"><b>6.6&#160;&#160;Special&#160;precautions for disposal&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft751">Any unused&#160;medicinal&#160;product&#160;or&#160;waste&#160;material&#160;should be&#160;disposed of&#160;in&#160;accordance&#160;with local&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft751">requirements.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft752"><b>7.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft752"><b>MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft751">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft751">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft751">94250 Gentilly&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft751">France&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft752"><b>8.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft752"><b>MARKETING&#160;AUTHORISATION NUMBERS&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft751">EU/1/97/049/026-030&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft751">EU/1/97/049/033&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft751">EU/1/97/049/036&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft751">EU/1/97/049/039&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft752"><b>9.&#160;</b></p>
<p style="position:absolute;top:1050px;left:149px;white-space:nowrap" class="ft752"><b>DATE&#160;OF&#160;FIRST&#160;AUTHORISATION&#160;/&#160;RENEWAL&#160;OF&#160;THE&#160;AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft752"><b>&#160;</b></p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft751">Date of&#160;first&#160;authorisation:&#160;27 August&#160;1997&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft751">Date of&#160;latest&#160;renewal:&#160;27&#160;August&#160;2007&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft751">&#160;</p>
</div>
<!-- Page 76 -->
<a name="76"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page76-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft760">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft760">76&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft762"><b>10.&#160;&#160;DATE OF&#160;REVISION&#160;OF&#160;THE TEXT&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft761">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft761">Detailed&#160;information on&#160;this&#160;medicinal&#160;product&#160;is&#160;available&#160;on the&#160;website&#160;of&#160;the&#160;European Medicines&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft761">Agency http://www.ema.europa.eu&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft761">&#160;</p>
</div>
<!-- Page 77 -->
<a name="77"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page77-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft770">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft770">77&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft771">&#160;</p>
<p style="position:absolute;top:405px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:424px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:443px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:462px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:481px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:500px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:519px;left:409px;white-space:nowrap" class="ft772"><b>ANNEX II&#160;</b></p>
<p style="position:absolute;top:538px;left:446px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:557px;left:181px;white-space:nowrap" class="ft772"><b>A.&#160;</b></p>
<p style="position:absolute;top:557px;left:234px;white-space:nowrap" class="ft772"><b>MANUFACTURERS&#160;RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:576px;left:181px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:595px;left:181px;white-space:nowrap" class="ft772"><b>B.&#160;</b></p>
<p style="position:absolute;top:595px;left:234px;white-space:nowrap" class="ft772"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;REGARDING&#160;SUPPLY AND USE&#160;</b></p>
<p style="position:absolute;top:614px;left:181px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:633px;left:181px;white-space:nowrap" class="ft772"><b>C.&#160;</b></p>
<p style="position:absolute;top:633px;left:234px;white-space:nowrap" class="ft772"><b>OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE MARKETING&#160;</b></p>
<p style="position:absolute;top:652px;left:234px;white-space:nowrap" class="ft772"><b>AUTHORISATION&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft772"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:181px;white-space:nowrap" class="ft772"><b>D.&#160;</b></p>
<p style="position:absolute;top:690px;left:234px;white-space:nowrap" class="ft772"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;THE&#160;SAFE&#160;AND&#160;</b></p>
<p style="position:absolute;top:709px;left:234px;white-space:nowrap" class="ft772"><b>EFFECTIVE&#160;USE&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
</div>
<!-- Page 78 -->
<a name="78"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft787{font-size:17px;font-family:SJUUII+SymbolMT;color:#000000;}
	.ft788{font-size:17px;font-family:ILDBYC+ArialMT;color:#000000;}
-->
</style>
<div id="page78-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft780">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft780">78&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft782"><b>A.&#160;&#160;MANUFACTURERS&#160;RESPONSIBLE&#160;FOR BATCH&#160;RELEASE&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft781">Name&#160;and&#160;address of&#160;the&#160;manufacturers&#160;responsible for&#160;batch&#160;release&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft781">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft781">1 rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft781">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft781">F-33565&#160;Carbon&#160;Blanc Cedex&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft781">France&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft781">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft781">30-36 Avenue&#160;Gustave&#160;Eiffel, BP&#160;7166&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft781">F-37071&#160;Tours&#160;Cedex 2&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft781">France&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft781">SANOFI-AVENTIS,&#160;S.A.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft781">Ctra.&#160;C-35 (La&#160;Batlloria-Hostalric), km. 63.09&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft781">17404 Riells&#160;i&#160;Viabrea&#160;(Girona)&#160;-&#160;Spain&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft781">The&#160;printed package&#160;leaflet&#160;of&#160;the&#160;medicinal&#160;product&#160;must&#160;state&#160;the name and&#160;address of&#160;the&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft781">manufacturer&#160;responsible&#160;for&#160;the&#160;release of&#160;the concerned&#160;batch.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft782"><b>B.&#160;</b></p>
<p style="position:absolute;top:538px;left:149px;white-space:nowrap" class="ft782"><b>CONDITIONS&#160;OR RESTRICTIONS&#160;REGARDING&#160;SUPPLY AND USE</b>&#160;&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft781">Medicinal&#160;product&#160;subject&#160;to&#160;medical&#160;prescription.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft782"><b>C.&#160;&#160;OTHER CONDITIONS&#160;AND REQUIREMENTS&#160;OF&#160;THE&#160;MARKETING&#160;</b></p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft782"><b>AUTHORISATION</b>&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft782"><b>&#160;</b></p>
<p style="position:absolute;top:692px;left:106px;white-space:nowrap" class="ft787">•</p>
<p style="position:absolute;top:691px;left:114px;white-space:nowrap" class="ft788">&#160;</p>
<p style="position:absolute;top:691px;left:147px;white-space:nowrap" class="ft782"><b>Periodic Safety&#160;Update Reports&#160;(PSURs)<i>&#160;</i></b></p>
<p style="position:absolute;top:710px;left:149px;white-space:nowrap" class="ft782"><b>&#160;</b></p>
<p style="position:absolute;top:729px;left:106px;white-space:nowrap" class="ft781">The&#160;requirements&#160;for&#160;submission&#160;of&#160;PSURs&#160;for&#160;this&#160;medicinal&#160;product&#160;are&#160;set out&#160;in the&#160;list&#160;of&#160;Union&#160;</p>
<p style="position:absolute;top:748px;left:106px;white-space:nowrap" class="ft781">reference dates (EURD&#160;list)&#160;provided&#160;for&#160;under&#160;Article&#160;107c(7)&#160;of&#160;Directive&#160;2001/83/EC&#160;and&#160;any&#160;</p>
<p style="position:absolute;top:767px;left:106px;white-space:nowrap" class="ft781">subsequent&#160;updates&#160;published on the&#160;European&#160;medicines&#160;web-portal.&#160;</p>
<p style="position:absolute;top:786px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:805px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:824px;left:106px;white-space:nowrap" class="ft782"><b>D.&#160;&#160;CONDITIONS&#160;OR RESTRICTIONS&#160;WITH&#160;REGARD TO&#160;THE&#160;SAFE&#160;AND&#160;</b></p>
<p style="position:absolute;top:843px;left:149px;white-space:nowrap" class="ft782"><b>EFFECTIVE USE&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:862px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
<p style="position:absolute;top:883px;left:106px;white-space:nowrap" class="ft787">•</p>
<p style="position:absolute;top:882px;left:114px;white-space:nowrap" class="ft788">&#160;</p>
<p style="position:absolute;top:882px;left:147px;white-space:nowrap" class="ft782"><b>Risk&#160;Management&#160;Plan (RMP)<i>&#160;</i></b></p>
<p style="position:absolute;top:901px;left:149px;white-space:nowrap" class="ft782"><b>&#160;</b></p>
<p style="position:absolute;top:920px;left:106px;white-space:nowrap" class="ft781">Not&#160;applicable.&#160;</p>
<p style="position:absolute;top:939px;left:106px;white-space:nowrap" class="ft781">&#160;</p>
</div>
<!-- Page 79 -->
<a name="79"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page79-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft790">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft790">79&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:519px;left:405px;white-space:nowrap" class="ft792"><b>ANNEX III&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
<p style="position:absolute;top:557px;left:293px;white-space:nowrap" class="ft792"><b>LABELLING&#160;AND PACKAGE&#160;LEAFLET&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft791">&#160;</p>
</div>
<!-- Page 80 -->
<a name="80"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page80-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft800">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft800">80&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft801">&#160;</p>
<p style="position:absolute;top:519px;left:387px;white-space:nowrap" class="ft802"><b>A.&#160;LABELLING&#160;</b></p>
</div>
<!-- Page 81 -->
<a name="81"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page81-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft810">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft810">81&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft812"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft812"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft812"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft812"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft812"><b>NAME&#160;OF&#160;THE MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft811">Karvea&#160;75&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft811">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft812"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft812"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft811">Each&#160;tablet&#160;contains:&#160;irbesartan 75&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft812"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft812"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft811">Excipients:&#160;also&#160;contains&#160;lactose&#160;monohydrate.&#160;See&#160;leaflet&#160;for&#160;further information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft812"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft812"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft811">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft811">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft811">56&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft811">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft811">98&#160;tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft812"><b>5.&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft812"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft811">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft812"><b>6.&#160;</b></p>
<p style="position:absolute;top:776px;left:151px;white-space:nowrap" class="ft812"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;</b></p>
<p style="position:absolute;top:795px;left:151px;white-space:nowrap" class="ft812"><b>OF&#160;THE SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft811">Keep&#160;out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft812"><b>7.&#160;</b></p>
<p style="position:absolute;top:895px;left:149px;white-space:nowrap" class="ft812"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft812"><b>8.&#160;</b></p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft812"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft811">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft812"><b>9.&#160;</b></p>
<p style="position:absolute;top:1055px;left:149px;white-space:nowrap" class="ft812"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft811">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft811">&#160;</p>
</div>
<!-- Page 82 -->
<a name="82"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page82-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft820">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft820">82&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft822"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:104px;left:151px;white-space:nowrap" class="ft822"><b>OR&#160;WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:123px;left:151px;white-space:nowrap" class="ft822"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft822"><b>11.&#160;&#160;NAME&#160;AND&#160;ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft821">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft821">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft821">94250&#160;Gentilly&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft821">France&#160;</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:341px;left:106px;white-space:nowrap" class="ft822"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft821">EU/1/97/049/010 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft821">EU/1/97/049/001 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft821">EU/1/97/049/002 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft821">EU/1/97/049/013 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:457px;left:106px;white-space:nowrap" class="ft821">EU/1/97/049/003 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:476px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft822"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft821">Lot<i>&#160;</i></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft822"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION&#160;FOR&#160;SUPPLY&#160;</b></p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft821">Medicinal&#160;product&#160;subject&#160;to&#160;medical&#160;prescription.&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft822"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft822"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft821">Karvea&#160;75&#160;mg&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft822"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft821">2D&#160;barcode&#160;carrying&#160;the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft821">&#160;</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft822"><b>18.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN&#160;READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft822"><b>&#160;</b></p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft821">PC:&#160;&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft821">SN:&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft821">NN:&#160;</p>
</div>
<!-- Page 83 -->
<a name="83"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page83-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft830">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft830">83&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft832"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON BLISTERS&#160;OR STRIPS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft832"><b>1.&#160;</b></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft832"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft831">Karvea&#160;75&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft831">irbesartan&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft832"><b>2.&#160;</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft832"><b>NAME&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft831">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft832"><b>3.&#160;</b></p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft832"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft831">EXP<i>&#160;</i></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft832"><b>4.&#160;</b></p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft832"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft831">Lot&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft832"><b>5.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft832"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft831">14 -&#160;28 -&#160;56 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft831">Mon&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft831">Tue&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft831">Wed&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft831">Thu&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft831">Fri&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft831">Sat&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft831">Sun&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft831">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft831">56 x 1&#160;tablets:&#160;</p>
</div>
<!-- Page 84 -->
<a name="84"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page84-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft840">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft840">84&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft842"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE OUTER&#160;PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft842"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft842"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft842"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft842"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft841">Karvea&#160;150&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft841">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft842"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft842"><b>STATEMENT OF&#160;ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft841">Each&#160;tablet&#160;contains:&#160;irbesartan&#160;150&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft842"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft842"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft841">Excipients:&#160;also&#160;contains lactose&#160;monohydrate.&#160;See&#160;leaflet&#160;for&#160;further&#160;information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft842"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft842"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft841">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft841">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft841">56&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft841">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft841">98 tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft842"><b>5.&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft842"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft841">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft842"><b>6.&#160;</b></p>
<p style="position:absolute;top:776px;left:151px;white-space:nowrap" class="ft842"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;</b></p>
<p style="position:absolute;top:795px;left:151px;white-space:nowrap" class="ft842"><b>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft841">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft842"><b>7.&#160;</b></p>
<p style="position:absolute;top:895px;left:149px;white-space:nowrap" class="ft842"><b>OTHER&#160;SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft842"><b>8.&#160;</b></p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft842"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft841">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft842"><b>9.&#160;</b></p>
<p style="position:absolute;top:1055px;left:149px;white-space:nowrap" class="ft842"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft841">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft841">&#160;</p>
</div>
<!-- Page 85 -->
<a name="85"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page85-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft850">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft850">85&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft852"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR&#160;DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:104px;left:151px;white-space:nowrap" class="ft852"><b>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:123px;left:151px;white-space:nowrap" class="ft852"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft852"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft851">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft851">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft851">94250 Gentilly&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft851">France&#160;</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:341px;left:106px;white-space:nowrap" class="ft852"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft851">EU/1/97/049/011 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft851">EU/1/97/049/004 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft851">EU/1/97/049/005 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft851">EU/1/97/049/014 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:457px;left:106px;white-space:nowrap" class="ft851">EU/1/97/049/006 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:476px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft852"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft851">Lot<i>&#160;</i></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft852"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft851">Medicinal&#160;product&#160;subject to&#160;medical prescription.&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft852"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft852"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft851">Karvea&#160;150&#160;mg&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft852"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft851">2D&#160;barcode&#160;carrying&#160;the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft851">&#160;</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft852"><b>18.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft852"><b>&#160;</b></p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft851">PC:&#160;&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft851">SN:&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft851">NN:&#160;</p>
</div>
<!-- Page 86 -->
<a name="86"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page86-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft860">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft860">86&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft862"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON&#160;BLISTERS OR&#160;STRIPS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft862"><b>1.&#160;</b></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft862"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft861">Karvea&#160;150&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft861">irbesartan&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft862"><b>2.&#160;</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft862"><b>NAME&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft861">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft862"><b>3.&#160;</b></p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft862"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft861">EXP<i>&#160;</i></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft862"><b>4.&#160;</b></p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft862"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft861">Lot&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft862"><b>5.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft862"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft861">14 -&#160;28 -&#160;56 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft861">Mon&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft861">Tue&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft861">Wed&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft861">Thu&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft861">Fri&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft861">Sat&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft861">Sun&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft861">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft861">56 x 1&#160;tablets:&#160;</p>
</div>
<!-- Page 87 -->
<a name="87"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page87-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft870">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft870">87&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft872"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft872"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft872"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft872"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft872"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft871">Karvea&#160;300&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft871">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft872"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft872"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft871">Each&#160;tablet&#160;contains: irbesartan&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft872"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft872"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft871">Excipients:&#160;also contains&#160;lactose&#160;monohydrate.&#160;See leaflet&#160;for&#160;further information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft872"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft872"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft871">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft871">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft871">56&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft871">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft871">98&#160;tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:677px;left:106px;white-space:nowrap" class="ft872"><b>5.&#160;</b></p>
<p style="position:absolute;top:677px;left:149px;white-space:nowrap" class="ft872"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft871">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft872"><b>6.&#160;</b></p>
<p style="position:absolute;top:776px;left:151px;white-space:nowrap" class="ft872"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST BE STORED&#160;OUT&#160;</b></p>
<p style="position:absolute;top:795px;left:151px;white-space:nowrap" class="ft872"><b>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft871">Keep out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:895px;left:106px;white-space:nowrap" class="ft872"><b>7.&#160;</b></p>
<p style="position:absolute;top:895px;left:149px;white-space:nowrap" class="ft872"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:916px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft872"><b>8.&#160;</b></p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft872"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft871">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:1055px;left:106px;white-space:nowrap" class="ft872"><b>9.&#160;</b></p>
<p style="position:absolute;top:1055px;left:149px;white-space:nowrap" class="ft872"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:1077px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:1096px;left:106px;white-space:nowrap" class="ft871">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:1115px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
<p style="position:absolute;top:1134px;left:106px;white-space:nowrap" class="ft871">&#160;</p>
</div>
<!-- Page 88 -->
<a name="88"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page88-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft880">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft880">88&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft882"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:104px;left:151px;white-space:nowrap" class="ft882"><b>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:123px;left:151px;white-space:nowrap" class="ft882"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft882"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft881">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft881">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft881">94250&#160;Gentilly&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft881">France&#160;</p>
<p style="position:absolute;top:301px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:320px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:341px;left:106px;white-space:nowrap" class="ft882"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft881">EU/1/97/049/012 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft881">EU/1/97/049/007 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft881">EU/1/97/049/008 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:438px;left:106px;white-space:nowrap" class="ft881">EU/1/97/049/015 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:457px;left:106px;white-space:nowrap" class="ft881">EU/1/97/049/009 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:476px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:495px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:516px;left:106px;white-space:nowrap" class="ft882"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft881">Lot<i>&#160;</i></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:616px;left:106px;white-space:nowrap" class="ft882"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION&#160;FOR&#160;SUPPLY&#160;</b></p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft881">Medicinal&#160;product&#160;subject to&#160;medical prescription.&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:715px;left:106px;white-space:nowrap" class="ft882"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:776px;left:106px;white-space:nowrap" class="ft882"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:798px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:817px;left:106px;white-space:nowrap" class="ft881">Karvea 300&#160;mg&#160;</p>
<p style="position:absolute;top:836px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:855px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:876px;left:106px;white-space:nowrap" class="ft882"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:896px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft881">2D&#160;barcode carrying&#160;the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:934px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
<p style="position:absolute;top:974px;left:106px;white-space:nowrap" class="ft882"><b>18.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
<p style="position:absolute;top:993px;left:106px;white-space:nowrap" class="ft882"><b>&#160;</b></p>
<p style="position:absolute;top:1012px;left:106px;white-space:nowrap" class="ft881">PC:&#160;&#160;</p>
<p style="position:absolute;top:1031px;left:106px;white-space:nowrap" class="ft881">SN:&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft881">NN:&#160;</p>
<p style="position:absolute;top:1069px;left:106px;white-space:nowrap" class="ft881">&#160;</p>
</div>
<!-- Page 89 -->
<a name="89"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page89-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft890">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft890">89&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft892"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON BLISTERS&#160;OR STRIPS&#160;</b></p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:166px;left:106px;white-space:nowrap" class="ft892"><b>1.&#160;</b></p>
<p style="position:absolute;top:166px;left:149px;white-space:nowrap" class="ft892"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft891">Karvea&#160;300&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft891">irbesartan&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft892"><b>2.&#160;</b></p>
<p style="position:absolute;top:284px;left:149px;white-space:nowrap" class="ft892"><b>NAME&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft891">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:383px;left:106px;white-space:nowrap" class="ft892"><b>3.&#160;</b></p>
<p style="position:absolute;top:383px;left:149px;white-space:nowrap" class="ft892"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft891">EXP<i>&#160;</i></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:483px;left:106px;white-space:nowrap" class="ft892"><b>4.&#160;</b></p>
<p style="position:absolute;top:483px;left:149px;white-space:nowrap" class="ft892"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft891">Lot&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:582px;left:106px;white-space:nowrap" class="ft892"><b>5.&#160;</b></p>
<p style="position:absolute;top:582px;left:149px;white-space:nowrap" class="ft892"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft891">14 -&#160;28 -&#160;56 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft891">Mon&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft891">Tue&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft891">Wed&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft891">Thu&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft891">Fri&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft891">Sat&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft891">Sun&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft891">&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft891">56 x 1&#160;tablets:&#160;</p>
</div>
<!-- Page 90 -->
<a name="90"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page90-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft900">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft900">90&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft902"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft902"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft902"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft902"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft902"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft901">Karvea&#160;75&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft901">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft902"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft902"><b>STATEMENT&#160;OF&#160;ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft901">Each&#160;tablet&#160;contains:&#160;irbesartan&#160;75&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft902"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft902"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft901">Excipients:&#160;also&#160;contains&#160;lactose&#160;monohydrate.&#160;See leaflet&#160;for&#160;further information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft902"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft902"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft901">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft901">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft901">30&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft901">56&#160;tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft901">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft901">84&#160;tablets&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft901">90&#160;tablets&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft901">98&#160;tablets&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft902"><b>5.&#160;</b></p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft902"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft901">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft902"><b>6.&#160;</b></p>
<p style="position:absolute;top:833px;left:151px;white-space:nowrap" class="ft902"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE STORED&#160;OUT&#160;</b></p>
<p style="position:absolute;top:852px;left:151px;white-space:nowrap" class="ft902"><b>OF&#160;THE&#160;SIGHT&#160;AND REACH OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft901">Keep out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft902"><b>7.&#160;</b></p>
<p style="position:absolute;top:952px;left:149px;white-space:nowrap" class="ft902"><b>OTHER SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft902"><b>8.&#160;</b></p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft902"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft901">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft901">&#160;</p>
</div>
<!-- Page 91 -->
<a name="91"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page91-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft910">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft910">91&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft912"><b>9.&#160;</b></p>
<p style="position:absolute;top:85px;left:149px;white-space:nowrap" class="ft912"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft911">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft912"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:203px;left:151px;white-space:nowrap" class="ft912"><b>OR&#160;WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:223px;left:151px;white-space:nowrap" class="ft912"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft912"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft911">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft911">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft911">94250 Gentilly&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft911">France&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft912"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/016 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/017 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/034 -&#160;30&#160;tablets&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/018 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/019 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/031 -&#160;84&#160;tablets&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/037 -&#160;90&#160;tablets&#160;</p>
<p style="position:absolute;top:613px;left:106px;white-space:nowrap" class="ft911">EU/1/97/049/020 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:632px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft912"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft911">Lot&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft912"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION&#160;FOR&#160;SUPPLY&#160;</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft911">Medicinal&#160;product&#160;subject&#160;to&#160;medical&#160;prescription.&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft912"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft912"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft911">Karvea 75&#160;mg&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft912"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D&#160;BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft911">2D&#160;barcode carrying the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:1109px;left:106px;white-space:nowrap" class="ft911">&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft912"><b>18.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
</div>
<!-- Page 92 -->
<a name="92"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page92-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft920">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft920">92&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft922"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft921">PC:&#160;&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft921">SN:&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft921">NN:&#160;</p>
</div>
<!-- Page 93 -->
<a name="93"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page93-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft930">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft930">93&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft932"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON&#160;BLISTERS&#160;OR&#160;STRIPS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft932"><b>1.&#160;</b></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft932"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft931">Karvea&#160;75&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft931">irbesartan&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft932"><b>2.&#160;</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft932"><b>NAME&#160;OF THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft931">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft932"><b>3.&#160;</b></p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft932"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft931">EXP<i>&#160;</i></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft932"><b>4.&#160;</b></p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft932"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft931">Lot&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft932"><b>5.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft932"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft931">14 -&#160;28 -&#160;56 -&#160;84 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft931">Mon&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft931">Tue&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft931">Wed&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft931">Thu&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft931">Fri&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft931">Sat&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft931">Sun&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft931">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft931">30 -&#160;56 x 1 -&#160;90&#160;tablets:&#160;</p>
</div>
<!-- Page 94 -->
<a name="94"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page94-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft940">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft940">94&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft942"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft942"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft942"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft942"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft942"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft941">Karvea&#160;150&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft941">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft942"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft942"><b>STATEMENT OF&#160;ACTIVE&#160;SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft941">Each&#160;tablet&#160;contains:&#160;irbesartan&#160;150&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft942"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft942"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft941">Excipients:&#160;also contains&#160;lactose&#160;monohydrate.&#160;See leaflet&#160;for&#160;further&#160;information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft942"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft942"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft941">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft941">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft941">30&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft941">56&#160;tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft941">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft941">84&#160;tablets&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft941">90&#160;tablets&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft941">98&#160;tablets&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft942"><b>5.&#160;</b></p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft942"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft941">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft942"><b>6.&#160;</b></p>
<p style="position:absolute;top:833px;left:151px;white-space:nowrap" class="ft942"><b>SPECIAL&#160;WARNING&#160;THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;</b></p>
<p style="position:absolute;top:852px;left:151px;white-space:nowrap" class="ft942"><b>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft941">Keep&#160;out&#160;of&#160;the&#160;sight&#160;and reach of&#160;children.&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft942"><b>7.&#160;</b></p>
<p style="position:absolute;top:952px;left:149px;white-space:nowrap" class="ft942"><b>OTHER&#160;SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft942"><b>8.&#160;</b></p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft942"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft941">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft941">&#160;</p>
</div>
<!-- Page 95 -->
<a name="95"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page95-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft950">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft950">95&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft952"><b>9.&#160;</b></p>
<p style="position:absolute;top:85px;left:149px;white-space:nowrap" class="ft952"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft951">Do not&#160;store above&#160;30°C.&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft952"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED&#160;MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:203px;left:151px;white-space:nowrap" class="ft952"><b>OR WASTE&#160;MATERIALS&#160;DERIVED FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:223px;left:151px;white-space:nowrap" class="ft952"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft952"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft951">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft951">82 avenue Raspail&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft951">94250 Gentilly&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft951">France&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:419px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:440px;left:106px;white-space:nowrap" class="ft952"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/021 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/022 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/035 -&#160;30&#160;tablets&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/023 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/024 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/032 -&#160;84&#160;tablets&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/038 -&#160;90&#160;tablets&#160;</p>
<p style="position:absolute;top:613px;left:106px;white-space:nowrap" class="ft951">EU/1/97/049/025 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:632px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:651px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:673px;left:106px;white-space:nowrap" class="ft952"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft951">Lot&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:751px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:772px;left:106px;white-space:nowrap" class="ft952"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR&#160;SUPPLY&#160;</b></p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft951">Medicinal&#160;product&#160;subject&#160;to&#160;medical&#160;prescription.&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:850px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:871px;left:106px;white-space:nowrap" class="ft952"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:933px;left:106px;white-space:nowrap" class="ft952"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft951">Karvea&#160;150&#160;mg&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:1011px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft952"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft951">2D&#160;barcode&#160;carrying the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:1109px;left:106px;white-space:nowrap" class="ft951">&#160;</p>
<p style="position:absolute;top:1130px;left:106px;white-space:nowrap" class="ft952"><b>18.&#160;&#160;UNIQUE IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
</div>
<!-- Page 96 -->
<a name="96"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page96-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft960">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft960">96&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft962"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft961">PC:&#160;&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft961">SN:&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft961">NN:&#160;</p>
</div>
<!-- Page 97 -->
<a name="97"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page97-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft970">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft970">97&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft972"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR&#160;ON&#160;BLISTERS&#160;OR&#160;STRIPS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft972"><b>1.&#160;</b></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft972"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft971">Karvea&#160;150&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft971">irbesartan&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft972"><b>2.&#160;</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft972"><b>NAME&#160;OF&#160;THE MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft971">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft972"><b>3.&#160;</b></p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft972"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft971">EXP<i>&#160;</i></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft972"><b>4.&#160;</b></p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft972"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft971">Lot&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft972"><b>5.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft972"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft971">14 -&#160;28 -&#160;56 -&#160;84 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft971">Mon&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft971">Tue&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft971">Wed&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft971">Thu&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft971">Fri&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft971">Sat&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft971">Sun&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft971">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft971">30 -&#160;56 x 1 -&#160;90&#160;tablets:&#160;</p>
</div>
<!-- Page 98 -->
<a name="98"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page98-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft980">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft980">98&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft982"><b>PARTICULARS&#160;TO&#160;APPEAR ON THE&#160;OUTER PACKAGING&#160;&#160;</b></p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft982"><b>&#160;</b></p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft982"><b>OUTER CARTON&#160;</b></p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft982"><b>1.&#160;</b></p>
<p style="position:absolute;top:185px;left:149px;white-space:nowrap" class="ft982"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft981">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablets&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft981">irbesartan&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:282px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:303px;left:106px;white-space:nowrap" class="ft982"><b>2.&#160;</b></p>
<p style="position:absolute;top:303px;left:149px;white-space:nowrap" class="ft982"><b>STATEMENT OF&#160;ACTIVE SUBSTANCE(S)&#160;</b></p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft981">Each&#160;tablet&#160;contains:&#160;irbesartan&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:402px;left:106px;white-space:nowrap" class="ft982"><b>3.&#160;</b></p>
<p style="position:absolute;top:402px;left:149px;white-space:nowrap" class="ft982"><b>LIST OF&#160;EXCIPIENTS&#160;</b></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft981">Excipients:&#160;also contains&#160;lactose&#160;monohydrate.&#160;See leaflet&#160;for&#160;further information.&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:502px;left:106px;white-space:nowrap" class="ft982"><b>4.&#160;</b></p>
<p style="position:absolute;top:502px;left:149px;white-space:nowrap" class="ft982"><b>PHARMACEUTICAL&#160;FORM&#160;AND CONTENTS&#160;</b></p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft981">14&#160;tablets&#160;</p>
<p style="position:absolute;top:561px;left:106px;white-space:nowrap" class="ft981">28&#160;tablets&#160;</p>
<p style="position:absolute;top:580px;left:106px;white-space:nowrap" class="ft981">30&#160;tablets&#160;</p>
<p style="position:absolute;top:599px;left:106px;white-space:nowrap" class="ft981">56 tablets&#160;</p>
<p style="position:absolute;top:618px;left:106px;white-space:nowrap" class="ft981">56 x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:637px;left:106px;white-space:nowrap" class="ft981">84&#160;tablets&#160;</p>
<p style="position:absolute;top:656px;left:106px;white-space:nowrap" class="ft981">90&#160;tablets&#160;</p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft981">98&#160;tablets&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:734px;left:106px;white-space:nowrap" class="ft982"><b>5.&#160;</b></p>
<p style="position:absolute;top:734px;left:149px;white-space:nowrap" class="ft982"><b>METHOD AND ROUTE(S)&#160;OF&#160;ADMINISTRATION&#160;</b></p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft981">Oral&#160;use.&#160;Read&#160;the package&#160;leaflet&#160;before use.&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:833px;left:106px;white-space:nowrap" class="ft982"><b>6.&#160;</b></p>
<p style="position:absolute;top:833px;left:151px;white-space:nowrap" class="ft982"><b>SPECIAL&#160;WARNING THAT&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;MUST&#160;BE&#160;STORED OUT&#160;</b></p>
<p style="position:absolute;top:852px;left:151px;white-space:nowrap" class="ft982"><b>OF&#160;THE&#160;SIGHT&#160;AND REACH&#160;OF&#160;CHILDREN&#160;</b></p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft981">Keep out&#160;of&#160;the&#160;sight&#160;and&#160;reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:912px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:930px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:952px;left:106px;white-space:nowrap" class="ft982"><b>7.&#160;</b></p>
<p style="position:absolute;top:952px;left:149px;white-space:nowrap" class="ft982"><b>OTHER&#160;SPECIAL&#160;WARNING(S),&#160;IF&#160;NECESSARY&#160;</b></p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft982"><b>8.&#160;</b></p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft982"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:1053px;left:106px;white-space:nowrap" class="ft981">EXP<i>&#160;</i></p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
<p style="position:absolute;top:1091px;left:106px;white-space:nowrap" class="ft981">&#160;</p>
</div>
<!-- Page 99 -->
<a name="99"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page99-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft990">&#160;</p>
<p style="position:absolute;top:1193px;left:440px;white-space:nowrap" class="ft990">99&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft992"><b>9.&#160;</b></p>
<p style="position:absolute;top:85px;left:149px;white-space:nowrap" class="ft992"><b>SPECIAL&#160;STORAGE&#160;CONDITIONS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft991">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:145px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:163px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:185px;left:106px;white-space:nowrap" class="ft992"><b>10.&#160;&#160;SPECIAL&#160;PRECAUTIONS&#160;FOR DISPOSAL&#160;OF&#160;UNUSED MEDICINAL&#160;PRODUCTS&#160;</b></p>
<p style="position:absolute;top:203px;left:151px;white-space:nowrap" class="ft992"><b>OR WASTE&#160;MATERIALS&#160;DERIVED&#160;FROM&#160;SUCH&#160;MEDICINAL&#160;PRODUCTS,&#160;IF&#160;</b></p>
<p style="position:absolute;top:223px;left:151px;white-space:nowrap" class="ft992"><b>APPROPRIATE&#160;</b></p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:263px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:284px;left:106px;white-space:nowrap" class="ft992"><b>11.&#160;&#160;NAME&#160;AND ADDRESS&#160;OF&#160;THE&#160;MARKETING&#160;AUTHORISATION&#160;HOLDER&#160;</b></p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft991">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft991">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:362px;left:106px;white-space:nowrap" class="ft991">94250 Gentilly&#160;</p>
<p style="position:absolute;top:381px;left:106px;white-space:nowrap" class="ft991">France&#160;</p>
<p style="position:absolute;top:400px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:421px;left:106px;white-space:nowrap" class="ft992"><b>12.&#160;&#160;MARKETING&#160;AUTHORISATION NUMBER(S)&#160;</b></p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:462px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/026 -&#160;14&#160;tablets&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/027 -&#160;28&#160;tablets&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/036 -&#160;30&#160;tablets&#160;</p>
<p style="position:absolute;top:518px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/028 -&#160;56&#160;tablets&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/029 -&#160;56&#160;x 1&#160;tablets&#160;</p>
<p style="position:absolute;top:556px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/033 -&#160;84&#160;tablets&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/039 -&#160;90&#160;tablets&#160;</p>
<p style="position:absolute;top:594px;left:106px;white-space:nowrap" class="ft991">EU/1/97/049/030 -&#160;98&#160;tablets&#160;</p>
<p style="position:absolute;top:613px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:632px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:653px;left:106px;white-space:nowrap" class="ft992"><b>13.&#160;&#160;BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:675px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:694px;left:106px;white-space:nowrap" class="ft991">Lot&#160;</p>
<p style="position:absolute;top:713px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:732px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:753px;left:106px;white-space:nowrap" class="ft992"><b>14.&#160;&#160;GENERAL&#160;CLASSIFICATION FOR SUPPLY&#160;</b></p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft991">Medicinal&#160;product&#160;subject to&#160;medical prescription.&#160;</p>
<p style="position:absolute;top:812px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:831px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:852px;left:106px;white-space:nowrap" class="ft992"><b>15.&#160;&#160;INSTRUCTIONS&#160;ON USE&#160;</b></p>
<p style="position:absolute;top:874px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:892px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:914px;left:106px;white-space:nowrap" class="ft992"><b>16.&#160;&#160;INFORMATION IN BRAILLE&#160;</b></p>
<p style="position:absolute;top:935px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:954px;left:106px;white-space:nowrap" class="ft991">Karvea&#160;300&#160;mg&#160;</p>
<p style="position:absolute;top:973px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:992px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft992"><b>17.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;–&#160;2D BARCODE</b><i>&#160;</i></p>
<p style="position:absolute;top:1033px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:1052px;left:106px;white-space:nowrap" class="ft991">2D&#160;barcode&#160;carrying&#160;the&#160;unique&#160;identifier&#160;included.&#160;</p>
<p style="position:absolute;top:1071px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:1090px;left:106px;white-space:nowrap" class="ft991">&#160;</p>
<p style="position:absolute;top:1111px;left:106px;white-space:nowrap" class="ft992"><b>18.&#160;&#160;UNIQUE&#160;IDENTIFIER&#160;-&#160;HUMAN READABLE&#160;DATA</b><i>&#160;</i></p>
</div>
<!-- Page 100 -->
<a name="100"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page100-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1000">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1000">100&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1002"><b>&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1001">PC:&#160;&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1001">SN:&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1001">NN:&#160;</p>
</div>
<!-- Page 101 -->
<a name="101"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page101-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1010">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1010">101&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1012"><b>MINIMUM&#160;PARTICULARS&#160;TO&#160;APPEAR ON&#160;BLISTERS&#160;OR&#160;STRIPS&#160;</b></p>
<p style="position:absolute;top:107px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:126px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:147px;left:106px;white-space:nowrap" class="ft1012"><b>1.&#160;</b></p>
<p style="position:absolute;top:147px;left:149px;white-space:nowrap" class="ft1012"><b>NAME&#160;OF&#160;THE&#160;MEDICINAL&#160;PRODUCT&#160;</b></p>
<p style="position:absolute;top:168px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:187px;left:106px;white-space:nowrap" class="ft1011">Karvea&#160;300&#160;mg&#160;tablets&#160;</p>
<p style="position:absolute;top:206px;left:106px;white-space:nowrap" class="ft1011">irbesartan&#160;</p>
<p style="position:absolute;top:225px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:244px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:265px;left:106px;white-space:nowrap" class="ft1012"><b>2.&#160;</b></p>
<p style="position:absolute;top:265px;left:149px;white-space:nowrap" class="ft1012"><b>NAME OF&#160;THE&#160;MARKETING&#160;AUTHORISATION HOLDER&#160;</b></p>
<p style="position:absolute;top:286px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:305px;left:106px;white-space:nowrap" class="ft1011">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:324px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:343px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:364px;left:106px;white-space:nowrap" class="ft1012"><b>3.&#160;</b></p>
<p style="position:absolute;top:364px;left:149px;white-space:nowrap" class="ft1012"><b>EXPIRY DATE&#160;</b></p>
<p style="position:absolute;top:386px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1011">EXP<i>&#160;</i></p>
<p style="position:absolute;top:424px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:464px;left:106px;white-space:nowrap" class="ft1012"><b>4.&#160;</b></p>
<p style="position:absolute;top:464px;left:149px;white-space:nowrap" class="ft1012"><b>BATCH&#160;NUMBER&#160;</b></p>
<p style="position:absolute;top:485px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:504px;left:106px;white-space:nowrap" class="ft1011">Lot&#160;</p>
<p style="position:absolute;top:523px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:542px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:563px;left:106px;white-space:nowrap" class="ft1012"><b>5.&#160;</b></p>
<p style="position:absolute;top:563px;left:149px;white-space:nowrap" class="ft1012"><b>OTHER&#160;</b></p>
<p style="position:absolute;top:585px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:603px;left:106px;white-space:nowrap" class="ft1011">14 -&#160;28 -&#160;56 -&#160;84 -&#160;98&#160;tablets:&#160;</p>
<p style="position:absolute;top:622px;left:106px;white-space:nowrap" class="ft1011">Mon&#160;</p>
<p style="position:absolute;top:641px;left:106px;white-space:nowrap" class="ft1011">Tue&#160;</p>
<p style="position:absolute;top:660px;left:106px;white-space:nowrap" class="ft1011">Wed&#160;</p>
<p style="position:absolute;top:679px;left:106px;white-space:nowrap" class="ft1011">Thu&#160;</p>
<p style="position:absolute;top:698px;left:106px;white-space:nowrap" class="ft1011">Fri&#160;</p>
<p style="position:absolute;top:717px;left:106px;white-space:nowrap" class="ft1011">Sat&#160;</p>
<p style="position:absolute;top:736px;left:106px;white-space:nowrap" class="ft1011">Sun&#160;</p>
<p style="position:absolute;top:755px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
<p style="position:absolute;top:774px;left:106px;white-space:nowrap" class="ft1011">30 -&#160;56 x 1 -&#160;90&#160;tablets:&#160;</p>
<p style="position:absolute;top:793px;left:106px;white-space:nowrap" class="ft1011">&#160;</p>
</div>
<!-- Page 102 -->
<a name="102"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page102-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1020">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1020">102&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1021">&#160;</p>
<p style="position:absolute;top:519px;left:355px;white-space:nowrap" class="ft1022"><b>B.&#160;PACKAGE LEAFLET&#160;</b></p>
</div>
<!-- Page 103 -->
<a name="103"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft1039{font-size:17px;font-family:MASKCU+Wingdings;color:#000000;}
-->
</style>
<div id="page103-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1030">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1030">103&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1032"><b>Package leaflet: Information&#160;for the&#160;user&#160;</b></p>
<p style="position:absolute;top:102px;left:371px;white-space:nowrap" class="ft1032"><b>Karvea&#160;75&#160;mg&#160;tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1031">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1032"><b>Read&#160;all&#160;of&#160;this&#160;leaflet carefully&#160;before&#160;you&#160;start&#160;taking this&#160;medicine&#160;because it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1032"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1031">Keep&#160;this&#160;leaflet.&#160;You&#160;may&#160;need to&#160;read it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1031">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1031">This medicine has been&#160;prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others.&#160;It&#160;may&#160;harm them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1031">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the same&#160;as&#160;yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1031">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1031">effects not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;See section 4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1032"><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1031">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1031">What&#160;Karvea&#160;is and&#160;what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1031">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1031">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1031">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1031">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1031">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1031">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1031">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1031">How to&#160;store Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1031">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1031">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1032"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1032"><b>What&#160;Karvea&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1032"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1031">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines known&#160;as&#160;angiotensin-II&#160;receptor&#160;antagonists.&#160;Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1031">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1031">This results&#160;in&#160;an&#160;increase&#160;in blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding&#160;of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1031">receptors, causing the&#160;blood&#160;vessels&#160;to relax and the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1031">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and type&#160;2 diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1031">Karvea&#160;is used in adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1031">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1031">to&#160;protect&#160;the&#160;kidney in&#160;patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1031">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1032"><b>2.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft1032"><b>What&#160;you&#160;need&#160;to&#160;know&#160;before you take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1032"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1032"><b>Do not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1031">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1032"><b>allergic</b>&#160;to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1031">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1032"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>. (It&#160;is&#160;also better&#160;to&#160;avoid&#160;Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1031">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1032"><b>if&#160;you&#160;have&#160;diabetes or impaired&#160;kidney&#160;function&#160;</b>and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1031">lowering medicine&#160;containing&#160;aliskiren.&#160;<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1031">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1032"><b>Warning and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1031">Talk&#160;to your&#160;doctor before taking&#160;Karvea&#160;and</p>
<p style="position:absolute;top:956px;left:406px;white-space:nowrap" class="ft1032"><b>&#160;if&#160;any&#160;of&#160;the&#160;following&#160;apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1031">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1032"><b>excessive&#160;vomiting&#160;or diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1031">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1032"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1031">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1032"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1031">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1032"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1031">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels in&#160;case of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1031">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1032"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1031">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1031">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1039">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1031">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1032"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1039"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1038">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1031">if&#160;you are&#160;taking&#160;any of&#160;the&#160;following&#160;medicines&#160;used to&#160;treat&#160;high&#160;blood&#160;pressure:&#160;</p>
</div>
<!-- Page 104 -->
<a name="104"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10410{font-size:17px;font-family:IUUMYC+CourierNewPSMT;color:#000000;}
-->
</style>
<div id="page104-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1040">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1040">104&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft10410">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1041">diabetes-related kidney&#160;problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft10410">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1041">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount&#160;of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1041">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1041">See&#160;also information under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1041">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1041">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1041">may&#160;cause serious harm&#160;to&#160;your&#160;baby if&#160;used at&#160;that&#160;stage&#160;(see&#160;pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1042"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1041">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used&#160;in&#160;children&#160;and&#160;adolescents because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1041">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1042"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1042"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1041">Tell your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking, have&#160;recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1041">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1041">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1041">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1041">Karvea” and&#160;“Warnings&#160;and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1042"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1049"></p>
<p style="position:absolute;top:557px;left:114px;white-space:nowrap" class="ft1048">&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1041">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1049"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1048">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1041">salt&#160;substitutes containing&#160;potassium&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1049"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1048">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1041">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1049"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1048">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1041">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1049"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1048">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1041">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1041">If&#160;you&#160;take&#160;certain&#160;painkillers, called non-steroidal&#160;anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1041">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1042"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1041">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1042"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1042"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1041">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant. Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1041">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1041">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1041">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause&#160;serious&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1041">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1042"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1041">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is not&#160;recommended&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1041">for&#160;mothers&#160;who&#160;are&#160;breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you&#160;if&#160;you wish&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1041">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1042"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1041">Karvea&#160;is&#160;unlikely&#160;to&#160;affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1041">weariness&#160;may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1041">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1041">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft1042"><b>Karvea contains&#160;lactose</b>. If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you have&#160;an&#160;intolerance&#160;to some&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1041">sugars&#160;(e.g.&#160;lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
</div>
<!-- Page 105 -->
<a name="105"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10511{font-size:15px;font-family:BHIWEQ+MS-Gothic;color:#000000;}
-->
</style>
<div id="page105-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1050">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1050">105&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1052"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains less&#160;than&#160;1&#160;mmol&#160;sodium&#160;(23&#160;mg)&#160;per&#160;tablet,&#160;that&#160;is&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1051">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1052"><b>3.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1052"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1052"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1051">Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as your&#160;doctor&#160;has told&#160;you.&#160;Check&#160;with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1051">if&#160;you&#160;are not&#160;sure.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1052"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1051">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:292px;left:197px;white-space:nowrap" class="ft1052"><b>oral&#160;use</b>. Swallow&#160;the&#160;tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1051">You&#160;can take&#160;Karvea&#160;with&#160;or&#160;without&#160;food. Try&#160;to&#160;take&#160;your&#160;daily dose&#160;at&#160;about&#160;the&#160;same time each&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1051">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to&#160;take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1059"></p>
<p style="position:absolute;top:368px;left:114px;white-space:nowrap" class="ft1058">&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1052"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1051">The usual&#160;dose&#160;is 150&#160;mg once-a-day&#160;(two tablets&#160;a&#160;day).&#160;The&#160;dose&#160;may&#160;later&#160;be&#160;increased to&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1051">300&#160;mg&#160;(four&#160;tablets a&#160;day)&#160;once&#160;daily depending&#160;on blood&#160;pressure&#160;response.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1059"></p>
<p style="position:absolute;top:443px;left:114px;white-space:nowrap" class="ft1058">&#160;</p>
<p style="position:absolute;top:443px;left:149px;white-space:nowrap" class="ft1052"><b>Patients&#160;with&#160;high&#160;blood pressure&#160;and type&#160;2&#160;diabetes&#160;with&#160;kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:463px;left:149px;white-space:nowrap" class="ft1051">In patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2 diabetes, 300&#160;mg&#160;(four&#160;tablets&#160;a&#160;day)&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1051">is the preferred&#160;maintenance dose&#160;for&#160;the treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1051">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially&#160;when starting treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1051">those&#160;on&#160;</p>
<p style="position:absolute;top:538px;left:166px;white-space:nowrap" class="ft1052"><b>haemodialysis</b>, or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1051">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning treatment.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1052"><b>Use in&#160;children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1051">Karvea&#160;should&#160;not&#160;be&#160;given to&#160;children&#160;under&#160;18&#160;years&#160;of&#160;age.&#160;If&#160;a child&#160;swallows&#160;some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1051">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1052"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than&#160;you&#160;should&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1051">If&#160;you accidentally&#160;take&#160;too&#160;many tablets, contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1052"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1051">If&#160;you accidentally&#160;miss a daily&#160;dose,&#160;just&#160;take the next&#160;dose as normal.&#160;Do&#160;not&#160;take&#160;a double dose&#160;to&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1051">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1051">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1052"><b>&#160;</b></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1052"><b>4.&#160;</b></p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1052"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1052"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1051">Like&#160;all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1051">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1051">As&#160;with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as&#160;well&#160;as localised&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1051">swelling&#160;of&#160;the&#160;face, lips&#160;and/or&#160;tongue&#160;have&#160;been&#160;reported&#160;in patients&#160;taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1051">of&#160;these symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:1013px;left:381px;white-space:nowrap" class="ft1052"><b>stop taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1051">The&#160;frequency of&#160;the&#160;side&#160;effects&#160;listed&#160;below&#160;is&#160;defined using the&#160;following&#160;convention:&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1051">Very&#160;common:&#160;may affect&#160;more&#160;than 1&#160;in 10&#160;people&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1051">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1051">Uncommon:&#160;may&#160;affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1051">&#160;</p>
</div>
<!-- Page 106 -->
<a name="106"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10612{font-size:17px;font-family:UYDQKE+TimesNewRomanPSMT;color:#0000ff;}
-->
</style>
<div id="page106-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1060">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1060">106&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1061">Side effects reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1069"></p>
<p style="position:absolute;top:102px;left:114px;white-space:nowrap" class="ft1068">&#160;</p>
<p style="position:absolute;top:102px;left:149px;white-space:nowrap" class="ft1061">Very common&#160;(may affect&#160;more&#160;than 1&#160;in 10&#160;people):&#160;if&#160;you suffer&#160;from&#160;high&#160;blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:121px;left:149px;white-space:nowrap" class="ft1061">type&#160;2&#160;diabetes&#160;with kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1069"></p>
<p style="position:absolute;top:159px;left:114px;white-space:nowrap" class="ft1068">&#160;</p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1061">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people):&#160;dizziness,&#160;feeling sick/vomiting, fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1061">tests&#160;may&#160;show&#160;raised&#160;levels of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1061">kinase&#160;enzyme).&#160;In&#160;patients&#160;with&#160;high&#160;blood&#160;pressure&#160;and type&#160;2 diabetes&#160;with kidney disease,&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1061">dizziness&#160;when&#160;getting up&#160;from&#160;a&#160;lying or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1061">from&#160;a&#160;lying&#160;or&#160;sitting position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1061">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also&#160;reported.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft1069"></p>
<p style="position:absolute;top:292px;left:114px;white-space:nowrap" class="ft1068">&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1061">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100&#160;people):&#160;heart&#160;rate&#160;increased, flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:311px;left:149px;white-space:nowrap" class="ft1061">indigestion/heartburn, sexual&#160;dysfunction&#160;(problems&#160;with&#160;sexual&#160;performance), chest&#160;pain.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1061">Some undesirable effects&#160;have&#160;been reported&#160;since&#160;marketing&#160;of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1061">frequency is&#160;not&#160;known are:&#160;feeling of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1061">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells&#160;(anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1061">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when&#160;exercising,&#160;dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1061">reduced number&#160;of&#160;platelets, abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels,&#160;impaired&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1061">kidney&#160;function, inflammation&#160;of&#160;small&#160;blood vessels&#160;mainly&#160;affecting the&#160;skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1061">leukocytoclastic&#160;vasculitis),&#160;severe&#160;allergic reactions (anaphylactic&#160;shock)&#160;and low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1061">Uncommon&#160;cases&#160;of&#160;jaundice&#160;(yellowing of&#160;the&#160;skin and/or&#160;whites&#160;of&#160;the eyes)&#160;have also&#160;been&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1061">reported.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1061">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1061">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk to&#160;your&#160;doctor&#160;or&#160;pharmacist.&#160;This&#160;includes any&#160;possible side&#160;effects&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1061">not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;You can also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national reporting system&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1061">listed&#160;in&#160;Appendix V. By reporting&#160;side&#160;effects&#160;you&#160;can&#160;help&#160;provide&#160;more&#160;information on&#160;the&#160;safety&#160;of&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1061">this medicine.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1062"><b>5.&#160;</b></p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1062"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1062"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1061">Keep&#160;this medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1061">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date&#160;which&#160;is stated on the&#160;carton and&#160;on&#160;the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1061">EXP. The&#160;expiry&#160;date&#160;refers&#160;to&#160;the&#160;last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1061">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1061">Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1061">throw away&#160;of&#160;medicines&#160;you no longer&#160;use.&#160;These&#160;measures&#160;will&#160;help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1062"><b>6.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft1062"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1062"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1062"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1069">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1061">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;75 mg contains&#160;75&#160;mg&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1069">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1061">The&#160;other&#160;ingredients are&#160;microcrystalline cellulose,&#160;croscarmellose&#160;sodium,&#160;lactose&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1061">monohydrate,&#160;magnesium&#160;stearate, colloidal&#160;hydrated&#160;silica, pregelatinized&#160;maize starch,&#160;and&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1061">poloxamer&#160;188.&#160;Please&#160;see section&#160;2&#160;“Karvea&#160;contains lactose”.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1062"><b>What&#160;Karvea&#160;looks&#160;like&#160;and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1061">Karvea&#160;75&#160;mg tablets&#160;are&#160;white&#160;to&#160;off-white, biconvex, and&#160;oval-shaped&#160;with&#160;a&#160;heart&#160;debossed&#160;on&#160;one&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1061">side&#160;and the&#160;number&#160;2771 engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1061">&#160;</p>
</div>
<!-- Page 107 -->
<a name="107"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft10713{font-size:17px;font-family:AXWVQS+TimesNewRomanPS;color:#000000;}
-->
</style>
<div id="page107-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1070">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1070">107&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1071">Karvea&#160;75&#160;mg tablets&#160;are&#160;supplied in blister&#160;packs&#160;of&#160;14, 28, 56 or&#160;98&#160;tablets.&#160;Unidose&#160;blister&#160;packs&#160;of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1071">56&#160;x&#160;1&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;available.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1071">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1072"><b>Marketing&#160;Authorisation Holder:&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1071">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1071">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1071">94250 Gentilly&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1071">France&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1072"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1071">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1071">1, rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1071">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1071">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1071">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1071">30-36&#160;Avenue&#160;Gustave Eiffel,&#160;BP&#160;7166&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1071">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1071">For&#160;any information&#160;about&#160;this&#160;medicinal&#160;product,&#160;please&#160;contact&#160;the&#160;local&#160;representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1071">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1072"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1071">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1071">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1072"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:558px;left:455px;white-space:nowrap" class="ft1071">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1071">Tel: +370 5&#160;236 91&#160;40&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft10713"><b>България&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1071">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1076">Тел.: +359 (0)2&#160;4942 480&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1072"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1071">Sanofi Belgium&#160;&#160;</p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1071">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft10713"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1071">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1071">Tel:&#160;+420 233 086&#160;111&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft10713"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft1071">SANOFI-AVENTIS&#160;Zrt.&#160;</p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1071">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:747px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1072"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1071">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1071">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1072"><b>Malta&#160;</b></p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft1071">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1071">Tel:&#160;+39&#160;02&#160;39394275&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1072"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1071">Sanofi-Aventis&#160;Deutschland GmbH&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1071">Tel:&#160;0800 52 52 010&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1071">Tel.&#160;aus dem&#160;Ausland:&#160;+49 69&#160;305&#160;21 131&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1072"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1071">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1071">Tel:&#160;+31&#160;20&#160;245&#160;4000&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1072"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1071">Swixx Biopharma&#160;OÜ&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1071">Tel:&#160;+372&#160;640 10 30&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1072"><b>Norge&#160;</b></p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1071">sanofi-aventis Norge&#160;AS&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1071">Tlf:&#160;+47 67 10 71&#160;00&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft10713"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1071">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1076">Τηλ:&#160;+30 210&#160;900 16&#160;00&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:1013px;left:455px;white-space:nowrap" class="ft1072"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1071">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1071">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1072"><b>España&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1071">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1071">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1071">&#160;</p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1072"><b>Polska&#160;</b></p>
<p style="position:absolute;top:1108px;left:455px;white-space:nowrap" class="ft1071">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:1127px;left:455px;white-space:nowrap" class="ft1071">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:1146px;left:455px;white-space:nowrap" class="ft1071">&#160;</p>
</div>
<!-- Page 108 -->
<a name="108"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page108-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1080">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1080">108&#160;</p>
<p style="position:absolute;top:83px;left:104px;white-space:nowrap" class="ft1082"><b>France&#160;</b></p>
<p style="position:absolute;top:102px;left:104px;white-space:nowrap" class="ft1081">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:121px;left:104px;white-space:nowrap" class="ft1081">Tél:&#160;0 800 222 555&#160;</p>
<p style="position:absolute;top:140px;left:104px;white-space:nowrap" class="ft1081">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1 57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:159px;left:104px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1082"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1081">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1081">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1082"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1081">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1081">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1082"><b>România&#160;</b></p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1081">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:216px;left:454px;white-space:nowrap" class="ft1081">Tel:&#160;+40&#160;(0)&#160;21&#160;317 31 36&#160;</p>
<p style="position:absolute;top:235px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1082"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1081">sanofi-aventis Ireland&#160;Ltd.&#160;T/A SANOFI&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1081">Tel:&#160;+353&#160;(0)&#160;1 403 56 00&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1082"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1081">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:292px;left:455px;white-space:nowrap" class="ft1081">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:311px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1082"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1081">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1081">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft10813"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1081">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:368px;left:455px;white-space:nowrap" class="ft1081">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1082"><b>Italia&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1081">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1081">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft1082"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1081">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1081">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft10813"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1081">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1086">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft1082"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1081">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1081">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1082"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1081">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1081">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1082"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1081">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1081">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1082"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1081">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1081">Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1081">http://www.ema.europa.eu/&#160;</p>
</div>
<!-- Page 109 -->
<a name="109"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page109-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1090">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1090">109&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1092"><b>Package leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:102px;left:367px;white-space:nowrap" class="ft1092"><b>Karvea 150&#160;mg tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1091">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1092"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before&#160;you&#160;start&#160;taking&#160;this&#160;medicine because&#160;it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1092"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1091">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1091">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1091">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1091">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1091">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1091">effects not&#160;listed&#160;in&#160;this leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1092"><b>What&#160;is&#160;in&#160;this leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1091">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1091">What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1091">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1091">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1091">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1091">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1091">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1091">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1091">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1091">How&#160;to store&#160;Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1091">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1091">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1092"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1092"><b>What&#160;Karvea&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1092"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1091">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines&#160;known as&#160;angiotensin-II&#160;receptor&#160;antagonists. Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1091">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to&#160;receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1091">This&#160;results in&#160;an&#160;increase&#160;in&#160;blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1091">receptors, causing the&#160;blood vessels&#160;to&#160;relax&#160;and&#160;the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1091">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1091">Karvea&#160;is&#160;used in&#160;adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1091">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1091">to protect&#160;the&#160;kidney&#160;in patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1091">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1092"><b>2.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft1092"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1092"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1092"><b>Do not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1091">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1092"><b>allergic</b>&#160;to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1091">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1092"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>.&#160;(It is&#160;also&#160;better&#160;to&#160;avoid&#160;Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1091">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:880px;left:147px;white-space:nowrap" class="ft1092"><b>if&#160;you&#160;have&#160;diabetes&#160;or&#160;impaired kidney&#160;function&#160;</b>and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:147px;white-space:nowrap" class="ft1091">lowering medicine&#160;containing&#160;aliskiren.&#160;<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1091">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1092"><b>Warning and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1091">Talk&#160;to your&#160;doctor&#160;before&#160;taking&#160;Karvea&#160;and</p>
<p style="position:absolute;top:956px;left:406px;white-space:nowrap" class="ft1092"><b>&#160;if&#160;any of&#160;the&#160;following apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1091">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1092"><b>excessive&#160;vomiting or&#160;diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1091">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1092"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1091">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1092"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1091">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1092"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1091">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels&#160;in&#160;case&#160;of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1091">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1092"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1091">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1091">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1099">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1091">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1092"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1099"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1098">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1091">if&#160;you are&#160;taking&#160;any of&#160;the&#160;following&#160;medicines&#160;used to&#160;treat&#160;high&#160;blood&#160;pressure:&#160;</p>
</div>
<!-- Page 110 -->
<a name="110"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page110-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1100">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1100">110&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft11010">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1101">diabetes-related&#160;kidney&#160;problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft11010">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1101">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount&#160;of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1101">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1101">See&#160;also&#160;information&#160;under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1101">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1101">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1101">may&#160;cause serious harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;at&#160;that&#160;stage (see pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1102"><b>Children&#160;and adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1101">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used&#160;in&#160;children&#160;and&#160;adolescents because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1101">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1102"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1102"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1101">Tell&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking,&#160;have&#160;recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1101">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1101">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1101">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1101">Karvea”&#160;and&#160;“Warnings and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1102"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1109"></p>
<p style="position:absolute;top:557px;left:114px;white-space:nowrap" class="ft1108">&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1101">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1109"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1108">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1101">salt&#160;substitutes containing&#160;potassium&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1109"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1108">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1101">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1109"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1108">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1101">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1109"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1108">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1101">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1101">If&#160;you take&#160;certain painkillers, called non-steroidal&#160;anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1101">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1102"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1101">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1102"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1102"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1101">You must&#160;tell&#160;your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1101">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1101">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1101">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause&#160;serious&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1101">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1102"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1101">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1101">for&#160;mothers&#160;who&#160;are breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you&#160;if&#160;you wish&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1101">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1102"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1101">Karvea&#160;is&#160;unlikely&#160;to affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1101">weariness&#160;may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1101">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1101">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft1102"><b>Karvea&#160;contains lactose</b>. If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you&#160;have an&#160;intolerance&#160;to&#160;some&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1101">sugars&#160;(e.g.&#160;lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
</div>
<!-- Page 111 -->
<a name="111"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page111-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1110">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1110">111&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1112"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet, that&#160;is&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1111">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1112"><b>3.&#160;</b></p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1112"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1112"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1111">Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1111">if&#160;you&#160;are&#160;not&#160;sure.&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1112"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1111">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:273px;left:197px;white-space:nowrap" class="ft1112"><b>oral&#160;use</b>.&#160;Swallow&#160;the&#160;tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1111">You&#160;can take&#160;Karvea&#160;with&#160;or&#160;without&#160;food. Try&#160;to&#160;take&#160;your&#160;daily dose&#160;at&#160;about&#160;the&#160;same&#160;time&#160;each&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1111">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:351px;left:106px;white-space:nowrap" class="ft1119"></p>
<p style="position:absolute;top:349px;left:114px;white-space:nowrap" class="ft1118">&#160;</p>
<p style="position:absolute;top:348px;left:149px;white-space:nowrap" class="ft1112"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1111">The usual&#160;dose&#160;is 150&#160;mg once-a-day. The&#160;dose&#160;may later&#160;be&#160;increased to 300&#160;mg&#160;(two&#160;tablets&#160;a&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1111">day)&#160;once&#160;daily depending&#160;on blood pressure&#160;response.&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:427px;left:106px;white-space:nowrap" class="ft1119"></p>
<p style="position:absolute;top:425px;left:114px;white-space:nowrap" class="ft1118">&#160;</p>
<p style="position:absolute;top:424px;left:149px;white-space:nowrap" class="ft1112"><b>Patients with&#160;high&#160;blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes&#160;with kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:443px;left:149px;white-space:nowrap" class="ft1111">In patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2 diabetes, 300&#160;mg&#160;(two&#160;tablets a day)&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:463px;left:149px;white-space:nowrap" class="ft1111">is the preferred&#160;maintenance dose&#160;for&#160;the treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1111">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially when starting treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1111">those&#160;on&#160;</p>
<p style="position:absolute;top:519px;left:166px;white-space:nowrap" class="ft1112"><b>haemodialysis</b>, or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1111">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning treatment.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1112"><b>Use in children and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1111">Karvea&#160;should not&#160;be&#160;given&#160;to children&#160;under&#160;18&#160;years&#160;of&#160;age.&#160;If&#160;a child&#160;swallows&#160;some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1111">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1112"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than you should&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1111">If&#160;you accidentally take&#160;too&#160;many&#160;tablets,&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1112"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1111">If&#160;you accidentally&#160;miss a daily&#160;dose, just&#160;take&#160;the&#160;next&#160;dose&#160;as&#160;normal. Do not&#160;take&#160;a&#160;double&#160;dose&#160;to&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1111">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1111">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1112"><b>&#160;</b></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1112"><b>4.&#160;</b></p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1112"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1112"><b>&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1111">Like all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1111">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1111">As with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as&#160;well&#160;as&#160;localised&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1111">swelling of&#160;the&#160;face, lips&#160;and/or&#160;tongue&#160;have&#160;been&#160;reported&#160;in patients&#160;taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1111">of&#160;these&#160;symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:994px;left:381px;white-space:nowrap" class="ft1112"><b>stop&#160;taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1111">The&#160;frequency of&#160;the&#160;side&#160;effects&#160;listed below&#160;is&#160;defined&#160;using the&#160;following convention:&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1111">Very&#160;common:&#160;may affect&#160;more&#160;than 1&#160;in 10&#160;people&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1111">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1111">Uncommon:&#160;may&#160;affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1111">&#160;</p>
</div>
<!-- Page 112 -->
<a name="112"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page112-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1120">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1120">112&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1121">Side effects reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1129"></p>
<p style="position:absolute;top:102px;left:114px;white-space:nowrap" class="ft1128">&#160;</p>
<p style="position:absolute;top:102px;left:149px;white-space:nowrap" class="ft1121">Very&#160;common&#160;(may&#160;affect&#160;more&#160;than&#160;1 in&#160;10 people):&#160;if&#160;you suffer&#160;from&#160;high&#160;blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:121px;left:149px;white-space:nowrap" class="ft1121">type&#160;2&#160;diabetes with&#160;kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1129"></p>
<p style="position:absolute;top:159px;left:114px;white-space:nowrap" class="ft1128">&#160;</p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1121">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people): dizziness,&#160;feeling&#160;sick/vomiting,&#160;fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1121">tests&#160;may&#160;show&#160;raised&#160;levels of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1121">kinase&#160;enzyme). In patients&#160;with high blood&#160;pressure&#160;and type&#160;2 diabetes&#160;with kidney&#160;disease,&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1121">dizziness&#160;when&#160;getting up&#160;from&#160;a&#160;lying&#160;or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1121">from&#160;a&#160;lying&#160;or&#160;sitting position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1121">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also&#160;reported.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft1129"></p>
<p style="position:absolute;top:292px;left:114px;white-space:nowrap" class="ft1128">&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1121">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100 people):&#160;heart&#160;rate increased, flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:311px;left:149px;white-space:nowrap" class="ft1121">indigestion/heartburn, sexual&#160;dysfunction&#160;(problems&#160;with&#160;sexual&#160;performance), chest&#160;pain.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1121">Some undesirable effects have been&#160;reported&#160;since&#160;marketing&#160;of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1121">frequency is&#160;not&#160;known are:&#160;feeling&#160;of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1121">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells&#160;(anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1121">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when exercising, dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1121">reduced number&#160;of&#160;platelets,&#160;abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels,&#160;impaired&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1121">kidney&#160;function,&#160;inflammation of&#160;small&#160;blood&#160;vessels&#160;mainly&#160;affecting&#160;the skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1121">leukocytoclastic vasculitis),&#160;severe allergic&#160;reactions&#160;(anaphylactic&#160;shock)&#160;and low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1121">Uncommon&#160;cases&#160;of&#160;jaundice&#160;(yellowing of&#160;the&#160;skin and/or&#160;whites of&#160;the eyes)&#160;have also&#160;been&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1121">reported.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1121">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1121">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible side&#160;effects&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1121">not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1121">listed&#160;in&#160;Appendix V. By reporting&#160;side&#160;effects you&#160;can&#160;help provide&#160;more&#160;information&#160;on the&#160;safety of&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1121">this&#160;medicine.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1122"><b>5.&#160;</b></p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1122"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1122"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1121">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1121">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which&#160;is&#160;stated&#160;on&#160;the carton and&#160;on&#160;the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1121">EXP. The&#160;expiry&#160;date&#160;refers&#160;to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1121">Do not&#160;store above&#160;30°C.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1121">Do not&#160;throw&#160;away any&#160;medicines&#160;via&#160;wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1121">throw&#160;away of&#160;medicines&#160;you no longer&#160;use. These&#160;measures&#160;will&#160;help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1122"><b>6.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft1122"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1122"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1122"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1129">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1121">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;150&#160;mg contains&#160;150&#160;mg irbesartan.&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1129">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1121">The other&#160;ingredients are&#160;microcrystalline cellulose,&#160;croscarmellose&#160;sodium,&#160;lactose&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1121">monohydrate,&#160;magnesium&#160;stearate, colloidal&#160;hydrated silica, pregelatinized&#160;maize starch,&#160;and&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1121">poloxamer&#160;188.&#160;Please&#160;see section&#160;2&#160;“Karvea&#160;contains lactose”.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft1122"><b>What&#160;Karvea&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1121">Karvea&#160;150&#160;mg&#160;tablets are&#160;white&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1121">side&#160;and the&#160;number&#160;2772 engraved on&#160;the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft1121">&#160;</p>
</div>
<!-- Page 113 -->
<a name="113"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page113-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1130">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1130">113&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1131">Karvea&#160;150&#160;mg tablets&#160;are&#160;supplied&#160;in blister&#160;packs&#160;of&#160;14, 28, 56 or&#160;98&#160;tablets.&#160;Unidose blister&#160;packs&#160;of&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1131">56&#160;x&#160;1&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;available.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1131">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1132"><b>Marketing Authorisation&#160;Holder:&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1131">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1131">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1131">94250 Gentilly&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1131">France&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1132"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1131">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1131">1, rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1131">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1131">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1131">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1131">30-36&#160;Avenue&#160;Gustave Eiffel,&#160;BP&#160;7166&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1131">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1131">For&#160;any&#160;information&#160;about this&#160;medicinal&#160;product,&#160;please&#160;contact the&#160;local representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1131">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1132"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1131">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1131">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1132"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:558px;left:455px;white-space:nowrap" class="ft1131">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1131">Tel:&#160;+370&#160;5&#160;236 91&#160;40&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft11313"><b>България&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1131">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1136">Тел.: +359 (0)2&#160;4942 480&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1132"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1131">Sanofi&#160;Belgium&#160;&#160;</p>
<p style="position:absolute;top:652px;left:454px;white-space:nowrap" class="ft1131">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft11313"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1131">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1131">Tel:&#160;+420&#160;233&#160;086 111&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft11313"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft1131">SANOFI-AVENTIS&#160;Zrt.&#160;</p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1131">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:747px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1132"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1131">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1131">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1132"><b>Malta&#160;</b></p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft1131">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1131">Tel:&#160;+39 02&#160;39394275&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1132"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1131">Sanofi-Aventis Deutschland GmbH&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1131">Tel:&#160;0800 52 52 010&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1131">Tel.&#160;aus&#160;dem&#160;Ausland:&#160;+49&#160;69 305 21&#160;131&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1132"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1131">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1131">Tel:&#160;+31 20&#160;245 4000&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1132"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1131">Swixx Biopharma&#160;OÜ&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1131">Tel:&#160;+372&#160;640 10 30&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:918px;left:455px;white-space:nowrap" class="ft1132"><b>Norge&#160;</b></p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1131">sanofi-aventis&#160;Norge&#160;AS&#160;</p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1131">Tlf:&#160;+47 67 10 71&#160;00&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft11313"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1131">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1136">Τηλ:&#160;+30 210&#160;900 16&#160;00&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1132"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1013px;left:455px;white-space:nowrap" class="ft1131">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1131">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1132"><b>España&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1131">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1131">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1131">&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1132"><b>Polska&#160;</b></p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1131">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:1108px;left:455px;white-space:nowrap" class="ft1131">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:1127px;left:455px;white-space:nowrap" class="ft1131">&#160;</p>
</div>
<!-- Page 114 -->
<a name="114"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page114-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1140">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1140">114&#160;</p>
<p style="position:absolute;top:83px;left:104px;white-space:nowrap" class="ft1142"><b>France&#160;</b></p>
<p style="position:absolute;top:102px;left:104px;white-space:nowrap" class="ft1141">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:121px;left:104px;white-space:nowrap" class="ft1141">Tél:&#160;0 800 222 555&#160;</p>
<p style="position:absolute;top:140px;left:104px;white-space:nowrap" class="ft1141">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1 57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:159px;left:104px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1142"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1141">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1141">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1142"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1141">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1141">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1142"><b>România&#160;</b></p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1141">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:216px;left:454px;white-space:nowrap" class="ft1141">Tel:&#160;+40&#160;(0)&#160;21&#160;317 31 36&#160;</p>
<p style="position:absolute;top:235px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1142"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1141">sanofi-aventis Ireland&#160;Ltd.&#160;T/A SANOFI&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1141">Tel:&#160;+353&#160;(0)&#160;1 403 56 00&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1142"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1141">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:292px;left:455px;white-space:nowrap" class="ft1141">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:311px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1142"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1141">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1141">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft11413"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1141">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:368px;left:455px;white-space:nowrap" class="ft1141">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1142"><b>Italia&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1141">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1141">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft1142"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1141">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1141">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft11413"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1141">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1146">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft1142"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1141">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1141">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1142"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1141">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1141">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1142"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1141">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1141">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1142"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1141">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1141">Detailed&#160;information&#160;on this&#160;medicine&#160;is&#160;available&#160;on the&#160;European Medicines&#160;Agency&#160;web site:&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1141">http://www.ema.europa.eu/&#160;</p>
</div>
<!-- Page 115 -->
<a name="115"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page115-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1150">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1150">115&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1152"><b>Package leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:102px;left:367px;white-space:nowrap" class="ft1152"><b>Karvea 300&#160;mg tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1151">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1152"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before&#160;you&#160;start taking&#160;this&#160;medicine&#160;because it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1152"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1151">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1151">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1151">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1151">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1151">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1151">effects not&#160;listed&#160;in&#160;this leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1152"><b>What&#160;is&#160;in&#160;this leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1151">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1151">What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1151">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1151">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1151">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1151">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1151">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1151">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1151">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1151">How&#160;to store&#160;Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1151">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1151">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1152"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1152"><b>What&#160;Karvea&#160;is&#160;and&#160;what&#160;it&#160;is&#160;used&#160;for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1152"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1151">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines&#160;known as&#160;angiotensin-II&#160;receptor&#160;antagonists. Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1151">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to&#160;receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1151">This&#160;results in&#160;an&#160;increase&#160;in&#160;blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1151">receptors, causing the&#160;blood vessels&#160;to&#160;relax&#160;and&#160;the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1151">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1151">Karvea&#160;is&#160;used in&#160;adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1151">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1151">to protect&#160;the&#160;kidney&#160;in patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1151">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1152"><b>2.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft1152"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1152"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1152"><b>Do not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1151">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1152"><b>allergic</b>&#160;to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1151">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1152"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>.&#160;(It is&#160;also&#160;better&#160;to&#160;avoid&#160;Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1151">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:880px;left:147px;white-space:nowrap" class="ft1152"><b>if&#160;you&#160;have&#160;diabetes&#160;or&#160;impaired kidney&#160;</b>function and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:147px;white-space:nowrap" class="ft1151">lowering medicine&#160;containing&#160;aliskiren.<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1151">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1152"><b>Warning and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1151">Talk&#160;to your&#160;doctor&#160;before&#160;taking&#160;Karvea&#160;and</p>
<p style="position:absolute;top:956px;left:406px;white-space:nowrap" class="ft1152"><b>&#160;if&#160;any of&#160;the&#160;following apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1151">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1152"><b>excessive&#160;vomiting&#160;or diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1151">if&#160;you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1152"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1151">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1152"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1151">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1152"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1151">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels&#160;in&#160;case&#160;of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1151">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1152"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1151">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1151">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1159">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1151">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1152"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1159"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1158">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1151">if&#160;you are&#160;taking&#160;any of&#160;the&#160;following&#160;medicines&#160;used to&#160;treat&#160;high&#160;blood&#160;pressure:&#160;</p>
</div>
<!-- Page 116 -->
<a name="116"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page116-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1160">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1160">116&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft11610">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1161">diabetes-related&#160;kidney&#160;problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft11610">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1161">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount&#160;of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1161">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1161">See&#160;also&#160;information&#160;under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1161">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1161">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1161">may&#160;cause serious harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;at&#160;that&#160;stage (see pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1162"><b>Children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1161">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used&#160;in&#160;children&#160;and&#160;adolescents because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1161">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1162"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1162"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1161">Tell&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking,&#160;have&#160;recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1161">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1161">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1161">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1161">Karvea”&#160;and&#160;“Warnings and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1162"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1169"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1168">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1161">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1169"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1168">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1161">salt&#160;substitutes containing&#160;potassium&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1169"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1168">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1161">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1169"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1168">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1161">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:655px;left:106px;white-space:nowrap" class="ft1169"></p>
<p style="position:absolute;top:652px;left:114px;white-space:nowrap" class="ft1168">&#160;</p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft1161">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1161">If&#160;you take&#160;certain painkillers, called non-steroidal anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1161">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1162"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1161">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1162"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1162"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1161">You must&#160;tell&#160;your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1161">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1161">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1161">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause&#160;serious&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1161">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1162"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1161">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1161">for&#160;mothers&#160;who&#160;are breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you&#160;if&#160;you wish&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1161">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1162"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1161">Karvea&#160;is&#160;unlikely&#160;to affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1161">weariness&#160;may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1161">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1161">&#160;</p>
</div>
<!-- Page 117 -->
<a name="117"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page117-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1170">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1170">117&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1172"><b>Karvea&#160;contains&#160;lactose</b>.&#160;If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you&#160;have an&#160;intolerance&#160;to&#160;some&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1171">sugars&#160;(e.g.&#160;lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1172"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet, that&#160;is&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1171">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1172"><b>3.&#160;</b></p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1172"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1172"><b>&#160;</b></p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1171">Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1171">if&#160;you&#160;are&#160;not&#160;sure.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1172"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1171">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:330px;left:197px;white-space:nowrap" class="ft1172"><b>oral&#160;use</b>.&#160;Swallow&#160;the&#160;tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1171">You&#160;can take&#160;Karvea&#160;with&#160;or&#160;without&#160;food. Try&#160;to&#160;take&#160;your&#160;daily dose&#160;at&#160;about&#160;the&#160;same&#160;time&#160;each&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1171">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:408px;left:106px;white-space:nowrap" class="ft1179"></p>
<p style="position:absolute;top:406px;left:114px;white-space:nowrap" class="ft1178">&#160;</p>
<p style="position:absolute;top:405px;left:149px;white-space:nowrap" class="ft1172"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1171">The usual&#160;dose&#160;is 150&#160;mg once-a-day. The&#160;dose&#160;may later&#160;be&#160;increased to 300&#160;mg once&#160;daily&#160;</p>
<p style="position:absolute;top:443px;left:149px;white-space:nowrap" class="ft1171">depending on blood pressure&#160;response.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:484px;left:106px;white-space:nowrap" class="ft1179"></p>
<p style="position:absolute;top:481px;left:114px;white-space:nowrap" class="ft1178">&#160;</p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1172"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes&#160;with&#160;kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1171">In&#160;patients&#160;with&#160;high blood&#160;pressure&#160;and type&#160;2 diabetes, 300&#160;mg&#160;once daily&#160;is the&#160;preferred&#160;</p>
<p style="position:absolute;top:519px;left:149px;white-space:nowrap" class="ft1171">maintenance dose for&#160;the&#160;treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1171">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially&#160;when&#160;starting&#160;treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1171">those&#160;on&#160;</p>
<p style="position:absolute;top:576px;left:166px;white-space:nowrap" class="ft1172"><b>haemodialysis</b>,&#160;or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1171">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning treatment.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1172"><b>Use in&#160;children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1171">Karvea&#160;should not&#160;be&#160;given&#160;to children&#160;under&#160;18&#160;years&#160;of&#160;age.&#160;If&#160;a child&#160;swallows some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1171">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1172"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than you should&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1171">If&#160;you accidentally take&#160;too&#160;many&#160;tablets,&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1172"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1171">If&#160;you&#160;accidentally&#160;miss a daily&#160;dose,&#160;just&#160;take the next&#160;dose as&#160;normal. Do not&#160;take&#160;a&#160;double&#160;dose&#160;to&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1171">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1171">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1172"><b>&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1172"><b>4.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft1172"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1172"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1171">Like all&#160;medicines,&#160;this medicine can&#160;cause&#160;side effects,&#160;although&#160;not&#160;everybody&#160;gets&#160;them.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1171">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1171">As with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as&#160;well&#160;as localised&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1171">swelling of&#160;the&#160;face,&#160;lips&#160;and/or&#160;tongue&#160;have&#160;been reported&#160;in patients&#160;taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1171">of&#160;these&#160;symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:1051px;left:381px;white-space:nowrap" class="ft1172"><b>stop&#160;taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1171">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1171">The&#160;frequency of&#160;the&#160;side&#160;effects&#160;listed below&#160;is&#160;defined using the&#160;following&#160;convention:&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1171">Very&#160;common:&#160;may&#160;affect&#160;more&#160;than&#160;1 in&#160;10 people&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1171">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1171">Uncommon:&#160;may&#160;affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
</div>
<!-- Page 118 -->
<a name="118"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page118-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1180">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1180">118&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1181">Side&#160;effects&#160;reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
<p style="position:absolute;top:123px;left:106px;white-space:nowrap" class="ft1189"></p>
<p style="position:absolute;top:121px;left:114px;white-space:nowrap" class="ft1188">&#160;</p>
<p style="position:absolute;top:121px;left:149px;white-space:nowrap" class="ft1181">Very common&#160;(may affect&#160;more&#160;than 1&#160;in 10&#160;people):&#160;if&#160;you suffer&#160;from&#160;high&#160;blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:140px;left:149px;white-space:nowrap" class="ft1181">type&#160;2&#160;diabetes with&#160;kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:180px;left:106px;white-space:nowrap" class="ft1189"></p>
<p style="position:absolute;top:178px;left:114px;white-space:nowrap" class="ft1188">&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1181">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people):&#160;dizziness,&#160;feeling sick/vomiting, fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1181">tests may&#160;show&#160;raised&#160;levels&#160;of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1181">kinase&#160;enzyme). In patients&#160;with high blood&#160;pressure&#160;and type&#160;2 diabetes&#160;with kidney disease,&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1181">dizziness&#160;when&#160;getting up&#160;from&#160;a&#160;lying&#160;or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1181">from&#160;a&#160;lying&#160;or&#160;sitting position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1181">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also&#160;reported.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:313px;left:106px;white-space:nowrap" class="ft1189"></p>
<p style="position:absolute;top:311px;left:114px;white-space:nowrap" class="ft1188">&#160;</p>
<p style="position:absolute;top:311px;left:149px;white-space:nowrap" class="ft1181">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100&#160;people):&#160;heart&#160;rate&#160;increased, flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:330px;left:149px;white-space:nowrap" class="ft1181">indigestion/heartburn, sexual&#160;dysfunction&#160;(problems&#160;with&#160;sexual&#160;performance),&#160;chest&#160;pain.&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1181">Some undesirable effects have been&#160;reported&#160;since&#160;marketing&#160;of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1181">frequency is&#160;not&#160;known are:&#160;feeling of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1181">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells&#160;(anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1181">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when exercising, dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1181">reduced number&#160;of&#160;platelets, abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels,&#160;impaired&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1181">kidney&#160;function, inflammation of&#160;small&#160;blood&#160;vessels&#160;mainly&#160;affecting the&#160;skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1181">leukocytoclastic vasculitis),&#160;severe&#160;allergic reactions (anaphylactic&#160;shock)&#160;and&#160;low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1181">Uncommon&#160;cases of&#160;jaundice (yellowing&#160;of&#160;the&#160;skin&#160;and/or&#160;whites of&#160;the eyes)&#160;have also&#160;been&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1181">reported.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1181">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1181">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1181">not&#160;listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1181">listed&#160;in&#160;Appendix V. By reporting&#160;side&#160;effects you&#160;can&#160;help&#160;provide&#160;more&#160;information&#160;on the&#160;safety of&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1181">this medicine.&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1182"><b>5.&#160;</b></p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1182"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1182"><b>&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1181">Keep&#160;this&#160;medicine out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1181">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date&#160;which is&#160;stated on the&#160;carton and&#160;on&#160;the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1181">EXP.&#160;The&#160;expiry date&#160;refers&#160;to&#160;the&#160;last&#160;day&#160;of&#160;that month.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1181">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1181">Do not&#160;throw&#160;away any&#160;medicines&#160;via&#160;wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1181">throw&#160;away of&#160;medicines&#160;you no longer&#160;use.&#160;These&#160;measures&#160;will&#160;help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1182"><b>6.&#160;</b></p>
<p style="position:absolute;top:937px;left:149px;white-space:nowrap" class="ft1182"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1182"><b>&#160;</b></p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1182"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1189">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1181">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;300&#160;mg contains&#160;300&#160;mg irbesartan.&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1189">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1181">The other&#160;ingredients are&#160;microcrystalline cellulose,&#160;croscarmellose&#160;sodium,&#160;lactose&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1181">monohydrate,&#160;magnesium&#160;stearate, colloidal&#160;hydrated silica,&#160;pregelatinized&#160;maize starch,&#160;and&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1181">poloxamer&#160;188.&#160;Please&#160;see section&#160;2&#160;“Karvea&#160;contains lactose”.&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1181">&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1182"><b>What&#160;Karvea&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1181">Karvea&#160;300&#160;mg&#160;tablets are&#160;white&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;debossed on one&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft1181">side&#160;and the&#160;number&#160;2773 engraved on&#160;the&#160;other&#160;side.&#160;</p>
</div>
<!-- Page 119 -->
<a name="119"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page119-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1190">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1190">119&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1191">Karvea&#160;300&#160;mg tablets&#160;are&#160;supplied&#160;in blister&#160;packs&#160;of&#160;14, 28, 56 or&#160;98&#160;tablets.&#160;Unidose blister&#160;packs&#160;of&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1191">56&#160;x&#160;1&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;available.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1191">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1192"><b>Marketing&#160;Authorisation&#160;Holder:&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1191">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1191">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1191">94250 Gentilly&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1191">France&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1192"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1191">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1191">1, rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1191">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1191">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1191">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1191">30-36&#160;Avenue&#160;Gustave&#160;Eiffel, BP&#160;7166&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1191">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1191">For&#160;any&#160;information&#160;about this&#160;medicinal&#160;product,&#160;please&#160;contact the&#160;local representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1191">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1192"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1191">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1191">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1192"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1191">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1191">Tel:&#160;+370&#160;5&#160;236 91&#160;40&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft11913"><b>България&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1191">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1196">Тел.: +359 (0)2&#160;4942 480&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1192"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1191">Sanofi&#160;Belgium&#160;&#160;</p>
<p style="position:absolute;top:671px;left:454px;white-space:nowrap" class="ft1191">Tél/Tel:&#160;+32 (0)2 710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft11913"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1191">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1191">Tel:&#160;+420&#160;233&#160;086 111&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft11913"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1191">SANOFI-AVENTIS Zrt.&#160;</p>
<p style="position:absolute;top:747px;left:455px;white-space:nowrap" class="ft1191">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1192"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1191">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1191">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft1192"><b>Malta&#160;</b></p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1191">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1191">Tel:&#160;+39 02&#160;39394275&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1192"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1191">Sanofi-Aventis&#160;Deutschland GmbH&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1191">Tel:&#160;0800 52 52 010&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1191">Tel.&#160;aus&#160;dem Ausland:&#160;+49&#160;69 305 21&#160;131&#160;</p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1192"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1191">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1191">Tel: +31&#160;20&#160;245 4000&#160;</p>
<p style="position:absolute;top:918px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1192"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1191">Swixx Biopharma&#160;OÜ&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1191">Tel:&#160;+372&#160;640 10 30&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1192"><b>Norge&#160;</b></p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1191">sanofi-aventis Norge&#160;AS&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1191">Tlf: +47&#160;67 10 71&#160;00&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft11913"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1191">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1196">Τηλ:&#160;+30 210&#160;900 16&#160;00&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:1013px;left:455px;white-space:nowrap" class="ft1192"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1191">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1191">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1192"><b>España&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1191">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1191">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1191">&#160;</p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1192"><b>Polska&#160;</b></p>
<p style="position:absolute;top:1108px;left:455px;white-space:nowrap" class="ft1191">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:1127px;left:455px;white-space:nowrap" class="ft1191">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:1146px;left:455px;white-space:nowrap" class="ft1191">&#160;</p>
</div>
<!-- Page 120 -->
<a name="120"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page120-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1200">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1200">120&#160;</p>
<p style="position:absolute;top:83px;left:104px;white-space:nowrap" class="ft1202"><b>France&#160;</b></p>
<p style="position:absolute;top:102px;left:104px;white-space:nowrap" class="ft1201">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:121px;left:104px;white-space:nowrap" class="ft1201">Tél:&#160;0 800 222 555&#160;</p>
<p style="position:absolute;top:140px;left:104px;white-space:nowrap" class="ft1201">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1 57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:159px;left:104px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1202"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1201">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1201">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1202"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1201">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1201">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1202"><b>România&#160;</b></p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1201">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:216px;left:454px;white-space:nowrap" class="ft1201">Tel:&#160;+40&#160;(0)&#160;21&#160;317 31 36&#160;</p>
<p style="position:absolute;top:235px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1202"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1201">sanofi-aventis Ireland&#160;Ltd.&#160;T/A SANOFI&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1201">Tel:&#160;+353&#160;(0)&#160;1 403 56 00&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1202"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1201">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:292px;left:455px;white-space:nowrap" class="ft1201">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:311px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1202"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1201">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1201">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft12013"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1201">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:368px;left:455px;white-space:nowrap" class="ft1201">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1202"><b>Italia&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1201">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1201">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft1202"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1201">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1201">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft12013"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1201">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1206">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft1202"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1201">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1201">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1202"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1201">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1201">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1202"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1201">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1201">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1202"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1201">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1201">Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1201">http://www.ema.europa.eu/&#160;</p>
</div>
<!-- Page 121 -->
<a name="121"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page121-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1210">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1210">121&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1212"><b>Package leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:102px;left:329px;white-space:nowrap" class="ft1212"><b>Karvea</b>&#160;<b>75</b>&#160;<b>mg&#160;film-coated&#160;tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1211">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1212"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before you&#160;start&#160;taking&#160;this&#160;medicine because&#160;it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1212"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1211">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1211">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1211">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1211">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1211">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1211">effects not&#160;listed&#160;in&#160;this leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1212"><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1211">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1211">What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1211">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1211">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1211">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1211">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1211">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1211">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1211">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1211">How&#160;to store&#160;Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1211">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1211">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1212"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1212"><b>What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1212"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1211">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines&#160;known as&#160;angiotensin-II&#160;receptor&#160;antagonists. Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1211">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to&#160;receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1211">This&#160;results&#160;in&#160;an increase&#160;in&#160;blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1211">receptors, causing the&#160;blood vessels&#160;to&#160;relax&#160;and&#160;the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1211">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1211">Karvea&#160;is&#160;used in adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1211">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1211">to protect&#160;the&#160;kidney&#160;in patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1211">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1212"><b>2.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft1212"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1212"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1212"><b>Do not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1211">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1212"><b>allergic</b>&#160;to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1211">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1212"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>.&#160;(It is&#160;also&#160;better&#160;to&#160;avoid&#160;Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1211">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:880px;left:147px;white-space:nowrap" class="ft1212"><b>if&#160;you&#160;have&#160;diabetes or impaired&#160;kidney&#160;function&#160;</b>and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:147px;white-space:nowrap" class="ft1211">lowering medicine&#160;containing&#160;aliskiren.&#160;<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1211">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1212"><b>Warnings&#160;and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1211">Talk&#160;to your&#160;doctor&#160;before&#160;taking&#160;Karvea</p>
<p style="position:absolute;top:956px;left:378px;white-space:nowrap" class="ft1212"><b>&#160;</b>and&#160;<b>if&#160;any of&#160;the&#160;following apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1211">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1212"><b>excessive&#160;vomiting&#160;or diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1211">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1212"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1211">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1212"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1211">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1212"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1211">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels&#160;in&#160;case&#160;of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1211">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1212"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1211">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1211">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1219">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1211">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1212"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1219"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1218">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1211">if&#160;you are&#160;taking&#160;any of&#160;the&#160;following&#160;medicines&#160;used to&#160;treat&#160;high&#160;blood&#160;pressure:&#160;</p>
</div>
<!-- Page 122 -->
<a name="122"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page122-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1220">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1220">122&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft12210">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1221">diabetes-related&#160;kidney problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft12210">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1221">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount&#160;of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1221">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1221">See&#160;also&#160;information&#160;under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1221">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1221">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1221">may&#160;cause serious harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;at&#160;that&#160;stage (see pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1222"><b>Children&#160;and adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1221">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used&#160;in&#160;children&#160;and&#160;adolescents because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1221">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1222"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1222"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1221">Tell&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking,&#160;have recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1221">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1221">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1221">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1221">Karvea”&#160;and&#160;“Warnings and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1222"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1229"></p>
<p style="position:absolute;top:557px;left:114px;white-space:nowrap" class="ft1228">&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1221">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1229"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1228">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1221">salt&#160;substitutes containing&#160;potassium&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1229"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1228">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1221">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1229"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1228">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1221">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1229"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1228">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1221">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1221">If&#160;you take&#160;certain painkillers, called non-steroidal&#160;anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1221">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1222"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1221">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1222"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1222"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1221">You must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1221">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1221">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1221">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause&#160;serious&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1221">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1222"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1222"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1221">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1221">for&#160;mothers&#160;who&#160;are breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you&#160;if&#160;you wish&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1221">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1222"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1221">Karvea&#160;is&#160;unlikely&#160;to affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1221">weariness&#160;may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1221">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1221">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft1222"><b>Karvea&#160;contains&#160;lactose</b>. If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you&#160;have an&#160;intolerance&#160;to&#160;some&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1221">sugars&#160;(e.g.&#160;lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
</div>
<!-- Page 123 -->
<a name="123"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page123-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1230">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1230">123&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1232"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet, that&#160;is&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1231">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1232"><b>3.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1232"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1232"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1231">Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1231">if&#160;you&#160;are&#160;not&#160;sure.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1232"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1231">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:292px;left:197px;white-space:nowrap" class="ft1232"><b>oral&#160;use</b>.&#160;Swallow&#160;the tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1231">You&#160;can take&#160;Karvea&#160;with&#160;or&#160;without&#160;food. Try&#160;to&#160;take&#160;your&#160;daily dose&#160;at&#160;about&#160;the&#160;same&#160;time&#160;each&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1231">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1239"></p>
<p style="position:absolute;top:368px;left:114px;white-space:nowrap" class="ft1238">&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1232"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1231">The usual&#160;dose&#160;is 150&#160;mg once-a-day&#160;(two tablets&#160;a&#160;day).&#160;The&#160;dose&#160;may&#160;later&#160;be&#160;increased to&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1231">300&#160;mg&#160;(four&#160;tablets&#160;a&#160;day)&#160;once&#160;daily depending on&#160;blood pressure response.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1239"></p>
<p style="position:absolute;top:443px;left:114px;white-space:nowrap" class="ft1238">&#160;</p>
<p style="position:absolute;top:443px;left:149px;white-space:nowrap" class="ft1232"><b>Patients&#160;with&#160;high&#160;blood pressure&#160;and type&#160;2&#160;diabetes with&#160;kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:463px;left:149px;white-space:nowrap" class="ft1231">In patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2 diabetes, 300&#160;mg&#160;(four&#160;tablets&#160;a&#160;day)&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1231">is the preferred&#160;maintenance dose&#160;for&#160;the treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1231">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially&#160;when&#160;starting&#160;treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1231">those&#160;on&#160;</p>
<p style="position:absolute;top:538px;left:166px;white-space:nowrap" class="ft1232"><b>haemodialysis</b>, or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1231">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning&#160;treatment.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1232"><b>Use in&#160;children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1231">Karvea&#160;should&#160;not&#160;be&#160;given&#160;to children&#160;under&#160;18&#160;years&#160;of&#160;age.&#160;If&#160;a child&#160;swallows&#160;some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1231">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1232"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than you should:&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1231">If&#160;you accidentally take&#160;too&#160;many&#160;tablets,&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1232"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea:&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1231">If&#160;you&#160;accidentally&#160;miss a daily&#160;dose,&#160;just&#160;take the next&#160;dose as normal.&#160;Do&#160;not&#160;take&#160;a double dose&#160;to&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1231">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1231">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1232"><b>4.&#160;</b></p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1232"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1232"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1231">Like&#160;all&#160;medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1231">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1231">As&#160;with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as well&#160;as&#160;localised&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1231">swelling&#160;of&#160;the&#160;face, lips&#160;and/or&#160;tongue&#160;have&#160;been&#160;reported&#160;in patients&#160;taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1231">of&#160;these&#160;symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:1013px;left:381px;white-space:nowrap" class="ft1232"><b>stop&#160;taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1231">The&#160;frequency of&#160;the&#160;side&#160;effects listed&#160;below&#160;is&#160;defined using the&#160;following&#160;convention:&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1231">Very&#160;common:&#160;may affect&#160;more&#160;than 1&#160;in 10&#160;people&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1231">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1231">Uncommon:&#160;may&#160;affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1231">&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1231">Side&#160;effects&#160;reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
</div>
<!-- Page 124 -->
<a name="124"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page124-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1240">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1240">124&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1249"></p>
<p style="position:absolute;top:83px;left:114px;white-space:nowrap" class="ft1248">&#160;</p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft1241">Very common&#160;(may affect&#160;more&#160;than 1&#160;in 10&#160;people):&#160;if&#160;you suffer&#160;from&#160;high&#160;blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:102px;left:149px;white-space:nowrap" class="ft1241">type&#160;2&#160;diabetes with&#160;kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft1249"></p>
<p style="position:absolute;top:140px;left:114px;white-space:nowrap" class="ft1248">&#160;</p>
<p style="position:absolute;top:140px;left:149px;white-space:nowrap" class="ft1241">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people):&#160;dizziness,&#160;feeling&#160;sick/vomiting, fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1241">tests&#160;may&#160;show&#160;raised&#160;levels of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1241">kinase&#160;enzyme). In patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2 diabetes&#160;with kidney disease,&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1241">dizziness&#160;when&#160;getting up&#160;from a&#160;lying&#160;or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1241">from&#160;a&#160;lying&#160;or&#160;sitting position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1241">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also reported.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1249"></p>
<p style="position:absolute;top:273px;left:114px;white-space:nowrap" class="ft1248">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1241">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100 people):&#160;heart&#160;rate&#160;increased, flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1241">indigestion/heartburn, sexual&#160;dysfunction&#160;(problems&#160;with&#160;sexual&#160;performance), chest&#160;pain.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1241">Some undesirable effects have been&#160;reported&#160;since&#160;marketing of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1241">frequency is&#160;not&#160;known are:&#160;feeling of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1241">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells&#160;(anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1241">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when&#160;exercising,&#160;dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1241">reduced number&#160;of&#160;platelets,&#160;abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels, impaired&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1241">kidney&#160;function,&#160;inflammation of&#160;small&#160;blood vessels&#160;mainly&#160;affecting the&#160;skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1241">leukocytoclastic&#160;vasculitis),&#160;severe&#160;allergic reactions (anaphylactic&#160;shock)&#160;and low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1241">Uncommon&#160;cases of&#160;jaundice (yellowing of&#160;the&#160;skin and/or&#160;whites&#160;of&#160;the&#160;eyes)&#160;have also been&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1241">reported.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1241">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1241">If&#160;you get&#160;any&#160;side&#160;effects,&#160;talk to&#160;your&#160;doctor&#160;or pharmacist.&#160;This&#160;includes any&#160;possible side&#160;effects&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1241">not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects&#160;directly&#160;via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1241">listed in&#160;Appendix V. By reporting&#160;side&#160;effects&#160;you&#160;can&#160;help&#160;provide&#160;more&#160;information on&#160;the&#160;safety of&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1241">this medicine.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1242"><b>5.&#160;</b></p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft1242"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1242"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1241">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1241">Do&#160;not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry date&#160;which&#160;is&#160;stated on the&#160;carton and&#160;on&#160;the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1241">EXP. The&#160;expiry&#160;date&#160;refers&#160;to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1241">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1241">Do&#160;not&#160;throw&#160;away&#160;any&#160;medicines&#160;via wastewater&#160;or&#160;household&#160;waste.&#160;Ask&#160;your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1241">throw&#160;away&#160;medicines&#160;you no&#160;longer&#160;use.&#160;These&#160;measures will&#160;help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1242"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1242"><b>Contents&#160;of&#160;the&#160;pack&#160;and other information&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1242"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1242"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft1249">&#160;</p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft1241">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;75 mg contains&#160;75&#160;mg&#160;irbesartan.&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1249">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1241">The&#160;other&#160;ingredients&#160;are lactose&#160;monohydrate,&#160;microcrystalline&#160;cellulose,&#160;croscarmellose&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1241">sodium, hypromellose,&#160;silicon dioxide,&#160;magnesium stearate,&#160;titanium dioxide,&#160;macrogol&#160;3000,&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1241">carnauba wax.&#160;Please see section&#160;2&#160;“Karvea contains lactose”.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1242"><b>What&#160;Karvea&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1241">Karvea&#160;75&#160;mg&#160;film-coated&#160;tablets are&#160;white&#160;to&#160;off-white, biconvex, and oval-shaped with&#160;a&#160;heart&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1241">debossed on&#160;one&#160;side&#160;and&#160;the&#160;number&#160;2871&#160;engraved&#160;on the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1241">&#160;</p>
</div>
<!-- Page 125 -->
<a name="125"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page125-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1250">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1250">125&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1251">Karvea&#160;75&#160;mg&#160;film-coated&#160;tablets&#160;are&#160;supplied in blister&#160;packs&#160;of&#160;14, 28, 30, 56,&#160;84, 90&#160;or&#160;98&#160;film-</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1251">coated&#160;tablets.&#160;Unidose blister&#160;packs&#160;of&#160;56&#160;x&#160;1&#160;film-coated&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1251">available.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1251">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1252"><b>Marketing&#160;Authorisation Holder:&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1251">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1251">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1251">94250 Gentilly&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1251">France&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1252"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1251">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1251">1, rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1251">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1251">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1251">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1251">30-36&#160;Avenue&#160;Gustave&#160;Eiffel, BP&#160;7166&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1251">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1251">For&#160;any&#160;information about&#160;this&#160;medicinal&#160;product, please&#160;contact&#160;the&#160;local&#160;representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1251">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1252"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1251">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1251">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1252"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1251">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1251">Tel:&#160;+370&#160;5&#160;236 91&#160;40&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft12513"><b>България&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1251">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1256">Тел.: +359 (0)2&#160;4942 480&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1252"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1251">Sanofi&#160;Belgium&#160;&#160;</p>
<p style="position:absolute;top:671px;left:454px;white-space:nowrap" class="ft1251">Tél/Tel:&#160;+32 (0)2&#160;710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft12513"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1251">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1251">Tel:&#160;+420&#160;233&#160;086 111&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft12513"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1251">SANOFI-AVENTIS&#160;Zrt.&#160;</p>
<p style="position:absolute;top:747px;left:455px;white-space:nowrap" class="ft1251">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1252"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1251">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1251">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft1252"><b>Malta&#160;</b></p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1251">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1251">Tel: +39 02&#160;39394275&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1252"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1251">Sanofi-Aventis&#160;Deutschland&#160;GmbH&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1251">Tel:&#160;0800&#160;52 52 010&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1251">Tel.&#160;aus dem&#160;Ausland:&#160;+49&#160;69 305 21&#160;131&#160;</p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1252"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1251">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1251">Tel:&#160;+31 20&#160;245 4000&#160;</p>
<p style="position:absolute;top:918px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1252"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1251">Swixx Biopharma OÜ&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1251">Tel:&#160;+372&#160;640 10 30&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1252"><b>Norge&#160;</b></p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1251">sanofi-aventis Norge AS&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1251">Tlf: +47 67&#160;10 71&#160;00&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft12513"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1251">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1256">Τηλ:&#160;+30&#160;210&#160;900&#160;16 00&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:1013px;left:455px;white-space:nowrap" class="ft1252"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1251">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1251">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1252"><b>España&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1251">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1251">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1251">&#160;</p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1252"><b>Polska&#160;</b></p>
<p style="position:absolute;top:1108px;left:455px;white-space:nowrap" class="ft1251">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:1127px;left:455px;white-space:nowrap" class="ft1251">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:1146px;left:455px;white-space:nowrap" class="ft1251">&#160;</p>
</div>
<!-- Page 126 -->
<a name="126"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page126-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1260">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1260">126&#160;</p>
<p style="position:absolute;top:83px;left:104px;white-space:nowrap" class="ft1262"><b>France&#160;</b></p>
<p style="position:absolute;top:102px;left:104px;white-space:nowrap" class="ft1261">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:121px;left:104px;white-space:nowrap" class="ft1261">Tél:&#160;0 800 222 555&#160;</p>
<p style="position:absolute;top:140px;left:104px;white-space:nowrap" class="ft1261">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1&#160;57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:159px;left:104px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1262"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1261">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1261">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1262"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1261">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1261">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1262"><b>România&#160;</b></p>
<p style="position:absolute;top:178px;left:555px;white-space:nowrap" class="ft1262"><b>&#160;</b></p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1261">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:216px;left:454px;white-space:nowrap" class="ft1261">Tel:&#160;+40&#160;(0) 21 317&#160;31 36&#160;</p>
<p style="position:absolute;top:235px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1262"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1261">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1261">Tel:&#160;+353&#160;(0)&#160;1&#160;403 56 00&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1262"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1261">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:292px;left:455px;white-space:nowrap" class="ft1261">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:311px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1262"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1261">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1261">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft12613"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1261">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:368px;left:455px;white-space:nowrap" class="ft1261">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1262"><b>Italia&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1261">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1261">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft1262"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1261">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1261">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft12613"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1261">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1266">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft1262"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1261">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1261">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1262"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1261">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1261">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1262"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1261">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1261">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1262"><b>This leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1261">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1261">Detailed&#160;information&#160;on this&#160;medicine&#160;is&#160;available&#160;on the&#160;European Medicines&#160;Agency&#160;web site:&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1261">http://www.ema.europa.eu/&#160;</p>
</div>
<!-- Page 127 -->
<a name="127"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page127-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1270">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1270">127&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1272"><b>Package leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:102px;left:325px;white-space:nowrap" class="ft1272"><b>Karvea</b>&#160;<b>150</b>&#160;<b>mg&#160;film-coated tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1271">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1272"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully before&#160;you&#160;start&#160;taking this medicine&#160;because it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1272"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1271">Keep&#160;this leaflet.&#160;You&#160;may&#160;need&#160;to&#160;read&#160;it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1271">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1271">This&#160;medicine has been&#160;prescribed&#160;for&#160;you&#160;only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1271">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1271">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1271">effects not&#160;listed&#160;in&#160;this leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1272"><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1271">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1271">What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1271">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1271">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1271">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1271">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1271">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1271">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1271">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1271">How&#160;to store&#160;Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1271">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1271">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1272"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1272"><b>What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1272"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1271">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines&#160;known as&#160;angiotensin-II&#160;receptor&#160;antagonists. Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1271">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to&#160;receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1271">This results&#160;in&#160;an&#160;increase in&#160;blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1271">receptors, causing the&#160;blood vessels&#160;to&#160;relax&#160;and&#160;the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1271">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1271">Karvea&#160;is&#160;used in adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1271">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1271">to protect&#160;the&#160;kidney&#160;in patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1271">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1272"><b>2. &#160;&#160;&#160;What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1272"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1272"><b>Do&#160;not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1271">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1272"><b>allergic&#160;</b>to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this medicine (listed&#160;in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1271">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1272"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>.&#160;(It&#160;is&#160;also&#160;better&#160;to avoid Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1271">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:880px;left:148px;white-space:nowrap" class="ft1272"><b>if&#160;you&#160;have&#160;diabetes or impaired&#160;kidney&#160;function</b>&#160;and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:147px;white-space:nowrap" class="ft1271">lowering&#160;medicine&#160;containing&#160;aliskiren.<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1271">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1272"><b>Warnings&#160;and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1271">Talk&#160;to your&#160;doctor&#160;before&#160;taking&#160;Karvea</p>
<p style="position:absolute;top:956px;left:378px;white-space:nowrap" class="ft1272"><b>&#160;</b>and&#160;<b>if&#160;any of&#160;the&#160;following apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1271">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1272"><b>excessive&#160;vomiting&#160;or diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1271">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1272"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1271">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1272"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1271">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1272"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1271">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels&#160;in&#160;case&#160;of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1271">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1272"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1271">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1271">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1279">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1271">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1272"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1279"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1278">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1271">if you are&#160;taking&#160;any of&#160;the&#160;following&#160;medicines&#160;used to&#160;treat&#160;high&#160;blood&#160;pressure:&#160;</p>
</div>
<!-- Page 128 -->
<a name="128"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page128-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1280">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1280">128&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft12810">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1281">diabetes-related kidney&#160;problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft12810">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1281">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount&#160;of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1281">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1281">See&#160;also&#160;information&#160;under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1281">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1281">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1281">may&#160;cause serious harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;at&#160;that&#160;stage (see pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1282"><b>Children and adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1281">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used in children&#160;and&#160;adolescents because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1281">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1282"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1282"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1281">Tell&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking,&#160;have recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1281">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1281">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1281">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1281">Karvea”&#160;and&#160;“Warnings and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1282"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1289"></p>
<p style="position:absolute;top:557px;left:114px;white-space:nowrap" class="ft1288">&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1281">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1289"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1288">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1281">salt&#160;substitutes containing&#160;potassium&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1289"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1288">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1281">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1289"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1288">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1281">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1289"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1288">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1281">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1281">If&#160;you take&#160;certain painkillers, called non-steroidal&#160;anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1281">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1282"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1281">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1282"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1282"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1281">You must&#160;tell&#160;your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1281">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1281">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1281">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause&#160;serious&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1281">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1282"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1282"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1281">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1281">for&#160;mothers&#160;who are breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you&#160;if&#160;you wish&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1281">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1282"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1281">Karvea&#160;is&#160;unlikely&#160;to affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1281">weariness&#160;may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1281">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1281">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft1282"><b>Karvea&#160;contains&#160;lactose</b>. If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you have&#160;an&#160;intolerance to&#160;some&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1281">sugars&#160;(e.g.&#160;lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
</div>
<!-- Page 129 -->
<a name="129"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page129-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1290">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1290">129&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1292"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet, that&#160;is&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1291">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1292"><b>3.&#160;</b></p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1292"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1292"><b>&#160;</b></p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1291">Always&#160;take&#160;this&#160;medicine&#160;exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1291">if&#160;you&#160;are not&#160;sure.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1292"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1291">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:311px;left:197px;white-space:nowrap" class="ft1292"><b>oral&#160;use</b>.&#160;Swallow the tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1291">You can&#160;take&#160;Karvea&#160;with&#160;or&#160;without&#160;food. Try&#160;to&#160;take&#160;your&#160;daily dose&#160;at&#160;about&#160;the&#160;same&#160;time&#160;each&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1291">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:389px;left:106px;white-space:nowrap" class="ft1299"></p>
<p style="position:absolute;top:387px;left:114px;white-space:nowrap" class="ft1298">&#160;</p>
<p style="position:absolute;top:386px;left:149px;white-space:nowrap" class="ft1292"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1291">The usual&#160;dose&#160;is 150&#160;mg once-a-day.&#160;The&#160;dose&#160;may later&#160;be&#160;increased to 300&#160;mg&#160;(two&#160;tablets&#160;a&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1291">day)&#160;once&#160;daily depending&#160;on blood pressure&#160;response.&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:465px;left:106px;white-space:nowrap" class="ft1299"></p>
<p style="position:absolute;top:463px;left:114px;white-space:nowrap" class="ft1298">&#160;</p>
<p style="position:absolute;top:462px;left:149px;white-space:nowrap" class="ft1292"><b>Patients&#160;with&#160;high&#160;blood pressure&#160;and type&#160;2&#160;diabetes&#160;with kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1291">In&#160;patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2 diabetes, 300&#160;mg&#160;(two&#160;tablets a day)&#160;once&#160;daily&#160;</p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1291">is the preferred&#160;maintenance dose&#160;for&#160;the treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1291">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially when starting treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1291">those&#160;on&#160;</p>
<p style="position:absolute;top:557px;left:166px;white-space:nowrap" class="ft1292"><b>haemodialysis</b>, or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1291">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning treatment.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1292"><b>Use in&#160;children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1291">Karvea&#160;should not&#160;be&#160;given&#160;to children&#160;under&#160;18&#160;years&#160;of&#160;age.&#160;If&#160;a child&#160;swallows&#160;some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1291">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1292"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than you should:&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1291">If&#160;you accidentally take&#160;too&#160;many&#160;tablets,&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1292"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea:&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1291">If&#160;you accidentally&#160;miss&#160;a&#160;daily&#160;dose,&#160;just&#160;take the next&#160;dose as normal.&#160;Do&#160;not&#160;take&#160;a double&#160;dose&#160;to&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1291">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1291">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1292"><b>4.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1292"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1292"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1291">Like&#160;all medicines,&#160;this&#160;medicine&#160;can cause&#160;side&#160;effects, although not&#160;everybody gets&#160;them.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1291">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1291">As with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as&#160;well&#160;as&#160;localised&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1291">swelling of&#160;the face,&#160;lips and/or&#160;tongue&#160;have&#160;been&#160;reported&#160;in&#160;patients taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1291">of&#160;these&#160;symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:1032px;left:381px;white-space:nowrap" class="ft1292"><b>stop&#160;taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1291">The&#160;frequency of&#160;the&#160;side&#160;effects&#160;listed below&#160;is&#160;defined using&#160;the&#160;following convention:&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1291">Very&#160;common:&#160;may affect&#160;more&#160;than 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1291">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1291">Uncommon:&#160;may&#160;affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1291">&#160;</p>
</div>
<!-- Page 130 -->
<a name="130"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page130-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1300">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1300">130&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1301">Side effects reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
<p style="position:absolute;top:104px;left:106px;white-space:nowrap" class="ft1309"></p>
<p style="position:absolute;top:102px;left:114px;white-space:nowrap" class="ft1308">&#160;</p>
<p style="position:absolute;top:102px;left:149px;white-space:nowrap" class="ft1301">Very common&#160;(may&#160;affect&#160;more&#160;than&#160;1 in&#160;10 people):&#160;if&#160;you&#160;suffer&#160;from&#160;high blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:121px;left:149px;white-space:nowrap" class="ft1301">type&#160;2&#160;diabetes with&#160;kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:161px;left:106px;white-space:nowrap" class="ft1309"></p>
<p style="position:absolute;top:159px;left:114px;white-space:nowrap" class="ft1308">&#160;</p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1301">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people): dizziness,&#160;feeling&#160;sick/vomiting, fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1301">tests&#160;may&#160;show&#160;raised&#160;levels of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1301">kinase&#160;enzyme). In patients&#160;with high blood&#160;pressure&#160;and type&#160;2 diabetes&#160;with kidney&#160;disease,&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1301">dizziness&#160;when&#160;getting up&#160;from&#160;a&#160;lying&#160;or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1301">from&#160;a&#160;lying or&#160;sitting&#160;position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1301">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also&#160;reported.&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:294px;left:106px;white-space:nowrap" class="ft1309"></p>
<p style="position:absolute;top:292px;left:114px;white-space:nowrap" class="ft1308">&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1301">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100 people): heart rate&#160;increased,&#160;flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:311px;left:149px;white-space:nowrap" class="ft1301">indigestion/heartburn, sexual&#160;dysfunction (problems&#160;with&#160;sexual&#160;performance),&#160;chest&#160;pain.&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1301">Some undesirable effects have been&#160;reported&#160;since&#160;marketing&#160;of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1301">frequency is&#160;not&#160;known are:&#160;feeling&#160;of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1301">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells&#160;(anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1301">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when&#160;exercising,&#160;dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1301">reduced number&#160;of&#160;platelets,&#160;abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels,&#160;impaired&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1301">kidney&#160;function,&#160;inflammation of&#160;small&#160;blood&#160;vessels&#160;mainly&#160;affecting the&#160;skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1301">leukocytoclastic vasculitis),&#160;severe allergic reactions&#160;(anaphylactic&#160;shock)&#160;and low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1301">Uncommon cases&#160;of&#160;jaundice&#160;(yellowing of&#160;the&#160;skin and/or&#160;whites of&#160;the eyes)&#160;have also&#160;been&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1301">reported.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1301">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1301">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist.&#160;This&#160;includes any&#160;possible side&#160;effects&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1301">not&#160;listed&#160;in&#160;this&#160;leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1301">listed&#160;in&#160;Appendix V.&#160;By&#160;reporting side&#160;effects&#160;you&#160;can&#160;help provide&#160;more&#160;information&#160;on the&#160;safety of&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1301">this&#160;medicine.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1302"><b>5.&#160;</b></p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1302"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1302"><b>&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1301">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1301">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date which&#160;is&#160;stated&#160;on&#160;the carton and on the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1301">EXP. The&#160;expiry&#160;date&#160;refers&#160;to&#160;the&#160;last&#160;day of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1301">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1301">Do&#160;not&#160;throw&#160;away&#160;any&#160;medicines&#160;via wastewater&#160;or&#160;household waste. Ask your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1301">throw&#160;away&#160;medicines&#160;you&#160;no longer&#160;use. These&#160;measures&#160;will help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1302"><b>6.&#160;</b></p>
<p style="position:absolute;top:918px;left:149px;white-space:nowrap" class="ft1302"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1302"><b>&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1302"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1309">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1301">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;150&#160;mg contains&#160;150&#160;mg irbesartan.&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1309">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1301">The&#160;other&#160;ingredients&#160;are lactose&#160;monohydrate,&#160;microcrystalline&#160;cellulose,&#160;croscarmellose&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1301">sodium, hypromellose,&#160;silicon dioxide, magnesium&#160;stearate,&#160;titanium&#160;dioxide,&#160;macrogol&#160;3000,&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1301">carnauba wax.&#160;Please see section&#160;2 “Karvea contains lactose”.&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
<p style="position:absolute;top:1088px;left:106px;white-space:nowrap" class="ft1302"><b>What&#160;Karvea&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1301">Karvea&#160;150&#160;mg&#160;film-coated&#160;tablets are white&#160;to&#160;off-white, biconvex, and oval-shaped&#160;with&#160;a heart&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1301">debossed&#160;on one&#160;side and&#160;the&#160;number&#160;2872&#160;engraved&#160;on the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:1145px;left:106px;white-space:nowrap" class="ft1301">&#160;</p>
</div>
<!-- Page 131 -->
<a name="131"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page131-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1310">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1310">131&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1311">Karvea&#160;150&#160;mg&#160;film-coated&#160;tablets are supplied&#160;in&#160;blister&#160;packs of&#160;14,&#160;28, 30,&#160;56, 84, 90&#160;or&#160;98&#160;film-</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1311">coated&#160;tablets.&#160;Unidose blister&#160;packs of&#160;56&#160;x&#160;1&#160;film-coated&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1311">available.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1311">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1312"><b>Marketing&#160;Authorisation&#160;Holder:&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1311">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1311">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1311">94250 Gentilly&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1311">France&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1312"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1311">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1311">1,&#160;rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1311">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1311">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1311">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1311">30-36&#160;Avenue&#160;Gustave&#160;Eiffel, BP&#160;7166&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1311">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1311">SANOFI-AVENTIS,&#160;S.A.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1311">Ctra.&#160;C-35 (La&#160;Batlloria-Hostalric), km. 63.09&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1311">17404 Riells&#160;i&#160;Viabrea&#160;(Girona)&#160;–&#160;Spain&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1311">For&#160;any&#160;information&#160;about this&#160;medicinal&#160;product,&#160;please&#160;contact&#160;the local&#160;representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1311">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1312"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1311">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1311">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1312"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1311">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1311">Tel:&#160;+370&#160;5&#160;236 91&#160;40&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft13113"><b>България&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1311">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1316">Тел.: +359 (0)2&#160;4942&#160;480&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft1312"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1311">Sanofi&#160;Belgium&#160;&#160;</p>
<p style="position:absolute;top:747px;left:454px;white-space:nowrap" class="ft1311">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft13113"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1311">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1311">Tel:&#160;+420&#160;233&#160;086 111&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft13113"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1311">SANOFI-AVENTIS Zrt.&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1311">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1312"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1311">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1311">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1312"><b>Malta&#160;</b></p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1311">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1311">Tel:&#160;+39 02&#160;39394275&#160;</p>
<p style="position:absolute;top:918px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1312"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1311">Sanofi-Aventis&#160;Deutschland GmbH&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1311">Tel:&#160;0800 52 52 010&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1311">Tel. aus&#160;dem&#160;Ausland:&#160;+49&#160;69 305 21&#160;131&#160;</p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1312"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1311">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1311">Tel:&#160;+31 20&#160;245 4000&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1312"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1311">Swixx&#160;Biopharma&#160;OÜ&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1311">Tel:&#160;+372&#160;640 10&#160;30&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:1013px;left:455px;white-space:nowrap" class="ft1312"><b>Norge&#160;</b></p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1311">sanofi-aventis&#160;Norge&#160;AS&#160;</p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1311">Tlf:&#160;+47 67 10 71&#160;00&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft13113"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1311">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1316">Τηλ:&#160;+30 210&#160;900 16&#160;00&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1311">&#160;</p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1312"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:1108px;left:455px;white-space:nowrap" class="ft1311">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:1127px;left:455px;white-space:nowrap" class="ft1311">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:1146px;left:455px;white-space:nowrap" class="ft1311">&#160;</p>
</div>
<!-- Page 132 -->
<a name="132"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page132-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1320">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1320">132&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1322"><b>España&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1321">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1321">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1322"><b>Polska&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1321">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1321">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:159px;left:104px;white-space:nowrap" class="ft1322"><b>France&#160;</b></p>
<p style="position:absolute;top:178px;left:104px;white-space:nowrap" class="ft1321">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:197px;left:104px;white-space:nowrap" class="ft1321">Tél:&#160;0 800 222 555&#160;</p>
<p style="position:absolute;top:216px;left:104px;white-space:nowrap" class="ft1321">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1 57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:235px;left:104px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:159px;left:455px;white-space:nowrap" class="ft1322"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1321">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1321">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:216px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1322"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1321">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1321">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1322"><b>România&#160;</b></p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1321">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:292px;left:454px;white-space:nowrap" class="ft1321">Tel:&#160;+40&#160;(0)&#160;21&#160;317 31 36&#160;</p>
<p style="position:absolute;top:311px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1322"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1321">sanofi-aventis Ireland&#160;Ltd.&#160;T/A SANOFI&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1321">Tel:&#160;+353&#160;(0)&#160;1 403 56 00&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft1322"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1321">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:368px;left:455px;white-space:nowrap" class="ft1321">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1322"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1321">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1321">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft13213"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1321">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1321">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1322"><b>Italia&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1321">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1321">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft1322"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1321">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1321">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft13213"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1321">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1326">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1322"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1321">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1321">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1322"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1321">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1321">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1322"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1321">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1321">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1322"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1321">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1321">Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1321">http://www.ema.europa.eu/&#160;</p>
</div>
<!-- Page 133 -->
<a name="133"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page133-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1330">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1330">133&#160;</p>
<p style="position:absolute;top:83px;left:303px;white-space:nowrap" class="ft1332"><b>Package leaflet:&#160;Information&#160;for&#160;the user&#160;</b></p>
<p style="position:absolute;top:102px;left:325px;white-space:nowrap" class="ft1332"><b>Karvea</b>&#160;<b>300</b>&#160;<b>mg&#160;film-coated tablets&#160;</b></p>
<p style="position:absolute;top:121px;left:414px;white-space:nowrap" class="ft1331">irbesartan&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1332"><b>Read&#160;all&#160;of&#160;this&#160;leaflet&#160;carefully&#160;before you&#160;start&#160;taking&#160;this&#160;medicine because&#160;it&#160;contains&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1332"><b>important information&#160;for&#160;you.&#160;</b></p>
<p style="position:absolute;top:199px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1331">Keep&#160;this&#160;leaflet.&#160;You&#160;may&#160;need to&#160;read it&#160;again.&#160;</p>
<p style="position:absolute;top:218px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1331">If&#160;you have&#160;any&#160;further&#160;questions,&#160;ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:237px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1331">This&#160;medicine&#160;has&#160;been prescribed&#160;for&#160;you only. Do&#160;not&#160;pass&#160;it&#160;on&#160;to others. It&#160;may&#160;harm&#160;them,&#160;</p>
<p style="position:absolute;top:254px;left:149px;white-space:nowrap" class="ft1331">even&#160;if&#160;their&#160;signs&#160;of&#160;illness&#160;are the&#160;same as yours.&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1331">If&#160;you get&#160;any&#160;side&#160;effects, talk&#160;to your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1331">effects not&#160;listed&#160;in&#160;this leaflet.&#160;See section&#160;4.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1332"><b>What&#160;is&#160;in&#160;this&#160;leaflet&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1331">1.&#160;</p>
<p style="position:absolute;top:349px;left:149px;white-space:nowrap" class="ft1331">What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1331">2.&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1331">What&#160;you need&#160;to know&#160;before&#160;you take&#160;Karvea&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1331">3.&#160;</p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1331">How&#160;to take&#160;Karvea&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1331">4.&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1331">Possible side&#160;effects&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1331">5.&#160;</p>
<p style="position:absolute;top:425px;left:149px;white-space:nowrap" class="ft1331">How&#160;to store&#160;Karvea&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1331">6.&#160;</p>
<p style="position:absolute;top:444px;left:149px;white-space:nowrap" class="ft1331">Contents&#160;of&#160;the&#160;pack and other&#160;information&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1332"><b>1.&#160;</b></p>
<p style="position:absolute;top:500px;left:149px;white-space:nowrap" class="ft1332"><b>What&#160;Karvea&#160;is&#160;and what&#160;it&#160;is&#160;used for&#160;</b></p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1332"><b>&#160;</b></p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1331">Karvea&#160;belongs&#160;to a&#160;group&#160;of&#160;medicines&#160;known as&#160;angiotensin-II&#160;receptor&#160;antagonists. Angiotensin-II&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1331">is&#160;a&#160;substance&#160;produced&#160;in the&#160;body which binds&#160;to&#160;receptors&#160;in blood vessels&#160;causing them&#160;to&#160;tighten.&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1331">This results&#160;in&#160;an&#160;increase in&#160;blood&#160;pressure.&#160;Karvea&#160;prevents&#160;the&#160;binding of&#160;angiotensin-II&#160;to&#160;these&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1331">receptors, causing the&#160;blood&#160;vessels&#160;to relax and the&#160;blood pressure&#160;to lower.&#160;Karvea&#160;slows&#160;the&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1331">decrease&#160;of&#160;kidney function&#160;in patients&#160;with high blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes.&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1331">Karvea&#160;is&#160;used in adult&#160;patients&#160;</p>
<p style="position:absolute;top:674px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:671px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:671px;left:149px;white-space:nowrap" class="ft1331">to treat&#160;high blood&#160;pressure&#160;(<i>essential&#160;hypertension</i>)&#160;</p>
<p style="position:absolute;top:693px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:690px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:690px;left:149px;white-space:nowrap" class="ft1331">to protect the&#160;kidney&#160;in&#160;patients&#160;with&#160;high blood pressure, type&#160;2&#160;diabetes&#160;and laboratory&#160;</p>
<p style="position:absolute;top:709px;left:149px;white-space:nowrap" class="ft1331">evidence&#160;of&#160;impaired&#160;kidney&#160;function.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1332"><b>2.&#160;</b></p>
<p style="position:absolute;top:766px;left:149px;white-space:nowrap" class="ft1332"><b>What&#160;you&#160;need&#160;to know&#160;before&#160;you&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1332"><b>&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1332"><b>Do not&#160;take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:825px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:823px;left:149px;white-space:nowrap" class="ft1331">if&#160;you are&#160;</p>
<p style="position:absolute;top:823px;left:216px;white-space:nowrap" class="ft1332"><b>allergic</b>&#160;to&#160;irbesartan&#160;or&#160;any other&#160;ingredients&#160;of&#160;this&#160;medicine&#160;(listed in&#160;section&#160;6)&#160;</p>
<p style="position:absolute;top:844px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:842px;left:149px;white-space:nowrap" class="ft1331">if&#160;you are&#160;</p>
<p style="position:absolute;top:842px;left:216px;white-space:nowrap" class="ft1332"><b>more&#160;than&#160;3&#160;months&#160;pregnant</b>.&#160;(It is&#160;also&#160;better&#160;to&#160;avoid&#160;Karvea&#160;in early pregnancy –&#160;</p>
<p style="position:absolute;top:861px;left:149px;white-space:nowrap" class="ft1331">see&#160;pregnancy&#160;section)&#160;</p>
<p style="position:absolute;top:882px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:880px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:880px;left:147px;white-space:nowrap" class="ft1332"><b>if&#160;you&#160;have&#160;diabetes or impaired&#160;kidney&#160;function</b>&#160;and you are&#160;treated with&#160;a blood&#160;pressure&#160;</p>
<p style="position:absolute;top:899px;left:147px;white-space:nowrap" class="ft1331">lowering medicine&#160;containing&#160;aliskiren.<i>&#160;</i></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1331">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1332"><b>Warnings&#160;and&#160;precautions&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1331">Talk&#160;to your&#160;doctor&#160;before&#160;taking&#160;Karvea</p>
<p style="position:absolute;top:956px;left:378px;white-space:nowrap" class="ft1332"><b>&#160;</b>and&#160;<b>if&#160;any of&#160;the&#160;following apply&#160;to you:&#160;</b></p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1331">if&#160;you get&#160;</p>
<p style="position:absolute;top:975px;left:216px;white-space:nowrap" class="ft1332"><b>excessive&#160;vomiting&#160;or diarrhoea</b>&#160;</p>
<p style="position:absolute;top:996px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1331">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:994px;left:271px;white-space:nowrap" class="ft1332"><b>kidney&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1015px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1331">if you&#160;suffer from&#160;</p>
<p style="position:absolute;top:1012px;left:271px;white-space:nowrap" class="ft1332"><b>heart&#160;problems</b>&#160;</p>
<p style="position:absolute;top:1034px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:1032px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:1032px;left:149px;white-space:nowrap" class="ft1331">if&#160;you receive&#160;Karvea&#160;for&#160;</p>
<p style="position:absolute;top:1032px;left:319px;white-space:nowrap" class="ft1332"><b>diabetic kidney&#160;disease</b>. In this&#160;case&#160;your&#160;doctor&#160;may perform&#160;regular&#160;</p>
<p style="position:absolute;top:1051px;left:149px;white-space:nowrap" class="ft1331">blood tests, especially&#160;for&#160;measuring&#160;blood potassium&#160;levels&#160;in&#160;case&#160;of&#160;poor&#160;kidney function&#160;</p>
<p style="position:absolute;top:1072px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:1070px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:1070px;left:149px;white-space:nowrap" class="ft1331">if&#160;you&#160;develop&#160;</p>
<p style="position:absolute;top:1069px;left:248px;white-space:nowrap" class="ft1332"><b>low&#160;blood&#160;sugar&#160;levels</b>&#160;(symptoms&#160;may include&#160;sweating, weakness, hunger,&#160;</p>
<p style="position:absolute;top:1089px;left:149px;white-space:nowrap" class="ft1331">dizziness,&#160;trembling,&#160;headache, flushing&#160;or&#160;paleness, numbness, having a&#160;fast, pounding&#160;</p>
<p style="position:absolute;top:1108px;left:149px;white-space:nowrap" class="ft1331">heartbeat), particularly&#160;if&#160;you are&#160;being&#160;treated&#160;for&#160;diabetes.&#160;</p>
<p style="position:absolute;top:1129px;left:106px;white-space:nowrap" class="ft1339">&#160;</p>
<p style="position:absolute;top:1127px;left:149px;white-space:nowrap" class="ft1331">if&#160;you are&#160;</p>
<p style="position:absolute;top:1126px;left:216px;white-space:nowrap" class="ft1332"><b>going to have&#160;an&#160;operation</b>&#160;(surgery) or&#160;<b>be given&#160;anaesthetics&#160;</b></p>
<p style="position:absolute;top:1148px;left:106px;white-space:nowrap" class="ft1339"></p>
<p style="position:absolute;top:1145px;left:114px;white-space:nowrap" class="ft1338">&#160;</p>
<p style="position:absolute;top:1145px;left:148px;white-space:nowrap" class="ft1331">if&#160;you are&#160;taking&#160;any of&#160;the&#160;following medicines&#160;used&#160;to treat&#160;high&#160;blood pressure:&#160;</p>
</div>
<!-- Page 134 -->
<a name="134"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page134-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1340">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1340">134&#160;</p>
<p style="position:absolute;top:83px;left:187px;white-space:nowrap" class="ft13410">o&#160;&#160;an&#160;ACE-inhibitor&#160;(for&#160;example&#160;enalapril,&#160;lisinopril, ramipril), in particular&#160;if&#160;you have&#160;</p>
<p style="position:absolute;top:102px;left:214px;white-space:nowrap" class="ft1341">diabetes-related&#160;kidney&#160;problems.&#160;</p>
<p style="position:absolute;top:121px;left:187px;white-space:nowrap" class="ft13410">o&#160;&#160;aliskiren&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1341">Your&#160;doctor&#160;may check your&#160;kidney&#160;function, blood pressure, and the&#160;amount of&#160;electrolytes&#160;(e.g.&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1341">potassium)&#160;in&#160;your&#160;blood at&#160;regular&#160;intervals.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1341">See&#160;also&#160;information&#160;under&#160;the&#160;heading “Do not&#160;take&#160;Karvea”.&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1341">You&#160;must&#160;tell&#160;your&#160;doctor&#160;if&#160;you think&#160;you are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Karvea&#160;is&#160;not&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1341">recommended in early&#160;pregnancy,&#160;and&#160;must&#160;not&#160;be&#160;taken if&#160;you are&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1341">may&#160;cause serious harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;at&#160;that&#160;stage (see pregnancy&#160;section).&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1342"><b>Children&#160;and adolescents&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1341">This&#160;medicinal&#160;product&#160;should&#160;not&#160;be&#160;used in children and&#160;adolescents&#160;because&#160;the safety&#160;and&#160;efficacy&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1341">have&#160;not&#160;yet&#160;been&#160;fully established.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1342"><b>&#160;</b></p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1342"><b>Other medicines&#160;and&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1341">Tell&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;if&#160;you are&#160;taking,&#160;have recently&#160;taken or&#160;might&#160;take&#160;any other&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1341">medicines.&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1341">Your&#160;doctor&#160;may need to change&#160;your&#160;dose&#160;and/or&#160;to take&#160;other&#160;precautions:&#160;</p>
<p style="position:absolute;top:482px;left:106px;white-space:nowrap" class="ft1341">&#160;If&#160;you are&#160;taking&#160;an&#160;ACE-inhibitor&#160;or&#160;aliskiren&#160;(see&#160;also information&#160;under&#160;the&#160;headings&#160;“Do not&#160;take&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1341">Karvea”&#160;and&#160;“Warnings and&#160;precautions”).&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1342"><b>You&#160;may need&#160;to&#160;have&#160;blood&#160;checks&#160;if&#160;you&#160;take:</b>&#160;</p>
<p style="position:absolute;top:560px;left:106px;white-space:nowrap" class="ft1349"></p>
<p style="position:absolute;top:557px;left:114px;white-space:nowrap" class="ft1348">&#160;</p>
<p style="position:absolute;top:557px;left:149px;white-space:nowrap" class="ft1341">potassium&#160;supplements&#160;</p>
<p style="position:absolute;top:579px;left:106px;white-space:nowrap" class="ft1349"></p>
<p style="position:absolute;top:576px;left:114px;white-space:nowrap" class="ft1348">&#160;</p>
<p style="position:absolute;top:576px;left:149px;white-space:nowrap" class="ft1341">salt&#160;substitutes&#160;containing potassium&#160;</p>
<p style="position:absolute;top:598px;left:106px;white-space:nowrap" class="ft1349"></p>
<p style="position:absolute;top:595px;left:114px;white-space:nowrap" class="ft1348">&#160;</p>
<p style="position:absolute;top:595px;left:149px;white-space:nowrap" class="ft1341">potassium-sparing&#160;medicines (such&#160;as certain&#160;diuretics)&#160;</p>
<p style="position:absolute;top:617px;left:106px;white-space:nowrap" class="ft1349"></p>
<p style="position:absolute;top:614px;left:114px;white-space:nowrap" class="ft1348">&#160;</p>
<p style="position:absolute;top:614px;left:149px;white-space:nowrap" class="ft1341">medicines&#160;containing&#160;lithium&#160;</p>
<p style="position:absolute;top:636px;left:106px;white-space:nowrap" class="ft1349"></p>
<p style="position:absolute;top:633px;left:114px;white-space:nowrap" class="ft1348">&#160;</p>
<p style="position:absolute;top:633px;left:149px;white-space:nowrap" class="ft1341">repaglinide&#160;(medication&#160;used for&#160;lowering blood sugar&#160;levels)&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1341">If&#160;you&#160;take&#160;certain painkillers, called non-steroidal&#160;anti-inflammatory drugs,&#160;the&#160;effect&#160;of&#160;irbesartan&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1341">may be&#160;reduced.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1342"><b>Karvea&#160;with food and drink&#160;</b></p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1341">Karvea&#160;can be&#160;taken with&#160;or&#160;without&#160;food.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1342"><b>Pregnancy&#160;and breast-feeding&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1342"><b>Pregnancy&#160;</b></p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1341">You&#160;must&#160;tell your&#160;doctor&#160;if&#160;you&#160;think you&#160;are&#160;(or&#160;might&#160;become)&#160;pregnant.&#160;Your&#160;doctor&#160;will&#160;normally&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1341">advise&#160;you to stop taking&#160;Karvea&#160;before&#160;you become&#160;pregnant&#160;or&#160;as&#160;soon as&#160;you&#160;know&#160;you are&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1341">pregnant&#160;and will&#160;advise&#160;you to&#160;take&#160;another&#160;medicine&#160;instead of&#160;Karvea.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1341">in early pregnancy, and must&#160;not&#160;be&#160;taken when&#160;more&#160;than 3&#160;months pregnant,&#160;as&#160;it&#160;may&#160;cause serious&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1341">harm&#160;to&#160;your&#160;baby&#160;if&#160;used&#160;after&#160;the&#160;third&#160;month of&#160;pregnancy.&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1342"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1342"><b>Breast-feeding&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1341">Tell&#160;your&#160;doctor&#160;if&#160;you&#160;are&#160;breast-feeding or&#160;about&#160;to start&#160;breast-feeding.&#160;Karvea&#160;is&#160;not&#160;recommended&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1341">for&#160;mothers&#160;who&#160;are breast-feeding,&#160;and your&#160;doctor&#160;may choose&#160;another&#160;treatment&#160;for&#160;you if&#160;you&#160;wish&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1341">to breast-feed, especially&#160;if&#160;your&#160;baby is&#160;newborn, or&#160;was&#160;born prematurely.&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1342"><b>Driving and&#160;using&#160;machines&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1341">Karvea&#160;is&#160;unlikely&#160;to affect&#160;your&#160;ability to drive&#160;or&#160;use&#160;machines.&#160;However,&#160;occasionally&#160;dizziness or&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1341">weariness may occur&#160;during treatment&#160;of&#160;high blood pressure.&#160;If&#160;you experience&#160;these,&#160;talk to your&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1341">doctor&#160;before&#160;attempting to&#160;drive&#160;or&#160;use&#160;machines.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1341">&#160;</p>
<p style="position:absolute;top:1126px;left:106px;white-space:nowrap" class="ft1342"><b>Karvea&#160;contains lactose</b>. If&#160;you have&#160;been&#160;told by your&#160;doctor&#160;that&#160;you&#160;have an&#160;intolerance&#160;to&#160;some&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1341">sugars&#160;(e.g. lactose), contact&#160;your&#160;doctor&#160;before&#160;taking&#160;this&#160;medicinal&#160;product.&#160;</p>
</div>
<!-- Page 135 -->
<a name="135"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page135-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1350">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1350">135&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1352"><b>Karvea&#160;contains&#160;sodium.&#160;</b>This&#160;medicine&#160;contains&#160;less&#160;than 1&#160;mmol&#160;sodium&#160;(23 mg)&#160;per&#160;tablet, that&#160;is&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1351">to say essentially ‘sodium-free’.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1352"><b>3.&#160;</b></p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1352"><b>How&#160;to take&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1352"><b>&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1351">Always take this medicine exactly&#160;as&#160;your&#160;doctor&#160;has&#160;told you. Check with&#160;your&#160;doctor&#160;or&#160;pharmacist&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1351">if&#160;you&#160;are&#160;not&#160;sure.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1352"><b>Method&#160;of&#160;administration&#160;</b></p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1351">Karvea&#160;is&#160;for&#160;</p>
<p style="position:absolute;top:292px;left:197px;white-space:nowrap" class="ft1352"><b>oral&#160;use</b>.&#160;Swallow the tablets&#160;with&#160;a&#160;sufficient&#160;amount&#160;of&#160;fluid (e.g.&#160;one&#160;glass&#160;of&#160;water).&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1351">You&#160;can take&#160;Karvea&#160;with&#160;or&#160;without&#160;food.&#160;Try&#160;to&#160;take&#160;your&#160;daily&#160;dose at&#160;about&#160;the same&#160;time&#160;each&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1351">day. It&#160;is&#160;important&#160;that&#160;you&#160;continue&#160;to take&#160;Karvea&#160;until&#160;your&#160;doctor&#160;tells&#160;you&#160;otherwise.&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:370px;left:106px;white-space:nowrap" class="ft1359"></p>
<p style="position:absolute;top:368px;left:114px;white-space:nowrap" class="ft1358">&#160;</p>
<p style="position:absolute;top:368px;left:149px;white-space:nowrap" class="ft1352"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;</b></p>
<p style="position:absolute;top:387px;left:149px;white-space:nowrap" class="ft1351">The usual&#160;dose&#160;is 150&#160;mg once-a-day.&#160;The dose may&#160;later&#160;be&#160;increased to 300&#160;mg once&#160;daily&#160;</p>
<p style="position:absolute;top:406px;left:149px;white-space:nowrap" class="ft1351">depending on blood pressure&#160;response.&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:446px;left:106px;white-space:nowrap" class="ft1359"></p>
<p style="position:absolute;top:443px;left:114px;white-space:nowrap" class="ft1358">&#160;</p>
<p style="position:absolute;top:443px;left:149px;white-space:nowrap" class="ft1352"><b>Patients&#160;with&#160;high&#160;blood&#160;pressure&#160;and&#160;type&#160;2&#160;diabetes&#160;with&#160;kidney&#160;disease&#160;</b></p>
<p style="position:absolute;top:463px;left:149px;white-space:nowrap" class="ft1351">In patients&#160;with high blood&#160;pressure&#160;and type&#160;2 diabetes, 300&#160;mg&#160;once daily&#160;is the&#160;preferred&#160;</p>
<p style="position:absolute;top:481px;left:149px;white-space:nowrap" class="ft1351">maintenance&#160;dose&#160;for&#160;the&#160;treatment&#160;of&#160;associated&#160;kidney&#160;disease.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1351">The&#160;doctor&#160;may advise&#160;a&#160;lower&#160;dose, especially&#160;when&#160;starting&#160;treatment&#160;in&#160;certain&#160;patients such&#160;as&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1351">those&#160;on&#160;</p>
<p style="position:absolute;top:538px;left:166px;white-space:nowrap" class="ft1352"><b>haemodialysis</b>,&#160;or&#160;those&#160;<b>over&#160;the&#160;age&#160;of&#160;75&#160;years.&#160;</b></p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1351">The&#160;maximal&#160;blood pressure&#160;lowering effect&#160;should be&#160;reached 4-6&#160;weeks&#160;after&#160;beginning treatment.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1352"><b>Use in&#160;children&#160;and&#160;adolescents&#160;</b></p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1351">Karvea&#160;should&#160;not&#160;be&#160;given&#160;to children&#160;under&#160;18&#160;years&#160;of&#160;age. If&#160;a&#160;child swallows&#160;some&#160;tablets,&#160;contact&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1351">your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1352"><b>If&#160;you&#160;take&#160;more&#160;Karvea&#160;than you should:&#160;</b></p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1351">If&#160;you accidentally&#160;take&#160;too&#160;many tablets, contact&#160;your&#160;doctor&#160;immediately.&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1352"><b>If&#160;you&#160;forget&#160;to&#160;take&#160;Karvea:&#160;</b></p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1351">If&#160;you&#160;accidentally&#160;miss a daily&#160;dose,&#160;just&#160;take the&#160;next&#160;dose&#160;as&#160;normal. Do not&#160;take&#160;a&#160;double&#160;dose&#160;to&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1351">make&#160;up for&#160;a&#160;forgotten dose.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1351">If&#160;you have&#160;any&#160;further&#160;questions&#160;on&#160;the&#160;use&#160;of&#160;this&#160;medicine, ask your&#160;doctor&#160;or&#160;pharmacist.&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1352"><b>4.&#160;</b></p>
<p style="position:absolute;top:880px;left:149px;white-space:nowrap" class="ft1352"><b>Possible side&#160;effects&#160;</b></p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1352"><b>&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1351">Like all&#160;medicines,&#160;this medicine can&#160;cause&#160;side effects, although&#160;not&#160;everybody gets&#160;them.&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1351">Some of&#160;these effects&#160;may&#160;be serious and&#160;may&#160;require&#160;medical&#160;attention.&#160;</p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1351">As with&#160;similar&#160;medicines,&#160;rare cases of&#160;allergic&#160;skin&#160;reactions (rash,&#160;urticaria),&#160;as&#160;well&#160;as localised&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1351">swelling of&#160;the&#160;face,&#160;lips&#160;and/or&#160;tongue&#160;have&#160;been&#160;reported&#160;in patients&#160;taking&#160;irbesartan. If&#160;you&#160;get&#160;any&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1351">of&#160;these&#160;symptoms&#160;or&#160;get&#160;short&#160;of&#160;breath,&#160;</p>
<p style="position:absolute;top:1013px;left:381px;white-space:nowrap" class="ft1352"><b>stop&#160;taking&#160;Karvea&#160;and&#160;contact&#160;your&#160;doctor&#160;immediately.&#160;</b></p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1351">The&#160;frequency of&#160;the&#160;side&#160;effects&#160;listed below&#160;is&#160;defined using the&#160;following&#160;convention:&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1351">Very&#160;common:&#160;may&#160;affect&#160;more&#160;than&#160;1 in&#160;10 people&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1351">Common:&#160;may&#160;affect&#160;up to 1&#160;in&#160;10 people&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1351">Uncommon:&#160;may affect&#160;up to&#160;1 in&#160;100 people&#160;</p>
<p style="position:absolute;top:1127px;left:106px;white-space:nowrap" class="ft1351">&#160;</p>
<p style="position:absolute;top:1146px;left:106px;white-space:nowrap" class="ft1351">Side&#160;effects&#160;reported&#160;in&#160;clinical&#160;studies for&#160;patients treated&#160;with&#160;Karvea&#160;were:&#160;</p>
</div>
<!-- Page 136 -->
<a name="136"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page136-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1360">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1360">136&#160;</p>
<p style="position:absolute;top:85px;left:106px;white-space:nowrap" class="ft1369"></p>
<p style="position:absolute;top:83px;left:114px;white-space:nowrap" class="ft1368">&#160;</p>
<p style="position:absolute;top:83px;left:149px;white-space:nowrap" class="ft1361">Very common&#160;(may affect&#160;more&#160;than 1&#160;in 10&#160;people):&#160;if&#160;you suffer&#160;from&#160;high&#160;blood pressure&#160;and&#160;</p>
<p style="position:absolute;top:102px;left:149px;white-space:nowrap" class="ft1361">type&#160;2&#160;diabetes with&#160;kidney&#160;disease,&#160;blood&#160;tests&#160;may&#160;show&#160;an&#160;increased&#160;level&#160;of&#160;potassium.&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:142px;left:106px;white-space:nowrap" class="ft1369"></p>
<p style="position:absolute;top:140px;left:114px;white-space:nowrap" class="ft1368">&#160;</p>
<p style="position:absolute;top:140px;left:149px;white-space:nowrap" class="ft1361">Common (may&#160;affect&#160;up&#160;to&#160;1 10 people):&#160;dizziness,&#160;feeling sick/vomiting, fatigue&#160;and&#160;blood&#160;</p>
<p style="position:absolute;top:159px;left:149px;white-space:nowrap" class="ft1361">tests may&#160;show&#160;raised&#160;levels&#160;of&#160;an&#160;enzyme that&#160;measures the muscle&#160;and&#160;heart&#160;function&#160;(creatine&#160;</p>
<p style="position:absolute;top:178px;left:149px;white-space:nowrap" class="ft1361">kinase enzyme).&#160;In&#160;patients&#160;with&#160;high blood&#160;pressure&#160;and type 2 diabetes&#160;with kidney disease,&#160;</p>
<p style="position:absolute;top:197px;left:149px;white-space:nowrap" class="ft1361">dizziness&#160;when&#160;getting up&#160;from&#160;a&#160;lying&#160;or&#160;sitting position, low&#160;blood pressure&#160;when getting up&#160;</p>
<p style="position:absolute;top:216px;left:149px;white-space:nowrap" class="ft1361">from&#160;a lying&#160;or&#160;sitting position,&#160;pain in joints&#160;or&#160;muscles&#160;and decreased levels&#160;of&#160;a&#160;protein in the&#160;</p>
<p style="position:absolute;top:235px;left:149px;white-space:nowrap" class="ft1361">red&#160;blood cells&#160;(haemoglobin)&#160;were&#160;also&#160;reported.&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:275px;left:106px;white-space:nowrap" class="ft1369"></p>
<p style="position:absolute;top:273px;left:114px;white-space:nowrap" class="ft1368">&#160;</p>
<p style="position:absolute;top:273px;left:149px;white-space:nowrap" class="ft1361">Uncommon&#160;(may&#160;affect&#160;up to&#160;1 in&#160;100 people):&#160;heart&#160;rate&#160;increased, flushing, cough, diarrhoea,&#160;</p>
<p style="position:absolute;top:292px;left:149px;white-space:nowrap" class="ft1361">indigestion/heartburn, sexual&#160;dysfunction&#160;(problems&#160;with&#160;sexual&#160;performance), chest&#160;pain.&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1361">Some&#160;undesirable&#160;effects have been&#160;reported&#160;since&#160;marketing&#160;of&#160;Karvea.&#160;Undesirable effects where&#160;the&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1361">frequency is&#160;not&#160;known are:&#160;feeling of&#160;spinning, headache, taste&#160;disturbance,&#160;ringing in&#160;the&#160;ears,&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1361">muscle cramps,&#160;pain&#160;in joints&#160;and muscles,&#160;decreased number&#160;of&#160;red blood cells (anaemia&#160;–&#160;symptoms&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1361">may&#160;include&#160;tiredness, headaches, being short&#160;of&#160;breath&#160;when exercising, dizziness&#160;and looking pale),&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1361">reduced number&#160;of&#160;platelets, abnormal&#160;liver&#160;function,&#160;increased blood&#160;potassium&#160;levels,&#160;impaired&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1361">kidney&#160;function, inflammation&#160;of&#160;small&#160;blood vessels&#160;mainly&#160;affecting the&#160;skin&#160;(a&#160;condition known&#160;as&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1361">leukocytoclastic&#160;vasculitis),&#160;severe&#160;allergic reactions (anaphylactic&#160;shock)&#160;and low&#160;blood&#160;sugar&#160;levels.&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1361">Uncommon&#160;cases of&#160;jaundice (yellowing&#160;of&#160;the&#160;skin&#160;and/or&#160;whites of&#160;the eyes)&#160;have&#160;also been&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1361">reported.&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1361">Reporting&#160;of&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1361">If&#160;you&#160;get&#160;any side effects,&#160;talk to&#160;your&#160;doctor&#160;or&#160;pharmacist. This&#160;includes&#160;any&#160;possible&#160;side&#160;effects&#160;</p>
<p style="position:absolute;top:558px;left:106px;white-space:nowrap" class="ft1361">not listed&#160;in&#160;this leaflet.&#160;You&#160;can&#160;also&#160;report&#160;side effects directly&#160;via&#160;the&#160;national&#160;reporting system&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1361">listed&#160;in&#160;Appendix V. By reporting&#160;side&#160;effects&#160;you&#160;can help&#160;provide&#160;more&#160;information&#160;on the&#160;safety of&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1361">this medicine.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1362"><b>5.&#160;</b></p>
<p style="position:absolute;top:652px;left:149px;white-space:nowrap" class="ft1362"><b>How&#160;to&#160;store&#160;Karvea&#160;</b></p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1362"><b>&#160;</b></p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1361">Keep&#160;this&#160;medicine&#160;out&#160;of&#160;the&#160;sight&#160;and reach&#160;of&#160;children.&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1361">Do not&#160;use&#160;this&#160;medicine&#160;after&#160;the&#160;expiry&#160;date&#160;which&#160;is stated&#160;on&#160;the&#160;carton and&#160;on&#160;the&#160;blister&#160;after&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1361">EXP.&#160;The&#160;expiry&#160;date&#160;refers&#160;to&#160;the last&#160;day&#160;of&#160;that&#160;month.&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1361">Do not&#160;store&#160;above&#160;30°C.&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1361">Do not&#160;throw&#160;away any&#160;medicines&#160;via wastewater&#160;or&#160;household&#160;waste.&#160;Ask&#160;your&#160;pharmacist&#160;how&#160;to&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1361">throw&#160;away medicines&#160;you no&#160;longer&#160;use.&#160;These&#160;measures will&#160;help&#160;protect&#160;the&#160;environment.&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1362"><b>6.&#160;</b></p>
<p style="position:absolute;top:899px;left:149px;white-space:nowrap" class="ft1362"><b>Contents&#160;of&#160;the&#160;pack&#160;and other&#160;information&#160;</b></p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1362"><b>&#160;</b></p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1362"><b>What&#160;Karvea&#160;contains&#160;</b></p>
<p style="position:absolute;top:958px;left:106px;white-space:nowrap" class="ft1369">&#160;</p>
<p style="position:absolute;top:956px;left:149px;white-space:nowrap" class="ft1361">The active substance&#160;is&#160;irbesartan.&#160;Each&#160;tablet&#160;of&#160;Karvea&#160;300&#160;mg contains&#160;300&#160;mg irbesartan.&#160;</p>
<p style="position:absolute;top:977px;left:106px;white-space:nowrap" class="ft1369">&#160;</p>
<p style="position:absolute;top:975px;left:149px;white-space:nowrap" class="ft1361">The other&#160;ingredients are&#160;lactose&#160;monohydrate,&#160;microcrystalline&#160;cellulose,&#160;croscarmellose&#160;</p>
<p style="position:absolute;top:994px;left:149px;white-space:nowrap" class="ft1361">sodium, hypromellose,&#160;silicon dioxide, magnesium&#160;stearate, titanium&#160;dioxide,&#160;macrogol&#160;3000,&#160;</p>
<p style="position:absolute;top:1013px;left:149px;white-space:nowrap" class="ft1361">carnauba wax.&#160;Please see section&#160;2&#160;“Karvea&#160;contains lactose”.&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
<p style="position:absolute;top:1050px;left:106px;white-space:nowrap" class="ft1362"><b>What&#160;Karvea&#160;looks&#160;like and&#160;contents of&#160;the pack&#160;</b></p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1361">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablets are white&#160;to&#160;off-white, biconvex, and oval-shaped&#160;with&#160;a heart&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1361">debossed on&#160;one&#160;side&#160;and&#160;the&#160;number&#160;2873&#160;engraved&#160;on the&#160;other&#160;side.&#160;</p>
<p style="position:absolute;top:1108px;left:106px;white-space:nowrap" class="ft1361">&#160;</p>
</div>
<!-- Page 137 -->
<a name="137"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}-->
</style>
<div id="page137-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1370">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1370">137&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft1371">Karvea&#160;300&#160;mg&#160;film-coated&#160;tablets are supplied&#160;in&#160;blister&#160;packs of&#160;14, 28,&#160;30,&#160;56, 84, 90&#160;or&#160;98&#160;film-</p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1371">coated&#160;tablets.&#160;Unidose blister&#160;packs of&#160;56&#160;x&#160;1&#160;film-coated&#160;tablet&#160;for&#160;delivery&#160;in&#160;hospitals are also&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1371">available.&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1371">Not&#160;all&#160;pack&#160;sizes&#160;may&#160;be&#160;marketed.&#160;</p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1372"><b>Marketing&#160;Authorisation Holder:&#160;</b></p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1371">Sanofi&#160;Winthrop Industrie&#160;</p>
<p style="position:absolute;top:235px;left:106px;white-space:nowrap" class="ft1371">82 avenue&#160;Raspail&#160;</p>
<p style="position:absolute;top:254px;left:106px;white-space:nowrap" class="ft1371">94250 Gentilly&#160;</p>
<p style="position:absolute;top:273px;left:106px;white-space:nowrap" class="ft1371">France&#160;</p>
<p style="position:absolute;top:292px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:311px;left:106px;white-space:nowrap" class="ft1372"><b>Manufacturer:&#160;</b></p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1371">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1371">1, rue&#160;de&#160;la&#160;Vierge&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1371">Ambarès &amp;&#160;Lagrave&#160;</p>
<p style="position:absolute;top:387px;left:106px;white-space:nowrap" class="ft1371">F-33565&#160;Carbon&#160;Blanc Cedex&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:406px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1371">SANOFI&#160;WINTHROP&#160;INDUSTRIE&#160;</p>
<p style="position:absolute;top:443px;left:106px;white-space:nowrap" class="ft1371">30-36&#160;Avenue&#160;Gustave&#160;Eiffel, BP&#160;7166&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1371">F-37071&#160;Tours&#160;Cedex&#160;2&#160;-&#160;France&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1371">SANOFI-AVENTIS,&#160;S.A.&#160;</p>
<p style="position:absolute;top:519px;left:106px;white-space:nowrap" class="ft1371">Ctra.&#160;C-35 (La&#160;Batlloria-Hostalric), km. 63.09&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1371">17404 Riells&#160;i&#160;Viabrea&#160;(Girona)&#160;–&#160;Spain&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1371">For&#160;any&#160;information about&#160;this&#160;medicinal&#160;product, please&#160;contact&#160;the local&#160;representative&#160;of&#160;the&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1371">Marketing Authorisation Holder.&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft1372"><b>België/Belgique/Belgien&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1371">Sanofi&#160;Belgium&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1371">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1372"><b>Lietuva&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1371">Swixx Biopharma&#160;UAB&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1371">Tel:&#160;+370&#160;5&#160;236 91 40&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft13713"><b>България&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1371">Swixx Biopharma&#160;EOOD&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1376">Тел.: +359 (0)2&#160;4942 480&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft1372"><b>Luxembourg/Luxemburg&#160;</b></p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1371">Sanofi&#160;Belgium&#160;&#160;</p>
<p style="position:absolute;top:747px;left:454px;white-space:nowrap" class="ft1371">Tél/Tel:&#160;+32&#160;(0)2 710&#160;54 00 (Belgique/Belgien)&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft13713"><b>Česká&#160;republika&#160;</b></p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1371">sanofi-aventis, s.r.o.&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1371">Tel:&#160;+420&#160;233&#160;086 111&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:785px;left:455px;white-space:nowrap" class="ft13713"><b>Magyarország&#160;</b></p>
<p style="position:absolute;top:804px;left:455px;white-space:nowrap" class="ft1371">SANOFI-AVENTIS Zrt.&#160;</p>
<p style="position:absolute;top:823px;left:455px;white-space:nowrap" class="ft1371">Tel.:&#160;+36 1&#160;505 0050&#160;</p>
<p style="position:absolute;top:842px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1372"><b>Danmark&#160;</b></p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1371">Sanofi&#160;A/S&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1371">Tlf:&#160;+45 45 16 70&#160;00&#160;</p>
<p style="position:absolute;top:918px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:861px;left:455px;white-space:nowrap" class="ft1372"><b>Malta&#160;</b></p>
<p style="position:absolute;top:880px;left:455px;white-space:nowrap" class="ft1371">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:899px;left:455px;white-space:nowrap" class="ft1371">Tel:&#160;+39 02&#160;39394275&#160;</p>
<p style="position:absolute;top:918px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:937px;left:106px;white-space:nowrap" class="ft1372"><b>Deutschland&#160;</b></p>
<p style="position:absolute;top:956px;left:106px;white-space:nowrap" class="ft1371">Sanofi-Aventis Deutschland GmbH&#160;</p>
<p style="position:absolute;top:975px;left:106px;white-space:nowrap" class="ft1371">Tel:&#160;0800 52 52 010&#160;</p>
<p style="position:absolute;top:994px;left:106px;white-space:nowrap" class="ft1371">Tel. aus&#160;dem&#160;Ausland:&#160;+49&#160;69 305 21&#160;131&#160;</p>
<p style="position:absolute;top:1013px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:937px;left:455px;white-space:nowrap" class="ft1372"><b>Nederland&#160;</b></p>
<p style="position:absolute;top:956px;left:455px;white-space:nowrap" class="ft1371">Genzyme&#160;Europe&#160;B.V.&#160;</p>
<p style="position:absolute;top:975px;left:455px;white-space:nowrap" class="ft1371">Tel:&#160;+31 20&#160;245 4000&#160;</p>
<p style="position:absolute;top:994px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:1032px;left:106px;white-space:nowrap" class="ft1372"><b>Eesti&#160;</b></p>
<p style="position:absolute;top:1051px;left:106px;white-space:nowrap" class="ft1371">Swixx Biopharma&#160;OÜ&#160;</p>
<p style="position:absolute;top:1070px;left:106px;white-space:nowrap" class="ft1371">Tel:&#160;+372&#160;640 10 30&#160;</p>
<p style="position:absolute;top:1089px;left:106px;white-space:nowrap" class="ft1371">&#160;</p>
<p style="position:absolute;top:1032px;left:455px;white-space:nowrap" class="ft1372"><b>Norge&#160;</b></p>
<p style="position:absolute;top:1051px;left:455px;white-space:nowrap" class="ft1371">sanofi-aventis Norge&#160;AS&#160;</p>
<p style="position:absolute;top:1070px;left:455px;white-space:nowrap" class="ft1371">Tlf:&#160;+47 67 10 71&#160;00&#160;</p>
<p style="position:absolute;top:1089px;left:455px;white-space:nowrap" class="ft1371">&#160;</p>
</div>
<!-- Page 138 -->
<a name="138"></a>
<style type="text/css">
<!--
	p {margin: 0; padding: 0;}	.ft13814{font-size:14px;font-family:MVTFCU+Verdana;color:#000000;}
-->
</style>
<div id="page138-div" style="position:relative;width:892px;height:1262px;">
<p style="position:absolute;top:1193px;left:106px;white-space:nowrap" class="ft1380">&#160;</p>
<p style="position:absolute;top:1193px;left:437px;white-space:nowrap" class="ft1380">138&#160;</p>
<p style="position:absolute;top:83px;left:106px;white-space:nowrap" class="ft13813"><b>Ελλάδα&#160;</b></p>
<p style="position:absolute;top:102px;left:106px;white-space:nowrap" class="ft1381">Sanofi-Aventis&#160;Μονοπρόσωπη&#160;ΑΕΒΕ&#160;</p>
<p style="position:absolute;top:121px;left:106px;white-space:nowrap" class="ft1386">Τηλ:&#160;+30 210&#160;900 16&#160;00&#160;</p>
<p style="position:absolute;top:140px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:83px;left:455px;white-space:nowrap" class="ft1382"><b>Österreich&#160;</b></p>
<p style="position:absolute;top:102px;left:455px;white-space:nowrap" class="ft1381">sanofi-aventis GmbH&#160;</p>
<p style="position:absolute;top:121px;left:455px;white-space:nowrap" class="ft1381">Tel:&#160;+43&#160;1 80&#160;185&#160;–&#160;0&#160;</p>
<p style="position:absolute;top:140px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:159px;left:106px;white-space:nowrap" class="ft1382"><b>España&#160;</b></p>
<p style="position:absolute;top:178px;left:106px;white-space:nowrap" class="ft1381">sanofi-aventis, S.A.&#160;</p>
<p style="position:absolute;top:197px;left:106px;white-space:nowrap" class="ft1381">Tel:&#160;+34 93&#160;485 94&#160;00&#160;</p>
<p style="position:absolute;top:216px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:159px;left:455px;white-space:nowrap" class="ft1382"><b>Polska&#160;</b></p>
<p style="position:absolute;top:178px;left:455px;white-space:nowrap" class="ft1381">sanofi-aventis&#160;Sp.&#160;z&#160;o.o.&#160;</p>
<p style="position:absolute;top:197px;left:455px;white-space:nowrap" class="ft1381">Tel.:&#160;+48 22&#160;280 00 00&#160;</p>
<p style="position:absolute;top:216px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:235px;left:104px;white-space:nowrap" class="ft1382"><b>France&#160;</b></p>
<p style="position:absolute;top:254px;left:104px;white-space:nowrap" class="ft1381">sanofi-aventis France&#160;</p>
<p style="position:absolute;top:273px;left:104px;white-space:nowrap" class="ft1381">Tél:&#160;0&#160;800&#160;222 555&#160;</p>
<p style="position:absolute;top:292px;left:104px;white-space:nowrap" class="ft1381">Appel&#160;depuis&#160;l’étranger&#160;:&#160;+33 1 57 63&#160;23 23&#160;</p>
<p style="position:absolute;top:311px;left:104px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:235px;left:455px;white-space:nowrap" class="ft1382"><b>Portugal&#160;</b></p>
<p style="position:absolute;top:254px;left:455px;white-space:nowrap" class="ft1381">Sanofi&#160;-&#160;Produtos&#160;Farmacêuticos, Lda&#160;</p>
<p style="position:absolute;top:273px;left:455px;white-space:nowrap" class="ft1381">Tel:&#160;+351 21 35 89&#160;400&#160;</p>
<p style="position:absolute;top:292px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:330px;left:106px;white-space:nowrap" class="ft1382"><b>Hrvatska&#160;</b></p>
<p style="position:absolute;top:349px;left:106px;white-space:nowrap" class="ft1381">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:368px;left:106px;white-space:nowrap" class="ft1381">Tel:&#160;+385&#160;1&#160;2078 500&#160;</p>
<p style="position:absolute;top:330px;left:455px;white-space:nowrap" class="ft1382"><b>România&#160;</b></p>
<p style="position:absolute;top:349px;left:455px;white-space:nowrap" class="ft1381">Sanofi&#160;Romania&#160;SRL&#160;</p>
<p style="position:absolute;top:368px;left:454px;white-space:nowrap" class="ft1381">Tel:&#160;+40&#160;(0)&#160;21&#160;317 31 36&#160;</p>
<p style="position:absolute;top:387px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:405px;left:106px;white-space:nowrap" class="ft1382"><b>Ireland&#160;</b></p>
<p style="position:absolute;top:425px;left:106px;white-space:nowrap" class="ft1381">sanofi-aventis&#160;Ireland&#160;Ltd.&#160;T/A SANOFI&#160;</p>
<p style="position:absolute;top:444px;left:106px;white-space:nowrap" class="ft1381">Tel:&#160;+353&#160;(0)&#160;1 403 56 00&#160;</p>
<p style="position:absolute;top:463px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:405px;left:455px;white-space:nowrap" class="ft1382"><b>Slovenija&#160;</b></p>
<p style="position:absolute;top:425px;left:455px;white-space:nowrap" class="ft1381">Swixx&#160;Biopharma&#160;d.o.o.&#160;</p>
<p style="position:absolute;top:444px;left:455px;white-space:nowrap" class="ft1381">Tel:&#160;+386&#160;1&#160;235 51&#160;00&#160;</p>
<p style="position:absolute;top:463px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:481px;left:106px;white-space:nowrap" class="ft1382"><b>Ísland&#160;</b></p>
<p style="position:absolute;top:500px;left:106px;white-space:nowrap" class="ft1381">Vistor&#160;hf.&#160;</p>
<p style="position:absolute;top:520px;left:106px;white-space:nowrap" class="ft1381">Sími:&#160;+354 535 7000&#160;</p>
<p style="position:absolute;top:538px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:481px;left:455px;white-space:nowrap" class="ft13813"><b>Slovenská&#160;republika&#160;</b></p>
<p style="position:absolute;top:500px;left:455px;white-space:nowrap" class="ft1381">Swixx&#160;Biopharma&#160;s.r.o.&#160;</p>
<p style="position:absolute;top:520px;left:455px;white-space:nowrap" class="ft1381">Tel: +421 2&#160;208 33&#160;600&#160;</p>
<p style="position:absolute;top:538px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:557px;left:106px;white-space:nowrap" class="ft1382"><b>Italia&#160;</b></p>
<p style="position:absolute;top:576px;left:106px;white-space:nowrap" class="ft1381">Sanofi&#160;S.r.l.&#160;</p>
<p style="position:absolute;top:595px;left:106px;white-space:nowrap" class="ft1381">Tel:&#160;800&#160;536389&#160;</p>
<p style="position:absolute;top:614px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:557px;left:455px;white-space:nowrap" class="ft1382"><b>Suomi/Finland&#160;</b></p>
<p style="position:absolute;top:576px;left:455px;white-space:nowrap" class="ft1381">Sanofi&#160;Oy&#160;</p>
<p style="position:absolute;top:595px;left:455px;white-space:nowrap" class="ft1381">Puh/Tel:&#160;+358 (0)&#160;201&#160;200&#160;300&#160;</p>
<p style="position:absolute;top:614px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:633px;left:106px;white-space:nowrap" class="ft13813"><b>Κύπρος&#160;</b></p>
<p style="position:absolute;top:652px;left:106px;white-space:nowrap" class="ft1381">C.A. Papaellinas&#160;Ltd.&#160;</p>
<p style="position:absolute;top:671px;left:106px;white-space:nowrap" class="ft1386">Τηλ: +357 22&#160;741741&#160;</p>
<p style="position:absolute;top:690px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:633px;left:455px;white-space:nowrap" class="ft1382"><b>Sverige&#160;</b></p>
<p style="position:absolute;top:652px;left:455px;white-space:nowrap" class="ft1381">Sanofi&#160;AB&#160;</p>
<p style="position:absolute;top:671px;left:455px;white-space:nowrap" class="ft1381">Tel:&#160;+46 (0)8&#160;634&#160;50 00&#160;</p>
<p style="position:absolute;top:690px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:709px;left:106px;white-space:nowrap" class="ft1382"><b>Latvija&#160;</b></p>
<p style="position:absolute;top:728px;left:106px;white-space:nowrap" class="ft1381">Swixx&#160;Biopharma&#160;SIA&#160;</p>
<p style="position:absolute;top:747px;left:106px;white-space:nowrap" class="ft1381">Tel:&#160;+371&#160;6&#160;616 47&#160;50&#160;</p>
<p style="position:absolute;top:766px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:709px;left:455px;white-space:nowrap" class="ft1382"><b>United Kingdom&#160;(Northern&#160;Ireland)&#160;</b></p>
<p style="position:absolute;top:728px;left:455px;white-space:nowrap" class="ft1381">sanofi-aventis&#160;Ireland Ltd.&#160;T/A&#160;SANOFI&#160;</p>
<p style="position:absolute;top:747px;left:455px;white-space:nowrap" class="ft1381">Tel:&#160;+44 (0)&#160;800&#160;035 2525&#160;</p>
<p style="position:absolute;top:766px;left:455px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:785px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:804px;left:106px;white-space:nowrap" class="ft1382"><b>This&#160;leaflet&#160;was&#160;last&#160;revised&#160;in</b>&#160;</p>
<p style="position:absolute;top:823px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:842px;left:106px;white-space:nowrap" class="ft1381">Detailed&#160;information on&#160;this&#160;medicine&#160;is&#160;available&#160;on&#160;the&#160;European&#160;Medicines&#160;Agency web&#160;site:&#160;</p>
<p style="position:absolute;top:861px;left:106px;white-space:nowrap" class="ft1381">http://www.ema.europa.eu/&#160;&#160;</p>
<p style="position:absolute;top:880px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
<p style="position:absolute;top:899px;left:106px;white-space:nowrap" class="ft1381">&#160;</p>
</div>
<a name="outline"></a><h1>Document Outline</h1>
<ul>
<li><a href="karvea-epar-product-information_en.html#1">SUMMARY OF PRODUCT CHARACTERISTICS</a></li>
<li><a href="karvea-epar-product-information_en.html#78">A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE</a></li>
<li><a href="karvea-epar-product-information_en.html#78">B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE</a></li>
<li><a href="karvea-epar-product-information_en.html#78">C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION</a></li>
<li><a href="karvea-epar-product-information_en.html#78">D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT</a></li>
<li><a href="karvea-epar-product-information_en.html#80">A. LABELLING</a></li>
<li><a href="karvea-epar-product-information_en.html#102">B. PACKAGE LEAFLET</a></li>
</ul>
<hr/>
</body>
</html>
